0001558370-20-009814.txt : 20200807 0001558370-20-009814.hdr.sgml : 20200807 20200807073150 ACCESSION NUMBER: 0001558370-20-009814 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200807 DATE AS OF CHANGE: 20200807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 201083735 BUSINESS ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 10-Q 1 acrs-20200630x10q.htm 10-Q
000042691114us-gaap:OtherLiabilitiesCurrentus-gaap:OtherLiabilitiesNoncurrent4148563800000000Accelerated Filer0001557746--12-312020Q2false0001557746us-gaap:CommonStockMember2020-04-012020-06-300001557746us-gaap:CommonStockMember2020-01-012020-03-310001557746us-gaap:CommonStockMember2019-04-012019-06-300001557746us-gaap:CommonStockMember2019-01-012019-03-310001557746us-gaap:RetainedEarningsMember2020-06-300001557746us-gaap:AdditionalPaidInCapitalMember2020-06-300001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001557746us-gaap:RetainedEarningsMember2020-03-310001557746us-gaap:AdditionalPaidInCapitalMember2020-03-310001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-3100015577462020-03-310001557746us-gaap:RetainedEarningsMember2019-12-310001557746us-gaap:AdditionalPaidInCapitalMember2019-12-310001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001557746us-gaap:RetainedEarningsMember2019-06-300001557746us-gaap:AdditionalPaidInCapitalMember2019-06-300001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300001557746us-gaap:RetainedEarningsMember2019-03-310001557746us-gaap:AdditionalPaidInCapitalMember2019-03-310001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-3100015577462019-03-310001557746us-gaap:RetainedEarningsMember2018-12-310001557746us-gaap:AdditionalPaidInCapitalMember2018-12-310001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-3100015577462019-01-012019-12-310001557746acrs:EquityCompensation2017InducementPlanMember2020-06-300001557746acrs:EquityCompensationPlan2012Member2019-12-310001557746acrs:EquityCompensationPlan2012Member2012-01-012015-09-140001557746acrs:EquityCompensationPlan2012Member2020-06-300001557746acrs:EquityIncentivePlan2015Member2015-09-300001557746acrs:EquityIncentivePlan2015Member2020-01-012020-01-010001557746us-gaap:RestrictedStockUnitsRSUMember2020-06-300001557746us-gaap:RestrictedStockUnitsRSUMember2019-12-310001557746us-gaap:RestrictedStockUnitsRSUMemberacrs:EquityCompensation2017InducementPlanMember2020-06-300001557746acrs:EquityCompensationPlan2012Member2020-01-012020-06-300001557746acrs:OtherRevenueMember2020-04-012020-06-300001557746acrs:LaboratoryResearchRevenueMember2020-04-012020-06-300001557746us-gaap:IntersegmentEliminationMemberacrs:ContractResearchSegmentMember2020-01-012020-06-300001557746acrs:EPIHealthLLCMemberus-gaap:RoyaltyMember2020-01-012020-06-300001557746acrs:OtherRevenueMember2020-01-012020-06-300001557746acrs:LaboratoryResearchRevenueMember2020-01-012020-06-300001557746acrs:LaboratoryResearchRevenueMember2019-04-012019-06-300001557746us-gaap:IntersegmentEliminationMemberacrs:ContractResearchSegmentMember2019-01-012019-06-300001557746acrs:EPIHealthLLCMemberus-gaap:RoyaltyMember2019-01-012019-06-300001557746acrs:LaboratoryResearchRevenueMember2019-01-012019-06-300001557746us-gaap:LeaseholdImprovementsMember2020-06-300001557746us-gaap:FurnitureAndFixturesMember2020-06-300001557746us-gaap:ComputerEquipmentMember2020-06-300001557746acrs:LaboratoryEquipmentMember2020-06-300001557746us-gaap:LeaseholdImprovementsMember2019-12-310001557746us-gaap:FurnitureAndFixturesMember2019-12-310001557746us-gaap:ComputerEquipmentMember2019-12-310001557746acrs:LaboratoryEquipmentMember2019-12-310001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-300001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-3100015577462019-02-2800015577462017-11-300001557746us-gaap:RetainedEarningsMember2020-04-012020-06-300001557746us-gaap:RetainedEarningsMember2020-01-012020-03-310001557746us-gaap:RetainedEarningsMember2019-04-012019-06-300001557746us-gaap:RetainedEarningsMember2019-01-012019-03-310001557746srt:ExecutiveOfficerMember2020-01-242020-01-240001557746us-gaap:OtherIntangibleAssetsMember2020-01-012020-06-300001557746us-gaap:InProcessResearchAndDevelopmentMember2020-06-300001557746us-gaap:InProcessResearchAndDevelopmentMember2019-12-310001557746us-gaap:OtherIntangibleAssetsMember2020-06-300001557746us-gaap:OtherIntangibleAssetsMember2019-12-310001557746us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-06-300001557746acrs:EmployeeConsultantsAndDirectorsStockOptionsMember2020-01-012020-06-300001557746us-gaap:ProductMember2019-04-012019-06-300001557746acrs:RhofadeProductMember2019-04-012019-06-300001557746acrs:EskataProductMember2019-04-012019-06-300001557746us-gaap:ProductMember2019-01-012019-06-300001557746acrs:RhofadeProductMember2019-01-012019-06-300001557746acrs:EskataProductMember2019-01-012019-06-300001557746acrs:DermatologyTherapeuticsSegmentMember2020-04-012020-06-300001557746acrs:DermatologyTherapeuticsSegmentMember2020-01-012020-06-300001557746acrs:DermatologyTherapeuticsSegmentMember2019-04-012019-06-300001557746acrs:DermatologyTherapeuticsSegmentMember2019-01-012019-06-300001557746acrs:RhofadeProductMember2019-12-310001557746acrs:TermLoanFacilityMember2020-03-310001557746acrs:TermLoanFacilityMemberus-gaap:PrimeRateMember2020-03-012020-03-310001557746us-gaap:CorporateNonSegmentMember2020-04-012020-06-300001557746acrs:ContractResearchSegmentMember2020-04-012020-06-300001557746us-gaap:CorporateNonSegmentMember2020-01-012020-06-300001557746acrs:ContractResearchSegmentMember2020-01-012020-06-300001557746us-gaap:CorporateNonSegmentMember2019-04-012019-06-300001557746acrs:ContractResearchSegmentMember2019-04-012019-06-300001557746us-gaap:CorporateNonSegmentMember2019-01-012019-06-300001557746acrs:ContractResearchSegmentMember2019-01-012019-06-300001557746us-gaap:CommonStockMember2020-06-300001557746us-gaap:CommonStockMember2020-03-310001557746us-gaap:CommonStockMember2019-12-310001557746us-gaap:CommonStockMember2019-06-300001557746us-gaap:CommonStockMember2019-03-310001557746us-gaap:CommonStockMember2018-12-310001557746us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-06-300001557746us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001557746acrs:SiliconValleyBankMember2020-03-3100015577462019-06-3000015577462018-12-310001557746acrs:ConfluenceMember2020-01-012020-06-300001557746us-gaap:FixedIncomeSecuritiesMember2020-06-300001557746us-gaap:FixedIncomeSecuritiesMember2019-12-310001557746us-gaap:AssetBackedSecuritiesMember2020-06-300001557746us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-06-300001557746us-gaap:CorporateDebtSecuritiesMember2020-06-300001557746us-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310001557746us-gaap:CorporateDebtSecuritiesMember2019-12-310001557746us-gaap:AssetBackedSecuritiesMember2019-12-310001557746us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-06-300001557746us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-06-300001557746us-gaap:FairValueMeasurementsRecurringMember2020-06-300001557746us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001557746us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001557746us-gaap:FairValueMeasurementsRecurringMember2019-12-310001557746us-gaap:WarrantMember2020-01-012020-06-300001557746us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-06-300001557746acrs:EmployeeConsultantsAndDirectorsStockOptionsMember2020-01-012020-06-300001557746us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-06-300001557746acrs:EmployeeConsultantsAndDirectorsStockOptionsMember2019-01-012019-06-300001557746us-gaap:ResearchAndDevelopmentExpenseMember2020-04-012020-06-300001557746us-gaap:GeneralAndAdministrativeExpenseMember2020-04-012020-06-300001557746us-gaap:CostOfSalesMember2020-04-012020-06-300001557746us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-06-300001557746us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-06-300001557746us-gaap:CostOfSalesMember2020-01-012020-06-300001557746us-gaap:ResearchAndDevelopmentExpenseMember2019-04-012019-06-300001557746us-gaap:GeneralAndAdministrativeExpenseMember2019-04-012019-06-300001557746us-gaap:CostOfSalesMember2019-04-012019-06-300001557746us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-06-300001557746us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-06-300001557746us-gaap:CostOfSalesMember2019-01-012019-06-300001557746us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001557746us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100015577462020-01-012020-03-310001557746us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-300001557746us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-3100015577462019-01-012019-03-310001557746acrs:OperatingLeasesMember2020-06-300001557746acrs:OperatingLeasesMember2019-12-310001557746acrs:MallinckrodtPlc.Member2020-06-300001557746acrs:MallinckrodtPlc.Member2019-12-3100015577462020-08-060001557746acrs:EquityIncentivePlan2015Member2020-06-300001557746acrs:ConfluenceMemberacrs:AgreementAndPlanOfMergerMember2017-08-012017-08-310001557746srt:MinimumMember2020-01-012020-06-300001557746srt:MaximumMember2020-01-012020-06-300001557746acrs:RigelPharmaceuticalsIncMember2019-09-300001557746acrs:RigelPharmaceuticalsIncMember2019-07-012019-09-300001557746acrs:TermLoanFacilityMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2020-03-302020-03-300001557746acrs:TermLoanFacilityMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2020-03-302020-03-300001557746acrs:TermLoanFacilityMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2020-03-302020-03-300001557746acrs:TermLoanFacilityMember2020-03-012020-03-3100015577462020-04-012020-06-3000015577462019-04-012019-06-3000015577462019-01-012019-06-300001557746acrs:EpiHealthLlcMember2020-06-300001557746acrs:RigelPharmaceuticalsIncMember2020-06-300001557746acrs:ConfluenceMemberacrs:AgreementAndPlanOfMergerMember2018-11-012018-11-300001557746acrs:ConfluenceMemberacrs:AgreementAndPlanOfMergerMember2017-08-310001557746acrs:EPIHealthLLCMember2020-06-300001557746acrs:RhofadeProductMember2020-06-300001557746acrs:RigelPharmaceuticalsIncMember2019-10-310001557746acrs:EPIHealthLLCMember2019-10-012019-10-310001557746acrs:LicenseAndCollaborationAgreementMember2015-08-012015-08-3100015577462020-06-3000015577462019-12-3100015577462020-01-012020-06-30iso4217:USDxbrli:sharesacrs:Voteacrs:itemxbrli:pureacrs:installmentiso4217:USDxbrli:sharesutr:sqftacrs:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark one)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                      

Commission File Number 001-37581

Aclaris Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of
Incorporation or Organization)

46-0571712
(I.R.S. Employer
Identification No.)

640 Lee Road, Suite 200
Wayne, PA
(Address of principal executive offices)

19087
(Zip Code)

Registrant’s telephone number, including area code: (484324-7933

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class:

 

Trading Symbol(s)

Name of Each Exchange on which Registered

Common Stock, $0.00001 par value

 

ACRS

The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934:

Large accelerated filer  

Accelerated filer  

Non-accelerated filer  

Smaller reporting company  

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).   Yes  No 

The number of outstanding shares of the registrant’s common stock, par value $0.00001 per share, as of the close of business on August 6, 2020 was 42,722,780.

ACLARIS THERAPEUTICS, INC.

INDEX TO FORM 10-Q

    

PAGE

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

2

Unaudited Condensed Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019

2

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2020 and 2019

3

Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2020 and 2019

4

Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2020 and 2019

5

Notes to Unaudited Condensed Consolidated Financial Statements

6

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

24

Item 3. Quantitative and Qualitative Disclosures about Market Risk

41

Item 4. Controls and Procedures

41

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

42

Item 1A. Risk Factors

43

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

45

Item 6. Exhibits

45

Signatures

47

Part I. FINANCIAL INFORMATION

Item 1. Financial Statements

ACLARIS THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share and per share data)

    

June 30, 

December 31, 

 

    

2020

    

2019

 

 

Assets

Current assets:

Cash and cash equivalents

$

32,587

$

35,937

Marketable securities

 

35,528

 

39,078

Accounts receivable, net

775

704

Prepaid expenses and other current assets

 

2,065

 

3,118

Discontinued operations - current assets

4,966

Total current assets

 

70,955

 

83,803

Property and equipment, net

 

2,230

 

2,470

Intangible assets

7,161

7,199

Other assets

 

4,653

 

4,825

Total assets

$

84,999

$

98,297

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

5,502

$

9,917

Accrued expenses

 

9,344

 

7,721

Current portion of lease liabilities

610

637

Discontinued operations - current liabilities

2,289

4,157

Total current liabilities

 

17,745

 

22,432

Other liabilities

3,331

 

3,736

Long-term debt, net

10,573

Contingent consideration

3,435

1,668

Deferred tax liability

 

549

 

549

Total liabilities

 

35,633

 

28,385

Stockholders’ Equity:

Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at June 30, 2020 and December 31, 2019

Common stock, $0.00001 par value; 100,000,000 shares authorized at June 30, 2020 and December 31, 2019; 42,691,114 and 41,485,638 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively

 

 

Additional paid‑in capital

 

530,061

 

523,505

Accumulated other comprehensive income (loss)

 

15

 

(66)

Accumulated deficit

 

(480,710)

 

(453,527)

Total stockholders’ equity

 

49,366

 

69,912

Total liabilities and stockholders’ equity

$

84,999

$

98,297

The accompanying notes are an integral part of these condensed consolidated financial statements.

2

ACLARIS THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except share and per share data)

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2020

    

2019

    

2020

    

2019

Revenues:

Contract research

$

1,853

$

886

$

3,042

$

2,149

Other revenue

193

411

Total revenue

2,046

886

3,453

2,149

Costs and expenses:

Cost of revenue

1,389

994

2,658

2,201

Research and development

 

6,466

17,519

 

15,909

 

37,161

General and administrative

 

5,572

7,469

 

11,773

 

14,926

Goodwill impairment

18,504

18,504

Total costs and expenses

 

13,427

 

44,486

 

30,340

 

72,792

Loss from operations

 

(11,381)

 

(43,600)

 

(26,887)

 

(70,643)

Other income (expense), net

 

(189)

 

(85)

 

(11)

 

(315)

Loss from continuing operations

(11,570)

(43,685)

(26,898)

(70,958)

Loss from discontinued operations

(27)

(6,191)

(285)

(16,483)

Net loss

$

(11,597)

$

(49,876)

$

(27,183)

$

(87,441)

Net loss per share, basic and diluted

$

(0.28)

$

(1.21)

$

(0.65)

$

(2.12)

Weighted average common shares outstanding, basic and diluted

 

42,133,646

 

41,274,808

 

41,876,037

 

41,261,808

Other comprehensive income (loss):

Unrealized gain (loss) on marketable securities, net of tax of $0

$

(37)

$

30

$

23

$

64

Foreign currency translation adjustments

5

27

58

13

Total other comprehensive income (loss)

 

(32)

 

57

 

81

 

77

Comprehensive loss

$

(11,629)

$

(49,819)

$

(27,102)

$

(87,364)

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

ACLARIS THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF

STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands, except share data)

Accumulated

 

Common Stock

Additional

Other

Total

 

Par

Paidin

Comprehensive

Accumulated

Stockholders’

 

  

  Shares 

  

Value

  

Capital

  

Income (Loss)

  

Deficit

  

Equity

 

Balance at December 31, 2019

41,485,638

$

$

523,505

$

(66)

$

(453,527)

$

69,912

Vesting of restricted stock units

346,582

(121)

(121)

Fair value of warrants issued

378

378

Unrealized gain on marketable securities

60

60

Foreign currency translation adjustment

53

53

Stock-based compensation expense

3,453

3,453

Net loss

(15,586)

(15,586)

Balance at March 31, 2020

41,832,220

$

$

527,215

$

47

$

(469,113)

$

58,149

Vesting of restricted stock units

858,894

(463)

(463)

Unrealized loss on marketable securities

(37)

(37)

Foreign currency translation adjustment

5

5

Stock-based compensation expense

3,309

3,309

Net loss

(11,597)

(11,597)

Balance at June 30, 2020

42,691,114

$

$

530,061

$

15

$

(480,710)

$

49,366

Accumulated

Common Stock

Additional

Other

Total

Par

Paidin

Comprehensive

Accumulated

Stockholders’

  

  Shares 

  

Value

  

Capital

  

Income (Loss)

  

Deficit

  

Equity

Balance at December 31, 2018

41,210,725

$

$

507,366

$

(69)

$

(292,173)

$

215,124

Vesting of restricted stock units

58,918

(188)

(188)

Unrealized gain on marketable securities

34

34

Foreign currency translation adjustment

(14)

(14)

Stock-based compensation expense

4,862

4,862

Net loss

(37,565)

(37,565)

Balance at March 31, 2019

41,269,643

$

$

512,040

$

(49)

$

(329,738)

$

182,253

Exercise of stock options and vesting of restricted stock units

8,927

(18)

(18)

Unrealized gain on marketable securities

30

30

Foreign currency translation adjustment

27

27

Stock-based compensation expense

4,814

4,814

Net loss

(49,876)

(49,876)

Balance at June 30, 2019

41,278,570

$

$

516,836

$

8

$

(379,614)

$

137,230

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

ACLARIS THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

Six Months Ended

 

June 30, 

    

2020

    

2019

 

Cash flows from operating activities:

    

    

    

    

Net loss

$

(27,183)

$

(87,441)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

 

1,182

 

4,457

Stock-based compensation expense

 

6,762

 

9,676

Change in fair value of contingent consideration

1,767

734

Goodwill impairment charge

18,504

Changes in operating assets and liabilities:

Accounts receivable

4,895

(14,509)

Prepaid expenses and other assets

 

890

 

2,579

Accounts payable

 

(6,026)

 

(583)

Accrued expenses

 

87

 

13,887

Net cash used in operating activities

 

(17,626)

 

(52,696)

Cash flows from investing activities:

Purchases of property and equipment

 

(141)

 

(525)

Purchases of marketable securities

 

(27,139)

 

(89,407)

Proceeds from sales and maturities of marketable securities

 

30,735

 

117,500

Net cash provided by (used in) investing activities

 

3,455

 

27,568

Cash flows from financing activities:

Proceeds from debt financing (including warrants), net of issuance costs

10,913

Finance lease payments

(92)

(240)

Proceeds from exercise of employee stock options and the issuance of stock

3

Net cash provided by (used in) financing activities

 

10,821

 

(237)

Net decrease in cash and cash equivalents

 

(3,350)

 

(25,365)

Cash, cash equivalents and restricted cash at beginning of period

 

35,937

 

57,019

Cash, cash equivalents and restricted cash at end of period

$

32,587

$

31,654

Supplemental disclosure of non-cash investing and financing activities:

Additions to property and equipment included in accounts payable

$

339

$

392

Operating lease asset recorded as a result of new accounting standard

$

$

2,132

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

ACLARIS THERAPEUTICS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in thousands, except share and per share data)

1. Organization and Nature of Business

Overview

Aclaris Therapeutics, Inc. was incorporated under the laws of the State of Delaware in 2012.  In July 2015, Aclaris Therapeutics International Limited (“ATIL”) was established under the laws of the United Kingdom as a wholly-owned subsidiary of Aclaris Therapeutics, Inc.  In August 2017, Confluence Life Sciences, Inc. (now known as Aclaris Life Sciences, Inc.) (“Confluence”) was acquired by Aclaris Therapeutics, Inc. and became a wholly-owned subsidiary thereof.  Aclaris Therapeutics, Inc., ATIL and Confluence are referred to collectively as the “Company.”  The Company is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company currently has a pipeline of drug candidates focused on immuno-inflammatory diseases, as well as one product approved by the U.S. Food and Drug Administration (“FDA”) that it is not currently distributing, marketing or selling, and other investigational drug candidates.  In September 2019, the Company announced the completion of a strategic review of its business, as a result of which it refocused its resources on its immuno-inflammatory development programs.  The Company is pursuing strategic alternatives, including identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its drug candidates and ESKATA (hydrogen peroxide) topical solution, 40% (w/w) (“ESKATA”), the Company’s non-marketed FDA-approved product.  

Liquidity

The Company’s condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business.  As of June 30, 2020, the Company had cash, cash equivalents and restricted cash and marketable securities of $68,115 and an accumulated deficit of $480,710. Since inception, the Company has incurred net losses and negative cash flows from its operations.  Prior to the acquisition of Confluence in August 2017, the Company had never generated revenue.  There can be no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis.  In addition, development activities, including clinical and preclinical testing of the Company’s drug candidates, will require significant additional financing.  The future viability of the Company is dependent on its ability to successfully develop its drug candidates and to generate revenue from identifying and consummating transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize its development assets or to raise additional capital to finance its operations.  The Company will require additional capital to complete the clinical development of ATI-450 and ATI-1777, to develop its preclinical compounds, and to support its discovery efforts.  Additional funds may not be available on a timely basis, on commercially acceptable terms, or at all, and such funds, if raised, may not be sufficient to enable the Company to continue to implement its long-term business strategy.  The Company’s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.  If the Company is unable to raise sufficient additional capital or generate revenue from transactions with third-party partners for the development and/or commercialization of its drug candidates, it may need to substantially curtail planned operations. The Company’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.  

In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that its consolidated financial statements are issued.  As of the report date, the Company believes the actions described below are probable of being implemented effectively and of alleviating the conditions or events that exist which raise substantial doubt about its ability to continue as a going concern within one year after the date of the issuance of these condensed consolidated financial statements.  The Company believes its existing

6

cash, cash equivalents and marketable securities are sufficient to fund its operating and capital expenditure requirements for a period greater than 12 months from the date of issuance of these condensed consolidated financial statements.  

The Company has taken a number of actions to support its operations and meet its liquidity needs.  In September 2019, the Company announced the completion of a strategic review and its decision to refocus its resources on its immuno-inflammatory development programs and to pursue strategic alternatives, including identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its drug candidates and ESKATA.  As a result of this decision, the Company restructured its operations and terminated employees, which lowered operating costs.  In October 2019, the Company sold the worldwide rights to RHOFADE (oxymetazoline hydrochloride) cream, 1% (“RHOFADE”) to further its focus on its development programs and improve cash flow.  In March 2020, the Company borrowed $11,000 under a term loan facility with Silicon Valley Bank.

The Company’s plans to further alleviate the substantial doubt about its going concern, which are probable of effectively being implemented and mitigating these conditions, primarily include its ability to control the timing and spending on its research and development programs.  The Company may also consider other plans to fund its operations including: (1) raising additional capital through debt or equity financings; (2) identifying third-party partners to further develop, obtain marketing approval for and/or commercialize its drug candidates and ESKATA, which may generate revenue and/or milestone payments; (3) reducing spending on one or more research and development programs by delaying or discontinuing development; and/or (4) further restructuring its operations to change its overhead structure. Finally, additional funds may not be available on a timely basis, on commercially acceptable terms, or at all, and such funds, if raised, may not be sufficient to enable the Company to continue to implement its long-term business strategy.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).  The condensed consolidated financial statements of the Company include the accounts of the operating parent company, Aclaris Therapeutics, Inc., and its wholly-owned subsidiaries, ATIL and Confluence.  All significant intercompany transactions have been eliminated.  Based upon the revenue from contract research services, the Company believes that gross profit does not provide a meaningful measure of profitability and, therefore, has not included a line item for gross profit on the condensed consolidated statement of operations.  

Discontinued Operations

In September 2019, the Company announced the completion of a strategic review and its decision to refocus its resources on its immuno-inflammatory development programs and to actively seek partners for its commercial products.  

The accompanying condensed consolidated financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to the Company’s commercial products as discontinued operations (see Note 15).  

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods.  Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development expenses, contingent consideration and the valuation of stock-based awards.  Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  The COVID-19 pandemic has resulted in a global slowdown of economic activity.  As of the date of issuance of these financial statements, the Company is not aware of any specific event

7

or circumstance that would require an update to its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities.  Actual results could differ from the Company’s estimates.

Unaudited Interim Financial Information

The accompanying condensed consolidated balance sheet as of June 30, 2020, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2020 and 2019, the condensed consolidated statement of stockholders’ equity for the three and six months ended June 30, 2020 and 2019, and the condensed consolidated statements of cash flows for the six months ended June 30, 2020 and 2019 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements contained in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 25, 2020 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of June 30, 2020, the results of its operations and comprehensive loss for the three and six months ended June 30, 2020 and 2019, its changes in stockholders’ equity for the three and six months ended June 30, 2020 and 2019 and its cash flows for the six months ended June 30, 2020 and 2019.  The condensed consolidated balance sheet data as of December 31, 2019 was derived from audited financial statements but does not include all disclosures required by GAAP.  The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2020 and 2019 are unaudited. The results for the three and six months ended June 30, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020, any other interim periods, or any future year or period.  The unaudited interim financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2019 included in the Company’s annual report on Form 10-K filed with the SEC on February 25, 2020.  

Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2019 included in the Company’s annual report on Form 10-K filed with the SEC on February 25, 2020.

Cash, Cash Equivalents and Restricted Cash

The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents.  Cash equivalents, which have consisted of money market accounts, commercial paper and corporate debt securities with original maturities of less than three months, are stated at fair value.  Restricted cash as of June 30, 2020 consisted of $1,753 placed in escrow pursuant to the asset purchase agreement with EPI Health, LLC (“EPI Health”) (see Note 13 for additional information).

Revenue Recognition

The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers.  Under ASC Topic 606, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.  

To determine revenue recognition in accordance with ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) performance obligations are satisfied.  At contract inception, the Company assesses the goods or services promised within a contract with a customer to identify the performance obligations, and to determine if they are distinct.  The Company recognizes the revenue that is allocated to each distinct performance obligation when (or as) that

8

performance obligation is satisfied.  The Company only recognizes revenue when collection of the consideration it is entitled to under a contract with a customer is probable.  

Contract Research

The Company earns contract research revenue from the provision of laboratory services to clients through Confluence, its wholly-owned subsidiary.  Contract research revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis and are generally billed on a monthly basis in arrears for services rendered.  Revenue related to these contracts is generally recognized as the laboratory services are performed, based upon the rates specified in the contracts.  Under ASC Topic 606, the Company elected to apply the “right to invoice” practical expedient when recognizing contract research revenue.  The Company recognizes contract research revenue in the amount to which it has the right to invoice.  

Other Revenue

Licenses of Intellectual Property – The Company recognizes revenue received from non-refundable, upfront fees related to the licensing of intellectual property when the intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the license has been transferred to the customer, and the customer is able to use and benefit from the license.  

Milestone Payments – At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the amount allocated to the license of intellectual property.  Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.  

Intangible Assets

Intangible assets include both definite-lived and indefinite-lived assets.  Definite-lived intangible assets are amortized over their estimated useful life based on the pattern over which the intangible assets are consumed or otherwise used up.  If that pattern cannot be reliably determined, the straight-line method of amortization is used.  Definite-lived intangible assets consist of a research technology platform the Company acquired through the acquisition of Confluence.  Indefinite-lived intangible assets consist of an in-process research and development (“IPR&D”) drug candidate acquired through the acquisition of Confluence.  IPR&D assets are considered indefinite-lived until the completion or abandonment of the associated research and development efforts.  The cost of IPR&D is either amortized over its estimated useful life beginning when the underlying drug candidate is approved and launched commercially, or expensed immediately if development of the drug candidate is abandoned.  

Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable.  Indefinite-lived intangible assets are tested for impairment at least annually, which the Company performs during the fourth quarter, or when indicators of an impairment are present.  The Company recognizes impairment losses when and to the extent that the estimated fair value of an intangible asset is less than its carrying value.  

Leases

Leases represent a company’s right to use an underlying asset and a corresponding obligation to make payments to a lessor for the right to use those assets.  The Company evaluates leases at their inception to determine if they are an operating lease or a finance lease.  A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows are substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the

9

underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term.  Leases that do not meet the finance lease criteria are accounted for as an operating lease.  

The Company recognizes assets and liabilities for leases at their inception based upon the present value of all payments due under the lease.  The Company uses an implicit interest rate to determine the present value of finance leases, and its incremental borrowing rate to determine the present value of operating leases.  The Company determines incremental borrowing rates by referencing collateralized borrowing rates for debt instruments with terms similar to the respective lease.  The Company recognizes expense for operating and finance leases on a straight-line basis over the term of each lease, and interest expense related to finance leases is recognized over the lease term based on the effective interest method.  The Company includes estimates for any residual value guarantee obligations under its leases in lease liabilities recorded on its condensed consolidated balance sheet.  

Right-of-use assets are included in other assets and property and equipment, net on the Company’s condensed consolidated balance sheet for operating and finance leases, respectively.  Obligations for lease payments are included in current portion of lease liabilities and other liabilities on the Company’s condensed consolidated balance sheet for both operating and finance leases.  

Contingent Consideration

The Company initially recorded a contingent consideration liability related to future potential payments based upon the achievement of certain development, regulatory and commercial milestones, as well as future projected sales performance, resulting from the acquisition of Confluence, at its estimated fair value on the date of acquisition.  The ultimate amount of future payments, if any, is based on criteria such as sales performance and the achievement of certain regulatory and sales milestones.  The Company estimates the fair value of the contingent consideration liability related to the achievement of regulatory milestones by assigning an achievement probability to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return.  The Company estimates the fair value of the contingent consideration liability associated with sales milestones and royalties by estimating future sales levels, assigning an achievement probability and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.  Significant assumptions used in the Company’s estimates include the probability of success of achieving regulatory and sales milestones, which are based upon an asset’s current stage of development and ranged between 4% and 15%.  The Company evaluates fair value estimates of contingent consideration liabilities on a periodic basis.  Any change in fair value reflects new information about the likelihood of the payment of the contingent consideration and the passage of time. For example, if the timing of the development of an acquired drug candidate, or the size of potential commercial opportunities related to an acquired drug, differ from the Company’s assumptions, then the fair value of contingent consideration would be adjusted accordingly. Future changes in the fair value of the contingent consideration, if any, will be recorded as income or expense in the Company’s condensed consolidated statement of operations.  

Concentration of Credit Risk and of Significant Suppliers

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds all cash, cash equivalents and marketable securities balances at one accredited financial institution, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

The Company is dependent on third-party manufacturers to supply drug product, including all underlying components, for its research and development activities, including preclinical and clinical testing.  These activities could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients or other components.  

10

Recently Issued Accounting Pronouncements

In November 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606.  The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  

In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40).  ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.  The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within such fiscal years.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).  The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements.  This update eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some of the existing disclosure requirements.  The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within such fiscal years.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  

3. Fair Value of Financial Assets and Liabilities

The following tables present information about the fair value measurements of the Company’s financial assets and liabilities which are measured at fair value on a recurring and non-recurring basis, and indicate the level of the fair value hierarchy utilized to determine such fair values:

June 30, 2020

 

    

Level 1

    

Level 2

    

Level 3

    

Total

 

Assets:

    

    

    

    

    

    

    

    

Cash equivalents

$

16,754

$

$

$

16,754

Marketable securities

 

35,528

35,528

Total assets

$

16,754

$

35,528

$

$

52,282

Liabilities:

Acquisition-related contingent consideration

$

$

$

3,435

$

3,435

Total liabilities

$

$

$

3,435

$

3,435

11

December 31, 2019

 

    

Level 1

    

Level 2

    

Level 3

    

Total

 

Assets:

    

    

    

    

    

    

    

    

Cash equivalents

$

21,277

$

$

$

21,277

Marketable securities

 

39,078

39,078

Total assets

$

21,277

$

39,078

$

$

60,355

Liabilities:

Acquisition-related contingent consideration

$

$

$

1,668

$

1,668

Total liabilities

$

$

$

1,668

$

1,668

As of June 30, 2020 and December 31, 2019, the Company’s cash equivalents consisted of investments with maturities of less than three months and included a money market fund, which was valued based upon Level 1 inputs, and the Company’s marketable securities consisted of investments with maturities of more than three months and included commercial paper, corporate debt, asset-backed securities and government obligations, which were valued based upon Level 2 inputs.  In determining the fair value of its Level 2 investments, the Company relied on quoted prices for identical securities in markets that are not active. These quoted prices were obtained by the Company with the assistance of a third-party pricing service based on available trade, bid and other observable market data for identical securities.  Quarterly, the Company compares the quoted prices obtained from the third-party pricing service to other available independent pricing information to validate the reasonableness of the quoted prices provided.  The Company evaluates whether adjustments to third-party pricing is necessary and, historically, the Company has not made adjustments to quoted prices obtained from the third-party pricing service.  During the six months ended June 30, 2020 and 2019, there were no transfers between Level 1, Level 2 and Level 3.  The increase in contingent consideration of $1,767 during the six months ended June 30, 2020 was the result of updates to the Company’s assumptions as a result of the successful completion of a Phase 1 clinical trial for ATI-450.  

As of June 30, 2020 and December 31, 2019, the fair value of the Company’s available for sale marketable securities by type of security was as follows:

June 30, 2020

 

Gross

Gross

 

Amortized

Unrealized

Unrealized

Fair

 

Cost

Gain

Loss

Value

 

Marketable securities:

Corporate debt securities

$

5,688

$

2

$

$

5,690

Commercial paper

15,768

15,768

Asset-backed securities

1,408

(1)

1,407

U.S. government agency debt securities

12,637

26

12,663

Total marketable securities

$

35,501

$

28

$

(1)

$

35,528

December 31, 2019

 

Gross

Gross

 

Amortized

Unrealized

Unrealized

Fair

 

Cost

Gain

Loss

Value

 

Marketable securities:

    

    

    

    

    

    

    

    

Corporate debt securities

$

7,815

$

2

$

$

7,817

Commercial paper

15,129

15,129

Asset-backed securities

8,004

4

8,008

U.S. government agency debt securities

 

8,126

1

(3)

 

8,124

Total marketable securities

$

39,074

$

7

$

(3)

$

39,078

12

4. Property and Equipment, Net

Property and equipment, net consisted of the following:

June 30, 

December 31, 

2020

2019

 

Computer equipment

    

$

1,317

    

$

1,315

Finance lease right-of-use assets

435

435

Lab equipment

1,292

1,250

Furniture and fixtures

647

647

Leasehold improvements

1,200

889

Property and equipment, gross

 

4,891

 

4,536

Accumulated depreciation

 

(2,661)

 

(2,066)

Property and equipment, net

$

2,230

$

2,470

Depreciation expense was $297 and $393 for the three months ended June 30, 2020 and 2019, respectively, and $595 and $795 for the six months ended June 30, 2020 and 2019, respectively.  

5. Intangible Assets

Intangible assets consisted of the following:

Gross Cost

Accumulated Amortization

Remaining

June 30, 

December 31, 

June 30, 

December 31, 

Life (years)

2020

2019

 

2020

2019

Other intangible assets

7.1

751

751

219

181

Total definite-lived intangible assets

751

751

219

181

IPR&D

na

6,629

6,629

Total intangible assets

$

7,380

$

7,380

$

219

$

181

As of June 30, 2020, estimated future amortization expense is as follows:

Year Ending December 31, 

    

    

2020

$

37

2021

 

75

2022

 

75

2023

75

2024

75

Thereafter

195

Total

$

532

6. Accrued Expenses

Accrued expenses consisted of the following:

June 30, 

December 31, 

2020

2019

 

Employee compensation expenses

$

2,489

$

3,321

Research and development expenses

1,134

2,857

Professional fees

112

168

Payable to EPI Health

4,950

Other

 

659

 

1,375

Total accrued expenses

$

9,344

$

7,721

13

Payable to EPI Health

As of June 30, 2020, the Company had $4,950 payable to EPI Health (see Note 15 for additional information).

7. Debt

Loan and Security Agreement – Silicon Valley Bank

In March 2020, the Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”).  The Loan and Security Agreement provides for $11,000 in term loans, of which the Company borrowed the entire amount on March 30, 2020.  The Loan and Security Agreement is secured by substantially all of the assets of the Company other than intellectual property.  In connection with the Loan and Security Agreement, the Company issued to SVB a warrant to purchase up to 460,251 shares of common stock (the “Warrant”).  The proceeds of the Loan and Security Agreement were allocated to the term loan and Warrant using a relative fair value approach.  

The term loan repayment schedule provides for interest only payments beginning April 1, 2020 and continuing through March 1, 2022, followed by 24 consecutive equal monthly installments of principal, plus monthly payments of accrued interest, starting on April 1, 2022 and continuing through the maturity date of March 1, 2024. All outstanding principal and accrued and unpaid interest will be due and payable on the maturity date.  The Loan and Security Agreement provides for an annual interest rate equal to the greater of (i) the prime rate then in effect as reported in The Wall Street Journal plus 2% and (ii) 6.75%.  

The Loan and Security Agreement includes a final payment fee equal to 5% of the original principal amount borrowed.  The Company has the option to prepay the outstanding balance of the term loans in full, subject to a prepayment premium of (i) 3% of the original principal amount borrowed for any prepayment on or prior to the first anniversary of March 30, 2020, (ii) 2% of the original principal amount borrowed for any prepayment after the first anniversary and on or before the second anniversary of March 30, 2020 or (iii) 1% of the original principal amount borrowed for any prepayment after the second anniversary of March 30, 2020 but before March 1, 2024.  

8. Stockholders’ Equity

Preferred Stock

As of June 30, 2020 and December 31, 2019, the Company’s amended and restated certificate of incorporation authorized the Company to issue 10,000,000 shares of undesignated preferred stock.  There were no shares of preferred stock outstanding as of June 30, 2020 or December 31, 2019.

Common Stock

As of June 30, 2020 and December 31, 2019, the Company’s amended and restated certificate of incorporation authorized the Company to issue 100,000,000 shares of $0.00001 par value common stock.

Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to any preferential dividend rights of any series of preferred stock that may be outstanding. No dividends have been declared through June 30, 2020.  

Warrants

In connection with the Loan and Security Agreement with SVB, the Company issued the Warrant to SVB.  The Warrant has an initial exercise price of $0.956 per share, subject to adjustment as provided in the Warrant. The Warrant became immediately exercisable in full upon the funding of the term loan facility. The Warrant will terminate, if not earlier exercised, on the earlier of March 29, 2030 and the closing of certain merger or other transactions in which the consideration is cash, stock of a publicly-traded acquirer or a combination thereof. The Company assigned a fair value of

14

$378 to the Warrant using a Black-Scholes valuation methodology, and also concluded that the Warrant was indexed to its own stock and therefore classified the Warrant as an equity instrument.  

9. Stock-Based Awards

2015 Equity Incentive Plan

In September 2015, the Company’s board of directors adopted the 2015 Equity Incentive Plan (the “2015 Plan”), and the Company’s stockholders approved the 2015 Plan. The 2015 Plan became effective in connection with the Company’s initial public offering in October 2015.  Beginning at the time the 2015 Plan became effective, no further grants may be made under the Company’s 2012 Equity Compensation Plan, as amended and restated (the “2012 Plan”).  The 2015 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit (“RSU”) awards, performance stock awards, cash-based awards and other stock-based awards. The number of shares initially reserved for issuance under the 2015 Plan was 1,643,872 shares of common stock. The number of shares of common stock that may be issued under the 2015 Plan will automatically increase on January 1 of each year ending on January 1, 2025, in an amount equal to the lesser of (i) 4.0% of the shares of the Company’s common stock outstanding on December 31 of the preceding calendar year or (ii) an amount determined by the Company’s board of directors. The shares of common stock underlying any awards that expire, are otherwise terminated, settled in cash or repurchased by the Company under the 2015 Plan and the 2012 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan.  As of January 1, 2020, the number of shares of common stock that may be issued under the 2015 Plan was increased by 1,451,997 shares.  As of June 30, 2020, 1,922,147 shares remained available for grant under the 2015 Plan.  

2017 Inducement Plan

In July 2017, the Company’s board of directors adopted the 2017 Inducement Plan (the “2017 Inducement Plan”).  The 2017 Inducement Plan is a non-stockholder approved stock plan adopted pursuant to the “inducement exception” provided under Nasdaq listing rules.  The Company had 443,000 stock options and 44,390 RSUs outstanding as of June 30, 2020 under the 2017 Inducement Plan.  All shares of common stock that were eligible for issuance under the 2017 Inducement Plan after October 1, 2018, including any shares underlying any awards that expire or are otherwise terminated, reacquired to satisfy tax withholding obligations, settled in cash or repurchased by the Company in the future that would have been eligible for re-issuance under the 2017 Inducement Plan, were retired.  

2012 Equity Compensation Plan

Upon the 2015 Plan becoming effective, no further grants can be made under the 2012 Plan. The Company granted stock options to purchase a total of 1,140,524 shares under the 2012 Plan, of which 609,628 and 745,735 were outstanding as of June 30, 2020 and December 31, 2019, respectively.  Stock options granted under the 2012 Plan vested over four years and expire after ten years.  

Stock Option Valuation

The weighted average assumptions the Company used to estimate the fair value of stock options granted during the six months ended June 30, 2020 and 2019 were as follows:

    

Six Months Ended

June 30, 

2020

2019

 

Risk-free interest rate

 

0.87

%

2.53

%

Expected term (in years)

 

6.1

6.3

Expected volatility

 

85.19

%

101.70

%

Expected dividend yield

 

0

%

0

%

15

The Company recognizes compensation expense for awards over their vesting period.  Compensation expense for awards includes the impact of forfeitures in the period when they occur.  

Stock Options

The following table summarizes stock option activity for the six months ended June 30, 2020:

    

    

    

Weighted

    

 

Weighted

Average

 

Average

Remaining

Aggregate

 

Number

Exercise

Contractual

Intrinsic

 

of Shares

Price

Term

Value

 

(in years)

 

Outstanding as of December 31, 2019

 

3,102,221

$

20.33

 

6.55

$

148

Granted

 

734,800

1.30

Exercised

 

Forfeited and cancelled

 

(557,222)

21.33

Outstanding as of June 30, 2020

 

3,279,799

$

15.90

 

6.99

$

316

Options vested and expected to vest as of June 30, 2020

 

3,279,799

$

15.90

 

6.99

$

316

Options exercisable as of June 30, 2020

 

1,897,671

$

19.16

 

5.79

$

79

The weighted average grant date fair value of stock options granted during the six months ended June 30, 2020 was $0.93 per share.

Restricted Stock Units

The following table summarizes RSU activity for the six months ended June 30, 2020:

Weighted

Average

Grant Date

Number

Fair Value

of Shares

Per Share

Outstanding as of December 31, 2019

3,592,915

$

4.62

Granted

998,385

1.26

Vested

(1,618,634)

3.09

Forfeited and cancelled

(444,265)

4.12

Outstanding as of June 30, 2020

2,528,401

$

4.36

16

Stock-Based Compensation

Stock-based compensation expense included in total costs and expenses on the condensed consolidated statement of operations included the following:

Three Months Ended

Six Months Ended

 

June 30, 

June 30, 

 

    

2020

    

2019

    

2020

    

2019

 

Cost of revenue

    

$

252

    

$

223

  

$

512

    

$

429

Research and development

939

1,721

1,755

3,315

General and administrative

 

2,118

 

2,654

 

4,495

 

5,126

Total stock-based compensation expense

$

3,309

$

4,598

$

6,762

$

8,870

As of June 30, 2020, the Company had unrecognized stock-based compensation expense for stock options and RSUs of $8,195 and $8,604, respectively, which is expected to be recognized over weighted average periods of 1.52 years and 2.13 years, respectively.  

10. Net Loss per Share

Basic and diluted net loss per share is summarized in the following table:

Three Months Ended

Six Months Ended

 

June 30, 

June 30, 

 

2020

2019

    

2020

    

2019

Numerator:

    

    

    

    

    

    

    

Net loss

$

(11,597)

$

(49,876)

$

(27,183)

$

(87,441)

Denominator:

Weighted average shares of common stock outstanding

 

42,133,646

 

41,274,808

 

41,876,037

 

41,261,808

Net loss per share, basic and diluted

$

(0.28)

$

(1.21)

$

(0.65)

$

(2.12)

The Company’s potentially dilutive securities, which included stock options, RSUs and warrants, have been excluded from the computation of diluted net loss per share since the effect would be to reduce the net loss per share. Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.  The following table presents potential shares of common stock excluded from the calculation of diluted net loss per share attributable to common stockholders for the three and six months ended June 30, 2020 and 2019.  All share amounts presented in the table below represent the total number outstanding as of June 30, 2020 and 2019.

 

June 30, 

2020

2019

 

Options to purchase common stock

3,279,799

4,010,423

Restricted stock unit awards

2,528,401

1,959,587

Warrants issued to SVB

460,251

Total potential shares of common stock

6,268,451

5,970,010

17

11. Leases

Operating Leases

Agreements for Office Space

In November 2017, the Company entered into a sublease agreement with Auxilium Pharmaceuticals, LLC (the “Sublandlord”) pursuant to which it subleases 33,019 square feet of office space for its headquarters in Wayne, Pennsylvania. The sublease has a term that runs through October 2023. If for any reason the lease between Chesterbrook Partners, LP (“the Landlord”) and Sublandlord is terminated or expires prior to October 2023, the Company’s sublease will automatically terminate.

In February 2019, the Company entered into a sublease agreement with a third party for 21,056 square feet of office and laboratory space in St. Louis, Missouri. The lease commenced in June 2019 and has a term that runs through June 2029.

Supplemental balance sheet information related to operating leases is as follows:  

June 30, 

December 31, 

Operating Leases:

2020

2019

Gross cost

$

5,213

$

5,213

Accumulated amortization

(789)

(480)

Other assets

$

4,424

$

4,733

Other current liabilities

$

567

$

526

Other liabilities

3,253

3,548

Total operating lease liabilities

$

3,820

$

4,074

Amortization expense related to operating lease right-of-use assets and liabilities was $253 and $143 for the three months ended June 30, 2020 and 2019, respectively, and $510 and $286 for the six months ended June 30, 2020 and 2019, respectively.

Finance Leases

Laboratory Equipment

The Company leases laboratory equipment which is used in its laboratory space in St. Louis, Missouri under two finance lease financing arrangements which the Company entered into in August 2017 and October 2017.  The leases have terms which end in October 2020 and December 2020, respectively.  

12. Related Party Transactions

Mallinckrodt plc

In April 2018, Bryan Reasons was appointed to the Company’s board of directors. Subsequently, in March 2019, Mr. Reasons became the Chief Financial Officer of Mallinckrodt plc.  Prior to Mr. Reasons joining Mallinckrodt plc, the Company entered into a master services agreement with a subsidiary (“Mallinckrodt”) of Mallinckrodt plc in November 2018, pursuant to which Confluence provides laboratory services to Mallinckrodt in the ordinary course of business. Mr. Reasons was not involved in the negotiation or execution of the agreement, but may be deemed to have an interest in the ongoing transactions based on his employment as an executive officer of Mallinckrodt plc.  As of June 30, 2020 and December 31, 2019, the Company had invoiced Mallinckrodt for $292 and $57, respectively, under the master services agreement.  Mr. Reasons had no financial interest in these transactions.  

18

13. Agreements Related to Intellectual Property

Asset Purchase Agreement – EPI Health, LLC

In October 2019, the Company sold RHOFADE to EPI Health pursuant to an asset purchase agreement.  EPI Health agreed to pay the Company a high single-digit royalty calculated as a percentage of net sales on a country-by-country basis until the date that the patent rights related to RHOFADE have expired or, if later, 10 years from the date of the first commercial sale of RHOFADE in such country.  The Company recorded royalty income under the asset purchase agreement of $411 and $0 during the six months ended June 30, 2020 and 2019, respectively.  EPI Health has also agreed to pay the Company potential sales milestone payments of up to $20,000 in the aggregate upon the achievement of specified levels of net sales of products covered by the asset purchase agreement, and 25% of any upfront, license, milestone, maintenance or fixed payment received by EPI Health in connection with any license or sublicense of the assets transferred in the disposition in any territory outside of the United States, subject to specified exceptions.  

Agreement and Plan of Merger – Confluence

In August 2017, the Company entered into an Agreement and Plan of Merger, pursuant to which it acquired Confluence (the “Confluence Agreement”).  In November 2018, the Company achieved a development milestone specified in the Confluence Agreement, as a result of which the Company paid the former Confluence equity holders $2,500 in cash and issued them 253,208 shares of its common stock with a fair value of $2,200.  Under the Confluence Agreement, the Company also agreed to pay the former Confluence equity holders aggregate remaining contingent consideration of up to $75,000 based upon the achievement of specified regulatory and commercial milestones.  In addition, the Company agreed to pay the former Confluence equity holders future royalty payments calculated as a low single-digit percentage of annual net sales, subject to specified reductions, limitations and other adjustments, until the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis or, in specified circumstances, ten years from the first commercial sale of such product.  In addition, if the Company sells, licenses or transfers any of the intellectual property acquired from Confluence pursuant to the Confluence Agreement to a third party, the Company will be obligated to pay the former Confluence equity holders a portion of any consideration received from such sale, license or transfer in specified circumstances.  

License and Collaboration Agreement – Rigel Pharmaceuticals, Inc.

In August 2015, the Company entered into an exclusive, worldwide license and collaboration agreement with Rigel Pharmaceuticals, Inc. (“Rigel”) for the development and commercialization of products containing two specified JAK inhibitors, which the Company refers to as ATI-501 and ATI-502.  Under the agreement, the Company agreed to make aggregate payments of up to $80,000 upon the achievement of specified development milestones.  In September 2019, the Company made a milestone payment of $4,000 to Rigel upon the achievement of a specified development milestone.  With respect to any products the Company commercializes under the agreement, the Company will pay Rigel quarterly tiered royalties on its annual net sales of each product at a high single-digit percentage of annual net sales, subject to specified reductions, until the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis or, in specified countries under specified circumstances, ten years from the first commercial sale of such product.  

In connection with an amendment of the agreement with Rigel in October 2019, the Company paid Rigel an amendment fee of $1,500 in three installments of $500 in each of January 2020, April 2020 and July 2020.  In addition, the parties modified certain other development milestones, and the Company agreed to increase the potential payments payable upon the achievement of such milestones from $10,000 to $10,500 in the aggregate.

19

14. Income Taxes

The Company did not record a federal or state income tax benefit for losses incurred during the six months ended June 30, 2020 and 2019 due to the Company’s conclusion that a valuation allowance was required for those periods.  

15. Discontinued Operations

The components of loss from discontinued operations as reported in the Company’s condensed consolidated statement of operations were as follows:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2020

    

2019

2020

    

2019

Revenues:

Product sales, net

    

$

    

$

4,979

    

$

    

$

8,757

Total revenue, net

4,979

8,757

Costs and expenses:

Cost of revenue

1,709

3,279

Research and development

 

103

1

380

Sales and marketing

27

6,805

283

16,499

General and administrative

 

893

1

1,763

Amortization of definite-lived intangible

1,660

3,319

Total costs and expenses

 

27

 

11,170

285

25,240

Loss from discontinued operations

 

$

(27)

$

(6,191)

$

(285)

$

(16,483)

Net loss from discontinued operations per share, basic and diluted

$

(0.00)

$

(0.15)

$

(0.01)

$

(0.40)

Weighted average common shares outstanding, basic and diluted

 

42,133,646

 

41,274,808

 

41,876,037

 

41,261,808

The following table presents the details of product sales, net included in discontinued operations:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2020

    

2019

2020

    

2019

ESKATA

  

$

    

$

272

$

    

$

344

RHOFADE

4,707

8,413

Total product sales, net

$

$

4,979

$

$

8,757

20

The following table presents information related to assets and liabilities reported as discontinued operations in the Company’s condensed consolidated balance sheet:

June 30, 

December 31,

    

2020

    

2019

Accounts receivable, net

  

$

    

$

4,966

Discontinued operations - current assets

$

$

4,966

Accounts payable

$

36

$

1,705

Accrued expenses

  

2,253

2,452

Discontinued operations - current liabilities

$

2,289

$

4,157

The following table presents certain non-cash items related to discontinued operations, which are included in the Company’s condensed consolidated statement of cash flows:

Six Months Ended

June 30, 

2020

    

2019

Depreciation and amortization

$

    

$

3,552

Stock-based compensation expense

806

Total non-cash items

$

$

4,358

The Company relied on Allergan Sales, LLC (“Allergan”) to distribute RHOFADE on its behalf pursuant to the terms of a transition services agreement.  Accounts receivable, net as of June 30, 2020 and December 31, 2019 included $0 and $4,966, respectively, related to amounts invoiced by Allergan for sales of RHOFADE.  In addition, during the three months ended June 30, 2020, in accordance with the asset purchase agreement with EPI Health (see Note 13 for additional information), the Company received cash from Allergan related to sales of RHOFADE that occurred after the date the Company sold RHOFADE to EPI Health.  Accordingly, the Company had $4,950 payable to EPI Health, which is included in accrued expenses on the Company’s condensed consolidated balance sheet as of June 30, 2020.  

16. Segment Information

The Company has two reportable segments, therapeutics and contract research.  The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.  The contract research segment earns revenue from the provision of laboratory services to clients through Confluence, the Company’s wholly-owned subsidiary.  Contract research revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis.  Corporate and other includes general and administrative expenses as well as eliminations of intercompany transactions.  The Company does not report balance sheet information by segment since it is not reviewed by the chief operating decision maker, and all of the Company’s tangible assets are held in the United States.  

21

The Company’s results of operations by segment for the three and six months ended June 30, 2020 and 2019 are summarized in the tables below:

Contract

Corporate

Total

Three Months Ended June 30, 2020

Therapeutics

Research

and Other

Company

Total revenue

$

193

$

3,657

$

(1,804)

$

2,046

Cost of revenue

3,082

(1,693)

1,389

Research and development

6,577

(111)

6,466

General and administrative

688

4,884

5,572

Loss from operations

$

(6,384)

$

(113)

$

(4,884)

$

(11,381)

Loss from discontinued operations

$

(27)

$

$

$

(27)

Contract

Corporate

Total

Three Months Ended June 30, 2019

Therapeutics

Research

and Other

Company

Total revenue

$

$

3,807

$

(2,921)

$

886

Cost of revenue

3,819

(2,825)

994

Research and development

17,615

(96)

17,519

General and administrative

359

613

6,497

7,469

Goodwill impairment

18,504

18,504

Loss from operations

$

(36,478)

$

(625)

$

(6,497)

$

(43,600)

Loss from discontinued operations

$

(5,298)

$

$

(893)

$

(6,191)

Contract

Corporate

Total

Six Months Ended June 30, 2020

Therapeutics

Research

and Other

Company

Total revenue

$

411

$

7,064

$

(4,022)

$

3,453

Cost of revenue

6,468

(3,810)

2,658

Research and development

16,121

(212)

15,909

General and administrative

1,440

10,333

11,773

Loss from operations

$

(15,710)

$

(844)

$

(10,333)

$

(26,887)

Loss from discontinued operations

$

(284)

$

$

(1)

$

(285)

Contract

Corporate

Total

Six Months Ended June 30, 2019

Therapeutics

Research

and Other

Company

Total revenue

$

$

8,995

$

(6,846)

$

2,149

Cost of revenue

8,856

(6,655)

2,201

Research and development

37,352

(191)

37,161

General and administrative

477

1,145

13,304

14,926

Goodwill impairment

18,504

18,504

Loss from operations

$

(56,333)

$

(1,006)

$

(13,304)

$

(70,643)

Loss from discontinued operations

$

(14,720)

$

$

(1,763)

$

(16,483)

Intersegment Revenue

Revenue for the contract research segment included $4,022 and $6,846 for services performed on behalf of the therapeutics segment for the six months ended June 30, 2020 and 2019, respectively.  All intersegment revenue has been eliminated in the Company’s condensed consolidated statement of operations.  

22

17. Legal Proceedings

Securities Class Action

On July 30, 2019, plaintiff Linda Rosi (“Rosi”) filed a putative class action complaint captioned Rosi v. Aclaris Therapeutics, Inc., et al. in the U.S. District Court for the Southern District of New York against the Company and certain of its executive officers.  The complaint alleges that the defendants violated federal securities laws by, among other things, failing to disclose an alleged likelihood that regulators would scrutinize advertising materials related to ESKATA and find that the materials minimized the risks or overstated the efficacy of the product.  The complaint seeks unspecified compensatory damages on behalf of Rosi and all other persons and entities that purchased or otherwise acquired the Company’s securities between May 8, 2018 and June 20, 2019. 

On September 5, 2019, an additional plaintiff, Robert Fulcher (“Fulcher”), filed a substantially identical putative class action complaint captioned Fulcher v. Aclaris Therapeutics, Inc., et al. in the same court against the same defendants.

On November 6, 2019, the court consolidated the Rosi and Fulcher actions (together, the “Consolidated Securities Action”) and appointed Fulcher “lead plaintiff” for the putative class. 

On January 24, 2020, Fulcher filed a consolidated amended complaint in the Consolidated Securities Action, naming two additional executive officers as defendants, extending the putative class period to August 12, 2019, and adding allegations concerning, among other things, alleged statements and omissions throughout the putative class period concerning ESKATA’s risks, tolerability and effectiveness. The defendants filed a motion to dismiss the consolidated amended complaint on April 17, 2020. Fulcher filed an opposition to the defendants’ motion on June 15, 2020, and the defendants filed a reply to such opposition on August 4, 2020. The motion remains under judicial consideration.

The Company and the other defendants dispute plaintiffs’ claims in the Consolidated Securities Action and intend to defend the matter vigorously.

Stockholder Derivative Action

On November 15, 2019, plaintiff Keith Allred (“Allred”) filed a derivative stockholder complaint captioned Allred v. Walker et al. in the U.S. District Court for the Southern District of New York against certain of the Company’s directors and executive officers.  The complaint alleges that the defendants, among other things, breached their fiduciary duties as directors and/or officers in connection with the claims alleged in the Consolidated Securities Action.  The complaint seeks, among other things, unspecified compensatory damages on behalf of the Company.  

On November 25, 2019, an additional plaintiff, Bruce Brown (“Brown”), filed a substantially identical complaint captioned Brown v. Walker et al. in the same court against the same defendants.

On December 12, 2019, the court consolidated the Allred and Brown actions under the caption In re Aclaris Therapeutics, Inc. Derivative Litigation (the “Consolidated Derivative Action”) and directed that future derivative cases filed in or transferred to the court arising out of substantially the same transactions or events be similarly consolidated.  Thereafter, on January 11, 2020, the court stayed – subject to certain conditions – all deadlines in the Consolidated Derivative Action pending resolution of the defendants’ anticipated motion to dismiss the Consolidated Securities Action.

The defendants dispute plaintiffs’ claims in the Consolidated Derivative Action and intend to defend the matter vigorously.

23

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Certain statements contained in this Quarterly Report on Form 10-Q may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions, or the negative of such words or phrases, are intended to identify “forward-looking statements.” We have based these forward-looking statements on our current expectations and projections about future events. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include those below in this Quarterly Report on Form 10-Q and those in our Annual Report on Form 10-K, in each case under the caption “Risk Factors,” and in our other filings with the Securities and Exchange Commission, or SEC. Statements made herein are as of the date of the filing of this Form 10-Q with the SEC and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim, any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes that appear in Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and related notes for the year ended December 31, 2019, which are included in our Annual Report on Form 10-K filed with the SEC on February 25, 2020.

Overview

We are a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases.  We currently have a pipeline of drug candidates focused on immuno-inflammatory diseases, as well as one product approved by the U.S. Food and Drug Administration, or FDA, that we are not currently distributing, marketing or selling, and other investigational drug candidates. In September 2019, we announced the completion of a strategic review of our business, as a result of which we refocused our resources on our immuno-inflammatory development programs. We are pursuing strategic alternatives, including identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize our drug candidates and ESKATA (hydrogen peroxide) topical solution, 40% (w/w), or ESKATA, our non-marketed FDA-approved product.

We submitted an Investigational New Drug Application, or IND, in April 2019 for ATI-450, an investigational oral, novel, small molecule selective mitogen-activated protein kinase-activated protein kinase 2, or MK2, inhibitor compound, for the treatment of rheumatoid arthritis, which was allowed by the FDA in May 2019.  MK2 is a key regulator of pro-inflammatory mediators including TNFα, IL1β, IL6, IL8 and other essential pathogenic signals in chronic immuno-inflammatory diseases, as well as in cancer.  As an oral drug candidate, we are developing ATI-450 as a potential alternative to injectable anti-TNF/IL1/IL6 biologics for treating certain immuno-inflammatory diseases.

We initiated a Phase 1 single and multiple ascending dose clinical trial in 77 healthy subjects in August 2019. Final data from this trial demonstrated that ATI-450 resulted in marked inhibition of TNFα, IL1β, IL8 and IL6. We also observed that ATI-450 had dose-proportional pharmacokinetics with a terminal half-life of 9-12 hours in the multiple ascending dose cohort, and had no meaningful food effect or drug-drug interaction with methotrexate.  ATI-450 was generally well-tolerated at all doses tested in the trial.  The most common adverse events (reported by 2 or more subjects who received ATI-450) observed during the trial were dizziness, headache, upper respiratory tract infection, constipation, abdominal pain, and nausea. 

Following the completion of the Phase 1 clinical trial, in March 2020 we initiated a Phase 2a clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450 in subjects with moderate to severe rheumatoid arthritis. Due to the COVID-19 pandemic, we temporarily paused enrollment. We resumed enrolling subjects, and the first subject was dosed, in May 2020. At this time, we are actively recruiting for this trial. Given the continuing evolution of the COVID-19 pandemic, we now anticipate reporting data from this trial in the first half of 2021.

24

We are also planning to initiate a Phase 2a clinical trial of ATI-450 in cryopyrin-associated periodic syndrome (CAPS), an Ilβ-driven disease, in the second half of 2020.

We are also supporting an investigator-initiated Phase 2a, randomized, double-blind, placebo-controlled clinical trial to investigate the safety and efficacy of ATI-450, when used in addition to standard of care therapy, as a potential treatment for cytokine release syndrome in 36 hospitalized patients with COVID-19. The primary endpoint in this trial is the proportion of subjects who are free from respiratory failure by day 14. We are providing funding and clinical drug supply to the University of Kansas Medical Center, the sponsor of the trial. The first subject was dosed in August 2020.

We submitted an IND in June 2020 for ATI-1777, an investigational topical “soft” Janus kinase, or JAK, 1/3 inhibitor compound, for the treatment of moderate to severe atopic dermatitis, and now plan to progress to the first-in-human trial of ATI-1777 in subjects with moderate to severe atopic dermatitis. “Soft” JAK inhibitors are designed to be topically applied and active in the skin, but rapidly metabolized and inactivated when they enter the bloodstream, which may result in low systemic exposure.  We expect to initiate a Phase 1/2a multicenter, randomized, double-blind, vehicle-controlled trial to investigate the safety, tolerability, pharmacokinetics and efficacy of topically applied ATI-1777 in subjects with moderate to severe atopic dermatitis in the second half of 2020. The primary endpoint will assess efficacy at four weeks.

We are developing ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, as a potential treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases.  The ITJ compound interrupts T cell signaling through the combined inhibition of ITK/TXK/JAK3 pathways in lymphocytes. We expect to file an IND for ATI-2138 in 2021.

We are pursuing strategic alternatives, including seeking a partner, to further develop, obtain regulatory approval and/or commercialize, as applicable, our drug candidate A-101 45% Topical Solution as a potential treatment for common warts, as well as ATI-501 and ATI-502, our other JAK inhibitor candidates, as potential treatments for alopecia, and ESKATA, our non-marketed FDA-approved product.

Since our inception, we have incurred significant operating losses.  Our net loss was $27.2 million for the six months ended June 30, 2020 and $161.4 million for the year ended December 31, 2019.  As of June 30, 2020, we had an accumulated deficit of $480.7 million.  We expect to incur significant expenses and operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical and clinical development.  In addition, our drug candidates, even if they are approved by regulatory agencies for marketing, may not achieve commercial success.  We may also not be successful in pursuing strategic alternatives, including identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize our drug candidates or ESKATA.  Furthermore, we have incurred and expect to continue to incur significant costs associated with operating as a public company, including legal, accounting, investor relations and other expenses.  As a result, we will need substantial additional funding to support our continuing operations.  

We have historically financed our operations primarily with sales of equity securities and incurring indebtedness in the form of loans from commercial lenders.  In the near term, we expect to finance our operations through these and  other capital sources, including potential partnerships with other companies or other strategic transactions.  We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on commercially acceptable terms, or at all.  If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development of one or more of our drug candidates.  

Impact of COVID-19 on Our Business

The global outbreak of COVID-19 continues to rapidly evolve. We have implemented a virtual operations strategy, including telecommuting and other alternative work arrangements for our employees, intended to protect the health and safety of our employees while enabling us to continue to develop our pipeline of drug candidates and provide contract research services to our clients. We are focused on ensuring the continuity of our operations. In March 2020, we

25

initiated a Phase 2a clinical trial of ATI-450 as a potential treatment for moderate to severe rheumatoid arthritis. Due to the COVID-19 pandemic, we temporarily paused enrollment. We resumed enrolling subjects, and the first subject was dosed, in May 2020. At this time, we are actively recruiting for this trial. Given the continuing evolution of the COVID-19 pandemic, we now anticipate reporting data from this trial in the first half of 2021.

If COVID-19 continues to spread, we may experience additional disruptions that could severely impact our business, results of operations and prospects, including the timing of our clinical trials and development programs. The extent to which the COVID-19 pandemic impacts our business, our preclinical and clinical development and our regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted, such as the geographic spread of the disease, the duration of the outbreak, travel restrictions, quarantines, stay-at-home orders, social distancing requirements, business closures and supply chain and other disruptions in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.  Accordingly, we do not yet know the full extent of the potential impacts on our business, our preclinical and clinical development and regulatory activities.

Components of Our Results of Operations

Revenue

Contract Research

We earn revenue from the provision of laboratory services to clients through Confluence Life Sciences, Inc. (now known as Aclaris Life Sciences, Inc.), or Confluence, our wholly-owned subsidiary.  Contract research revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis and are generally billed on a monthly basis in arrears for services rendered.  

Cost of Revenue

Cost of revenue consists of the costs incurred in connection with the provision of contract research services to our clients through Confluence.  Cost of revenue primarily includes:

employee-related expenses, which include salaries, benefits and stock-based compensation;
outsourced professional scientific services;
depreciation of laboratory equipment;
facility-related costs; and
laboratory materials and supplies used to support the services provided.

Research and Development Expenses

Research and development expenses consist of expenses incurred in connection with the discovery and development of our drug candidates.  These expenses primarily include:

expenses incurred under agreements with contract research organizations, or CROs, as well as investigative sites and consultants that conduct our clinical trials and preclinical studies;
manufacturing scale-up expenses and the cost of acquiring and manufacturing active pharmaceutical ingredients and preclinical and clinical trial materials;
outsourced professional scientific development services;
medical affairs expenses related to our drug candidates, including investigator-initiated studies;
employee-related expenses, which include salaries, benefits and stock-based compensation;
depreciation of manufacturing equipment;
payments made under agreements with third parties under which we have acquired or licensed intellectual property;
expenses relating to regulatory activities, including filing fees paid to regulatory agencies;

26

laboratory materials and supplies used to support our research activities; and
non-cash charges related to the revaluation of contingent consideration.

Research and development activities are central to our business model.  Drug candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect to continue to incur research and development expenses in the near term as we continue the clinical development of ATI-450 as a potential treatment for rheumatoid arthritis and other immuno-inflammatory diseases and ATI-1777 as a potential treatment for moderate to severe atopic dermatitis, continue the development of our preclinical compounds, and continue to identify, research and develop additional drug candidates.  We expense research and development costs as incurred.  Our direct research and development expenses primarily consist of external costs including fees paid to CROs, consultants, investigator sites, regulatory agencies and third parties that manufacture our preclinical and clinical trial materials, and are tracked on a program-by-program basis.  We do not allocate personnel costs, facilities or other indirect expenses, to specific research and development programs.  

The successful development of our drug candidates is highly uncertain. We cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when, if ever, material net cash inflows may commence from any of our drug candidates. This uncertainty is due to the numerous risks and uncertainties associated with the duration and cost of clinical trials, which vary significantly over the life of a project as a result of many factors, including:

the number of clinical sites included in the trials;
the length of time required to enroll suitable subjects;
the number of subjects that ultimately participate in the trials;
the number of doses subjects receive;
the impact on the timing of our clinical trials due to the COVID-19 pandemic;
the duration of subject follow-up; and
the results of our clinical trials.

Our expenditures are subject to additional uncertainties, including the preparation of regulatory filings for our drug candidates, and the expense of filing, prosecuting, defending and enforcing any patent claims or other intellectual property rights.  We may obtain unexpected results from our clinical trials or other development activities.  We may elect to discontinue, delay or modify the development, including clinical trials, of some drug candidates or focus on others.  A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate.  For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.

General and Administrative Expenses

General and administrative expenses consist principally of salaries and related costs for personnel in executive, administrative, finance, investor relations and legal functions, including stock-based compensation and travel expenses.  General and administrative expenses also include facility-related costs, patent filing and prosecution costs, professional fees for legal, auditing and tax services, and insurance costs.  We anticipate that we will incur increased director and officer insurance premiums and legal expenses associated with defending the current lawsuits described in this report.

Other Income (Expense), Net

Other income (expense), net primarily consists of interest earned on our cash, cash equivalents and marketable securities, interest expense related to our debt obligations and finance leases, and gains and losses on transactions denominated in foreign currencies.

27

Critical Accounting Policies and Significant Judgments and Estimates

This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  We evaluate our estimates and judgments on an ongoing basis.  Our actual results may differ from these estimates under different assumptions or conditions.  Except as described below, we believe there have been no material changes to our significant accounting policies and use of estimates as disclosed in the footnotes to our audited consolidated financial statements for the year ended December 31, 2019 included in our Annual Report on Form 10-K filed with the SEC on February 25, 2020.  

Revenue Recognition

We account for revenue in accordance with Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers.  Under ASC Topic 606, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services.  

To determine revenue recognition in accordance with ASC Topic 606, we perform the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) performance obligations are satisfied.  We recognize revenue when collection of the consideration we are entitled to under a contract with a customer is probable.  At contract inception, we assess the goods or services promised within a contract with a customer to identify the performance obligations, and to determine if they are distinct.  We recognize revenue that is allocated to each distinct performance obligation when (or as) that performance obligation is satisfied.  

Contract Research

Revenue related to laboratory services is generally recognized as the laboratory services are performed, based upon the rates specified in the contracts.  Under ASC Topic 606, we elected to apply the “right to invoice” practical expedient when recognizing contract research revenue.  We recognize contract research revenue in the amount to which we have the right to invoice.  

Intangible Assets

Our intangible assets include both definite-lived and indefinite-lived assets.  Definite-lived intangible assets are amortized over their estimated useful life based on the pattern over which the intangible assets are consumed or otherwise used up. If that pattern cannot be reliably determined, the straight-line method of amortization is used.  Our definite-lived intangible assets consist of a research technology platform acquired through the acquisition of Confluence.  Our indefinite-lived intangible assets consist of an in-process research and development, or IPR&D, drug candidate also acquired through the acquisition of Confluence.  IPR&D assets are considered indefinite-lived until the completion or abandonment of the associated research and development efforts.  The cost of IPR&D assets is either amortized over their estimated useful life beginning when the underlying drug candidate is approved and launched commercially, or expensed immediately if development of the drug candidate is abandoned.  

Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable.  Indefinite-lived intangible assets are tested for impairment at least

28

annually, which we perform during the fourth quarter, or when indicators of an impairment are present.  We recognize impairment losses when and to the extent that the estimated fair value of an intangible asset is less than its carrying value.  

Leases

Leases represent a company’s right to use an underlying asset and a corresponding obligation to make payments to a lessor for the right to use those assets.  We evaluate leases at their inception to determine if they are an operating lease or a finance lease.  A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows are substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term.  Leases that do not meet the finance lease criteria are accounted for as an operating lease.  

We recognize assets and liabilities for leases at their inception based upon the present value of all payments due under the lease.  We use an implicit interest rate to determine the present value of finance leases, and our incremental borrowing rate to determine the present value of operating leases.  We determine incremental borrowing rates by referencing collateralized borrowing rates for debt instruments with terms similar to the respective lease.  We recognize expense for operating and finance leases on a straight-line basis over the term of each lease, and interest expense related to finance leases is recognized over the lease term based on the effective interest method.  We include estimates for any residual value guarantee obligations under our leases in lease liabilities recorded on our condensed consolidated balance sheet.  

Right-of-use assets are included in other assets and property and equipment, net on our condensed consolidated balance sheet for operating and finance leases, respectively.  Obligations for lease payments are included in current portion of lease liabilities and other liabilities on our condensed consolidated balance sheet for both operating and finance leases.  

Contingent Consideration

We initially recorded a contingent consideration liability related to future potential payments based upon the achievement of certain development, regulatory and commercial milestones, as well as future projected sales performance, resulting from the acquisition of Confluence, at its estimated fair value on the date of acquisition.  The ultimate amount of future payments, if any, is based on criteria such as sales performance and the achievement of certain regulatory and sales milestones.  We estimate the fair value of the contingent consideration liability related to the achievement of regulatory milestones by assigning an achievement probability to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return.  We estimate the fair value of the contingent consideration liability associated with sales milestones and royalties by estimating future sales levels, assigning an achievement probability and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.  Significant assumptions used in our estimates include the probability of success of achieving regulatory and sales milestones, which are based upon an asset’s current stage of development and ranged between 4% and 15%.  We evaluate fair value estimates of contingent consideration liabilities on a periodic basis.  Any change in fair value reflects new information about the likelihood of the payment of the contingent consideration and the passage of time. For example, if the timing of the development of an acquired drug candidate, or the size of potential commercial opportunities related to an acquired drug, differ from our assumptions, then the fair value of contingent consideration would be adjusted accordingly. Future changes in the fair value of the contingent consideration, if any, will be recorded as income or expense in our condensed consolidated statement of operations.  

Recently Issued Accounting Pronouncements

In November 2018, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606,

29

which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606.  The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  We adopted this standard as of January 1, 2020, the impact of which on our consolidated financial statements was not significant.  

In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40).  ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in Accounting Standards Codification, or ASC, 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.  The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within such fiscal years.  We adopted this standard as of January 1, 2020, the impact of which on our consolidated financial statements was not significant.  

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).  The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements.  This update eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some of the existing disclosure requirements.  The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within such fiscal years.  We adopted this standard as of January 1, 2020, the impact of which on our consolidated financial statements was not significant.  

30

Results of Operations

Comparison of Three Months Ended June 30, 2020 and 2019

Three Months Ended June 30, 

 

    

2020

    

2019

    

Change

 

(In thousands)

 

Revenues:

Contract research

$

1,853

$

886

$

967

Other revenue

193

193

Total revenue

2,046

886

1,160

Costs and expenses:

Cost of revenue

1,389

994

395

Research and development

 

6,466

 

17,519

 

(11,053)

General and administrative

 

5,572

 

7,469

 

(1,897)

Goodwill impairment

18,504

(18,504)

Total costs and expenses

 

13,427

 

44,486

 

(31,059)

Loss from operations

 

(11,381)

 

(43,600)

 

32,219

Other income (expense), net

 

(189)

 

(85)

 

(104)

Loss from continuing operations

(11,570)

(43,685)

32,115

Loss from discontinued operations

(27)

(6,191)

6,164

Net loss

$

(11,597)

$

(49,876)

$

38,279

Revenue

Contract research revenue was $1.9 million and $0.9 million for the three months ended June 30, 2020 and 2019, respectively, and was comprised primarily of fees earned from the provision of laboratory services to clients through Confluence.  Other revenue consisted of $0.2 million of royalties earned on net sales of RHOFADE (oxymetazoline hydrochloride) cream, 1%, or RHOFADE, pursuant to the asset purchase agreement with EPI Health, LLC, or EPI Health.  

Cost of Revenue

Cost of revenue was $1.4 million and $1.0 million for the three months ended June 30, 2020 and 2019, respectively, and related to providing laboratory services to our clients through Confluence.

31

Research and Development Expenses

The following table summarizes our research and development expenses:

Three Months Ended

June 30, 

2020

    

2019

Change

(In thousands)

ATI-450

    

$

740

    

$

1,184

  

$

(444)

ATI-1777

1,102

653

449

ATI-2138

1,102

781

321

Other JAK inhibitors

186

4,765

(4,579)

A-101 45% Topical Solution

52

4,403

(4,351)

Other research and development expenses

601

686

(85)

Personnel expenses

1,744

2,592

(848)

Stock-based compensation

939

1,721

(782)

Change in contingent consideration

734

(734)

Total research and development expenses

$

6,466

$

17,519

$

(11,053)

Research and development expenses for ATI-450 primarily consisted of preclinical development activities during the three months ended June 30, 2019 and initial activities for a Phase 2a clinical trial during the three months ended June 30, 2020.  Expenses for ATI-1777 were higher during the three months ended June 30, 2020 primarily due to initial activities related to a Phase 1/2a clinical trial which we expect to initiate in the second half of 2020.  Expenses for ATI-2138 were higher primarily due to preclinical development activities during the three months ended June 30, 2020.  Expenses related to our other JAK inhibitors decreased primarily as a result of the completion of several Phase 2 clinical trials of ATI-501 and ATI-502 during 2019.  Expenses related to A-101 45% Topical Solution decreased primarily due to the completion of our Phase 3 clinical trials during 2019.  Other research and development expenses, which primarily included expenses for medical affairs activities as well as drug discovery, were lower primarily as a result of lower medical affairs related activities during the three months ended June 30, 2020 primarily resulting from our clinical trials that were completed during 2019 for A-101 45% Topical Solution, ATI-501 and ATI-502.  Personnel expenses and stock-based compensation decreased due to lower headcount primarily as a result of the restructuring we announced in September 2019.  The change in contingent consideration during the three months ended June 30, 2019 was the result of updates to our assumptions as a result of the filing of an IND for ATI-450.  

General and Administrative Expenses

The following table summarizes our general and administrative expenses:

Three Months Ended

June 30, 

2020

    

2019

Change

(In thousands)

Personnel expenses

    

$

1,671

    

$

2,136

  

$

(465)

Professional and legal fees

831

1,184

(353)

Facility and support services

 

422

 

652

 

(230)

Other general and administrative expenses

530

843

(313)

Stock-based compensation

2,118

2,654

(536)

Total general and administrative expenses

$

5,572

$

7,469

$

(1,897)

Personnel and stock-based compensation expenses decreased primarily due to lower headcount.  Professional and legal fees included accounting, legal, investor relations and corporate communication costs, as well as legal fees related to patents and current lawsuits described in this report, and were lower year-over-year primarily as a result of lower legal fees.  Facility and support services included general office expenses, information technology costs and other expenses, and have decreased primarily due to lower information technology costs resulting from lower headcount.  Other general and

32

administrative expenses included travel, insurance and marketing costs, and were lower primarily due to reduced travel-related activities in light of the COVID-19 pandemic.  

Goodwill Impairment

During the three months ended June 30, 2019, we performed an interim impairment analysis due to a decline in our stock price.  Our impairment analysis noted that our stock price, including a reasonable control premium, resulted in a fair value for the therapeutics reporting unit which was less than its carrying value.  As a result, we recorded a goodwill impairment charge of $18.5 million writing off the full balance of goodwill.  

Other Income (Expense), net

Other expense, net for the three months ended June 30, 2020 was $0.2 million and primarily included interest expense related to our term loan facility with Silicon Valley Bank, or SVB, which we borrowed in March 2020, as well as interest on our finance leases, partially offset by interest income earned on our cash and investments.  Other expense, net for the three months ended June 30, 2019 was $0.1 million and primarily included interest expense incurred on our debt with Oxford Finance LLC, which we borrowed in October 2018 and repaid in full in October 2019, partially offset by interest income earned on our cash and investments.  

Loss from Discontinued Operations

In September 2019, we announced the completion of a strategic review and our decision to refocus on our immuno-inflammatory development programs and to actively seek partners for our commercial products.  The condensed consolidated financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to our commercial products as discontinued operations (see Note 15 to the condensed consolidated financial statements included in this report for additional information).  

33

Comparison of Six Months Ended June 30, 2020 and 2019

Six Months Ended June 30, 

 

    

2020

    

2019

    

Change

 

(In thousands)

 

Revenues:

Contract research

$

3,042

$

2,149

$

893

Other revenue

411

411

Total revenue

3,453

2,149

1,304

Costs and expenses:

Cost of revenue

2,658

2,201

457

Research and development

 

15,909

 

37,161

 

(21,252)

General and administrative

 

11,773

 

14,926

 

(3,153)

Goodwill impairment

18,504

(18,504)

Total costs and expenses

 

30,340

 

72,792

 

(42,452)

Loss from operations

 

(26,887)

 

(70,643)

 

43,756

Other income (expense), net

 

(11)

 

(315)

 

304

Loss from continuing operations

(26,898)

(70,958)

44,060

Loss from discontinued operations

(285)

(16,483)

16,198

Net loss

$

(27,183)

$

(87,441)

$

60,258

Revenue

Contract research revenue was $3.0 million and $2.1 million for the six months ended June 30, 2020 and 2019, respectively, and was comprised primarily of fees earned from the provision of laboratory services to clients through Confluence.  Other revenue consisted of $0.4 million of royalties earned on net sales of RHOFADE pursuant to the asset purchase agreement with EPI Health.  

Cost of Revenue

Cost of revenue was $2.7 million and $2.2 million for the six months ended June 30, 2020 and 2019, respectively, and related to providing laboratory services to our clients through Confluence.

Research and Development Expenses

The following table summarizes our research and development expenses:

Six Months Ended

June 30, 

2020

    

2019

Change

(In thousands)

ATI-450

    

$

2,734

    

$

3,419

  

$

(685)

ATI-1777

1,859

2,372

(513)

ATI-2138

1,603

1,683

(80)

Other JAK inhibitors

635

8,691

(8,056)

A-101 45% Topical Solution

532

9,863

(9,331)

Other research and development expenses

1,356

1,826

(470)

Personnel expenses

3,668

5,258

(1,590)

Stock-based compensation

1,755

3,315

(1,560)

Change in contingent consideration

1,767

734

1,033

Total research and development expenses

$

15,909

$

37,161

$

(21,252)

34

Research and development expenses for ATI-450 during the six months ended June 30, 2019 primarily consisted of preclinical development activities and activities related to a Phase 1 clinical trial that was completed in January 2020. Research and development expenses for ATI-450 during the six months ended June 30, 2020 primarily consisted of initial activities for a Phase 2a clinical trial.  Expenses for ATI-1777 were lower primarily due to the completion of preclinical development activities.  Expenses for ATI-2138 were comparable period over period as we completed early stage development work on candidate selection in 2019 and began preclinical development activities during the six months ended June 30, 2020.  Expenses related to our other JAK inhibitors decreased primarily as a result of the completion of several Phase 2 clinical trials of ATI-501 and ATI-502 during 2019.  Expenses related to A-101 45% Topical Solution decreased primarily due to the completion of our Phase 3 clinical trials during 2019.  Other research and development expenses, which primarily included expenses for medical affairs activities as well as drug discovery, were lower primarily as a result of lower medical affairs related activities during the six months ended June 30, 2020 primarily resulting from our clinical trials that were completed during 2019 for A-101 45% Topical Solution, ATI-501 and ATI-502.  Personnel expenses and stock-based compensation decreased due to lower headcount primarily as a result of the restructuring we announced in September 2019.  The change in contingent consideration during the six months ended June 30, 2020 was the result of updates to our assumptions as a result of the completion of a successful Phase 1 clinical trial for ATI-450, while the change in contingent consideration during the six months ended June 30, 2019 was the result of updates to our assumptions as a result of the filing of an IND for ATI-450.  

General and Administrative Expenses

The following table summarizes our general and administrative expenses:

Six Months Ended

June 30, 

2020

    

2019

Change

(In thousands)

Personnel expenses

    

$

3,268

    

$

4,590

  

$

(1,322)

Professional and legal fees

1,949

2,417

(468)

Facility and support services

 

933

 

1,356

 

(423)

Other general and administrative expenses

1,128

1,437

(309)

Stock-based compensation

4,495

5,126

(631)

Total general and administrative expenses

$

11,773

$

14,926

$

(3,153)

Personnel and stock-based compensation expenses decreased primarily due to lower headcount.  Professional and legal fees included accounting, legal, investor relations and corporate communication costs, as well as legal fees related to patents and current lawsuits described in this report, and were lower year-over-year primarily as a result of lower legal fees.  Facility and support services included general office expenses, information technology costs and other expenses, and have decreased primarily due to lower information technology costs resulting from lower headcount.  Other general and administrative expenses included travel, insurance and marketing costs, and were lower primarily due to reduced travel-related activities in light of the COVID-19 pandemic.  

Goodwill Impairment

During the six months ended June 30, 2019, we performed an interim impairment analysis due to a decline in our stock price.  Our impairment analysis noted that our stock price, including a reasonable control premium, resulted in a fair value for the therapeutics reporting unit which was less than its carrying value.  As a result, we recorded a goodwill impairment charge of $18.5 million writing off the full balance of goodwill.  

Other Income (Expense), net

Other expense, net for the six months ended June 30, 2020 was $11,000 and primarily included interest expense related to our term loan facility with SVB which we borrowed in March 2020, as well as interest on our finance leases, substantially offset by interest income earned on our cash and investments.  Other expense, net for the six months ended June 30, 2019 was $0.3 million and primarily included interest expense incurred on our debt with Oxford Finance LLC,

35

which we borrowed in October 2018 and repaid in full in October 2019, partially offset by interest income earned on our cash and investments.  

Loss from Discontinued Operations

In September 2019, we announced the completion of a strategic review and our decision to refocus on our immuno-inflammatory development programs and to actively seek partners for our commercial products.  The condensed consolidated financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to our commercial products as discontinued operations (see Note 15 to the condensed consolidated financial statements included in this report for additional information).  

Liquidity and Capital Resources

Since our inception, we have incurred net losses and negative cash flows from our operations.  Prior to our acquisition of Confluence in August 2017, we did not generate any revenue.  We have financed our operations over the last several years primarily through sales of our equity securities in public offerings and a private placement transaction.  In March 2020, we entered into the Loan and Security Agreement with SVB.  

As of June 30, 2020, we had cash, cash equivalents and restricted cash and marketable securities of $68.1 million.  Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view towards liquidity and capital preservation.  

We currently have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity, other than our term loan facility, lease obligations, and contingent obligations under acquisition and intellectual property licensing agreements, which are summarized below under “Contractual Obligations and Commitments.”  

Loan and Security Agreement with Silicon Valley Bank  

In March 2020 we entered into a Loan and Security Agreement with SVB.  The Loan and Security Agreement provides for $11.0 million in term loans, of which we borrowed the entire amount on March 30, 2020.  The Loan and Security Agreement is secured by substantially all of our assets other than intellectual property.  

The term loan repayment schedule provides for interest only payments beginning April 1, 2020 and continuing through March 1, 2022, followed by 24 consecutive equal monthly installments of principal, plus monthly payments of accrued interest, starting on April 1, 2022 and continuing through the maturity date of March 1, 2024. All outstanding principal and accrued and unpaid interest will be due and payable on the maturity date.  The Loan and Security Agreement provides for an annual interest rate equal to the greater of (i) the prime rate then in effect as reported in The Wall Street Journal plus 2% and (ii) 6.75%.  

The Loan and Security Agreement includes a final payment fee equal to 5% of the original principal amount borrowed.  We have the option to prepay the outstanding balance of the term loans in full, subject to a prepayment premium of (i) 3% of the original principal amount borrowed for any prepayment on or prior to the first anniversary of March 30, 2020, (ii) 2% of the original principal amount borrowed for any prepayment after the first anniversary and on or before the second anniversary of March 30, 2020 or (iii) 1% of the original principal amount borrowed for any prepayment after the second anniversary of March 30, 2020 but before March 1, 2024.

The Loan and Security Agreement contains a customary covenant that limits our ability, subject to specified exceptions, to incur additional indebtedness without the prior consent of SVB.

36

Cash Flows

The following table summarizes our cash flows for each of the periods presented:

Six Months Ended June 30, 

    

2020

    

2019

(In thousands)

Net cash used in operating activities

$

(17,626)

$

(52,696)

Net cash provided by (used in) investing activities

 

3,455

 

27,568

Net cash provided by (used in) financing activities

 

10,821

 

(237)

Net decrease in cash and cash equivalents

$

(3,350)

$

(25,365)

Operating Activities

During the six months ended June 30, 2020, operating activities used $17.6 million of cash primarily resulting from our net loss of $27.2 million, partially offset by non-cash adjustments of $9.7 million.  Net cash used by changes in our operating assets and liabilities during the six months ended June 30, 2020 consisted of a $5.9 million net decrease in accounts payable and accrued expenses, which were partially offset by a $4.9 million decrease in accounts receivable and a $0.9 million decrease in prepaid expenses and other assets.  The decrease in accounts receivable was primarily the result of cash received from Allergan Sales, LLC, or Allergan, related to sales of RHOFADE made during the year ended December 31, 2019.  The decrease in prepaid expenses and other assets was primarily due to amortization of the premiums for our corporate insurance policies, which we expense equally over the policy term.  The net decrease in accounts payable and accrued expenses was primarily driven by expenses incurred, but not yet paid, as of December 31, 2019, which were partially offset by cash received from Allergan which related to sales of RHOFADE that occurred after the date we sold RHOFADE to EPI Health.  Accordingly, we had $4.9 million payable to EPI Health as of June 30, 2020, which is included in accrued expenses on our condensed consolidated balance sheet.  Expenses incurred, as of December 31, 2019, and paid during the six months ended June 30, 2020, primarily included employee annual merit bonuses, as well as expenses related to preclinical development and Phase 1 clinical trial activities for ATI-450, and preclinical development activities for ATI-1777 and ATI-2138.  Non-cash expenses of $9.7 million were composed of stock-based compensation expense of $6.8 million, a charge of $1.7 million related to the change in contingent consideration and depreciation and amortization expense of $1.2 million.  

During the six months ended June 30, 2019, operating activities used $52.7 million of cash primarily resulting from our net loss of $87.4 million, partially offset by non-cash adjustments of $33.4 million.  Net cash provided by changes in our operating assets and liabilities during the six months ended June 30, 2019 consisted of a $13.3 million increase in accounts payable and accrued expenses and a $2.9 million decrease in prepaid expenses and other assets, which were partially offset by a $14.5 million increase in accounts receivable.  The increase in accounts payable and accrued expenses was primarily driven by expenses incurred, but not yet paid, as of June 30, 2019, as well as the timing of vendor invoicing and payments.  Expenses incurred, but not yet paid, as of June 30, 2019 primarily included sales discounts and allowances related to sales of RHOFADE, as well as expenses related to our Phase 3 clinical trials for A-101 45% Topical Solution, our Phase 2 clinical trials for ATI-501 and ATI-502 and preclinical development activities for ATI-450.  The decrease in prepaid expenses and other assets was due to research and development activities primarily related to preclinical development activities for ATI-450 and ATI-502 which concluded during the six months ended June 30, 2019 and sales and marketing expenses related to our national sales meeting which was held during the six months ended June 30, 2019.  The increase in accounts receivable was primarily the result of sales of RHOFADE.  Non-cash expenses of $33.4 million were composed of a goodwill impairment charge of $18.5 million, stock-based compensation expense of $9.7 million, a charge of $0.7 million related to the change in contingent consideration and depreciation and amortization expense of $4.5 million.  

Investing Activities

During the six months ended June 30, 2020, investing activities provided $3.5 million of cash, consisting of proceeds from sales and maturities of marketable securities of $30.7 million, partially offset by purchases of marketable securities of $27.1 million, and purchases of equipment of $0.1 million.

37

During the six months ended June 30, 2019, investing activities provided $27.6 million of cash, consisting of proceeds from sales and maturities of marketable securities of $117.5 million, partially offset by purchases of marketable securities of $89.4 million, and purchases of equipment of $0.5 million.

Financing Activities

During the six months ended June 30, 2020, financing activities provided $10.8 million of cash and consisted of $10.9 million of net borrowings pursuant to the Loan and Security Agreement with SVB offset by $0.1 million of finance lease payments.  

During the six months ended June 30, 2019, financing activities used $0.2 million of cash primarily related to finance lease payments.  

Funding Requirements

We anticipate we will incur net losses in the near term as we continue the clinical development of ATI-450 as a potential treatment for rheumatoid arthritis, other immuno-inflammatory diseases and COVID-19 and ATI-1777 as a potential treatment for moderate to severe atopic dermatitis, continue the development of our preclinical compounds, and continue to identify, research and develop additional drug candidates.  We may not be able to generate revenue from these programs if, among other things, our clinical trials are not successful, the FDA does not approve our drug candidates currently in clinical trials when we expect, or at all, or we are not able to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our drug candidates.  

Our primary uses of capital are, and we expect will continue in the near term to be, compensation and related expenses, clinical costs, external research and development services, laboratory and related supplies, legal and other regulatory expenses, and administrative and overhead costs.  Our future funding requirements will be heavily determined by the resources needed to support the development of our drug candidates.  

As a publicly traded company, we incur and will continue to incur significant legal, accounting and other expenses.  In addition, the Sarbanes-Oxley Act of 2002, as well as rules adopted by the SEC and the Nasdaq Stock Market LLC, requires public companies to implement specified corporate governance practices.  

We believe our existing cash, cash equivalents and marketable securities are sufficient to fund our operating and capital expenditure requirements for a period greater than 12 months from the date of issuance of our condensed consolidated financial statements that appear in Item 1 of this Quarterly Report on Form 10-Q based on our current operating assumptions.  We will require additional capital to complete the clinical development of ATI-450 and ATI-1777, to develop our preclinical compounds, and to support our discovery efforts.  Additional funds may not be available on a timely basis, on commercially acceptable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. If we are unable to raise sufficient additional capital or generate revenue from transactions with third-party partners for the development and/or commercialization of our drug candidates, we may need to substantially curtail our planned operations.  

We may raise additional capital through the sale of equity or debt securities. In such an event, our stockholders’ ownership will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of a holder of our common stock.

38

Because of the numerous risks and uncertainties associated with research and development of pharmaceutical drugs, we are unable to estimate the exact amount of our working capital requirements. Our funding requirements in the near term will depend on many factors, including:

the number and development requirements of the drug candidates that we may pursue;
the scope, progress, results and costs of preclinical development, laboratory testing and conducting preclinical and clinical trials for our drug candidates;
the costs, timing and outcome of regulatory review of our drug candidates;
the extent to which we in-license or acquire additional drug candidates and technologies;
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;
the impact on the timing of our preclinical studies and clinical trials and our business due to the COVID-19 pandemic;
our ability to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our drug candidates, and earn revenue from such arrangements; and
the revenue earned from our commercial products as a result of licenses to, or partnerships with, third parties.

Contractual Obligations and Commitments

We occupy space for our headquarters in Wayne, Pennsylvania under a sublease agreement which has a term through October 2023.  We occupy office and laboratory space in St. Louis, Missouri under a sublease agreement which has a term through June 2029.  

We lease laboratory equipment used in our laboratory space in St. Louis, Missouri under two capital lease financing arrangements which have terms through October 2020 and December 2020.  

In March 2020, we borrowed $11.0 million under the Loan and Security Agreement with SVB.  Amounts borrowed under the Loan and Security Agreement are subject to interest only through March 2022, after which we will be required to make principal and interest payments through the maturity date of March 2024. 

Under the assignment agreement with the Estate of Mickey Miller pursuant to which we acquired intellectual property, we have agreed to pay royalties on sales of ESKATA and related products at rates ranging in low single-digit percentages of net sales, as defined in the agreement.  Under the related finder’s services agreement with KPT Consulting, LLC, we have agreed to make a remaining payment of $3.0 million upon the achievement of a specified commercial milestone.  In addition, we have agreed to pay royalties on sales of ESKATA and related products at a low single-digit percentage of net sales, as defined in the agreement.  In August 2019, we voluntarily discontinued the commercialization of ESKATA in the United States and withdrew the marketing authorizations we had previously received for the product in all countries outside of the United States.

Under a license agreement with Rigel Pharmaceuticals, Inc., or Rigel, we have agreed to make remaining aggregate payments of up to $76.0 million upon the achievement of specified development milestones, such as clinical trials and regulatory approvals. Further, we have agreed to pay up to an additional $10.5 million to Rigel upon the achievement of a second set of development milestones. In addition, in connection with the amendment of the agreement in October 2019, we paid Rigel an amendment fee of $1.5 million in three installments of $500,000 in each of January 2020, April 2020 and July 2020. With respect to any products we commercialize under the agreement, we will pay Rigel quarterly tiered royalties on our annual net sales of each product developed using the licensed JAK inhibitors at a high single digit percentage of annual net sales, subject to specified reductions.  

Under a stock purchase agreement with the selling stockholders of one of our former subsidiaries, we are obligated to make aggregate payments of up to $18.0 million upon the achievement of specified pre-commercialization milestones for three products covered by the acquired patent rights in the United States, the European Union and Japan, and aggregate payments of up to $22.5 million upon the achievement of specified commercial milestones for products covered by the acquired patent rights.  We are also obligated to make an annual payment of $0.1 million through March 2022, which

39

amounts are creditable against any specified future payments that may be paid under the agreement.  With respect to any covered products that we commercialize under the agreement, we are obligated to pay a low single-digit percentage of annual net sales, subject to specified reductions, limitations and other adjustments, until the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis or, in specified circumstances, ten years from the first commercial sale of such product.  If we sublicense any of the patent rights and know-how acquired pursuant to the agreement, we will be obligated to pay a portion of any consideration we receive from such sublicenses in specified circumstances.

Under a license agreement with The Trustees of Columbia University in the City of New York, or Columbia, we are obligated to pay an annual license fee of $10,000, subject to specified adjustments for patent expenses incurred by Columbia and creditable against any royalties that may be paid under the license agreement.  We are also obligated to pay up to an aggregate of $11.6 million upon the achievement of specified commercial milestones, including specified levels of net sales of products covered by Columbia patent rights and/or know-how, and royalties at a sub-single-digit percentage of annual net sales of products covered by Columbia patent rights and/or know-how, subject to specified adjustments.  If we sublicense any of Columbia’s patent rights and know-how acquired pursuant to the agreement, we will be obligated to pay Columbia a portion of any consideration we receive from such sublicense in specified circumstances.

Under a merger agreement with Confluence, we are obligated to make remaining aggregate payments of up to $75.0 million upon the achievement of specified regulatory and commercialization milestones.  With respect to any covered products we commercialize, we are obligated to pay a low single-digit percentage of annual net sales, subject to specified reductions, limitations and other adjustments, until the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis or, in specified circumstances, ten years from the first commercial sale of such product.  If we sell, license or transfer any of the intellectual property acquired pursuant to the agreement, we will be obligated to pay a portion of any consideration we receive from such sale, license or transfer in specified circumstances.

We enter into contracts in the normal course of business with CROs for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice, and therefore we believe that our non-cancelable obligations under these agreements are not material.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.  

Emerging Growth Company Status

The JOBS Act permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to “opt out” of this provision and, as a result, we will comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies. We will cease to be an emerging growth company as of December 31, 2020.

40

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our cash equivalents and marketable securities consist of money market funds, asset-backed securities, commercial paper, corporate debt securities and government agency debt. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates.  Our marketable securities are subject to interest rate risk and will fall in value if market interest rates increase.  However, due to the short-term nature and low-risk profile of our investment portfolio, we do not expect that an immediate 10% change in market interest rates would have a material effect on the fair market value of our investment portfolio.  We have the ability to hold our marketable securities until maturity, and therefore we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investments.

The Loan and Security Agreement with SVB provides for an annual interest rate equal to the greater of (i) the prime rate then in effect as reported in The Wall Street Journal plus 2% and (ii) 6.75%.  To the extent that any present or future credit facilities that we enter into are based on a floating interest rate, we will be subject to risks relating to changes in market interest rates.  In periods of rising interest rates when we have such debt outstanding, our interest expense would increase.  Based upon our debt outstanding of $11.0 million as of June 30, 2020, a 100 basis-point increase in the interest rate on our loan with SVB would result in approximately $0.1 million of additional interest expense on an annualized basis.

The uncertainty that exists with respect to the economic impact of the global COVID-19 pandemic has introduced significant volatility in the financial markets during and subsequent to our quarter ended June 30, 2020.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.  

In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.  

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2020, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon such evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of such date at the reasonable assurance level.  

41

(b) Changes in Internal Control Over Financial Reporting

There have not been any changes in our internal control over financial reporting during our fiscal quarter ended June 30, 2020 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.  

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Securities Class Action

On July 30, 2019, plaintiff Linda Rosi, or Rosi, filed a putative class action complaint captioned Rosi v. Aclaris Therapeutics, Inc., et al. in the U.S. District Court for the Southern District of New York against us and certain of our executive officers.  The complaint alleges that the defendants violated federal securities laws by, among other things, failing to disclose an alleged likelihood that regulators would scrutinize advertising materials related to ESKATA and find that the materials minimized the risks or overstated the efficacy of the product.  The complaint seeks unspecified compensatory damages on behalf of Rosi and all other persons and entities that purchased or otherwise acquired our securities between May 8, 2018 and June 20, 2019. 

On September 5, 2019, an additional plaintiff, Robert Fulcher, or Fulcher, filed a substantially identical putative class action complaint captioned Fulcher v. Aclaris Therapeutics, Inc., et al. in the same court against the same defendants.

On November 6, 2019, the court consolidated the Rosi and Fulcher actions, or together, the Consolidated Securities Action, and appointed Fulcher “lead plaintiff” for the putative class. 

On January 24, 2020, Fulcher filed a consolidated amended complaint in the Consolidated Securities Action, naming two additional executive officers as defendants, extending the putative class period to August 12, 2019, and adding allegations concerning, among other things, alleged statements and omissions throughout the putative class period concerning ESKATA’s risks, tolerability and effectiveness. The defendants filed a motion to dismiss the consolidated amended complaint on April 17, 2020. Fulcher filed an opposition to the defendants’ motion on June 15, 2020, and the defendants filed a reply to such opposition on August 4, 2020. The motion remains under judicial consideration.

We and the other defendants dispute plaintiffs’ claims in the Consolidated Securities Action and intend to defend the matter vigorously.

Stockholder Derivative Action

On November 15, 2019, plaintiff Keith Allred, or Allred, filed a derivative stockholder complaint captioned Allred v. Walker et al. in the U.S. District Court for the Southern District of New York against certain of our directors and executive officers.  The complaint alleges that the defendants, among other things, breached their fiduciary duties as directors and/or officers in connection with the claims alleged in the Consolidated Securities Action.  The complaint seeks, among other things, unspecified compensatory damages on behalf of our company. 

On November 25, 2019, an additional plaintiff, Bruce Brown, or Brown, filed a substantially identical complaint captioned Brown v. Walker et al. in the same court against the same defendants.

On December 12, 2019, the court consolidated the Allred and Brown actions under the caption In re Aclaris Therapeutics, Inc. Derivative Litigation, or the Consolidated Derivative Action, and directed that future derivative cases filed in or transferred to the court arising out of substantially the same transactions or events be similarly consolidated.  Thereafter, on January 11, 2020, the court stayed – subject to certain conditions – all deadlines in the

42

Consolidated Derivative Action pending resolution of the defendants’ anticipated motion to dismiss the Consolidated Securities Action.

The defendants dispute plaintiffs’ claims in the Consolidated Derivative Action and intend to defend the matter vigorously.

In addition, from time to time, we are subject to litigation and claims arising in the ordinary course of business but, except as stated above, we are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.

Item 1A. Risk Factors

Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities.  Except as noted below, our risk factors have not changed materially from those described in “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on February 25, 2020.

Risks Related to Our Business, Our Financial Position and Capital Needs

Our business has been adversely impacted and could continue to be adversely affected by the evolving and ongoing COVID-19 global pandemic in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations. The COVID-19 pandemic could adversely affect our operations, including at our headquarters, which is currently subject to a stay-at-home order, and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.

Our business has been adversely affected by the effects of the recent and evolving COVID-19 pandemic, which was declared by the World Health Organization as a global pandemic. The COVID-19 pandemic has resulted in travel and other restrictions in order to reduce the spread of the disease, which, among other things, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, and order cessation of non-essential travel. In response to these public health directives and orders, we have implemented a virtual operations strategy, including telecommuting and other alternative work arrangements for all employees. The effects of our alternative work arrangement policies may negatively impact productivity, disrupt our business and delay our preclinical and clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.

Quarantines, executive and similar government orders, and business shutdowns, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. Some of our third-party manufacturers which we use for the supply of materials for our drug candidates or other materials necessary to manufacture drug product to conduct preclinical studies and clinical trials are located in countries affected by COVID-19, and should they experience disruptions, such as temporary closures or suspension of services, we would likely experience delays in advancing these studies and trials.

In addition, our clinical trials have been and may continue to be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some subjects may not be able to comply with clinical trial protocols if quarantines impede patient movement

43

or interrupt healthcare services. Similarly, our ability to recruit and retain subjects and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact our clinical trial operations.  For example, in March 2020, we initiated a Phase 2a clinical trial of ATI-450 as a potential treatment for moderate to severe rheumatoid arthritis. Due to the COVID-19 pandemic, we temporarily paused enrollment. We resumed enrolling subjects, and the first subject was dosed, in May 2020. At this time, we are actively recruiting for this trial. Given the continuing evolution of the COVID-19 pandemic, we now anticipate reporting data from this trial in the first half of 2021.

The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and impact our ability to make scheduled payments pursuant to our Loan and Security Agreement with SVB. In addition, a recession or market correction resulting from the further spread of COVID-19 could materially affect our business and the value of our common stock.

The global pandemic of COVID-19 continues to rapidly evolve. The extent to which the COVID-19 pandemic impacts our business, our preclinical and clinical development and our regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted, such as the geographic spread of the disease, the duration of the outbreak, travel restrictions, quarantines, stay-at-home orders, social distancing requirements and business closures and supply chain and other disruptions in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.  Accordingly, we do not yet know the full extent of the impacts on our business, our preclinical and clinical development and regulatory activities, healthcare systems or the global economy as a whole.  However, these impacts could adversely affect our business, financial condition, results of operations and growth prospects.

In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on February 25, 2020.

We may not be able to generate sufficient cash to service our indebtedness, including the Loan and Security Agreement with SVB.

In March 2020, we entered into the Loan and Security Agreement with SVB, pursuant to which we borrowed $11.0 million. Our obligations under the Loan and Security Agreement are secured by substantially all of our assets except for our intellectual property, and we may not encumber our intellectual property without SVB’s prior written consent. The Loan and Security Agreement contains customary representations, warranties and covenants by us, which covenants, among other things, limit our ability, subject to specified exceptions, to convey, sell, lease, transfer, assign or otherwise dispose of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; undergo specified change of control events; create, incur, assume or be liable for indebtedness; create, incur, allow or suffer any liens on our property; pay dividends and make other restricted payments; make investments; or enter into any material transactions with our affiliates. Our obligations under the Loan and Security Agreement are subject to acceleration upon the occurrence of specified events of default, including a material adverse change in our business, operations or financial condition. We may also enter into other debt agreements in the future which may contain similar or more restrictive terms.

Our ability to make scheduled monthly payments or to refinance our debt obligations depends on numerous factors, including the amount of our cash reserves and our actual and projected financial and operating performance. These amounts and our performance are subject to certain financial and business factors, as well as prevailing economic and competitive conditions, including the impact of the COVID-19 pandemic, some of which may be beyond our control. We cannot assure you that we will maintain a level of cash reserves or cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and interest on our existing or future indebtedness. If our cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay capital expenditures, sell assets or operations, seek additional capital or restructure or refinance our indebtedness. We cannot assure you that we

44

would be able to take any of these actions, or that these actions would permit us to meet our scheduled debt service obligations. Failure to comply with the covenants and conditions of the Loan and Security Agreement could result in an event of default, which could result in an acceleration of amounts due under the Loan and Security Agreement. We may not have sufficient funds or may be unable to arrange for additional financing to repay our indebtedness or to make any accelerated payments, and SVB could seek to enforce security interests in the collateral securing such indebtedness, which would harm our business.

Risks Related to Ownership of Our Common Stock

Exclusive forum provisions in our amended and restated certificate of incorporation and amended and restated bylaws could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws or (iv) any action asserting a claim governed by the internal affairs doctrine. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws provide the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation and our amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.

Our amended and restated certificate of incorporation and amended and restated bylaws further provide any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions. These exclusive forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 6. Exhibits

Exhibit
No.

    

Document

3.1

Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on October 13, 2015).

3.2

Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on June 24, 2020).

45

10.1

Second Amendment to Sublease, dated as of April 29, 2020, by and between the Registrant and Auxilium Pharmaceuticals, LLC (incorporated herein by reference to Exhibit 10.5 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37581), filed with the SEC on May 7, 2020).

10.2*#

First Amendment to Clinical and Commercial Supply Agreement, dated as of June 12, 2020, by and between the Registrant and PeroxyChem LLC.

31.1*

Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act.

31.2*

Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act.

32.1**

Certifications of Principal Executive Officer and Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act.

101.INS

XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*

Filed herewith.

**

These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

#

Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the SEC, certain portions of this exhibit have been redacted because such portions, indicated by asterisks, are both not material and would likely cause competitive harm to the Registrant if publicly disclosed. The Registrant hereby agrees to furnish supplementally to the SEC, upon its request, an unredacted copy of this exhibit.

46

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.  

ACLARIS THERAPEUTICS, INC.

Date: August 7, 2020

By:

/s/ Neal Walker

Neal Walker

President and Chief Executive Officer

(On behalf of the Registrant)

Date: August 7, 2020

By:

/s/ Frank Ruffo

Frank Ruffo

Chief Financial Officer

(Principal Financial Officer)

47

EX-10.2 2 acrs-20200630xex10d2.htm EX-10.2

Exhibit 10.2

FIRST AMENDMENT TO
CLINICAL AND COMMERCIAL SUPPLY AGREEMENT

This FIRST AMENDMENT TO CLINICAL AND COMMERCIAL SUPPLY AGREEMENT is entered into as of June 12, 2020 (this “First Amendment”), by and between Aclaris Therapeutics, Inc., a Delaware corporation (“Aclaris”), and PeroxyChem LLC, a Delaware limited liability company (“PeroxyChem”). Aclaris and PeroxyChem are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

RECITALS

WHEREAS, Aclaris and PeroxyChem are parties to that certain Clinical and Commercial Supply Agreement, effective as of August 6, 2014 (the “Agreement”);

WHEREAS, Aclaris and PeroxyChem desire to amend the Agreement as set forth in this First Amendment; and

WHEREAS, pursuant to Section 11.7 of the Agreement, the Agreement can be amended or modified only if made in writing and signed by an authorized representative of each of the Parties.

NOW, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements contained herein, PeroxyChem and Aclaris, intending to be legally bound, hereby agree as set forth herein.

AGREEMENT

1.Defined Terms.  Capitalized terms used but not defined herein shall have the meanings given to them in the Agreement.
2.Amendment.  Section 6.1(a) of the Agreement is hereby deleted in its entirety and replaced with the following:

“(a)  Within five (5) calendar days from the completion of PeroxyChem’s update of its hydrogen peroxide DMF, and annually thereafter on April 1 until the expiration of the Term of this Agreement, Aclaris will pay PeroxyChem an annual fee of [***] to maintain the hydrogen peroxide DMF and for Facility and related fees incurred by PeroxyChem in connection with the maintenance of cGMPs for the API, provided that if Aclaris requires the manufacture of API for any such annual period, then Aclaris shall pay PeroxyChem an additional [***] for such period. On an annual basis, the Parties agree to meet to discuss whether or not an adjustment to such fee is necessary as a result of an increase or decrease in Regulatory Authority or Third Party costs related to the maintenance of the hydrogen peroxide DMF, Facility and/or related fees.”

The Parties agree that the amendment to Section 6.1(a) above shall be effective commencing with the annual period beginning on April 1, 2020.

1

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED [***]


3.Miscellaneous.  Except as expressly provided in this First Amendment, all other terms and conditions of the Agreement remain in full force and effect. If there is a conflict between this First Amendment and the Agreement, the terms of this First Amendment will prevail.

[Remainder of page intentionally left blank; signatures appear on following page.]

2

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED [***]


IN WITNESS WHEREOF, the Parties have executed this First Amendment as of the date first above written.

PEROXYCHEM LLC

By:/s/ Stephanie Montag​ ​​ ​

Name:  Stephanie Montag

Title:  VP, PeroxyChem Specialties

ACLARIS THERAPEUTICS, INC.

By:​ ​/s/ Neal Walker​ ​​ ​​ ​

Name:  Neal Walker

Title:  President & CEO

[Signature Page to First Amendment to Clinical and Commercial Supply Agreement]

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED [***]


EX-31.1 3 acrs-20200630xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Neal Walker, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2020 of Aclaris Therapeutics, Inc. (the “registrant”);

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2020

/s/ Neal Walker

Neal Walker

President and Chief Executive Officer

(principal executive officer)


EX-31.2 4 acrs-20200630xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Frank Ruffo, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2020 of Aclaris Therapeutics, Inc. (the “registrant”);

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2020

/s/ Frank Ruffo

Frank Ruffo

Chief Financial Officer

(principal financial officer)


EX-32.1 5 acrs-20200630xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATIONS OF

PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Neal Walker, President and Chief Executive Officer of Aclaris Therapeutics, Inc. (the “Company”), and Frank Ruffo, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1.

The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2020, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 7th day of August, 2020.

/s/ Neal Walker

/s/ Frank Ruffo

Neal Walker

Frank Ruffo

President and Chief Executive Officer
(principal executive officer)

Chief Financial Officer
(principal financial officer)

*

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Aclaris Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.


EX-101.SCH 6 acrs-20200630.xsd EX-101.SCH 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Fair Value of Financial Assets and Liabilities - By Type (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Intangible Assets - Future Amortization Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 41106 - Disclosure - Leases - Future Maturities of Lease Liabilities (Details) - Calc 2 link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Discontinued Operations - Loss (Details) link:presentationLink link:calculationLink link:definitionLink 41502 - Disclosure - Discontinued Operations - Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 41503 - Disclosure - Discontinued Operations - Cash Flow (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Nature of Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Fair Value of Financial Assets and Liabilities link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Stock-Based Awards link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Agreements Related to Intellectual Property link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 11701 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Stock-Based Awards (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 31603 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization and Nature of Business (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Summary of Significant Accounting Policies - Recent Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Stock-Based Awards (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Stock-Based Awards - Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Stock-Based Awards - RSUs (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Stock-Based Awards - Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Net Loss per Share - Anti-dilution (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Agreements Related to Intellectual Property (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Income Taxes - Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 41504 - Disclosure - Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 41701 - Disclosure - Legal Proceedings (Details) link:presentationLink link:calculationLink link:definitionLink 31503 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 acrs-20200630_cal.xml EX-101.CAL EX-101.DEF 8 acrs-20200630_def.xml EX-101.DEF EX-101.LAB 9 acrs-20200630_lab.xml EX-101.LAB EX-101.PRE 10 acrs-20200630_pre.xml EX-101.PRE XML 11 acrs-20200630x10q_htm.xml IDEA: XBRL DOCUMENT 0001557746 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001557746 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001557746 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001557746 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001557746 us-gaap:RetainedEarningsMember 2020-06-30 0001557746 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001557746 us-gaap:RetainedEarningsMember 2020-03-31 0001557746 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001557746 2020-03-31 0001557746 us-gaap:RetainedEarningsMember 2019-12-31 0001557746 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001557746 us-gaap:RetainedEarningsMember 2019-06-30 0001557746 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001557746 us-gaap:RetainedEarningsMember 2019-03-31 0001557746 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001557746 2019-03-31 0001557746 us-gaap:RetainedEarningsMember 2018-12-31 0001557746 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001557746 2019-01-01 2019-12-31 0001557746 acrs:EquityCompensation2017InducementPlanMember 2020-06-30 0001557746 acrs:EquityCompensationPlan2012Member 2019-12-31 0001557746 acrs:EquityCompensationPlan2012Member 2012-01-01 2015-09-14 0001557746 acrs:EquityCompensationPlan2012Member 2020-06-30 0001557746 acrs:EquityIncentivePlan2015Member 2015-09-30 0001557746 acrs:EquityIncentivePlan2015Member 2020-01-01 2020-01-01 0001557746 us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0001557746 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001557746 us-gaap:RestrictedStockUnitsRSUMember acrs:EquityCompensation2017InducementPlanMember 2020-06-30 0001557746 acrs:EquityCompensationPlan2012Member 2020-01-01 2020-06-30 0001557746 acrs:OtherRevenueMember 2020-04-01 2020-06-30 0001557746 acrs:LaboratoryResearchRevenueMember 2020-04-01 2020-06-30 0001557746 us-gaap:IntersegmentEliminationMember acrs:ContractResearchSegmentMember 2020-01-01 2020-06-30 0001557746 us-gaap:RoyaltyMember acrs:EPIHealthLLCMember 2020-01-01 2020-06-30 0001557746 acrs:OtherRevenueMember 2020-01-01 2020-06-30 0001557746 acrs:LaboratoryResearchRevenueMember 2020-01-01 2020-06-30 0001557746 acrs:LaboratoryResearchRevenueMember 2019-04-01 2019-06-30 0001557746 us-gaap:IntersegmentEliminationMember acrs:ContractResearchSegmentMember 2019-01-01 2019-06-30 0001557746 us-gaap:RoyaltyMember acrs:EPIHealthLLCMember 2019-01-01 2019-06-30 0001557746 acrs:LaboratoryResearchRevenueMember 2019-01-01 2019-06-30 0001557746 us-gaap:LeaseholdImprovementsMember 2020-06-30 0001557746 us-gaap:FurnitureAndFixturesMember 2020-06-30 0001557746 us-gaap:ComputerEquipmentMember 2020-06-30 0001557746 acrs:LaboratoryEquipmentMember 2020-06-30 0001557746 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001557746 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001557746 us-gaap:ComputerEquipmentMember 2019-12-31 0001557746 acrs:LaboratoryEquipmentMember 2019-12-31 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001557746 2019-02-28 0001557746 2017-11-30 0001557746 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001557746 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001557746 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001557746 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001557746 srt:ExecutiveOfficerMember 2020-01-24 2020-01-24 0001557746 us-gaap:OtherIntangibleAssetsMember 2020-01-01 2020-06-30 0001557746 us-gaap:InProcessResearchAndDevelopmentMember 2020-06-30 0001557746 us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0001557746 us-gaap:OtherIntangibleAssetsMember 2020-06-30 0001557746 us-gaap:OtherIntangibleAssetsMember 2019-12-31 0001557746 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001557746 acrs:EmployeeConsultantsAndDirectorsStockOptionsMember 2020-01-01 2020-06-30 0001557746 us-gaap:ProductMember 2019-04-01 2019-06-30 0001557746 acrs:RhofadeProductMember 2019-04-01 2019-06-30 0001557746 acrs:EskataProductMember 2019-04-01 2019-06-30 0001557746 us-gaap:ProductMember 2019-01-01 2019-06-30 0001557746 acrs:RhofadeProductMember 2019-01-01 2019-06-30 0001557746 acrs:EskataProductMember 2019-01-01 2019-06-30 0001557746 acrs:DermatologyTherapeuticsSegmentMember 2020-04-01 2020-06-30 0001557746 acrs:DermatologyTherapeuticsSegmentMember 2020-01-01 2020-06-30 0001557746 acrs:DermatologyTherapeuticsSegmentMember 2019-04-01 2019-06-30 0001557746 acrs:DermatologyTherapeuticsSegmentMember 2019-01-01 2019-06-30 0001557746 acrs:RhofadeProductMember 2019-12-31 0001557746 acrs:TermLoanFacilityMember 2020-03-31 0001557746 acrs:TermLoanFacilityMember us-gaap:PrimeRateMember 2020-03-01 2020-03-31 0001557746 us-gaap:CorporateNonSegmentMember 2020-04-01 2020-06-30 0001557746 acrs:ContractResearchSegmentMember 2020-04-01 2020-06-30 0001557746 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-06-30 0001557746 acrs:ContractResearchSegmentMember 2020-01-01 2020-06-30 0001557746 us-gaap:CorporateNonSegmentMember 2019-04-01 2019-06-30 0001557746 acrs:ContractResearchSegmentMember 2019-04-01 2019-06-30 0001557746 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-06-30 0001557746 acrs:ContractResearchSegmentMember 2019-01-01 2019-06-30 0001557746 us-gaap:CommonStockMember 2020-06-30 0001557746 us-gaap:CommonStockMember 2020-03-31 0001557746 us-gaap:CommonStockMember 2019-12-31 0001557746 us-gaap:CommonStockMember 2019-06-30 0001557746 us-gaap:CommonStockMember 2019-03-31 0001557746 us-gaap:CommonStockMember 2018-12-31 0001557746 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001557746 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001557746 acrs:SiliconValleyBankMember 2020-03-31 0001557746 2019-06-30 0001557746 2018-12-31 0001557746 acrs:ConfluenceMember 2020-01-01 2020-06-30 0001557746 us-gaap:FixedIncomeSecuritiesMember 2020-06-30 0001557746 us-gaap:FixedIncomeSecuritiesMember 2019-12-31 0001557746 us-gaap:AssetBackedSecuritiesMember 2020-06-30 0001557746 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-06-30 0001557746 us-gaap:CorporateDebtSecuritiesMember 2020-06-30 0001557746 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001557746 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001557746 us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001557746 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001557746 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001557746 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001557746 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001557746 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001557746 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001557746 us-gaap:WarrantMember 2020-01-01 2020-06-30 0001557746 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001557746 acrs:EmployeeConsultantsAndDirectorsStockOptionsMember 2020-01-01 2020-06-30 0001557746 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001557746 acrs:EmployeeConsultantsAndDirectorsStockOptionsMember 2019-01-01 2019-06-30 0001557746 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001557746 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001557746 us-gaap:CostOfSalesMember 2020-04-01 2020-06-30 0001557746 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001557746 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001557746 us-gaap:CostOfSalesMember 2020-01-01 2020-06-30 0001557746 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001557746 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001557746 us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0001557746 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001557746 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001557746 us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0001557746 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001557746 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001557746 2020-01-01 2020-03-31 0001557746 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001557746 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001557746 2019-01-01 2019-03-31 0001557746 acrs:OperatingLeasesMember 2020-06-30 0001557746 acrs:OperatingLeasesMember 2019-12-31 0001557746 acrs:MallinckrodtPlc.Member 2020-06-30 0001557746 acrs:MallinckrodtPlc.Member 2019-12-31 0001557746 2020-08-06 0001557746 acrs:EquityIncentivePlan2015Member 2020-06-30 0001557746 acrs:ConfluenceMember acrs:AgreementAndPlanOfMergerMember 2017-08-01 2017-08-31 0001557746 srt:MinimumMember 2020-01-01 2020-06-30 0001557746 srt:MaximumMember 2020-01-01 2020-06-30 0001557746 acrs:RigelPharmaceuticalsIncMember 2019-09-30 0001557746 acrs:RigelPharmaceuticalsIncMember 2019-07-01 2019-09-30 0001557746 acrs:TermLoanFacilityMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2020-03-30 2020-03-30 0001557746 acrs:TermLoanFacilityMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2020-03-30 2020-03-30 0001557746 acrs:TermLoanFacilityMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2020-03-30 2020-03-30 0001557746 acrs:TermLoanFacilityMember 2020-03-01 2020-03-31 0001557746 2020-04-01 2020-06-30 0001557746 2019-04-01 2019-06-30 0001557746 2019-01-01 2019-06-30 0001557746 acrs:EpiHealthLlcMember 2020-06-30 0001557746 acrs:RigelPharmaceuticalsIncMember 2020-06-30 0001557746 acrs:ConfluenceMember acrs:AgreementAndPlanOfMergerMember 2018-11-01 2018-11-30 0001557746 acrs:ConfluenceMember acrs:AgreementAndPlanOfMergerMember 2017-08-31 0001557746 acrs:EPIHealthLLCMember 2020-06-30 0001557746 acrs:RhofadeProductMember 2020-06-30 0001557746 acrs:RigelPharmaceuticalsIncMember 2019-10-31 0001557746 acrs:EPIHealthLLCMember 2019-10-01 2019-10-31 0001557746 acrs:LicenseAndCollaborationAgreementMember 2015-08-01 2015-08-31 0001557746 2020-06-30 0001557746 2019-12-31 0001557746 2020-01-01 2020-06-30 iso4217:USD shares acrs:Vote acrs:item pure acrs:installment iso4217:USD shares utr:sqft acrs:segment 0 0 0 0 42691114 us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent 41485638 0 0 0 0 0 0 0 0 Accelerated Filer 0001557746 --12-31 2020 Q2 false 10-Q true 2020-06-30 false 001-37581 Aclaris Therapeutics, Inc. DE 46-0571712 640 Lee Road, Suite 200 Wayne PA 19087 484 324-7933 Common Stock ACRS NASDAQ Yes Yes true true true false 42722780 32587000 35937000 35528000 39078000 775000 704000 2065000 3118000 4966000 70955000 83803000 2230000 2470000 7161000 7199000 4653000 4825000 84999000 98297000 5502000 9917000 9344000 7721000 610000 637000 2289000 4157000 17745000 22432000 3331000 3736000 10573000 3435000 1668000 549000 549000 35633000 28385000 0.00001 0.00001 10000000 10000000 0 0 0.00001 0.00001 100000000 100000000 42691114 41485638 530061000 523505000 15000 -66000 -480710000 -453527000 49366000 69912000 84999000 98297000 1853000 886000 3042000 2149000 193000 411000 2046000 886000 3453000 2149000 1389000 994000 2658000 2201000 6466000 17519000 15909000 37161000 5572000 7469000 11773000 14926000 18504000 18504000 13427000 44486000 30340000 72792000 -11381000 -43600000 -26887000 -70643000 -189000 -85000 -11000 -315000 -11570000 -43685000 -26898000 -70958000 -27000 -6191000 -285000 -16483000 -11597000 -49876000 -27183000 -87441000 -0.28 -1.21 -0.65 -2.12 42133646 41274808 41876037 41261808 0 0 0 0 -37000 30000 23000 64000 5000 27000 58000 13000 -32000 57000 81000 77000 -11629000 -49819000 -27102000 -87364000 41485638 523505000 -66000 -453527000 69912000 346582 -121000 -121000 378000 378000 60000 60000 53000 53000 3453000 3453000 -15586000 -15586000 41832220 527215000 47000 -469113000 58149000 858894 -463000 -463000 -37000 -37000 5000 5000 3309000 3309000 -11597000 -11597000 42691114 530061000 15000 -480710000 49366000 41210725 507366000 -69000 -292173000 215124000 58918 -188000 -188000 34000 34000 -14000 -14000 4862000 4862000 -37565000 -37565000 41269643 512040000 -49000 -329738000 182253000 8927 -18000 -18000 30000 30000 27000 27000 4814000 4814000 -49876000 -49876000 41278570 516836000 8000 -379614000 137230000 -27183000 -87441000 1182000 4457000 6762000 9676000 1767000 734000 18504000 -4895000 14509000 -890000 -2579000 -6026000 -583000 87000 13887000 -17626000 -52696000 141000 525000 27139000 89407000 30735000 117500000 3455000 27568000 10913000 92000 240000 3000 10821000 -237000 -3350000 -25365000 35937000 57019000 32587000 31654000 339000 392000 2132000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">1. Organization and Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Aclaris Therapeutics, Inc. was incorporated under the laws of the State of Delaware in 2012.  In July 2015, Aclaris Therapeutics International Limited (“ATIL”) was established under the laws of the United Kingdom as a wholly-owned subsidiary of Aclaris Therapeutics, Inc.  In August 2017, Confluence Life Sciences, Inc. (now known as Aclaris Life Sciences, Inc.) (“Confluence”) was acquired by Aclaris Therapeutics, Inc. and became a wholly-owned subsidiary thereof.  Aclaris Therapeutics, Inc., ATIL and Confluence are referred to collectively as the “Company.”  The Company is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company currently has a pipeline of drug candidates focused on immuno-inflammatory diseases, as well as one product approved by the U.S. Food and Drug Administration (“FDA”) that it is not currently distributing, marketing or selling, and other investigational drug candidates.  In September 2019, the Company announced the completion of a strategic review of its business, as a result of which it refocused its resources on its immuno-inflammatory development programs.  The Company is pursuing strategic alternatives, including identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its drug candidates and ESKATA (hydrogen peroxide) topical solution, 40% (w/w) (“ESKATA”), the Company’s non-marketed FDA-approved product.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business.  As of June 30, 2020, the Company had cash, cash equivalents and restricted cash and marketable securities of $68,115 and an accumulated deficit of $480,710. Since inception, the Company has incurred net losses and negative cash flows from its operations.  Prior to the acquisition of Confluence in August 2017, the Company had never generated revenue.  There can be no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis.  In addition, development activities, including clinical and preclinical testing of the Company’s drug candidates, will require significant additional financing.  The future viability of the Company is dependent on its ability to successfully develop its drug candidates and to generate revenue from identifying and consummating transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize its development assets or to raise additional capital to finance its operations.  The Company will require additional capital to complete the clinical development of ATI-450 and ATI-1777, to develop its preclinical compounds, and to support its discovery efforts.  Additional funds may not be available on a timely basis, on commercially acceptable terms, or at all, and such funds, if raised, may not be sufficient to enable the Company to continue to implement its long-term business strategy.  The Company’s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.  If the Company is unable to raise sufficient additional capital or generate revenue from transactions with third-party partners for the development and/or commercialization of its drug candidates, it may need to substantially curtail planned operations. The Company’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that its consolidated financial statements are issued.  As of the report date, the Company believes the actions described below are probable of being implemented effectively and of alleviating the conditions or events that exist which raise substantial doubt about its ability to continue as a going concern within one year after the date of the issuance of these condensed consolidated financial statements.  The Company believes its existing </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">cash, cash equivalents and marketable securities are sufficient to fund its operating and capital expenditure requirements for a period greater than 12 months from the date of issuance of these condensed consolidated financial statements.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has taken a number of actions to support its operations and meet its liquidity needs.  In September 2019, the Company announced the completion of a strategic review and its decision to refocus its resources on its immuno-inflammatory development programs and to pursue strategic alternatives, including identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its drug candidates and ESKATA.  As a result of this decision, the Company restructured its operations and terminated employees, which lowered operating costs.  In October 2019, the Company sold the worldwide rights to RHOFADE (oxymetazoline hydrochloride) cream, 1% (“RHOFADE”) to further its focus on its development programs and improve cash flow.  In March 2020, the Company borrowed $11,000 under a term loan facility with Silicon Valley Bank.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s plans to further alleviate the substantial doubt about its going concern, which are probable of effectively being implemented and mitigating these conditions, primarily include its ability to control the timing and spending on its research and development programs.  The Company may also consider other plans to fund its operations including: (1) raising additional capital through debt or equity financings; (2) identifying third-party partners to further develop, obtain marketing approval for and/or commercialize its drug candidates and ESKATA, which may generate revenue and/or milestone payments; (3) reducing spending on one or more research and development programs by delaying or discontinuing development; and/or (4) further restructuring its operations to change its overhead structure. Finally, additional funds may not be available on a timely basis, on commercially acceptable terms, or at all, and such funds, if raised, may not be sufficient to enable the Company to continue to implement its long-term business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p> 68115000 -480710000 11000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).  The condensed consolidated financial statements of the Company include the accounts of the operating parent company, Aclaris Therapeutics, Inc., and its wholly-owned subsidiaries, ATIL and Confluence.  All significant intercompany transactions have been eliminated.  Based upon the revenue from contract research services, the Company believes that gross profit does not provide a meaningful measure of profitability and, therefore, has not included a line item for gross profit on the condensed consolidated statement of operations.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Discontinued Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In September 2019, the Company announced the completion of a strategic review and its decision to refocus its resources on its immuno-inflammatory development programs and to actively seek partners for its commercial products.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying condensed consolidated financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to the Company’s commercial products as discontinued operations (see Note 15).  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods.  Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development expenses, contingent consideration and the valuation of stock-based awards.  Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  The COVID-19 pandemic has resulted in a global slowdown of economic activity.  As of the date of issuance of these financial statements, the Company is not aware of any specific event </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">or circumstance that would require an update to its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities.  Actual results could differ from the Company’s estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Unaudited Interim Financial Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying condensed consolidated balance sheet as of June 30, 2020, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2020 and 2019, the condensed consolidated statement of stockholders’ equity for the three and six months ended June 30, 2020 and 2019, and the condensed consolidated statements of cash flows for the six months ended June 30, 2020 and 2019 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements contained in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 25, 2020 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of June 30, 2020, the results of its operations and comprehensive loss for the three and six months ended June 30, 2020 and 2019, its changes in stockholders’ equity for the three and six months ended June 30, 2020 and 2019 and its cash flows for the six months ended June 30, 2020 and 2019.  The condensed consolidated balance sheet data as of December 31, 2019 was derived from audited financial statements but does not include all disclosures required by GAAP.  The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2020 and 2019 are unaudited. The results for the three and six months ended June 30, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020, any other interim periods, or any future year or period.  The unaudited interim financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2019 included in the Company’s annual report on Form 10-K filed with the SEC on February 25, 2020.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2019 included in the Company’s annual report on Form 10-K filed with the SEC on February 25, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents.  Cash equivalents, which have consisted of money market accounts, commercial paper and corporate debt securities with original maturities of less than three months, are stated at fair value.  Restricted cash as of June 30, 2020 consisted of $1,753 placed in escrow pursuant to the asset purchase agreement with EPI Health, LLC (“EPI Health”) (see Note 13 for additional information). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers.  Under ASC Topic 606, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To determine revenue recognition in accordance with ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) performance obligations are satisfied.  At contract inception, the Company assesses the goods or services promised within a contract with a customer to identify the performance obligations, and to determine if they are distinct.  The Company recognizes the revenue that is allocated to each distinct performance obligation when (or as) that </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">performance obligation is satisfied.  The Company only recognizes revenue when collection of the consideration it is entitled to under a contract with a customer is probable.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><i style="font-style:italic;">Contract Research</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company earns contract research revenue from the provision of laboratory services to clients through Confluence, its wholly-owned subsidiary.  Contract research revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis and are generally billed on a monthly basis in arrears for services rendered.  Revenue related to these contracts is generally recognized as the laboratory services are performed, based upon the rates specified in the contracts.  Under ASC Topic 606, the Company elected to apply the “right to invoice” practical expedient when recognizing contract research revenue.  The Company recognizes contract research revenue in the amount to which it has the right to invoice.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Other Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Licenses of Intellectual Property</i> – The Company recognizes revenue received from non-refundable, upfront fees related to the licensing of intellectual property when the intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the license has been transferred to the customer, and the customer is able to use and benefit from the license.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Milestone Payments</i> – At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the amount allocated to the license of intellectual property.  Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Intangible Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Intangible assets include both definite-lived and indefinite-lived assets.  Definite-lived intangible assets are amortized over their estimated useful life based on the pattern over which the intangible assets are consumed or otherwise used up.  If that pattern cannot be reliably determined, the straight-line method of amortization is used.  Definite-lived intangible assets consist of a research technology platform the Company acquired through the acquisition of Confluence.  Indefinite-lived intangible assets consist of an in-process research and development (“IPR&amp;D”) drug candidate acquired through the acquisition of Confluence.  IPR&amp;D assets are considered indefinite-lived until the completion or abandonment of the associated research and development efforts.  The cost of IPR&amp;D is either amortized over its estimated useful life beginning when the underlying drug candidate is approved and launched commercially, or expensed immediately if development of the drug candidate is abandoned.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable.  Indefinite-lived intangible assets are tested for impairment at least annually, which the Company performs during the fourth quarter, or when indicators of an impairment are present.  The Company recognizes impairment losses when and to the extent that the estimated fair value of an intangible asset is less than its carrying value.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Leases represent a company’s right to use an underlying asset and a corresponding obligation to make payments to a lessor for the right to use those assets.  The Company evaluates leases at their inception to determine if they are an operating lease or a finance lease.  A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows are substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term.  Leases that do not meet the finance lease criteria are accounted for as an operating lease.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recognizes assets and liabilities for leases at their inception based upon the present value of all payments due under the lease.  The Company uses an implicit interest rate to determine the present value of finance leases, and its incremental borrowing rate to determine the present value of operating leases.  The Company determines incremental borrowing rates by referencing collateralized borrowing rates for debt instruments with terms similar to the respective lease.  The Company recognizes expense for operating and finance leases on a straight-line basis over the term of each lease, and interest expense related to finance leases is recognized over the lease term based on the effective interest method.  The Company includes estimates for any residual value guarantee obligations under its leases in lease liabilities recorded on its condensed consolidated balance sheet.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Right-of-use assets are included in other assets and property and equipment, net on the Company’s condensed consolidated balance sheet for operating and finance leases, respectively.  Obligations for lease payments are included in current portion of lease liabilities and other liabilities on the Company’s condensed consolidated balance sheet for both operating and finance leases.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Contingent Consideration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company initially recorded a contingent consideration liability related to future potential payments based upon the achievement of certain development, regulatory and commercial milestones, as well as future projected sales performance, resulting from the acquisition of Confluence, at its estimated fair value on the date of acquisition.  The ultimate amount of future payments, if any, is based on criteria such as sales performance and the achievement of certain regulatory and sales milestones.  The Company estimates the fair value of the contingent consideration liability related to the achievement of regulatory milestones by assigning an achievement probability to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return.  The Company estimates the fair value of the contingent consideration liability associated with sales milestones and royalties by estimating future sales levels, assigning an achievement probability and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.  Significant assumptions used in the Company’s estimates include the probability of success of achieving regulatory and sales milestones, which are based upon an asset’s current stage of development and ranged between 4% and 15%.  The Company evaluates fair value estimates of contingent consideration liabilities on a periodic basis.  Any change in fair value reflects new information about the likelihood of the payment of the contingent consideration and the passage of time. For example, if the timing of the development of an acquired drug candidate, or the size of potential commercial opportunities related to an acquired drug, differ from the Company’s assumptions, then the fair value of contingent consideration would be adjusted accordingly. Future changes in the fair value of the contingent consideration, if any, will be recorded as income or expense in the Company’s condensed consolidated statement of operations.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Concentration of Credit Risk and of Significant Suppliers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds all cash, cash equivalents and marketable securities balances at one accredited financial institution, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is dependent on third-party manufacturers to supply drug product, including all underlying components, for its research and development activities, including preclinical and clinical testing.  These activities could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients or other components.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Recently Issued Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In November 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606.  The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40).  ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.  The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within such fiscal years.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).  The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements.  This update eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some of the existing disclosure requirements.  The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within such fiscal years.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).  The condensed consolidated financial statements of the Company include the accounts of the operating parent company, Aclaris Therapeutics, Inc., and its wholly-owned subsidiaries, ATIL and Confluence.  All significant intercompany transactions have been eliminated.  Based upon the revenue from contract research services, the Company believes that gross profit does not provide a meaningful measure of profitability and, therefore, has not included a line item for gross profit on the condensed consolidated statement of operations.  </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Discontinued Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In September 2019, the Company announced the completion of a strategic review and its decision to refocus its resources on its immuno-inflammatory development programs and to actively seek partners for its commercial products.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying condensed consolidated financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to the Company’s commercial products as discontinued operations (see Note 15).  </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods.  Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development expenses, contingent consideration and the valuation of stock-based awards.  Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  The COVID-19 pandemic has resulted in a global slowdown of economic activity.  As of the date of issuance of these financial statements, the Company is not aware of any specific event </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">or circumstance that would require an update to its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities.  Actual results could differ from the Company’s estimates.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Unaudited Interim Financial Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying condensed consolidated balance sheet as of June 30, 2020, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2020 and 2019, the condensed consolidated statement of stockholders’ equity for the three and six months ended June 30, 2020 and 2019, and the condensed consolidated statements of cash flows for the six months ended June 30, 2020 and 2019 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements contained in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 25, 2020 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of June 30, 2020, the results of its operations and comprehensive loss for the three and six months ended June 30, 2020 and 2019, its changes in stockholders’ equity for the three and six months ended June 30, 2020 and 2019 and its cash flows for the six months ended June 30, 2020 and 2019.  The condensed consolidated balance sheet data as of December 31, 2019 was derived from audited financial statements but does not include all disclosures required by GAAP.  The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2020 and 2019 are unaudited. The results for the three and six months ended June 30, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020, any other interim periods, or any future year or period.  The unaudited interim financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2019 included in the Company’s annual report on Form 10-K filed with the SEC on February 25, 2020.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2019 included in the Company’s annual report on Form 10-K filed with the SEC on February 25, 2020. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents.  Cash equivalents, which have consisted of money market accounts, commercial paper and corporate debt securities with original maturities of less than three months, are stated at fair value.  Restricted cash as of June 30, 2020 consisted of $1,753 placed in escrow pursuant to the asset purchase agreement with EPI Health, LLC (“EPI Health”) (see Note 13 for additional information). </p> 1753000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers.  Under ASC Topic 606, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To determine revenue recognition in accordance with ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) performance obligations are satisfied.  At contract inception, the Company assesses the goods or services promised within a contract with a customer to identify the performance obligations, and to determine if they are distinct.  The Company recognizes the revenue that is allocated to each distinct performance obligation when (or as) that </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">performance obligation is satisfied.  The Company only recognizes revenue when collection of the consideration it is entitled to under a contract with a customer is probable.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><i style="font-style:italic;">Contract Research</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company earns contract research revenue from the provision of laboratory services to clients through Confluence, its wholly-owned subsidiary.  Contract research revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis and are generally billed on a monthly basis in arrears for services rendered.  Revenue related to these contracts is generally recognized as the laboratory services are performed, based upon the rates specified in the contracts.  Under ASC Topic 606, the Company elected to apply the “right to invoice” practical expedient when recognizing contract research revenue.  The Company recognizes contract research revenue in the amount to which it has the right to invoice.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Other Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Licenses of Intellectual Property</i> – The Company recognizes revenue received from non-refundable, upfront fees related to the licensing of intellectual property when the intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the license has been transferred to the customer, and the customer is able to use and benefit from the license.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Milestone Payments</i> – At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the amount allocated to the license of intellectual property.  Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Intangible Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Intangible assets include both definite-lived and indefinite-lived assets.  Definite-lived intangible assets are amortized over their estimated useful life based on the pattern over which the intangible assets are consumed or otherwise used up.  If that pattern cannot be reliably determined, the straight-line method of amortization is used.  Definite-lived intangible assets consist of a research technology platform the Company acquired through the acquisition of Confluence.  Indefinite-lived intangible assets consist of an in-process research and development (“IPR&amp;D”) drug candidate acquired through the acquisition of Confluence.  IPR&amp;D assets are considered indefinite-lived until the completion or abandonment of the associated research and development efforts.  The cost of IPR&amp;D is either amortized over its estimated useful life beginning when the underlying drug candidate is approved and launched commercially, or expensed immediately if development of the drug candidate is abandoned.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable.  Indefinite-lived intangible assets are tested for impairment at least annually, which the Company performs during the fourth quarter, or when indicators of an impairment are present.  The Company recognizes impairment losses when and to the extent that the estimated fair value of an intangible asset is less than its carrying value.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Leases represent a company’s right to use an underlying asset and a corresponding obligation to make payments to a lessor for the right to use those assets.  The Company evaluates leases at their inception to determine if they are an operating lease or a finance lease.  A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows are substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term.  Leases that do not meet the finance lease criteria are accounted for as an operating lease.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recognizes assets and liabilities for leases at their inception based upon the present value of all payments due under the lease.  The Company uses an implicit interest rate to determine the present value of finance leases, and its incremental borrowing rate to determine the present value of operating leases.  The Company determines incremental borrowing rates by referencing collateralized borrowing rates for debt instruments with terms similar to the respective lease.  The Company recognizes expense for operating and finance leases on a straight-line basis over the term of each lease, and interest expense related to finance leases is recognized over the lease term based on the effective interest method.  The Company includes estimates for any residual value guarantee obligations under its leases in lease liabilities recorded on its condensed consolidated balance sheet.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Right-of-use assets are included in other assets and property and equipment, net on the Company’s condensed consolidated balance sheet for operating and finance leases, respectively.  Obligations for lease payments are included in current portion of lease liabilities and other liabilities on the Company’s condensed consolidated balance sheet for both operating and finance leases.  </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Contingent Consideration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company initially recorded a contingent consideration liability related to future potential payments based upon the achievement of certain development, regulatory and commercial milestones, as well as future projected sales performance, resulting from the acquisition of Confluence, at its estimated fair value on the date of acquisition.  The ultimate amount of future payments, if any, is based on criteria such as sales performance and the achievement of certain regulatory and sales milestones.  The Company estimates the fair value of the contingent consideration liability related to the achievement of regulatory milestones by assigning an achievement probability to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return.  The Company estimates the fair value of the contingent consideration liability associated with sales milestones and royalties by estimating future sales levels, assigning an achievement probability and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.  Significant assumptions used in the Company’s estimates include the probability of success of achieving regulatory and sales milestones, which are based upon an asset’s current stage of development and ranged between 4% and 15%.  The Company evaluates fair value estimates of contingent consideration liabilities on a periodic basis.  Any change in fair value reflects new information about the likelihood of the payment of the contingent consideration and the passage of time. For example, if the timing of the development of an acquired drug candidate, or the size of potential commercial opportunities related to an acquired drug, differ from the Company’s assumptions, then the fair value of contingent consideration would be adjusted accordingly. Future changes in the fair value of the contingent consideration, if any, will be recorded as income or expense in the Company’s condensed consolidated statement of operations.  </p> 0.04 0.15 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Concentration of Credit Risk and of Significant Suppliers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds all cash, cash equivalents and marketable securities balances at one accredited financial institution, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is dependent on third-party manufacturers to supply drug product, including all underlying components, for its research and development activities, including preclinical and clinical testing.  These activities could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients or other components.  </p> 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Recently Issued Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In November 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606.  The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40).  ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.  The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within such fiscal years.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).  The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements.  This update eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some of the existing disclosure requirements.  The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within such fiscal years.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">3. Fair Value of Financial Assets and Liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables present information about the fair value measurements of the Company’s financial assets and liabilities which are measured at fair value on a recurring and non-recurring basis, and indicate the level of the fair value hierarchy utilized to determine such fair values:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,528</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,528</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Acquisition-related contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,435</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,435</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,078</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,078</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Acquisition-related contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,668</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,668</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2020 and December 31, 2019, the Company’s cash equivalents consisted of investments with maturities of less than three months and included a money market fund, which was valued based upon Level 1 inputs, and the Company’s marketable securities consisted of investments with maturities of more than three months and included commercial paper, corporate debt, asset-backed securities and government obligations, which were valued based upon Level 2 inputs.  In determining the fair value of its Level 2 investments, the Company relied on quoted prices for identical securities in markets that are not active. These quoted prices were obtained by the Company with the assistance of a third-party pricing service based on available trade, bid and other observable market data for identical securities.  Quarterly, the Company compares the quoted prices obtained from the third-party pricing service to other available independent pricing information to validate the reasonableness of the quoted prices provided.  The Company evaluates whether adjustments to third-party pricing is necessary and, historically, the Company has not made adjustments to quoted prices obtained from the third-party pricing service.  During the six months ended June 30, 2020 and 2019, there were no transfers between Level 1, Level 2 and Level 3.  The increase in contingent consideration of $1,767 during the six months ended June 30, 2020 was the result of updates to the Company’s assumptions as a result of the successful completion of a Phase 1 clinical trial for ATI-450.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2020 and December 31, 2019, the fair value of the Company’s available for sale marketable securities by type of security was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:normal;width:38.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,688</p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,690</p></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,768</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,768</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Asset-backed securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,408</p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,407</p></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government agency debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,637</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,663</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,501</p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,528</p></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:37.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,129</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,129</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Asset-backed securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">U.S. government agency debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,126</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,124</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,528</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,528</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Acquisition-related contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,435</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,435</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,078</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,078</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Acquisition-related contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,668</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,668</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 16754000 16754000 35528000 35528000 16754000 35528000 52282000 3435000 3435000 3435000 3435000 21277000 21277000 39078000 39078000 21277000 39078000 60355000 1668000 1668000 1668000 1668000 1767000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:normal;width:38.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,688</p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,690</p></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,768</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,768</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Asset-backed securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,408</p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,407</p></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government agency debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,637</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,663</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,501</p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:6.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,528</p></td><td style="vertical-align:bottom;white-space:normal;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:37.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,129</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,129</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Asset-backed securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">U.S. government agency debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,126</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,124</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 5688000 2000 5690000 15768000 15768000 1408000 1000 1407000 12637000 26000 12663000 35501000 28000 1000 35528000 7815000 2000 7817000 15129000 15129000 8004000 4000 8008000 8126000 1000 3000 8124000 39074000 7000 3000 39078000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">4. Property and Equipment, Net</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Property and equipment, net consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Computer equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,317</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,315</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Lab equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,292</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,250</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,200</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 889</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accumulated depreciation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,661)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,066)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,470</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Depreciation expense was $297 and $393 for the three months ended June 30, 2020 and 2019, respectively, and $595 and $795 for the six months ended June 30, 2020 and 2019, respectively.  </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Computer equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,317</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,315</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Lab equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,292</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,250</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,200</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 889</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accumulated depreciation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,661)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,066)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,470</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 1317000 1315000 435000 435000 1292000 1250000 647000 647000 1200000 889000 4891000 4536000 2661000 2066000 2230000 2470000 297000 393000 595000 795000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5. Intangible Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Intangible assets consisted of the following: </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross Cost</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (years)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other intangible assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7.1 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 751</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 751</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 219</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total definite-lived intangible assets</p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 751</p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 751</p></td><td style="vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 219</p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">IPR&amp;D</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">na</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,629</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,629</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total intangible assets</p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,380</p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,380</p></td><td style="vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 219</p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of June 30, 2020, estimated future amortization expense is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 532</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross Cost</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (years)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other intangible assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7.1 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 751</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 751</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 219</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total definite-lived intangible assets</p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 751</p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 751</p></td><td style="vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 219</p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">IPR&amp;D</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">na</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,629</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,629</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total intangible assets</p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,380</p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,380</p></td><td style="vertical-align:bottom;white-space:normal;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 219</p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181</p></td></tr></table> P7Y1M6D 751000 751000 219000 181000 751000 751000 219000 181000 6629000 6629000 7380000 7380000 219000 181000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 532</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr></table> 37000 75000 75000 75000 75000 195000 532000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">6. Accrued Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Employee compensation expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,489</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,321</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,134</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Professional fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 168</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Payable to EPI Health</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 659</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,375</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Payable to EPI Health</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of June 30, 2020, the Company had $4,950 payable to EPI Health (see Note 15 for additional information). </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Employee compensation expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,489</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,321</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,134</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Professional fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 168</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Payable to EPI Health</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 659</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,375</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 2489000 3321000 1134000 2857000 112000 168000 4950000 659000 1375000 9344000 7721000 4950000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">7. Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Loan and Security Agreement – Silicon Valley Bank</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In March 2020, the Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”).  The Loan and Security Agreement provides for $11,000 in term loans, of which the Company borrowed the entire amount on March 30, 2020.  The Loan and Security Agreement is secured by substantially all of the assets of the Company other than intellectual property.  In connection with the Loan and Security Agreement, the Company issued to SVB a warrant to purchase up to 460,251 shares of common stock (the “Warrant”).  The proceeds of the Loan and Security Agreement were allocated to the term loan and Warrant using a relative fair value approach.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The term loan repayment schedule provides for interest only payments beginning April 1, 2020 and continuing through March 1, 2022, followed by 24 consecutive equal monthly installments of principal, plus monthly payments of accrued interest, starting on April 1, 2022 and continuing through the maturity date of March 1, 2024. All outstanding principal and accrued and unpaid interest will be due and payable on the maturity date.  The Loan and Security Agreement provides for an annual interest rate equal to the greater of (i) the prime rate then in effect as reported in The Wall Street Journal plus 2% and (ii) 6.75%.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Loan and Security Agreement includes a final payment fee equal to 5% of the original principal amount borrowed.  The Company has the option to prepay the outstanding balance of the term loans in full, subject to a prepayment premium of (i) 3% of the original principal amount borrowed for any prepayment on or prior to the first anniversary of March 30, 2020, (ii) 2% of the original principal amount borrowed for any prepayment after the first anniversary and on or before the second anniversary of March 30, 2020 or (iii) 1% of the original principal amount borrowed for any prepayment after the second anniversary of March 30, 2020 but before March 1, 2024.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p> 11000000 460251 24 0.02 0.0675 0.05 0.03 0.02 0.01 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">8. Stockholders’ Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2020 and December 31, 2019, the Company’s amended and restated certificate of incorporation authorized the Company to issue 10,000,000 shares of undesignated preferred stock.  There were no shares of preferred stock outstanding as of June 30, 2020 or December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2020 and December 31, 2019, the Company’s amended and restated certificate of incorporation authorized the Company to issue 100,000,000 shares of $0.00001 par value common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to any preferential dividend rights of any series of preferred stock that may be outstanding. No dividends have been declared through June 30, 2020.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the Loan and Security Agreement with SVB, the Company issued the Warrant to SVB.  The Warrant has an initial exercise price of $0.956 per share, subject to adjustment as provided in the Warrant. The Warrant became immediately exercisable in full upon the funding of the term loan facility. The Warrant will terminate, if not earlier exercised, on the earlier of March 29, 2030 and the closing of certain merger or other transactions in which the consideration is cash, stock of a publicly-traded acquirer or a combination thereof. The Company assigned a fair value of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$378 to the Warrant using a Black-Scholes valuation methodology, and also concluded that the Warrant was indexed to its own stock and therefore classified the Warrant as an equity instrument.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p> 10000000 10000000 0 0 100000000 100000000 0.00001 1 0 0.956 378000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">9. Stock-Based Awards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">2015 Equity Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In September 2015, the Company’s board of directors adopted the 2015 Equity Incentive Plan (the “2015 Plan”), and the Company’s stockholders approved the 2015 Plan. The 2015 Plan became effective in connection with the Company’s initial public offering in October 2015.  Beginning at the time the 2015 Plan became effective, no further grants may be made under the Company’s 2012 Equity Compensation Plan, as amended and restated (the “2012 Plan”).  The 2015 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit (“RSU”) awards, performance stock awards, cash-based awards and other stock-based awards. The number of shares initially reserved for issuance under the 2015 Plan was 1,643,872 shares of common stock. The number of shares of common stock that may be issued under the 2015 Plan will automatically increase on January 1 of each year ending on January 1, 2025, in an amount equal to the lesser of (i) 4.0% of the shares of the Company’s common stock outstanding on December 31 of the preceding calendar year or (ii) an amount determined by the Company’s board of directors. The shares of common stock underlying any awards that expire, are otherwise terminated, settled in cash or repurchased by the Company under the 2015 Plan and the 2012 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan.  As of January 1, 2020, the number of shares of common stock that may be issued under the 2015 Plan was increased by 1,451,997 shares.  As of June 30, 2020, 1,922,147 shares remained available for grant under the 2015 Plan.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">2017 Inducement Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In July 2017, the Company’s board of directors adopted the 2017 Inducement Plan (the “2017 Inducement Plan”).  The 2017 Inducement Plan is a non-stockholder approved stock plan adopted pursuant to the “inducement exception” provided under Nasdaq listing rules.  The Company had 443,000 stock options and 44,390 RSUs outstanding as of June 30, 2020 under the 2017 Inducement Plan.  All shares of common stock that were eligible for issuance under the 2017 Inducement Plan after October 1, 2018, including any shares underlying any awards that expire or are otherwise terminated, reacquired to satisfy tax withholding obligations, settled in cash or repurchased by the Company in the future that would have been eligible for re-issuance under the 2017 Inducement Plan, were retired.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">2012 Equity Compensation Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Upon the 2015 Plan becoming effective, no further grants can be made under the 2012 Plan. The Company granted stock options to purchase a total of 1,140,524 shares under the 2012 Plan, of which 609,628 and 745,735 were outstanding as of June 30, 2020 and December 31, 2019, respectively.  Stock options granted under the 2012 Plan vested over four years and expire after ten years.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Stock Option Valuation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average assumptions the Company used to estimate the fair value of stock options granted during the six months ended June 30, 2020 and 2019 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.53</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.19</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101.70</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recognizes compensation expense for awards over their vesting period.  Compensation expense for awards includes the impact of forfeitures in the period when they occur.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Stock Options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes stock option activity for the six months ended June 30, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of Shares</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in years)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,102,221</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.55</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 148</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 734,800</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.30</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (557,222)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.33</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of June 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,279,799</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.90</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.99</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 316</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and expected to vest as of June 30, 2020</p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,279,799</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.90</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.99</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 316</p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable as of June 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,897,671</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.79</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The weighted average grant date fair value of stock options granted during the six months ended June 30, 2020 was $0.93 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Restricted Stock Units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes RSU activity for the six months ended June 30, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of Shares</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per Share</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,592,915</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.62</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 998,385</p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.26</p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr style="height:14.05pt;"><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,618,634)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.09</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (444,265)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.12</p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of June 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,528,401</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.36</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Stock-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation expense included in total costs and expenses on the condensed consolidated statement of operations included the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:58.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:58.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:58.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cost of revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 252</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 223</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 512</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 429</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:58.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:58.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,118</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,654</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,495</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,126</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2020, the Company had unrecognized stock-based compensation expense for stock options and RSUs of $8,195 and $8,604, respectively, which is expected to be recognized over weighted average periods of 1.52 years and 2.13 years, respectively.  </p> 1643872 0.040 1451997 1922147 443000 44390 0 1140524 609628 745735 P4Y P10Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.53</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.19</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101.70</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 0.0087 0.0253 P6Y1M6D P6Y3M18D 0.8519 1.0170 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of Shares</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in years)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,102,221</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.55</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 148</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 734,800</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.30</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (557,222)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.33</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of June 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,279,799</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.90</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.99</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 316</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and expected to vest as of June 30, 2020</p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,279,799</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.90</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.99</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 316</p></td><td style="vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable as of June 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,897,671</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.79</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div> 3102221 20.33 P6Y6M18D 148000 734800 1.30 557222 21.33 3279799 15.90 P6Y11M26D 316000 3279799 15.90 P6Y11M26D 316000 1897671 19.16 P5Y9M14D 79000 0.93 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of Shares</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per Share</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,592,915</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.62</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 998,385</p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.26</p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr style="height:14.05pt;"><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,618,634)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.09</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (444,265)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.12</p></td><td style="vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of June 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,528,401</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.36</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr></table> 3592915 4.62 998385 1.26 1618634 3.09 444265 4.12 2528401 4.36 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:58.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:58.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:58.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cost of revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 252</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 223</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 512</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 429</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:58.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:58.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,118</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,654</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,495</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,126</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 252000 223000 512000 429000 939000 1721000 1755000 3315000 2118000 2654000 4495000 5126000 3309000 4598000 6762000 8870000 8195000 8604000 P1Y6M7D P2Y1M17D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">10. Net Loss per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Basic and diluted net loss per share is summarized in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,597)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (49,876)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (87,441)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average shares of common stock outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,133,646</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,274,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,876,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,261,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.28)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.21)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.65)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.12)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s potentially dilutive securities, which included stock options, RSUs and warrants, have been excluded from the computation of diluted net loss per share since the effect would be to reduce the net loss per share. Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.  The following table presents potential shares of common stock excluded from the calculation of diluted net loss per share attributable to common stockholders for the three and six months ended June 30, 2020 and 2019.  All share amounts presented in the table below represent the total number outstanding as of June 30, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Options to purchase common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,279,799</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,010,423</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Restricted stock unit awards</p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,528,401</p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,959,587</p></td><td style="vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Warrants issued to SVB</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 460,251</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total potential shares of common stock</p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,268,451</p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,970,010</p></td><td style="vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,597)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (49,876)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (87,441)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average shares of common stock outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,133,646</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,274,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,876,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,261,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.28)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.21)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.65)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.12)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> -11597000 -49876000 -27183000 -87441000 42133646 41274808 41876037 41261808 -0.28 -1.21 -0.65 -2.12 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Options to purchase common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,279,799</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,010,423</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Restricted stock unit awards</p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,528,401</p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,959,587</p></td><td style="vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Warrants issued to SVB</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 460,251</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total potential shares of common stock</p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,268,451</p></td><td style="vertical-align:bottom;white-space:normal;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,970,010</p></td><td style="vertical-align:bottom;white-space:normal;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 3279799 4010423 2528401 1959587 460251 6268451 5970010 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">11. Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Agreements for Office Space</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In November 2017, the Company entered into a sublease agreement with Auxilium Pharmaceuticals, LLC (the “Sublandlord”) pursuant to which it subleases 33,019 square feet of office space for its headquarters in Wayne, Pennsylvania. The sublease has a term that runs through October 2023. If for any reason the lease between Chesterbrook Partners, LP (“the Landlord”) and Sublandlord is terminated or expires prior to October 2023, the Company’s sublease will automatically terminate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In February 2019, the Company entered into a sublease agreement with a third party for 21,056 square feet of office and laboratory space in St. Louis, Missouri. The lease commenced in June 2019 and has a term that runs through June 2029. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Supplemental balance sheet information related to operating leases is as follows:  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating Leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gross cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,213</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,213</p></td></tr><tr><td style="vertical-align:middle;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (789)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (480)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,424</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,733</p></td></tr><tr><td style="vertical-align:bottom;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 567</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 526</p></td></tr><tr><td style="vertical-align:middle;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,548</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,820</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,074</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Amortization expense related to operating lease right-of-use assets and liabilities was $253 and $143 for the three months ended June 30, 2020 and 2019, respectively, and $510 and $286 for the six months ended June 30, 2020 and 2019, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Finance Leases </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Laboratory Equipment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company leases laboratory equipment which is used in its laboratory space in St. Louis, Missouri under two finance lease financing arrangements which the Company entered into in August 2017 and October 2017.  The leases have terms which end in October 2020 and December 2020, respectively.  </p> 33019 21056 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating Leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gross cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,213</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,213</p></td></tr><tr><td style="vertical-align:middle;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (789)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (480)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,424</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,733</p></td></tr><tr><td style="vertical-align:bottom;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 567</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 526</p></td></tr><tr><td style="vertical-align:middle;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,548</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,820</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,074</p></td></tr></table> 5213000 5213000 789000 480000 4424000 4733000 567000 526000 3253000 3548000 3820000 4074000 253000 143000 510000 286000 2 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">12. Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Mallinckrodt plc</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In April 2018, Bryan Reasons was appointed to the Company’s board of directors. Subsequently, in March 2019, Mr. Reasons became the Chief Financial Officer of Mallinckrodt plc.  Prior to Mr. Reasons joining Mallinckrodt plc, the Company entered into a master services agreement with a subsidiary (“Mallinckrodt”) of Mallinckrodt plc in November 2018, pursuant to which Confluence provides laboratory services to Mallinckrodt in the ordinary course of business. Mr. Reasons was not involved in the negotiation or execution of the agreement, but may be deemed to have an interest in the ongoing transactions based on his employment as an executive officer of Mallinckrodt plc.  As of June 30, 2020 and December 31, 2019, the Company had invoiced Mallinckrodt for $292 and $57, respectively, under the master services agreement.  Mr. Reasons had no financial interest in these transactions.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p> 292000 57000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">13.</b><span style="font-style:italic;font-weight:bold;"> </span><b style="font-weight:bold;">Agreements Related to Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Asset Purchase Agreement – </b><b style="font-weight:bold;">EPI Health, </b><b style="font-weight:bold;">LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2019, the Company sold RHOFADE to EPI Health pursuant to an asset purchase agreement.  EPI Health agreed to pay the Company a high single-digit royalty calculated as a percentage of net sales on a country-by-country basis until the date that the patent rights related to RHOFADE have expired or, if later, 10 years from the date of the first commercial sale of RHOFADE in such country.  The Company recorded royalty income under the asset purchase agreement of $411 and $0 during the six months ended June 30, 2020 and 2019, respectively.  EPI Health has also agreed to pay the Company potential sales milestone payments of up to $20,000 in the aggregate upon the achievement of specified levels of net sales of products covered by the asset purchase agreement, and 25% of any upfront, license, milestone, maintenance or fixed payment received by EPI Health in connection with any license or sublicense of the assets transferred in the disposition in any territory outside of the United States, subject to specified exceptions.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Agreement and Plan of Merger – Confluence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2017, the Company entered into an Agreement and Plan of Merger, pursuant to which it acquired Confluence (the “Confluence Agreement”).  In November 2018, the Company achieved a development milestone specified in the Confluence Agreement, as a result of which the Company paid the former Confluence equity holders $2,500 in cash and issued them 253,208 shares of its common stock with a fair value of $2,200.  Under the Confluence Agreement, the Company also agreed to pay the former Confluence equity holders aggregate remaining contingent consideration of up to $75,000 based upon the achievement of specified regulatory and commercial milestones.  In addition, the Company agreed to pay the former Confluence equity holders future royalty payments calculated as a low single-digit percentage of annual net sales, subject to specified reductions, limitations and other adjustments, until the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis or, in specified circumstances, ten years from the first commercial sale of such product.  In addition, if the Company sells, licenses or transfers any of the intellectual property acquired from Confluence pursuant to the Confluence Agreement to a third party, the Company will be obligated to pay the former Confluence equity holders a portion of any consideration received from such sale, license or transfer in specified circumstances.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">License and Collaboration Agreement – Rigel Pharmaceuticals, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2015, the Company entered into an exclusive, worldwide license and collaboration agreement with Rigel Pharmaceuticals, Inc. (“Rigel”) for the development and commercialization of products containing two specified JAK inhibitors, which the Company refers to as ATI-501 and ATI-502.  Under the agreement, the Company agreed to make aggregate payments of up to $80,000 upon the achievement of specified development milestones.  In September 2019, the Company made a milestone payment of $4,000 to Rigel upon the achievement of a specified development milestone.  With respect to any products the Company commercializes under the agreement, the Company will pay Rigel quarterly tiered royalties on its annual net sales of each product at a high single-digit percentage of annual net sales, subject to specified reductions, until the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis or, in specified countries under specified circumstances, ten years from the first commercial sale of such product.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with an amendment of the agreement with Rigel in October 2019, the Company paid Rigel an amendment fee of $1,500 in three installments of $500 in each of January 2020, April 2020 and July 2020.  In addition, the parties modified certain other development milestones, and the Company agreed to increase the potential payments payable upon the achievement of such milestones from $10,000 to $10,500 in the aggregate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> P10Y 411000 0 20000 0.25 2500000 253208 2200000 75000000 P10Y 80000000 4000000 P10Y 1500000 3 500000 10000000 10500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">14. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company did not record a federal or state income tax benefit for losses incurred during the six months ended June 30, 2020 and 2019 due to the Company’s conclusion that a valuation allowance was required for those periods.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">15. Discontinued Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The components of loss from discontinued operations as reported in the Company’s condensed consolidated statement of operations were as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Product sales, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,757</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenue, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,979</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,757</p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs and expenses:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,279</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 380</p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,499</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 893</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,763</p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization of definite-lived intangible</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,319</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total costs and expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,170</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 285</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,240</p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (285)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,483)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss from discontinued operations per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.00)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.01)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.40)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common shares outstanding, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,133,646</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,274,808</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,876,037</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,261,808</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table presents the details of product sales, net included in discontinued operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ESKATA</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 272</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 344</p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RHOFADE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,413</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Total product sales, net</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,979</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,757</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">The following table presents information related to assets and liabilities reported as discontinued operations in the Company’s condensed consolidated balance sheet: </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.08%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts receivable, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,966</p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Discontinued operations - current assets</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,966</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,705</p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,452</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Discontinued operations - current liabilities</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,289</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,157</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table presents certain non-cash items related to discontinued operations, which are included in the Company’s condensed consolidated statement of cash flows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,552</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">806</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total non-cash items</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,358</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company relied on Allergan Sales, LLC (“Allergan”) to distribute RHOFADE on its behalf pursuant to the terms of a transition services agreement.  Accounts receivable, net as of June 30, 2020 and December 31, 2019 included $0 and $4,966, respectively, related to amounts invoiced by Allergan for sales of RHOFADE.  In addition, during the three months ended June 30, 2020, in accordance with the asset purchase agreement with EPI Health (see Note 13 for additional information), the Company received cash from Allergan related to sales of RHOFADE that occurred after the date the Company sold RHOFADE to EPI Health.  Accordingly, the Company had $4,950 payable to EPI Health, which is included in accrued expenses on the Company’s condensed consolidated balance sheet as of June 30, 2020.  </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The components of loss from discontinued operations as reported in the Company’s condensed consolidated statement of operations were as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Product sales, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,757</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenue, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,979</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,757</p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs and expenses:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,279</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 380</p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,499</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 893</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,763</p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization of definite-lived intangible</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,319</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total costs and expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,170</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 285</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,240</p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (285)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,483)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss from discontinued operations per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.00)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.01)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.40)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common shares outstanding, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,133,646</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,274,808</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,876,037</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,261,808</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table presents the details of product sales, net included in discontinued operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ESKATA</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 272</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 344</p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RHOFADE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,413</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Total product sales, net</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,979</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,757</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">The following table presents information related to assets and liabilities reported as discontinued operations in the Company’s condensed consolidated balance sheet: </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.08%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts receivable, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,966</p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Discontinued operations - current assets</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,966</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,705</p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,452</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Discontinued operations - current liabilities</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,289</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,157</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table presents certain non-cash items related to discontinued operations, which are included in the Company’s condensed consolidated statement of cash flows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,552</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">806</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total non-cash items</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,358</p></td></tr></table> 4979000 8757000 4979000 8757000 1709000 3279000 103000 1000 380000 27000 6805000 283000 16499000 893000 1000 1763000 1660000 3319000 27000 11170000 285000 25240000 -27000 -6191000 -285000 -16483000 0.00 -0.15 -0.01 -0.40 42133646 41274808 41876037 41261808 272000 344000 4707000 8413000 4979000 8757000 4966000 4966000 36000 1705000 2253000 2452000 2289000 4157000 3552000 806000 4358000 0 4966000 4950000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">16. Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has two reportable segments, therapeutics and contract research.  The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.  The contract research segment earns revenue from the provision of laboratory services to clients through Confluence, the Company’s wholly-owned subsidiary.  Contract research revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis.  Corporate and other includes general and administrative expenses as well as eliminations of intercompany transactions.  The Company does not report balance sheet information by segment since it is not reviewed by the chief operating decision maker, and all of the Company’s tangible assets are held in the United States.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s results of operations by segment for the three and six months ended June 30, 2020 and 2019 are summarized in the tables below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Three Months Ended June 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 193</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,657</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,804)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,046</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,693)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,389</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,577</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (111)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,466</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,884</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,572</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (6,384)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (113)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (4,884)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (11,381)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (27)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Three Months Ended June 30, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,807</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (2,921)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 886</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (2,825)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 994</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,615</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (96)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,519</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,469</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Goodwill impairment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,504</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,504</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (36,478)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (625)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (6,497)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (43,600)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from discontinued operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (5,298)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (893)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (6,191)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Six Months Ended June 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 411</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,064</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (4,022)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,453</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,810)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,658</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,121</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (212)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,909</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,773</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (15,710)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (844)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (10,333)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (26,887)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (284)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (285)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Six Months Ended June 30, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,995</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (6,846)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,149</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (6,655)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,201</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,352</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (191)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,161</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,145</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,926</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Goodwill impairment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,504</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,504</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (56,333)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,006)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (13,304)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (70,643)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from discontinued operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (14,720)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,763)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (16,483)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Intersegment Revenue</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue for the contract research segment included $4,022 and $6,846 for services performed on behalf of the therapeutics segment for the six months ended June 30, 2020 and 2019, respectively.  All intersegment revenue has been eliminated in the Company’s condensed consolidated statement of operations.  </p> 2 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Three Months Ended June 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 193</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,657</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,804)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,046</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,693)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,389</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,577</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (111)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,466</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,884</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,572</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (6,384)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (113)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (4,884)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (11,381)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (27)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Three Months Ended June 30, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,807</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (2,921)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 886</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (2,825)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 994</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,615</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (96)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,519</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,469</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Goodwill impairment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,504</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,504</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (36,478)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (625)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (6,497)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (43,600)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from discontinued operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (5,298)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (893)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (6,191)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Six Months Ended June 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 411</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,064</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (4,022)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,453</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,810)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,658</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,121</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (212)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,909</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,773</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (15,710)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (844)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (10,333)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (26,887)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (284)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (285)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Six Months Ended June 30, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,995</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (6,846)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,149</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (6,655)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,201</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,352</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (191)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,161</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,145</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,926</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Goodwill impairment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,504</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,504</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (56,333)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,006)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (13,304)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (70,643)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from discontinued operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (14,720)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,763)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (16,483)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr></table> 193000 3657000 -1804000 2046000 3082000 -1693000 1389000 6577000 -111000 6466000 688000 4884000 5572000 -6384000 -113000 -4884000 -11381000 -27000 -27000 3807000 -2921000 886000 3819000 -2825000 994000 17615000 -96000 17519000 359000 613000 6497000 7469000 18504000 18504000 -36478000 -625000 -6497000 -43600000 -5298000 -893000 -6191000 411000 7064000 -4022000 3453000 6468000 -3810000 2658000 16121000 -212000 15909000 1440000 10333000 11773000 -15710000 -844000 -10333000 -26887000 -284000 -1000 -285000 8995000 -6846000 2149000 8856000 -6655000 2201000 37352000 -191000 37161000 477000 1145000 13304000 14926000 18504000 18504000 -56333000 -1006000 -13304000 -70643000 -14720000 -1763000 -16483000 -4022000 -6846000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">17. Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Securities Class Action</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On July 30, 2019, plaintiff Linda Rosi (“Rosi”) filed a putative class action complaint captioned <i style="font-style:italic;">Rosi v. Aclaris Therapeutics, Inc., et al.</i> in the U.S. District Court for the Southern District of New York against the Company and certain of its executive officers.  The complaint alleges that the defendants violated federal securities laws by, among other things, failing to disclose an alleged likelihood that regulators would scrutinize advertising materials related to ESKATA and find that the materials minimized the risks or overstated the efficacy of the product.  The complaint seeks unspecified compensatory damages on behalf of Rosi and all other persons and entities that purchased or otherwise acquired the Company’s securities between May 8, 2018 and June 20, 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On September 5, 2019, an additional plaintiff, Robert Fulcher (“Fulcher”), filed a substantially identical putative class action complaint captioned <i style="font-style:italic;">Fulcher v. Aclaris Therapeutics, Inc., et al.</i> in the same court against the same defendants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On November 6, 2019, the court consolidated the Rosi and Fulcher actions (together, the “Consolidated Securities Action”) and appointed Fulcher “lead plaintiff” for the putative class.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January 24, 2020, Fulcher filed a consolidated amended complaint in the Consolidated Securities Action, naming two additional executive officers as defendants, extending the putative class period to August 12, 2019, and adding allegations concerning, among other things, alleged statements and omissions throughout the putative class period concerning ESKATA’s risks, tolerability and effectiveness. The defendants filed a motion to dismiss the consolidated amended complaint on April 17, 2020. Fulcher filed an opposition to the defendants’ motion on June 15, 2020, and the defendants filed a reply to such opposition on August 4, 2020. The motion remains under judicial consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company and the other defendants dispute plaintiffs’ claims in the Consolidated Securities Action and intend to defend the matter vigorously.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Stockholder Derivative Action</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On November 15, 2019, plaintiff Keith Allred (“Allred”) filed a derivative stockholder complaint captioned <i style="font-style:italic;">Allred v. Walker et al.</i> in the U.S. District Court for the Southern District of New York against certain of the Company’s directors and executive officers.  The complaint alleges that the defendants, among other things, breached their fiduciary duties as directors and/or officers in connection with the claims alleged in the Consolidated Securities Action.  The complaint seeks, among other things, unspecified compensatory damages on behalf of the Company.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On November 25, 2019, an additional plaintiff, Bruce Brown (“Brown”), filed a substantially identical complaint captioned <i style="font-style:italic;">Brown v. Walker et al.</i> in the same court against the same defendants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December 12, 2019, the court consolidated the Allred and Brown actions under the caption <i style="font-style:italic;">In re Aclaris Therapeutics, Inc. Derivative Litigation</i> (the “Consolidated Derivative Action”) and directed that future derivative cases filed in or transferred to the court arising out of substantially the same transactions or events be similarly consolidated.  Thereafter, on January 11, 2020, the court stayed – subject to certain conditions – all deadlines in the Consolidated Derivative Action pending resolution of the defendants’ anticipated motion to dismiss the Consolidated Securities Action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The defendants dispute plaintiffs’ claims in the Consolidated Derivative Action and intend to defend the matter vigorously.</p> 2 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2020
Aug. 06, 2020
Document and Entity Information    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2020  
Entity File Number 001-37581  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 640 Lee Road, Suite 200  
Entity Tax Identification Number 46-0571712  
Entity Address, City or Town Wayne  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19087  
City Area Code 484  
Local Phone Number 324-7933  
Title of 12(b) Security Common Stock  
Trading Symbol ACRS  
Security Exchange Name NASDAQ  
Entity Registrant Name Aclaris Therapeutics, Inc.  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   42,722,780
Entity Central Index Key 0001557746  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q2  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 32,587 $ 35,937
Marketable securities 35,528 39,078
Accounts receivable, net 775 704
Prepaid expenses and other current assets 2,065 3,118
Discontinued operations - current assets   4,966
Total current assets 70,955 83,803
Property and equipment, net 2,230 2,470
Intangible assets 7,161 7,199
Other assets 4,653 4,825
Total assets 84,999 98,297
Current liabilities:    
Accounts payable 5,502 9,917
Accrued expenses 9,344 7,721
Current portion of lease liabilities 610 637
Discontinued operations - current liabilities 2,289 4,157
Total current liabilities 17,745 22,432
Other liabilities 3,331 3,736
Long-term debt, net 10,573  
Contingent consideration 3,435 1,668
Deferred tax liability 549 549
Total liabilities 35,633 28,385
Stockholders' Equity:    
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at June 30, 2020 and December 31, 2019
Common stock, $0.00001 par value; 100,000,000 shares authorized at June 30, 2020 and December 31, 2019; 42,691,114 and 41,485,638 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively
Additional paidin capital 530,061 523,505
Accumulated other comprehensive income (loss) 15 (66)
Accumulated deficit (480,710) (453,527)
Total stockholders' equity 49,366 69,912
Total liabilities and stockholders' equity $ 84,999 $ 98,297
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2020
Dec. 31, 2019
CONDENSED CONSOLIDATED BALANCE SHEETS    
Preferred stock, par value (in dollars per share) $ 0.00001 $ 0.00001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.00001 $ 0.00001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 42,691,114 41,485,638
Common stock, shares outstanding 42,691,114 41,485,638
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Revenue, net $ 2,046 $ 886 $ 3,453 $ 2,149
Costs and expenses:        
Cost of revenue 1,389 994 2,658 2,201
Research and development 6,466 17,519 15,909 37,161
General and administrative 5,572 7,469 11,773 14,926
Goodwill impairment   18,504   18,504
Total costs and expenses 13,427 44,486 30,340 72,792
Loss from operations (11,381) (43,600) (26,887) (70,643)
Other income (expense), net (189) (85) (11) (315)
Loss from continuing operations (11,570) (43,685) (26,898) (70,958)
Loss from discontinued operations (27) (6,191) (285) (16,483)
Net loss $ (11,597) $ (49,876) $ (27,183) $ (87,441)
Net loss per share, basic and diluted $ (0.28) $ (1.21) $ (0.65) $ (2.12)
Weighted average common shares outstanding, basic and diluted (in shares) 42,133,646 41,274,808 41,876,037 41,261,808
Other comprehensive income (loss):        
Unrealized gain (loss) on marketable securities, net of tax of $0 $ (37) $ 30 $ 23 $ 64
Foreign currency translation adjustments 5 27 58 13
Total other comprehensive income (loss) (32) 57 81 77
Comprehensive loss (11,629) (49,819) (27,102) (87,364)
Contract research        
Revenue, net 1,853 $ 886 3,042 $ 2,149
Other revenue        
Revenue, net $ 193   $ 411  
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS        
Unrealized gain (loss) on marketable securities, tax $ 0 $ 0 $ 0 $ 0
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Total
Balance at beginning of period at Dec. 31, 2018   $ 507,366,000 $ (69,000) $ (292,173,000) $ 215,124,000
Balance at beginning of period (in shares) at Dec. 31, 2018 41,210,725        
Increase (Decrease) in Stockholders' Equity          
Vesting of restricted stock units   (188,000)     (188,000)
Vesting of restricted stock units, shares 58,918        
Unrealized gain (loss) on marketable securities     34,000   34,000
Foreign currency translation adjustment     (14,000)   (14,000)
Stock-based compensation expense   4,862,000     4,862,000
Net loss       (37,565,000) (37,565,000)
Balance at end of period at Mar. 31, 2019   512,040,000 (49,000) (329,738,000) 182,253,000
Balance at end of period (in shares) at Mar. 31, 2019 41,269,643        
Balance at beginning of period at Dec. 31, 2018   507,366,000 (69,000) (292,173,000) 215,124,000
Balance at beginning of period (in shares) at Dec. 31, 2018 41,210,725        
Increase (Decrease) in Stockholders' Equity          
Unrealized gain (loss) on marketable securities         64,000
Net loss         (87,441,000)
Balance at end of period at Jun. 30, 2019   516,836,000 8,000 (379,614,000) 137,230,000
Balance at end of period (in shares) at Jun. 30, 2019 41,278,570        
Balance at beginning of period at Mar. 31, 2019   512,040,000 (49,000) (329,738,000) 182,253,000
Balance at beginning of period (in shares) at Mar. 31, 2019 41,269,643        
Increase (Decrease) in Stockholders' Equity          
Vesting of restricted stock units   (18,000)     (18,000)
Vesting of restricted stock units, shares 8,927        
Unrealized gain (loss) on marketable securities     30,000   30,000
Foreign currency translation adjustment     27,000   27,000
Stock-based compensation expense   4,814,000     4,814,000
Net loss       (49,876,000) (49,876,000)
Balance at end of period at Jun. 30, 2019   516,836,000 8,000 (379,614,000) 137,230,000
Balance at end of period (in shares) at Jun. 30, 2019 41,278,570        
Balance at beginning of period at Dec. 31, 2019   523,505,000 (66,000) (453,527,000) $ 69,912,000
Balance at beginning of period (in shares) at Dec. 31, 2019 41,485,638       41,485,638
Increase (Decrease) in Stockholders' Equity          
Vesting of restricted stock units   (121,000)     $ (121,000)
Vesting of restricted stock units, shares 346,582        
Fair value of warrants issued   378,000     378,000
Unrealized gain (loss) on marketable securities     60,000   60,000
Foreign currency translation adjustment     53,000   53,000
Stock-based compensation expense   3,453,000     3,453,000
Net loss       (15,586,000) (15,586,000)
Balance at end of period at Mar. 31, 2020   527,215,000 47,000 (469,113,000) 58,149,000
Balance at end of period (in shares) at Mar. 31, 2020 41,832,220        
Balance at beginning of period at Dec. 31, 2019   523,505,000 (66,000) (453,527,000) $ 69,912,000
Balance at beginning of period (in shares) at Dec. 31, 2019 41,485,638       41,485,638
Increase (Decrease) in Stockholders' Equity          
Unrealized gain (loss) on marketable securities         $ 23,000
Net loss         (27,183,000)
Balance at end of period at Jun. 30, 2020   530,061,000 15,000 (480,710,000) $ 49,366,000
Balance at end of period (in shares) at Jun. 30, 2020 42,691,114       42,691,114
Balance at beginning of period at Mar. 31, 2020   527,215,000 47,000 (469,113,000) $ 58,149,000
Balance at beginning of period (in shares) at Mar. 31, 2020 41,832,220        
Increase (Decrease) in Stockholders' Equity          
Vesting of restricted stock units $ 858,894 (463,000)     (463,000)
Unrealized gain (loss) on marketable securities     (37,000)   (37,000)
Foreign currency translation adjustment     5,000   5,000
Stock-based compensation expense   3,309,000     3,309,000
Net loss       (11,597,000) (11,597,000)
Balance at end of period at Jun. 30, 2020   $ 530,061,000 $ 15,000 $ (480,710,000) $ 49,366,000
Balance at end of period (in shares) at Jun. 30, 2020 42,691,114       42,691,114
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Cash flows from operating activities:    
Net loss $ (27,183) $ (87,441)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,182 4,457
Stock-based compensation expense 6,762 9,676
Change in fair value of contingent consideration 1,767 734
Goodwill impairment charge   18,504
Changes in operating assets and liabilities:    
Accounts receivable 4,895 (14,509)
Prepaid expenses and other assets 890 2,579
Accounts payable (6,026) (583)
Accrued expenses 87 13,887
Net cash used in operating activities (17,626) (52,696)
Cash flows from investing activities:    
Purchases of property and equipment (141) (525)
Purchases of marketable securities (27,139) (89,407)
Proceeds from sales and maturities of marketable securities 30,735 117,500
Net cash provided by (used in) investing activities 3,455 27,568
Cash flows from financing activities:    
Proceeds from debt financing (including warrants), net of issuance costs 10,913  
Finance lease payments (92) (240)
Proceeds from exercise of employee stock options and the issuance of stock   3
Net cash (used in) provided by financing activities 10,821 (237)
Net decrease in cash and cash equivalents (3,350) (25,365)
Cash, cash equivalents and restricted cash at beginning of period 35,937 57,019
Cash, cash equivalents and restricted cash at end of period 32,587 31,654
Supplemental disclosure of non-cash investing and financing activities:    
Additions to property and equipment included in accounts payable $ 339 392
Operating lease asset recorded as a result of new accounting standard   $ 2,132
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Nature of Business
6 Months Ended
Jun. 30, 2020
Organization and Nature of Business  
Organization and Nature of Business

1. Organization and Nature of Business

Overview

Aclaris Therapeutics, Inc. was incorporated under the laws of the State of Delaware in 2012.  In July 2015, Aclaris Therapeutics International Limited (“ATIL”) was established under the laws of the United Kingdom as a wholly-owned subsidiary of Aclaris Therapeutics, Inc.  In August 2017, Confluence Life Sciences, Inc. (now known as Aclaris Life Sciences, Inc.) (“Confluence”) was acquired by Aclaris Therapeutics, Inc. and became a wholly-owned subsidiary thereof.  Aclaris Therapeutics, Inc., ATIL and Confluence are referred to collectively as the “Company.”  The Company is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company currently has a pipeline of drug candidates focused on immuno-inflammatory diseases, as well as one product approved by the U.S. Food and Drug Administration (“FDA”) that it is not currently distributing, marketing or selling, and other investigational drug candidates.  In September 2019, the Company announced the completion of a strategic review of its business, as a result of which it refocused its resources on its immuno-inflammatory development programs.  The Company is pursuing strategic alternatives, including identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its drug candidates and ESKATA (hydrogen peroxide) topical solution, 40% (w/w) (“ESKATA”), the Company’s non-marketed FDA-approved product.  

Liquidity

The Company’s condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business.  As of June 30, 2020, the Company had cash, cash equivalents and restricted cash and marketable securities of $68,115 and an accumulated deficit of $480,710. Since inception, the Company has incurred net losses and negative cash flows from its operations.  Prior to the acquisition of Confluence in August 2017, the Company had never generated revenue.  There can be no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis.  In addition, development activities, including clinical and preclinical testing of the Company’s drug candidates, will require significant additional financing.  The future viability of the Company is dependent on its ability to successfully develop its drug candidates and to generate revenue from identifying and consummating transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize its development assets or to raise additional capital to finance its operations.  The Company will require additional capital to complete the clinical development of ATI-450 and ATI-1777, to develop its preclinical compounds, and to support its discovery efforts.  Additional funds may not be available on a timely basis, on commercially acceptable terms, or at all, and such funds, if raised, may not be sufficient to enable the Company to continue to implement its long-term business strategy.  The Company’s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.  If the Company is unable to raise sufficient additional capital or generate revenue from transactions with third-party partners for the development and/or commercialization of its drug candidates, it may need to substantially curtail planned operations. The Company’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.  

In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that its consolidated financial statements are issued.  As of the report date, the Company believes the actions described below are probable of being implemented effectively and of alleviating the conditions or events that exist which raise substantial doubt about its ability to continue as a going concern within one year after the date of the issuance of these condensed consolidated financial statements.  The Company believes its existing

cash, cash equivalents and marketable securities are sufficient to fund its operating and capital expenditure requirements for a period greater than 12 months from the date of issuance of these condensed consolidated financial statements.  

The Company has taken a number of actions to support its operations and meet its liquidity needs.  In September 2019, the Company announced the completion of a strategic review and its decision to refocus its resources on its immuno-inflammatory development programs and to pursue strategic alternatives, including identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its drug candidates and ESKATA.  As a result of this decision, the Company restructured its operations and terminated employees, which lowered operating costs.  In October 2019, the Company sold the worldwide rights to RHOFADE (oxymetazoline hydrochloride) cream, 1% (“RHOFADE”) to further its focus on its development programs and improve cash flow.  In March 2020, the Company borrowed $11,000 under a term loan facility with Silicon Valley Bank.

The Company’s plans to further alleviate the substantial doubt about its going concern, which are probable of effectively being implemented and mitigating these conditions, primarily include its ability to control the timing and spending on its research and development programs.  The Company may also consider other plans to fund its operations including: (1) raising additional capital through debt or equity financings; (2) identifying third-party partners to further develop, obtain marketing approval for and/or commercialize its drug candidates and ESKATA, which may generate revenue and/or milestone payments; (3) reducing spending on one or more research and development programs by delaying or discontinuing development; and/or (4) further restructuring its operations to change its overhead structure. Finally, additional funds may not be available on a timely basis, on commercially acceptable terms, or at all, and such funds, if raised, may not be sufficient to enable the Company to continue to implement its long-term business strategy.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2020
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).  The condensed consolidated financial statements of the Company include the accounts of the operating parent company, Aclaris Therapeutics, Inc., and its wholly-owned subsidiaries, ATIL and Confluence.  All significant intercompany transactions have been eliminated.  Based upon the revenue from contract research services, the Company believes that gross profit does not provide a meaningful measure of profitability and, therefore, has not included a line item for gross profit on the condensed consolidated statement of operations.  

Discontinued Operations

In September 2019, the Company announced the completion of a strategic review and its decision to refocus its resources on its immuno-inflammatory development programs and to actively seek partners for its commercial products.  

The accompanying condensed consolidated financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to the Company’s commercial products as discontinued operations (see Note 15).  

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods.  Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development expenses, contingent consideration and the valuation of stock-based awards.  Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  The COVID-19 pandemic has resulted in a global slowdown of economic activity.  As of the date of issuance of these financial statements, the Company is not aware of any specific event

or circumstance that would require an update to its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities.  Actual results could differ from the Company’s estimates.

Unaudited Interim Financial Information

The accompanying condensed consolidated balance sheet as of June 30, 2020, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2020 and 2019, the condensed consolidated statement of stockholders’ equity for the three and six months ended June 30, 2020 and 2019, and the condensed consolidated statements of cash flows for the six months ended June 30, 2020 and 2019 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements contained in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 25, 2020 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of June 30, 2020, the results of its operations and comprehensive loss for the three and six months ended June 30, 2020 and 2019, its changes in stockholders’ equity for the three and six months ended June 30, 2020 and 2019 and its cash flows for the six months ended June 30, 2020 and 2019.  The condensed consolidated balance sheet data as of December 31, 2019 was derived from audited financial statements but does not include all disclosures required by GAAP.  The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2020 and 2019 are unaudited. The results for the three and six months ended June 30, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020, any other interim periods, or any future year or period.  The unaudited interim financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2019 included in the Company’s annual report on Form 10-K filed with the SEC on February 25, 2020.  

Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2019 included in the Company’s annual report on Form 10-K filed with the SEC on February 25, 2020.

Cash, Cash Equivalents and Restricted Cash

The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents.  Cash equivalents, which have consisted of money market accounts, commercial paper and corporate debt securities with original maturities of less than three months, are stated at fair value.  Restricted cash as of June 30, 2020 consisted of $1,753 placed in escrow pursuant to the asset purchase agreement with EPI Health, LLC (“EPI Health”) (see Note 13 for additional information).

Revenue Recognition

The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers.  Under ASC Topic 606, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.  

To determine revenue recognition in accordance with ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) performance obligations are satisfied.  At contract inception, the Company assesses the goods or services promised within a contract with a customer to identify the performance obligations, and to determine if they are distinct.  The Company recognizes the revenue that is allocated to each distinct performance obligation when (or as) that

performance obligation is satisfied.  The Company only recognizes revenue when collection of the consideration it is entitled to under a contract with a customer is probable.  

Contract Research

The Company earns contract research revenue from the provision of laboratory services to clients through Confluence, its wholly-owned subsidiary.  Contract research revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis and are generally billed on a monthly basis in arrears for services rendered.  Revenue related to these contracts is generally recognized as the laboratory services are performed, based upon the rates specified in the contracts.  Under ASC Topic 606, the Company elected to apply the “right to invoice” practical expedient when recognizing contract research revenue.  The Company recognizes contract research revenue in the amount to which it has the right to invoice.  

Other Revenue

Licenses of Intellectual Property – The Company recognizes revenue received from non-refundable, upfront fees related to the licensing of intellectual property when the intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the license has been transferred to the customer, and the customer is able to use and benefit from the license.  

Milestone Payments – At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the amount allocated to the license of intellectual property.  Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.  

Intangible Assets

Intangible assets include both definite-lived and indefinite-lived assets.  Definite-lived intangible assets are amortized over their estimated useful life based on the pattern over which the intangible assets are consumed or otherwise used up.  If that pattern cannot be reliably determined, the straight-line method of amortization is used.  Definite-lived intangible assets consist of a research technology platform the Company acquired through the acquisition of Confluence.  Indefinite-lived intangible assets consist of an in-process research and development (“IPR&D”) drug candidate acquired through the acquisition of Confluence.  IPR&D assets are considered indefinite-lived until the completion or abandonment of the associated research and development efforts.  The cost of IPR&D is either amortized over its estimated useful life beginning when the underlying drug candidate is approved and launched commercially, or expensed immediately if development of the drug candidate is abandoned.  

Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable.  Indefinite-lived intangible assets are tested for impairment at least annually, which the Company performs during the fourth quarter, or when indicators of an impairment are present.  The Company recognizes impairment losses when and to the extent that the estimated fair value of an intangible asset is less than its carrying value.  

Leases

Leases represent a company’s right to use an underlying asset and a corresponding obligation to make payments to a lessor for the right to use those assets.  The Company evaluates leases at their inception to determine if they are an operating lease or a finance lease.  A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows are substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the

underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term.  Leases that do not meet the finance lease criteria are accounted for as an operating lease.  

The Company recognizes assets and liabilities for leases at their inception based upon the present value of all payments due under the lease.  The Company uses an implicit interest rate to determine the present value of finance leases, and its incremental borrowing rate to determine the present value of operating leases.  The Company determines incremental borrowing rates by referencing collateralized borrowing rates for debt instruments with terms similar to the respective lease.  The Company recognizes expense for operating and finance leases on a straight-line basis over the term of each lease, and interest expense related to finance leases is recognized over the lease term based on the effective interest method.  The Company includes estimates for any residual value guarantee obligations under its leases in lease liabilities recorded on its condensed consolidated balance sheet.  

Right-of-use assets are included in other assets and property and equipment, net on the Company’s condensed consolidated balance sheet for operating and finance leases, respectively.  Obligations for lease payments are included in current portion of lease liabilities and other liabilities on the Company’s condensed consolidated balance sheet for both operating and finance leases.  

Contingent Consideration

The Company initially recorded a contingent consideration liability related to future potential payments based upon the achievement of certain development, regulatory and commercial milestones, as well as future projected sales performance, resulting from the acquisition of Confluence, at its estimated fair value on the date of acquisition.  The ultimate amount of future payments, if any, is based on criteria such as sales performance and the achievement of certain regulatory and sales milestones.  The Company estimates the fair value of the contingent consideration liability related to the achievement of regulatory milestones by assigning an achievement probability to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return.  The Company estimates the fair value of the contingent consideration liability associated with sales milestones and royalties by estimating future sales levels, assigning an achievement probability and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.  Significant assumptions used in the Company’s estimates include the probability of success of achieving regulatory and sales milestones, which are based upon an asset’s current stage of development and ranged between 4% and 15%.  The Company evaluates fair value estimates of contingent consideration liabilities on a periodic basis.  Any change in fair value reflects new information about the likelihood of the payment of the contingent consideration and the passage of time. For example, if the timing of the development of an acquired drug candidate, or the size of potential commercial opportunities related to an acquired drug, differ from the Company’s assumptions, then the fair value of contingent consideration would be adjusted accordingly. Future changes in the fair value of the contingent consideration, if any, will be recorded as income or expense in the Company’s condensed consolidated statement of operations.  

Concentration of Credit Risk and of Significant Suppliers

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds all cash, cash equivalents and marketable securities balances at one accredited financial institution, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

The Company is dependent on third-party manufacturers to supply drug product, including all underlying components, for its research and development activities, including preclinical and clinical testing.  These activities could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients or other components.  

Recently Issued Accounting Pronouncements

In November 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606.  The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  

In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40).  ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.  The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within such fiscal years.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).  The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements.  This update eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some of the existing disclosure requirements.  The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within such fiscal years.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value of Financial Assets and Liabilities
6 Months Ended
Jun. 30, 2020
Fair Value of Financial Assets and Liabilities  
Fair Value of Financial Assets and Liabilities

3. Fair Value of Financial Assets and Liabilities

The following tables present information about the fair value measurements of the Company’s financial assets and liabilities which are measured at fair value on a recurring and non-recurring basis, and indicate the level of the fair value hierarchy utilized to determine such fair values:

June 30, 2020

 

    

Level 1

    

Level 2

    

Level 3

    

Total

 

Assets:

    

    

    

    

    

    

    

    

Cash equivalents

$

16,754

$

$

$

16,754

Marketable securities

 

35,528

35,528

Total assets

$

16,754

$

35,528

$

$

52,282

Liabilities:

Acquisition-related contingent consideration

$

$

$

3,435

$

3,435

Total liabilities

$

$

$

3,435

$

3,435

December 31, 2019

 

    

Level 1

    

Level 2

    

Level 3

    

Total

 

Assets:

    

    

    

    

    

    

    

    

Cash equivalents

$

21,277

$

$

$

21,277

Marketable securities

 

39,078

39,078

Total assets

$

21,277

$

39,078

$

$

60,355

Liabilities:

Acquisition-related contingent consideration

$

$

$

1,668

$

1,668

Total liabilities

$

$

$

1,668

$

1,668

As of June 30, 2020 and December 31, 2019, the Company’s cash equivalents consisted of investments with maturities of less than three months and included a money market fund, which was valued based upon Level 1 inputs, and the Company’s marketable securities consisted of investments with maturities of more than three months and included commercial paper, corporate debt, asset-backed securities and government obligations, which were valued based upon Level 2 inputs.  In determining the fair value of its Level 2 investments, the Company relied on quoted prices for identical securities in markets that are not active. These quoted prices were obtained by the Company with the assistance of a third-party pricing service based on available trade, bid and other observable market data for identical securities.  Quarterly, the Company compares the quoted prices obtained from the third-party pricing service to other available independent pricing information to validate the reasonableness of the quoted prices provided.  The Company evaluates whether adjustments to third-party pricing is necessary and, historically, the Company has not made adjustments to quoted prices obtained from the third-party pricing service.  During the six months ended June 30, 2020 and 2019, there were no transfers between Level 1, Level 2 and Level 3.  The increase in contingent consideration of $1,767 during the six months ended June 30, 2020 was the result of updates to the Company’s assumptions as a result of the successful completion of a Phase 1 clinical trial for ATI-450.  

As of June 30, 2020 and December 31, 2019, the fair value of the Company’s available for sale marketable securities by type of security was as follows:

June 30, 2020

 

Gross

Gross

 

Amortized

Unrealized

Unrealized

Fair

 

Cost

Gain

Loss

Value

 

Marketable securities:

Corporate debt securities

$

5,688

$

2

$

$

5,690

Commercial paper

15,768

15,768

Asset-backed securities

1,408

(1)

1,407

U.S. government agency debt securities

12,637

26

12,663

Total marketable securities

$

35,501

$

28

$

(1)

$

35,528

December 31, 2019

 

Gross

Gross

 

Amortized

Unrealized

Unrealized

Fair

 

Cost

Gain

Loss

Value

 

Marketable securities:

    

    

    

    

    

    

    

    

Corporate debt securities

$

7,815

$

2

$

$

7,817

Commercial paper

15,129

15,129

Asset-backed securities

8,004

4

8,008

U.S. government agency debt securities

 

8,126

1

(3)

 

8,124

Total marketable securities

$

39,074

$

7

$

(3)

$

39,078

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment, Net
6 Months Ended
Jun. 30, 2020
Property and Equipment, Net  
Property and Equipment, Net

4. Property and Equipment, Net

Property and equipment, net consisted of the following:

June 30, 

December 31, 

2020

2019

 

Computer equipment

    

$

1,317

    

$

1,315

Finance lease right-of-use assets

435

435

Lab equipment

1,292

1,250

Furniture and fixtures

647

647

Leasehold improvements

1,200

889

Property and equipment, gross

 

4,891

 

4,536

Accumulated depreciation

 

(2,661)

 

(2,066)

Property and equipment, net

$

2,230

$

2,470

Depreciation expense was $297 and $393 for the three months ended June 30, 2020 and 2019, respectively, and $595 and $795 for the six months ended June 30, 2020 and 2019, respectively.  

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets
6 Months Ended
Jun. 30, 2020
Intangible Assets  
Intangible Assets

5. Intangible Assets

Intangible assets consisted of the following:

Gross Cost

Accumulated Amortization

Remaining

June 30, 

December 31, 

June 30, 

December 31, 

Life (years)

2020

2019

 

2020

2019

Other intangible assets

7.1

751

751

219

181

Total definite-lived intangible assets

751

751

219

181

IPR&D

na

6,629

6,629

Total intangible assets

$

7,380

$

7,380

$

219

$

181

As of June 30, 2020, estimated future amortization expense is as follows:

Year Ending December 31, 

    

    

2020

$

37

2021

 

75

2022

 

75

2023

75

2024

75

Thereafter

195

Total

$

532

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Expenses
6 Months Ended
Jun. 30, 2020
Accrued Expenses  
Accrued Expenses

6. Accrued Expenses

Accrued expenses consisted of the following:

June 30, 

December 31, 

2020

2019

 

Employee compensation expenses

$

2,489

$

3,321

Research and development expenses

1,134

2,857

Professional fees

112

168

Payable to EPI Health

4,950

Other

 

659

 

1,375

Total accrued expenses

$

9,344

$

7,721

Payable to EPI Health

As of June 30, 2020, the Company had $4,950 payable to EPI Health (see Note 15 for additional information).

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Debt
6 Months Ended
Jun. 30, 2020
Debt  
Debt

7. Debt

Loan and Security Agreement – Silicon Valley Bank

In March 2020, the Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”).  The Loan and Security Agreement provides for $11,000 in term loans, of which the Company borrowed the entire amount on March 30, 2020.  The Loan and Security Agreement is secured by substantially all of the assets of the Company other than intellectual property.  In connection with the Loan and Security Agreement, the Company issued to SVB a warrant to purchase up to 460,251 shares of common stock (the “Warrant”).  The proceeds of the Loan and Security Agreement were allocated to the term loan and Warrant using a relative fair value approach.  

The term loan repayment schedule provides for interest only payments beginning April 1, 2020 and continuing through March 1, 2022, followed by 24 consecutive equal monthly installments of principal, plus monthly payments of accrued interest, starting on April 1, 2022 and continuing through the maturity date of March 1, 2024. All outstanding principal and accrued and unpaid interest will be due and payable on the maturity date.  The Loan and Security Agreement provides for an annual interest rate equal to the greater of (i) the prime rate then in effect as reported in The Wall Street Journal plus 2% and (ii) 6.75%.  

The Loan and Security Agreement includes a final payment fee equal to 5% of the original principal amount borrowed.  The Company has the option to prepay the outstanding balance of the term loans in full, subject to a prepayment premium of (i) 3% of the original principal amount borrowed for any prepayment on or prior to the first anniversary of March 30, 2020, (ii) 2% of the original principal amount borrowed for any prepayment after the first anniversary and on or before the second anniversary of March 30, 2020 or (iii) 1% of the original principal amount borrowed for any prepayment after the second anniversary of March 30, 2020 but before March 1, 2024.  

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Stockholders' Equity
6 Months Ended
Jun. 30, 2020
Stockholders' Equity  
Stockholders' Equity

8. Stockholders’ Equity

Preferred Stock

As of June 30, 2020 and December 31, 2019, the Company’s amended and restated certificate of incorporation authorized the Company to issue 10,000,000 shares of undesignated preferred stock.  There were no shares of preferred stock outstanding as of June 30, 2020 or December 31, 2019.

Common Stock

As of June 30, 2020 and December 31, 2019, the Company’s amended and restated certificate of incorporation authorized the Company to issue 100,000,000 shares of $0.00001 par value common stock.

Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to any preferential dividend rights of any series of preferred stock that may be outstanding. No dividends have been declared through June 30, 2020.  

Warrants

In connection with the Loan and Security Agreement with SVB, the Company issued the Warrant to SVB.  The Warrant has an initial exercise price of $0.956 per share, subject to adjustment as provided in the Warrant. The Warrant became immediately exercisable in full upon the funding of the term loan facility. The Warrant will terminate, if not earlier exercised, on the earlier of March 29, 2030 and the closing of certain merger or other transactions in which the consideration is cash, stock of a publicly-traded acquirer or a combination thereof. The Company assigned a fair value of

$378 to the Warrant using a Black-Scholes valuation methodology, and also concluded that the Warrant was indexed to its own stock and therefore classified the Warrant as an equity instrument.  

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Stock-Based Awards
6 Months Ended
Jun. 30, 2020
Stock-Based Awards  
Stock-Based Awards

9. Stock-Based Awards

2015 Equity Incentive Plan

In September 2015, the Company’s board of directors adopted the 2015 Equity Incentive Plan (the “2015 Plan”), and the Company’s stockholders approved the 2015 Plan. The 2015 Plan became effective in connection with the Company’s initial public offering in October 2015.  Beginning at the time the 2015 Plan became effective, no further grants may be made under the Company’s 2012 Equity Compensation Plan, as amended and restated (the “2012 Plan”).  The 2015 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit (“RSU”) awards, performance stock awards, cash-based awards and other stock-based awards. The number of shares initially reserved for issuance under the 2015 Plan was 1,643,872 shares of common stock. The number of shares of common stock that may be issued under the 2015 Plan will automatically increase on January 1 of each year ending on January 1, 2025, in an amount equal to the lesser of (i) 4.0% of the shares of the Company’s common stock outstanding on December 31 of the preceding calendar year or (ii) an amount determined by the Company’s board of directors. The shares of common stock underlying any awards that expire, are otherwise terminated, settled in cash or repurchased by the Company under the 2015 Plan and the 2012 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan.  As of January 1, 2020, the number of shares of common stock that may be issued under the 2015 Plan was increased by 1,451,997 shares.  As of June 30, 2020, 1,922,147 shares remained available for grant under the 2015 Plan.  

2017 Inducement Plan

In July 2017, the Company’s board of directors adopted the 2017 Inducement Plan (the “2017 Inducement Plan”).  The 2017 Inducement Plan is a non-stockholder approved stock plan adopted pursuant to the “inducement exception” provided under Nasdaq listing rules.  The Company had 443,000 stock options and 44,390 RSUs outstanding as of June 30, 2020 under the 2017 Inducement Plan.  All shares of common stock that were eligible for issuance under the 2017 Inducement Plan after October 1, 2018, including any shares underlying any awards that expire or are otherwise terminated, reacquired to satisfy tax withholding obligations, settled in cash or repurchased by the Company in the future that would have been eligible for re-issuance under the 2017 Inducement Plan, were retired.  

2012 Equity Compensation Plan

Upon the 2015 Plan becoming effective, no further grants can be made under the 2012 Plan. The Company granted stock options to purchase a total of 1,140,524 shares under the 2012 Plan, of which 609,628 and 745,735 were outstanding as of June 30, 2020 and December 31, 2019, respectively.  Stock options granted under the 2012 Plan vested over four years and expire after ten years.  

Stock Option Valuation

The weighted average assumptions the Company used to estimate the fair value of stock options granted during the six months ended June 30, 2020 and 2019 were as follows:

    

Six Months Ended

June 30, 

2020

2019

 

Risk-free interest rate

 

0.87

%

2.53

%

Expected term (in years)

 

6.1

6.3

Expected volatility

 

85.19

%

101.70

%

Expected dividend yield

 

0

%

0

%

The Company recognizes compensation expense for awards over their vesting period.  Compensation expense for awards includes the impact of forfeitures in the period when they occur.  

Stock Options

The following table summarizes stock option activity for the six months ended June 30, 2020:

    

    

    

Weighted

    

 

Weighted

Average

 

Average

Remaining

Aggregate

 

Number

Exercise

Contractual

Intrinsic

 

of Shares

Price

Term

Value

 

(in years)

 

Outstanding as of December 31, 2019

 

3,102,221

$

20.33

 

6.55

$

148

Granted

 

734,800

1.30

Exercised

 

Forfeited and cancelled

 

(557,222)

21.33

Outstanding as of June 30, 2020

 

3,279,799

$

15.90

 

6.99

$

316

Options vested and expected to vest as of June 30, 2020

 

3,279,799

$

15.90

 

6.99

$

316

Options exercisable as of June 30, 2020

 

1,897,671

$

19.16

 

5.79

$

79

The weighted average grant date fair value of stock options granted during the six months ended June 30, 2020 was $0.93 per share.

Restricted Stock Units

The following table summarizes RSU activity for the six months ended June 30, 2020:

Weighted

Average

Grant Date

Number

Fair Value

of Shares

Per Share

Outstanding as of December 31, 2019

3,592,915

$

4.62

Granted

998,385

1.26

Vested

(1,618,634)

3.09

Forfeited and cancelled

(444,265)

4.12

Outstanding as of June 30, 2020

2,528,401

$

4.36

Stock-Based Compensation

Stock-based compensation expense included in total costs and expenses on the condensed consolidated statement of operations included the following:

Three Months Ended

Six Months Ended

 

June 30, 

June 30, 

 

    

2020

    

2019

    

2020

    

2019

 

Cost of revenue

    

$

252

    

$

223

  

$

512

    

$

429

Research and development

939

1,721

1,755

3,315

General and administrative

 

2,118

 

2,654

 

4,495

 

5,126

Total stock-based compensation expense

$

3,309

$

4,598

$

6,762

$

8,870

As of June 30, 2020, the Company had unrecognized stock-based compensation expense for stock options and RSUs of $8,195 and $8,604, respectively, which is expected to be recognized over weighted average periods of 1.52 years and 2.13 years, respectively.  

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss per Share
6 Months Ended
Jun. 30, 2020
Net Loss per Share  
Net Loss per Share

10. Net Loss per Share

Basic and diluted net loss per share is summarized in the following table:

Three Months Ended

Six Months Ended

 

June 30, 

June 30, 

 

2020

2019

    

2020

    

2019

Numerator:

    

    

    

    

    

    

    

Net loss

$

(11,597)

$

(49,876)

$

(27,183)

$

(87,441)

Denominator:

Weighted average shares of common stock outstanding

 

42,133,646

 

41,274,808

 

41,876,037

 

41,261,808

Net loss per share, basic and diluted

$

(0.28)

$

(1.21)

$

(0.65)

$

(2.12)

The Company’s potentially dilutive securities, which included stock options, RSUs and warrants, have been excluded from the computation of diluted net loss per share since the effect would be to reduce the net loss per share. Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.  The following table presents potential shares of common stock excluded from the calculation of diluted net loss per share attributable to common stockholders for the three and six months ended June 30, 2020 and 2019.  All share amounts presented in the table below represent the total number outstanding as of June 30, 2020 and 2019.

 

June 30, 

2020

2019

 

Options to purchase common stock

3,279,799

4,010,423

Restricted stock unit awards

2,528,401

1,959,587

Warrants issued to SVB

460,251

Total potential shares of common stock

6,268,451

5,970,010

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Leases
6 Months Ended
Jun. 30, 2020
Leases  
Leases

11. Leases

Operating Leases

Agreements for Office Space

In November 2017, the Company entered into a sublease agreement with Auxilium Pharmaceuticals, LLC (the “Sublandlord”) pursuant to which it subleases 33,019 square feet of office space for its headquarters in Wayne, Pennsylvania. The sublease has a term that runs through October 2023. If for any reason the lease between Chesterbrook Partners, LP (“the Landlord”) and Sublandlord is terminated or expires prior to October 2023, the Company’s sublease will automatically terminate.

In February 2019, the Company entered into a sublease agreement with a third party for 21,056 square feet of office and laboratory space in St. Louis, Missouri. The lease commenced in June 2019 and has a term that runs through June 2029.

Supplemental balance sheet information related to operating leases is as follows:  

June 30, 

December 31, 

Operating Leases:

2020

2019

Gross cost

$

5,213

$

5,213

Accumulated amortization

(789)

(480)

Other assets

$

4,424

$

4,733

Other current liabilities

$

567

$

526

Other liabilities

3,253

3,548

Total operating lease liabilities

$

3,820

$

4,074

Amortization expense related to operating lease right-of-use assets and liabilities was $253 and $143 for the three months ended June 30, 2020 and 2019, respectively, and $510 and $286 for the six months ended June 30, 2020 and 2019, respectively.

Finance Leases

Laboratory Equipment

The Company leases laboratory equipment which is used in its laboratory space in St. Louis, Missouri under two finance lease financing arrangements which the Company entered into in August 2017 and October 2017.  The leases have terms which end in October 2020 and December 2020, respectively.  

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions
6 Months Ended
Jun. 30, 2020
Related Party Transactions  
Related Party Transactions

12. Related Party Transactions

Mallinckrodt plc

In April 2018, Bryan Reasons was appointed to the Company’s board of directors. Subsequently, in March 2019, Mr. Reasons became the Chief Financial Officer of Mallinckrodt plc.  Prior to Mr. Reasons joining Mallinckrodt plc, the Company entered into a master services agreement with a subsidiary (“Mallinckrodt”) of Mallinckrodt plc in November 2018, pursuant to which Confluence provides laboratory services to Mallinckrodt in the ordinary course of business. Mr. Reasons was not involved in the negotiation or execution of the agreement, but may be deemed to have an interest in the ongoing transactions based on his employment as an executive officer of Mallinckrodt plc.  As of June 30, 2020 and December 31, 2019, the Company had invoiced Mallinckrodt for $292 and $57, respectively, under the master services agreement.  Mr. Reasons had no financial interest in these transactions.  

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Agreements Related to Intellectual Property
6 Months Ended
Jun. 30, 2020
Agreements Related to Intellectual Property  
Agreements Related to Intellectual Property

13. Agreements Related to Intellectual Property

Asset Purchase Agreement – EPI Health, LLC

In October 2019, the Company sold RHOFADE to EPI Health pursuant to an asset purchase agreement.  EPI Health agreed to pay the Company a high single-digit royalty calculated as a percentage of net sales on a country-by-country basis until the date that the patent rights related to RHOFADE have expired or, if later, 10 years from the date of the first commercial sale of RHOFADE in such country.  The Company recorded royalty income under the asset purchase agreement of $411 and $0 during the six months ended June 30, 2020 and 2019, respectively.  EPI Health has also agreed to pay the Company potential sales milestone payments of up to $20,000 in the aggregate upon the achievement of specified levels of net sales of products covered by the asset purchase agreement, and 25% of any upfront, license, milestone, maintenance or fixed payment received by EPI Health in connection with any license or sublicense of the assets transferred in the disposition in any territory outside of the United States, subject to specified exceptions.  

Agreement and Plan of Merger – Confluence

In August 2017, the Company entered into an Agreement and Plan of Merger, pursuant to which it acquired Confluence (the “Confluence Agreement”).  In November 2018, the Company achieved a development milestone specified in the Confluence Agreement, as a result of which the Company paid the former Confluence equity holders $2,500 in cash and issued them 253,208 shares of its common stock with a fair value of $2,200.  Under the Confluence Agreement, the Company also agreed to pay the former Confluence equity holders aggregate remaining contingent consideration of up to $75,000 based upon the achievement of specified regulatory and commercial milestones.  In addition, the Company agreed to pay the former Confluence equity holders future royalty payments calculated as a low single-digit percentage of annual net sales, subject to specified reductions, limitations and other adjustments, until the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis or, in specified circumstances, ten years from the first commercial sale of such product.  In addition, if the Company sells, licenses or transfers any of the intellectual property acquired from Confluence pursuant to the Confluence Agreement to a third party, the Company will be obligated to pay the former Confluence equity holders a portion of any consideration received from such sale, license or transfer in specified circumstances.  

License and Collaboration Agreement – Rigel Pharmaceuticals, Inc.

In August 2015, the Company entered into an exclusive, worldwide license and collaboration agreement with Rigel Pharmaceuticals, Inc. (“Rigel”) for the development and commercialization of products containing two specified JAK inhibitors, which the Company refers to as ATI-501 and ATI-502.  Under the agreement, the Company agreed to make aggregate payments of up to $80,000 upon the achievement of specified development milestones.  In September 2019, the Company made a milestone payment of $4,000 to Rigel upon the achievement of a specified development milestone.  With respect to any products the Company commercializes under the agreement, the Company will pay Rigel quarterly tiered royalties on its annual net sales of each product at a high single-digit percentage of annual net sales, subject to specified reductions, until the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis or, in specified countries under specified circumstances, ten years from the first commercial sale of such product.  

In connection with an amendment of the agreement with Rigel in October 2019, the Company paid Rigel an amendment fee of $1,500 in three installments of $500 in each of January 2020, April 2020 and July 2020.  In addition, the parties modified certain other development milestones, and the Company agreed to increase the potential payments payable upon the achievement of such milestones from $10,000 to $10,500 in the aggregate.

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes
6 Months Ended
Jun. 30, 2020
Income Taxes  
Income Taxes

14. Income Taxes

The Company did not record a federal or state income tax benefit for losses incurred during the six months ended June 30, 2020 and 2019 due to the Company’s conclusion that a valuation allowance was required for those periods.  

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Discontinued Operations
6 Months Ended
Jun. 30, 2020
Discontinued Operations  
Discontinued Operations

15. Discontinued Operations

The components of loss from discontinued operations as reported in the Company’s condensed consolidated statement of operations were as follows:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2020

    

2019

2020

    

2019

Revenues:

Product sales, net

    

$

    

$

4,979

    

$

    

$

8,757

Total revenue, net

4,979

8,757

Costs and expenses:

Cost of revenue

1,709

3,279

Research and development

 

103

1

380

Sales and marketing

27

6,805

283

16,499

General and administrative

 

893

1

1,763

Amortization of definite-lived intangible

1,660

3,319

Total costs and expenses

 

27

 

11,170

285

25,240

Loss from discontinued operations

 

$

(27)

$

(6,191)

$

(285)

$

(16,483)

Net loss from discontinued operations per share, basic and diluted

$

(0.00)

$

(0.15)

$

(0.01)

$

(0.40)

Weighted average common shares outstanding, basic and diluted

 

42,133,646

 

41,274,808

 

41,876,037

 

41,261,808

The following table presents the details of product sales, net included in discontinued operations:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2020

    

2019

2020

    

2019

ESKATA

  

$

    

$

272

$

    

$

344

RHOFADE

4,707

8,413

Total product sales, net

$

$

4,979

$

$

8,757

The following table presents information related to assets and liabilities reported as discontinued operations in the Company’s condensed consolidated balance sheet:

June 30, 

December 31,

    

2020

    

2019

Accounts receivable, net

  

$

    

$

4,966

Discontinued operations - current assets

$

$

4,966

Accounts payable

$

36

$

1,705

Accrued expenses

  

2,253

2,452

Discontinued operations - current liabilities

$

2,289

$

4,157

The following table presents certain non-cash items related to discontinued operations, which are included in the Company’s condensed consolidated statement of cash flows:

Six Months Ended

June 30, 

2020

    

2019

Depreciation and amortization

$

    

$

3,552

Stock-based compensation expense

806

Total non-cash items

$

$

4,358

The Company relied on Allergan Sales, LLC (“Allergan”) to distribute RHOFADE on its behalf pursuant to the terms of a transition services agreement.  Accounts receivable, net as of June 30, 2020 and December 31, 2019 included $0 and $4,966, respectively, related to amounts invoiced by Allergan for sales of RHOFADE.  In addition, during the three months ended June 30, 2020, in accordance with the asset purchase agreement with EPI Health (see Note 13 for additional information), the Company received cash from Allergan related to sales of RHOFADE that occurred after the date the Company sold RHOFADE to EPI Health.  Accordingly, the Company had $4,950 payable to EPI Health, which is included in accrued expenses on the Company’s condensed consolidated balance sheet as of June 30, 2020.  

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information
6 Months Ended
Jun. 30, 2020
Segment Information  
Segment Information

16. Segment Information

The Company has two reportable segments, therapeutics and contract research.  The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.  The contract research segment earns revenue from the provision of laboratory services to clients through Confluence, the Company’s wholly-owned subsidiary.  Contract research revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis.  Corporate and other includes general and administrative expenses as well as eliminations of intercompany transactions.  The Company does not report balance sheet information by segment since it is not reviewed by the chief operating decision maker, and all of the Company’s tangible assets are held in the United States.  

The Company’s results of operations by segment for the three and six months ended June 30, 2020 and 2019 are summarized in the tables below:

Contract

Corporate

Total

Three Months Ended June 30, 2020

Therapeutics

Research

and Other

Company

Total revenue

$

193

$

3,657

$

(1,804)

$

2,046

Cost of revenue

3,082

(1,693)

1,389

Research and development

6,577

(111)

6,466

General and administrative

688

4,884

5,572

Loss from operations

$

(6,384)

$

(113)

$

(4,884)

$

(11,381)

Loss from discontinued operations

$

(27)

$

$

$

(27)

Contract

Corporate

Total

Three Months Ended June 30, 2019

Therapeutics

Research

and Other

Company

Total revenue

$

$

3,807

$

(2,921)

$

886

Cost of revenue

3,819

(2,825)

994

Research and development

17,615

(96)

17,519

General and administrative

359

613

6,497

7,469

Goodwill impairment

18,504

18,504

Loss from operations

$

(36,478)

$

(625)

$

(6,497)

$

(43,600)

Loss from discontinued operations

$

(5,298)

$

$

(893)

$

(6,191)

Contract

Corporate

Total

Six Months Ended June 30, 2020

Therapeutics

Research

and Other

Company

Total revenue

$

411

$

7,064

$

(4,022)

$

3,453

Cost of revenue

6,468

(3,810)

2,658

Research and development

16,121

(212)

15,909

General and administrative

1,440

10,333

11,773

Loss from operations

$

(15,710)

$

(844)

$

(10,333)

$

(26,887)

Loss from discontinued operations

$

(284)

$

$

(1)

$

(285)

Contract

Corporate

Total

Six Months Ended June 30, 2019

Therapeutics

Research

and Other

Company

Total revenue

$

$

8,995

$

(6,846)

$

2,149

Cost of revenue

8,856

(6,655)

2,201

Research and development

37,352

(191)

37,161

General and administrative

477

1,145

13,304

14,926

Goodwill impairment

18,504

18,504

Loss from operations

$

(56,333)

$

(1,006)

$

(13,304)

$

(70,643)

Loss from discontinued operations

$

(14,720)

$

$

(1,763)

$

(16,483)

Intersegment Revenue

Revenue for the contract research segment included $4,022 and $6,846 for services performed on behalf of the therapeutics segment for the six months ended June 30, 2020 and 2019, respectively.  All intersegment revenue has been eliminated in the Company’s condensed consolidated statement of operations.  

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Legal Proceedings
6 Months Ended
Jun. 30, 2020
Legal Proceedings  
Legal Proceedings

17. Legal Proceedings

Securities Class Action

On July 30, 2019, plaintiff Linda Rosi (“Rosi”) filed a putative class action complaint captioned Rosi v. Aclaris Therapeutics, Inc., et al. in the U.S. District Court for the Southern District of New York against the Company and certain of its executive officers.  The complaint alleges that the defendants violated federal securities laws by, among other things, failing to disclose an alleged likelihood that regulators would scrutinize advertising materials related to ESKATA and find that the materials minimized the risks or overstated the efficacy of the product.  The complaint seeks unspecified compensatory damages on behalf of Rosi and all other persons and entities that purchased or otherwise acquired the Company’s securities between May 8, 2018 and June 20, 2019. 

On September 5, 2019, an additional plaintiff, Robert Fulcher (“Fulcher”), filed a substantially identical putative class action complaint captioned Fulcher v. Aclaris Therapeutics, Inc., et al. in the same court against the same defendants.

On November 6, 2019, the court consolidated the Rosi and Fulcher actions (together, the “Consolidated Securities Action”) and appointed Fulcher “lead plaintiff” for the putative class. 

On January 24, 2020, Fulcher filed a consolidated amended complaint in the Consolidated Securities Action, naming two additional executive officers as defendants, extending the putative class period to August 12, 2019, and adding allegations concerning, among other things, alleged statements and omissions throughout the putative class period concerning ESKATA’s risks, tolerability and effectiveness. The defendants filed a motion to dismiss the consolidated amended complaint on April 17, 2020. Fulcher filed an opposition to the defendants’ motion on June 15, 2020, and the defendants filed a reply to such opposition on August 4, 2020. The motion remains under judicial consideration.

The Company and the other defendants dispute plaintiffs’ claims in the Consolidated Securities Action and intend to defend the matter vigorously.

Stockholder Derivative Action

On November 15, 2019, plaintiff Keith Allred (“Allred”) filed a derivative stockholder complaint captioned Allred v. Walker et al. in the U.S. District Court for the Southern District of New York against certain of the Company’s directors and executive officers.  The complaint alleges that the defendants, among other things, breached their fiduciary duties as directors and/or officers in connection with the claims alleged in the Consolidated Securities Action.  The complaint seeks, among other things, unspecified compensatory damages on behalf of the Company.  

On November 25, 2019, an additional plaintiff, Bruce Brown (“Brown”), filed a substantially identical complaint captioned Brown v. Walker et al. in the same court against the same defendants.

On December 12, 2019, the court consolidated the Allred and Brown actions under the caption In re Aclaris Therapeutics, Inc. Derivative Litigation (the “Consolidated Derivative Action”) and directed that future derivative cases filed in or transferred to the court arising out of substantially the same transactions or events be similarly consolidated.  Thereafter, on January 11, 2020, the court stayed – subject to certain conditions – all deadlines in the Consolidated Derivative Action pending resolution of the defendants’ anticipated motion to dismiss the Consolidated Securities Action.

The defendants dispute plaintiffs’ claims in the Consolidated Derivative Action and intend to defend the matter vigorously.

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2020
Summary of Significant Accounting Policies  
Basis of Presentation

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).  The condensed consolidated financial statements of the Company include the accounts of the operating parent company, Aclaris Therapeutics, Inc., and its wholly-owned subsidiaries, ATIL and Confluence.  All significant intercompany transactions have been eliminated.  Based upon the revenue from contract research services, the Company believes that gross profit does not provide a meaningful measure of profitability and, therefore, has not included a line item for gross profit on the condensed consolidated statement of operations.  

Discontinued Operations

Discontinued Operations

In September 2019, the Company announced the completion of a strategic review and its decision to refocus its resources on its immuno-inflammatory development programs and to actively seek partners for its commercial products.  

The accompanying condensed consolidated financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to the Company’s commercial products as discontinued operations (see Note 15).  

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods.  Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development expenses, contingent consideration and the valuation of stock-based awards.  Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  The COVID-19 pandemic has resulted in a global slowdown of economic activity.  As of the date of issuance of these financial statements, the Company is not aware of any specific event

or circumstance that would require an update to its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities.  Actual results could differ from the Company’s estimates.

Unaudited Interim Financial Information

Unaudited Interim Financial Information

The accompanying condensed consolidated balance sheet as of June 30, 2020, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2020 and 2019, the condensed consolidated statement of stockholders’ equity for the three and six months ended June 30, 2020 and 2019, and the condensed consolidated statements of cash flows for the six months ended June 30, 2020 and 2019 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements contained in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 25, 2020 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of June 30, 2020, the results of its operations and comprehensive loss for the three and six months ended June 30, 2020 and 2019, its changes in stockholders’ equity for the three and six months ended June 30, 2020 and 2019 and its cash flows for the six months ended June 30, 2020 and 2019.  The condensed consolidated balance sheet data as of December 31, 2019 was derived from audited financial statements but does not include all disclosures required by GAAP.  The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2020 and 2019 are unaudited. The results for the three and six months ended June 30, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020, any other interim periods, or any future year or period.  The unaudited interim financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2019 included in the Company’s annual report on Form 10-K filed with the SEC on February 25, 2020.  

Significant Accounting Policies

Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2019 included in the Company’s annual report on Form 10-K filed with the SEC on February 25, 2020.

Cash, Cash Equivalents and Restricted Cash

Cash, Cash Equivalents and Restricted Cash

The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents.  Cash equivalents, which have consisted of money market accounts, commercial paper and corporate debt securities with original maturities of less than three months, are stated at fair value.  Restricted cash as of June 30, 2020 consisted of $1,753 placed in escrow pursuant to the asset purchase agreement with EPI Health, LLC (“EPI Health”) (see Note 13 for additional information).

Revenue Recognition

Revenue Recognition

The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers.  Under ASC Topic 606, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.  

To determine revenue recognition in accordance with ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) performance obligations are satisfied.  At contract inception, the Company assesses the goods or services promised within a contract with a customer to identify the performance obligations, and to determine if they are distinct.  The Company recognizes the revenue that is allocated to each distinct performance obligation when (or as) that

performance obligation is satisfied.  The Company only recognizes revenue when collection of the consideration it is entitled to under a contract with a customer is probable.  

Contract Research

The Company earns contract research revenue from the provision of laboratory services to clients through Confluence, its wholly-owned subsidiary.  Contract research revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis and are generally billed on a monthly basis in arrears for services rendered.  Revenue related to these contracts is generally recognized as the laboratory services are performed, based upon the rates specified in the contracts.  Under ASC Topic 606, the Company elected to apply the “right to invoice” practical expedient when recognizing contract research revenue.  The Company recognizes contract research revenue in the amount to which it has the right to invoice.  

Other Revenue

Licenses of Intellectual Property – The Company recognizes revenue received from non-refundable, upfront fees related to the licensing of intellectual property when the intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the license has been transferred to the customer, and the customer is able to use and benefit from the license.  

Milestone Payments – At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the amount allocated to the license of intellectual property.  Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.  

Intangible Assets

Intangible Assets

Intangible assets include both definite-lived and indefinite-lived assets.  Definite-lived intangible assets are amortized over their estimated useful life based on the pattern over which the intangible assets are consumed or otherwise used up.  If that pattern cannot be reliably determined, the straight-line method of amortization is used.  Definite-lived intangible assets consist of a research technology platform the Company acquired through the acquisition of Confluence.  Indefinite-lived intangible assets consist of an in-process research and development (“IPR&D”) drug candidate acquired through the acquisition of Confluence.  IPR&D assets are considered indefinite-lived until the completion or abandonment of the associated research and development efforts.  The cost of IPR&D is either amortized over its estimated useful life beginning when the underlying drug candidate is approved and launched commercially, or expensed immediately if development of the drug candidate is abandoned.  

Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable.  Indefinite-lived intangible assets are tested for impairment at least annually, which the Company performs during the fourth quarter, or when indicators of an impairment are present.  The Company recognizes impairment losses when and to the extent that the estimated fair value of an intangible asset is less than its carrying value.  

Leases

Leases

Leases represent a company’s right to use an underlying asset and a corresponding obligation to make payments to a lessor for the right to use those assets.  The Company evaluates leases at their inception to determine if they are an operating lease or a finance lease.  A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows are substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the

underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term.  Leases that do not meet the finance lease criteria are accounted for as an operating lease.  

The Company recognizes assets and liabilities for leases at their inception based upon the present value of all payments due under the lease.  The Company uses an implicit interest rate to determine the present value of finance leases, and its incremental borrowing rate to determine the present value of operating leases.  The Company determines incremental borrowing rates by referencing collateralized borrowing rates for debt instruments with terms similar to the respective lease.  The Company recognizes expense for operating and finance leases on a straight-line basis over the term of each lease, and interest expense related to finance leases is recognized over the lease term based on the effective interest method.  The Company includes estimates for any residual value guarantee obligations under its leases in lease liabilities recorded on its condensed consolidated balance sheet.  

Right-of-use assets are included in other assets and property and equipment, net on the Company’s condensed consolidated balance sheet for operating and finance leases, respectively.  Obligations for lease payments are included in current portion of lease liabilities and other liabilities on the Company’s condensed consolidated balance sheet for both operating and finance leases.  

Contingent Consideration

Contingent Consideration

The Company initially recorded a contingent consideration liability related to future potential payments based upon the achievement of certain development, regulatory and commercial milestones, as well as future projected sales performance, resulting from the acquisition of Confluence, at its estimated fair value on the date of acquisition.  The ultimate amount of future payments, if any, is based on criteria such as sales performance and the achievement of certain regulatory and sales milestones.  The Company estimates the fair value of the contingent consideration liability related to the achievement of regulatory milestones by assigning an achievement probability to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return.  The Company estimates the fair value of the contingent consideration liability associated with sales milestones and royalties by estimating future sales levels, assigning an achievement probability and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.  Significant assumptions used in the Company’s estimates include the probability of success of achieving regulatory and sales milestones, which are based upon an asset’s current stage of development and ranged between 4% and 15%.  The Company evaluates fair value estimates of contingent consideration liabilities on a periodic basis.  Any change in fair value reflects new information about the likelihood of the payment of the contingent consideration and the passage of time. For example, if the timing of the development of an acquired drug candidate, or the size of potential commercial opportunities related to an acquired drug, differ from the Company’s assumptions, then the fair value of contingent consideration would be adjusted accordingly. Future changes in the fair value of the contingent consideration, if any, will be recorded as income or expense in the Company’s condensed consolidated statement of operations.  

Concentration of Credit Risk and of Significant Suppliers

Concentration of Credit Risk and of Significant Suppliers

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds all cash, cash equivalents and marketable securities balances at one accredited financial institution, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

The Company is dependent on third-party manufacturers to supply drug product, including all underlying components, for its research and development activities, including preclinical and clinical testing.  These activities could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients or other components.  

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

In November 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606.  The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  

In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40).  ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.  The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within such fiscal years.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).  The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements.  This update eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some of the existing disclosure requirements.  The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within such fiscal years.  The Company adopted this standard as of January 1, 2020, the impact of which on its consolidated financial statements was not significant.  

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value of Financial Assets and Liabilities (Tables)
6 Months Ended
Jun. 30, 2020
Fair Value of Financial Assets and Liabilities  
Schedule of assets and liabilities measured at fair value on a recurring basis

June 30, 2020

 

    

Level 1

    

Level 2

    

Level 3

    

Total

 

Assets:

    

    

    

    

    

    

    

    

Cash equivalents

$

16,754

$

$

$

16,754

Marketable securities

 

35,528

35,528

Total assets

$

16,754

$

35,528

$

$

52,282

Liabilities:

Acquisition-related contingent consideration

$

$

$

3,435

$

3,435

Total liabilities

$

$

$

3,435

$

3,435

December 31, 2019

 

    

Level 1

    

Level 2

    

Level 3

    

Total

 

Assets:

    

    

    

    

    

    

    

    

Cash equivalents

$

21,277

$

$

$

21,277

Marketable securities

 

39,078

39,078

Total assets

$

21,277

$

39,078

$

$

60,355

Liabilities:

Acquisition-related contingent consideration

$

$

$

1,668

$

1,668

Total liabilities

$

$

$

1,668

$

1,668

Schedule of the fair value of available for sale marketable securities

June 30, 2020

 

Gross

Gross

 

Amortized

Unrealized

Unrealized

Fair

 

Cost

Gain

Loss

Value

 

Marketable securities:

Corporate debt securities

$

5,688

$

2

$

$

5,690

Commercial paper

15,768

15,768

Asset-backed securities

1,408

(1)

1,407

U.S. government agency debt securities

12,637

26

12,663

Total marketable securities

$

35,501

$

28

$

(1)

$

35,528

December 31, 2019

 

Gross

Gross

 

Amortized

Unrealized

Unrealized

Fair

 

Cost

Gain

Loss

Value

 

Marketable securities:

    

    

    

    

    

    

    

    

Corporate debt securities

$

7,815

$

2

$

$

7,817

Commercial paper

15,129

15,129

Asset-backed securities

8,004

4

8,008

U.S. government agency debt securities

 

8,126

1

(3)

 

8,124

Total marketable securities

$

39,074

$

7

$

(3)

$

39,078

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment, Net (Tables)
6 Months Ended
Jun. 30, 2020
Property and Equipment, Net  
Schedule of property and equipment, net

June 30, 

December 31, 

2020

2019

 

Computer equipment

    

$

1,317

    

$

1,315

Finance lease right-of-use assets

435

435

Lab equipment

1,292

1,250

Furniture and fixtures

647

647

Leasehold improvements

1,200

889

Property and equipment, gross

 

4,891

 

4,536

Accumulated depreciation

 

(2,661)

 

(2,066)

Property and equipment, net

$

2,230

$

2,470

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets (Tables)
6 Months Ended
Jun. 30, 2020
Intangible Assets  
Schedule of intangible assets

Gross Cost

Accumulated Amortization

Remaining

June 30, 

December 31, 

June 30, 

December 31, 

Life (years)

2020

2019

 

2020

2019

Other intangible assets

7.1

751

751

219

181

Total definite-lived intangible assets

751

751

219

181

IPR&D

na

6,629

6,629

Total intangible assets

$

7,380

$

7,380

$

219

$

181

Schedule of estimated future amortization expenses

Year Ending December 31, 

    

    

2020

$

37

2021

 

75

2022

 

75

2023

75

2024

75

Thereafter

195

Total

$

532

XML 40 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Expenses (Tables)
6 Months Ended
Jun. 30, 2020
Accrued Expenses  
Schedule of accrued expenses

June 30, 

December 31, 

2020

2019

 

Employee compensation expenses

$

2,489

$

3,321

Research and development expenses

1,134

2,857

Professional fees

112

168

Payable to EPI Health

4,950

Other

 

659

 

1,375

Total accrued expenses

$

9,344

$

7,721

XML 41 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Stock-Based Awards (Tables)
6 Months Ended
Jun. 30, 2020
Stock-Based Awards  
Assumptions used to determine fair value of stock options granted

    

Six Months Ended

June 30, 

2020

2019

 

Risk-free interest rate

 

0.87

%

2.53

%

Expected term (in years)

 

6.1

6.3

Expected volatility

 

85.19

%

101.70

%

Expected dividend yield

 

0

%

0

%

Summary of stock option activity

    

    

    

Weighted

    

 

Weighted

Average

 

Average

Remaining

Aggregate

 

Number

Exercise

Contractual

Intrinsic

 

of Shares

Price

Term

Value

 

(in years)

 

Outstanding as of December 31, 2019

 

3,102,221

$

20.33

 

6.55

$

148

Granted

 

734,800

1.30

Exercised

 

Forfeited and cancelled

 

(557,222)

21.33

Outstanding as of June 30, 2020

 

3,279,799

$

15.90

 

6.99

$

316

Options vested and expected to vest as of June 30, 2020

 

3,279,799

$

15.90

 

6.99

$

316

Options exercisable as of June 30, 2020

 

1,897,671

$

19.16

 

5.79

$

79

Summary of restricted stock units activity

Weighted

Average

Grant Date

Number

Fair Value

of Shares

Per Share

Outstanding as of December 31, 2019

3,592,915

$

4.62

Granted

998,385

1.26

Vested

(1,618,634)

3.09

Forfeited and cancelled

(444,265)

4.12

Outstanding as of June 30, 2020

2,528,401

$

4.36

Stock-based compensation expense

Three Months Ended

Six Months Ended

 

June 30, 

June 30, 

 

    

2020

    

2019

    

2020

    

2019

 

Cost of revenue

    

$

252

    

$

223

  

$

512

    

$

429

Research and development

939

1,721

1,755

3,315

General and administrative

 

2,118

 

2,654

 

4,495

 

5,126

Total stock-based compensation expense

$

3,309

$

4,598

$

6,762

$

8,870

XML 42 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss per Share (Tables)
6 Months Ended
Jun. 30, 2020
Net Loss per Share  
Basic and diluted net loss per share

Three Months Ended

Six Months Ended

 

June 30, 

June 30, 

 

2020

2019

    

2020

    

2019

Numerator:

    

    

    

    

    

    

    

Net loss

$

(11,597)

$

(49,876)

$

(27,183)

$

(87,441)

Denominator:

Weighted average shares of common stock outstanding

 

42,133,646

 

41,274,808

 

41,876,037

 

41,261,808

Net loss per share, basic and diluted

$

(0.28)

$

(1.21)

$

(0.65)

$

(2.12)

Potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders

 

June 30, 

2020

2019

 

Options to purchase common stock

3,279,799

4,010,423

Restricted stock unit awards

2,528,401

1,959,587

Warrants issued to SVB

460,251

Total potential shares of common stock

6,268,451

5,970,010

XML 43 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Tables)
6 Months Ended
Jun. 30, 2020
Leases  
Schedule of supplemental balance sheet information related to operating leases

June 30, 

December 31, 

Operating Leases:

2020

2019

Gross cost

$

5,213

$

5,213

Accumulated amortization

(789)

(480)

Other assets

$

4,424

$

4,733

Other current liabilities

$

567

$

526

Other liabilities

3,253

3,548

Total operating lease liabilities

$

3,820

$

4,074

XML 44 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Discontinued Operations (Tables)
6 Months Ended
Jun. 30, 2020
Discontinued Operations  
Schedule of discontinued operations

The components of loss from discontinued operations as reported in the Company’s condensed consolidated statement of operations were as follows:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2020

    

2019

2020

    

2019

Revenues:

Product sales, net

    

$

    

$

4,979

    

$

    

$

8,757

Total revenue, net

4,979

8,757

Costs and expenses:

Cost of revenue

1,709

3,279

Research and development

 

103

1

380

Sales and marketing

27

6,805

283

16,499

General and administrative

 

893

1

1,763

Amortization of definite-lived intangible

1,660

3,319

Total costs and expenses

 

27

 

11,170

285

25,240

Loss from discontinued operations

 

$

(27)

$

(6,191)

$

(285)

$

(16,483)

Net loss from discontinued operations per share, basic and diluted

$

(0.00)

$

(0.15)

$

(0.01)

$

(0.40)

Weighted average common shares outstanding, basic and diluted

 

42,133,646

 

41,274,808

 

41,876,037

 

41,261,808

The following table presents the details of product sales, net included in discontinued operations:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2020

    

2019

2020

    

2019

ESKATA

  

$

    

$

272

$

    

$

344

RHOFADE

4,707

8,413

Total product sales, net

$

$

4,979

$

$

8,757

The following table presents information related to assets and liabilities reported as discontinued operations in the Company’s condensed consolidated balance sheet:

June 30, 

December 31,

    

2020

    

2019

Accounts receivable, net

  

$

    

$

4,966

Discontinued operations - current assets

$

$

4,966

Accounts payable

$

36

$

1,705

Accrued expenses

  

2,253

2,452

Discontinued operations - current liabilities

$

2,289

$

4,157

The following table presents certain non-cash items related to discontinued operations, which are included in the Company’s condensed consolidated statement of cash flows:

Six Months Ended

June 30, 

2020

    

2019

Depreciation and amortization

$

    

$

3,552

Stock-based compensation expense

806

Total non-cash items

$

$

4,358

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information (Tables)
6 Months Ended
Jun. 30, 2020
Segment Information  
Summary of results of operations by segment

Contract

Corporate

Total

Three Months Ended June 30, 2020

Therapeutics

Research

and Other

Company

Total revenue

$

193

$

3,657

$

(1,804)

$

2,046

Cost of revenue

3,082

(1,693)

1,389

Research and development

6,577

(111)

6,466

General and administrative

688

4,884

5,572

Loss from operations

$

(6,384)

$

(113)

$

(4,884)

$

(11,381)

Loss from discontinued operations

$

(27)

$

$

$

(27)

Contract

Corporate

Total

Three Months Ended June 30, 2019

Therapeutics

Research

and Other

Company

Total revenue

$

$

3,807

$

(2,921)

$

886

Cost of revenue

3,819

(2,825)

994

Research and development

17,615

(96)

17,519

General and administrative

359

613

6,497

7,469

Goodwill impairment

18,504

18,504

Loss from operations

$

(36,478)

$

(625)

$

(6,497)

$

(43,600)

Loss from discontinued operations

$

(5,298)

$

$

(893)

$

(6,191)

Contract

Corporate

Total

Six Months Ended June 30, 2020

Therapeutics

Research

and Other

Company

Total revenue

$

411

$

7,064

$

(4,022)

$

3,453

Cost of revenue

6,468

(3,810)

2,658

Research and development

16,121

(212)

15,909

General and administrative

1,440

10,333

11,773

Loss from operations

$

(15,710)

$

(844)

$

(10,333)

$

(26,887)

Loss from discontinued operations

$

(284)

$

$

(1)

$

(285)

Contract

Corporate

Total

Six Months Ended June 30, 2019

Therapeutics

Research

and Other

Company

Total revenue

$

$

8,995

$

(6,846)

$

2,149

Cost of revenue

8,856

(6,655)

2,201

Research and development

37,352

(191)

37,161

General and administrative

477

1,145

13,304

14,926

Goodwill impairment

18,504

18,504

Loss from operations

$

(56,333)

$

(1,006)

$

(13,304)

$

(70,643)

Loss from discontinued operations

$

(14,720)

$

$

(1,763)

$

(16,483)

XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Nature of Business (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Production information      
Cash, cash equivalents and marketable securities $ 68,115    
Accumulated deficit $ 480,710   $ 453,527
Term Loan Facility      
Production information      
Loan borrowed   $ 11,000  
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2020
USD ($)
Maximum  
Cash, Cash Equivalents and Restricted Cash  
Probability of success of achieving regulatory and sales milestones 15.00%
Minimum  
Cash, Cash Equivalents and Restricted Cash  
Probability of success of achieving regulatory and sales milestones 4.00%
EPI Health, LLC  
Cash, Cash Equivalents and Restricted Cash  
Cash deposited in escrow $ 1,753
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies - Goodwill (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2019
Summary of Significant Accounting Policies    
Goodwill impairment charge $ 18,504 $ 18,504
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies - Stock-Based Compensation (Details) - item
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Summary of Significant Accounting Policies    
Expected dividend yield (as a percent) 0.00% 0.00%
Number of financial institutions holding entity funds 1  
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies - Recent Pronouncements (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Summary of Significant Accounting Policies    
Lease liability $ 3,820 $ 4,074
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value of Financial Assets and Liabilities (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Assets:      
Marketable securities $ 35,528   $ 39,078
Liabilities:      
Transfers from Level 1 to Level 2 0 $ 0  
Transfers from Level 2 to Level 1 0 0  
Transfers into or out of Level 3 0 0  
Change in fair value of contingent consideration 1,767 $ 734  
Confluence      
Liabilities:      
Change in fair value of contingent consideration 1,767    
Recurring      
Assets:      
Cash equivalents 16,754   21,277
Marketable securities 35,528   39,078
Total assets measured at fair value 52,282   60,355
Liabilities:      
Acquisition-related contingent consideration 3,435   1,668
Total liabilities measured at fair value 3,435   1,668
Recurring | Level 1      
Assets:      
Cash equivalents 16,754   21,277
Total assets measured at fair value 16,754   21,277
Recurring | Level 2      
Assets:      
Marketable securities 35,528   39,078
Total assets measured at fair value 35,528   39,078
Recurring | Level 3      
Liabilities:      
Acquisition-related contingent consideration 3,435   1,668
Total liabilities measured at fair value $ 3,435   $ 1,668
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value of Financial Assets and Liabilities - By Type (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Marketable securities:    
Amortized Cost $ 35,501 $ 39,074
Gross Unrealized Gain 28 7
Gross Unrealized Loss (1) (3)
Fair Value 35,528 39,078
Corporate debt securities    
Marketable securities:    
Amortized Cost 5,688 7,815
Gross Unrealized Gain 2 2
Fair Value 5,690 7,817
Commercial paper    
Marketable securities:    
Amortized Cost 15,768 15,129
Fair Value 15,768 15,129
Asset-backed securities    
Marketable securities:    
Amortized Cost 1,408 8,004
Gross Unrealized Gain   4
Gross Unrealized Loss (1)  
Fair Value 1,407 8,008
U.S. government agency debt securities    
Marketable securities:    
Amortized Cost 12,637 8,126
Gross Unrealized Gain 26 1
Gross Unrealized Loss   (3)
Fair Value $ 12,663 $ 8,124
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment, Net (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Property and Equipment, Net          
Finance lease right-of-use assets $ 435   $ 435   $ 435
Property and equipment, gross 4,891   4,891   4,536
Accumulated depreciation (2,661)   (2,661)   (2,066)
Property and equipment, net 2,230   2,230   2,470
Depreciation 297 $ 393 595 $ 795  
Computer equipment          
Property and Equipment, Net          
Property and equipment, gross 1,317   1,317   1,315
Lab equipment          
Property and Equipment, Net          
Property and equipment, gross 1,292   1,292   1,250
Furniture and fixtures          
Property and Equipment, Net          
Property and equipment, gross 647   647   647
Leasehold improvements          
Property and Equipment, Net          
Property and equipment, gross $ 1,200   $ 1,200   $ 889
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2020
Dec. 31, 2019
Definite-lived intangible assets    
Gross Cost $ 751 $ 751
Accumulated Amortization 219 181
Intangible assets, net    
Gross cost 7,380 7,380
IPR&D    
Definite-lived intangible assets    
Gross Cost $ 6,629 6,629
Other intangible assets    
Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]    
Remaining life 7 years 1 month 6 days  
Definite-lived intangible assets    
Gross Cost $ 751 751
Accumulated Amortization $ 219 $ 181
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets - Future Amortization Expenses (Details)
$ in Thousands
Jun. 30, 2020
USD ($)
Future amortization expenses  
2020 $ 37
2021 75
2022 75
2023 75
2024 75
Thereafter 195
Total $ 532
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Expenses (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Accrued Expenses    
Employee compensation expenses $ 2,489 $ 3,321
Research and development expenses 1,134 2,857
Professional fees 112 168
Payable to EPI Health 4,950  
Other 659 1,375
Total accrued expenses $ 9,344 $ 7,721
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Debt (Details)
$ in Thousands
1 Months Ended
Mar. 30, 2020
Mar. 31, 2020
USD ($)
installment
shares
SVB    
Debt Instrument [Line Items]    
Common stock warrants | shares   460,251
Term Loan Facility    
Debt Instrument [Line Items]    
Loan borrowed | $   $ 11,000
Number of consecutive monthly installments | installment   24
Annual interest rate   6.75%
Final payment fee percentage   5.00%
Term Loan Facility | Prepayment prior to the first anniversary of the Funding Date    
Debt Instrument [Line Items]    
Prepayment fee percentage 3.00%  
Term Loan Facility | Prepayment between the first and second anniversaries of the Funding Date    
Debt Instrument [Line Items]    
Prepayment fee percentage 2.00%  
Term Loan Facility | Prepayment after the second anniversary of the Funding Date but before October 1, 2023    
Debt Instrument [Line Items]    
Prepayment fee percentage 1.00%  
Term Loan Facility | Prime Rate    
Debt Instrument [Line Items]    
Basis spread over LIBOR   2.00%
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Stockholders' Equity (Details)
$ / shares in Units, $ in Thousands
6 Months Ended
Jun. 30, 2020
USD ($)
Vote
$ / shares
shares
Dec. 31, 2019
$ / shares
shares
Stockholders' Equity    
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares outstanding 0 0
Common stock, shares authorized 100,000,000 100,000,000
Common stock, par value (in dollars per share) | $ / shares $ 0.00001 $ 0.00001
Dividend declared | $ $ 0  
Initial exercise price | $ / shares $ 0.956  
Number of votes per share | Vote 1  
Fair value of warrants | $ $ 378  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Stock-Based Awards (Details) - shares
6 Months Ended 44 Months Ended
Jan. 01, 2020
Jun. 30, 2020
Jun. 30, 2019
Sep. 14, 2015
Dec. 31, 2019
Sep. 30, 2015
Stock-based awards            
Options granted (in shares)   734,800        
Options outstanding   3,279,799     3,102,221  
Stock Option Valuation            
Risk-free interest rate (as a percent)   0.87% 2.53%      
Expected term (in years)   6 years 1 month 6 days 6 years 3 months 18 days      
Expected volatility (as a percent)   85.19% 101.70%      
Expected dividend yield (as a percent)   0.00% 0.00%      
2017 Inducement Plan            
Stock-based awards            
Options outstanding   443,000        
2017 Inducement Plan | Restricted stock unit awards            
Stock-based awards            
Number of shares outstanding   44,390        
2015 Equity Incentive Plan            
Stock-based awards            
Number of shares authorized           1,643,872
Number of shares available for grant   1,922,147        
Percentage increase to shares available for grant from common outstanding as of preceding December 31 (as a percent)   4.00%        
Additional shares available 1,451,997          
2012 Equity Compensation Plan            
Stock-based awards            
Number of shares available for grant   0        
Options granted (in shares)       1,140,524    
Options outstanding   609,628     745,735  
Vesting period (in years)   4 years        
Term of award (in years)   10 years        
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Stock-Based Awards - Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2020
Dec. 31, 2019
Options, Number of Shares    
Number of Shares, beginning balance 3,102,221  
Number of Shares, Granted 734,800  
Number of Shares, Forfeited and cancelled (557,222)  
Number of Shares, ending balance 3,279,799 3,102,221
Number of Shares, Options vested and expected to vest 3,279,799  
Number of Shares, Options exercisable 1,897,671  
Options, Weighted Average Exercise Price    
Weighted Average Exercise Price, beginning balance (in dollars per share) $ 20.33  
Weighted Average Exercise Price, Granted (in dollars per share) 1.30  
Weighted Average Exercise Price, Forfeited and cancelled (in dollars per share) 21.33  
Weighted Average Exercise Price, ending balance (in dollars per share) 15.90 $ 20.33
Weighted Average Exercise Price, Options vested and expected to vest (in dollars per share) 15.90  
Weighted Average Exercise Price, Options exercisable (in dollars per share) $ 19.16  
Options, Weighted Average Remaining Contractual Term    
Weighted Average Remaining Contractual Term (in years) 6 years 11 months 26 days 6 years 6 months 18 days
Weighted Average Remaining Contractual Term, Options vested and expected to vest (in years) 6 years 11 months 26 days  
Weighted Average Remaining Contractual Term, Options exercisable (in years) 5 years 9 months 14 days  
Aggregate Intrinsic Value    
Aggregate Intrinsic Value $ 316 $ 148
Aggregate Intrinsic Value, Options vested and expected to vest 316  
Aggregate Intrinsic Value, Options exercisable $ 79  
Weighted average grant-date fair value of stock options granted (in dollars per share) $ 0.93  
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Stock-Based Awards - RSUs (Details) - Restricted stock unit awards
6 Months Ended
Jun. 30, 2020
$ / shares
shares
RSU, Number of Units  
Units outstanding, beginning of period | shares 3,592,915
Granted | shares 998,385
Vested | shares (1,618,634)
Forfeited and cancelled | shares (444,265)
Units outstanding, end of period | shares 2,528,401
RSU, Weighted Average Grant Date Fair Value Per Unit  
Weighted average grant date fair value, beginning balance (in dollars per share) | $ / shares $ 4.62
Granted, estimated grant-date fair value (in dollars per share) | $ / shares 1.26
Weighted average grant date fair value, vested (in dollars per share) | $ / shares 3.09
Forfeited and cancelled, estimated grant date fair value (in dollars per share) | $ / shares 4.12
Weighted average grant date fair value, ending balance (in dollars per share) | $ / shares $ 4.36
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Stock-Based Awards - Compensation (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Stock-based compensation expense        
Stock-based compensation expense $ 3,309 $ 4,598 $ 6,762 $ 8,870
Unrecognized stock-based compensation cost, options 8,195   8,195  
Unrecognized compensation, RSUs 8,604   8,604  
Cost of revenue.        
Stock-based compensation expense        
Stock-based compensation expense 252 223 512 429
Research and development        
Stock-based compensation expense        
Stock-based compensation expense 939 1,721 1,755 3,315
General and administrative        
Stock-based compensation expense        
Stock-based compensation expense $ 2,118 $ 2,654 $ 4,495 $ 5,126
Options to purchase common stock        
Stock-based compensation expense        
Weighted average recognition period unrecognized stock-based compensation cost (in years)     1 year 6 months 7 days  
Restricted stock unit awards        
Stock-based compensation expense        
Weighted average recognition period unrecognized stock-based compensation cost (in years)     2 years 1 month 17 days  
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Numerator:            
Net loss $ (11,597) $ (15,586) $ (49,876) $ (37,565) $ (27,183) $ (87,441)
Denominator:            
Weighted average shares of common stock outstanding (in shares) 42,133,646   41,274,808   41,876,037 41,261,808
Net loss per share, basic and diluted $ (0.28)   $ (1.21)   $ (0.65) $ (2.12)
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss per Share - Anti-dilution (Details) - shares
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders 6,268,451 5,970,010
Options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders 3,279,799 4,010,423
Restricted stock unit awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders 2,528,401 1,959,587
Warrants issued to SVB    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders 460,251  
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
item
Jun. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Feb. 28, 2019
ft²
Nov. 30, 2017
ft²
Lessee, Lease, Description [Line Items]              
Area leased, sublease agreement | ft²           21,056 33,019
Number of lease financing arrangements | item     2        
Amortization expense $ 253 $ 143 $ 510 $ 286      
Operating Leases:              
Gross cost 4,891   4,891   $ 4,536    
Accumulated amortization (2,661)   (2,661)   (2,066)    
Property and equipment, net 2,230   2,230   2,470    
Other current liabilities 567   567   526    
Other liabilities 3,253   3,253   3,548    
Total operating lease liabilities 3,820   3,820   4,074    
Operating Leases              
Operating Leases:              
Gross cost 5,213   5,213   5,213    
Accumulated amortization (789)   (789)   (480)    
Property and equipment, net $ 4,424   $ 4,424   $ 4,733    
Financial position us-gaap:OtherLiabilitiesCurrent   us-gaap:OtherLiabilitiesCurrent        
Financial position us-gaap:OtherLiabilitiesNoncurrent   us-gaap:OtherLiabilitiesNoncurrent        
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Mallinckrodt plc.    
Related Party Transactions    
Invoice amount $ 292 $ 57
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Agreements Related to Intellectual Property (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Oct. 31, 2019
USD ($)
installment
Nov. 30, 2018
USD ($)
shares
Aug. 31, 2017
USD ($)
Aug. 31, 2015
Jun. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Agreements Related to Intellectual Property                  
Revenue, Net         $ 2,046,000   $ 886,000 $ 3,453,000 $ 2,149,000
EPI Health LLC                  
Agreements Related to Intellectual Property                  
Potential milestone payments         20,000     20,000  
Percentage of upfront and license fees 25.00%                
Term of agreement 10 years                
EPI Health LLC | Royalty                  
Agreements Related to Intellectual Property                  
Revenue, Net               411,000 $ 0
Rigel                  
Agreements Related to Intellectual Property                  
Potential milestones payable $ 10,500,000         $ 10,000,000      
Milestone payment           $ 4,000,000      
Aggregate milestone payments         $ 80,000,000     $ 80,000,000  
Amendment fees payable $ 1,500,000                
Number of installments | installment 3                
Amendment fees payable, per installment $ 500,000                
License and Collaboration Agreement                  
Agreements Related to Intellectual Property                  
Term of agreement       10 years          
Agreement and Plan of Merger | Confluence                  
Agreements Related to Intellectual Property                  
Payment in cash   $ 2,500,000              
Number of shares | shares   253,208              
Fair value of common stock   $ 2,200,000              
Additional contingent consideration based on milestones, maximum, per Agreement     $ 75,000,000            
Royalty term     10 years            
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes - Rate Reconciliation (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Income Taxes    
Federal income tax benefit $ 0 $ 0
State income tax benefit $ 0 $ 0
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.20.2
Discontinued Operations - Loss (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]        
Total revenue, net   $ 4,979   $ 8,757
Cost of revenue (excludes amortization)   1,709   3,279
Research and development   103 $ 1 380
Sales and marketing $ 27 6,805 283 16,499
General and administrative   893 1 1,763
Amortization of definite-lived intangible   1,660   3,319
Total costs and expenses 27 11,170 285 25,240
Loss from discontinued operations (27) (6,191) (285) (16,483)
Loss from discontinued operations $ (27) $ (6,191) $ (285) $ (16,483)
Net loss from discontinued operations per share, basic and diluted $ 0.00 $ (0.15) $ (0.01) $ (0.40)
Weighted average common shares outstanding, basic and diluted (in shares) 42,133,646 41,274,808 41,876,037 41,261,808
Product sales, net        
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]        
Total revenue, net   $ 4,979   $ 8,757
ESKATA        
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]        
Total revenue, net   272   344
RHOFADE        
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]        
Total revenue, net   $ 4,707   $ 8,413
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.20.2
Discontinued Operations - Assets and Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]    
Accounts receivable, net   $ 4,966
Discontinued operations - current assets   4,966
Accounts payable $ 36 1,705
Accrued expenses 2,253 2,452
Discontinued operations - current liabilities $ 2,289 $ 4,157
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.20.2
Discontinued Operations - Cash Flow (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2019
USD ($)
Net Cash Provided by (Used in) Discontinued Operations [Abstract]  
Depreciation and amortization $ 3,552
Stock-based compensation expense 806
Total non-cash items $ 4,358
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.20.2
Discontinued Operations (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Accounts receivable, net   $ 4,966
Payable to EPI Health $ 4,950  
RHOFADE    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Accounts receivable, net 0 $ 4,966
Payable to EPI Health $ 4,950  
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
segment
Jun. 30, 2019
USD ($)
Segment Reporting Information [Line Items]        
Number of reportable segments | segment     2  
Revenue, net $ 2,046 $ 886 $ 3,453 $ 2,149
Cost of revenue 1,389 994 2,658 2,201
Research and development 6,466 17,519 15,909 37,161
General and administrative 5,572 7,469 11,773 14,926
Goodwill impairment   18,504   18,504
Loss from operations (11,381) (43,600) (26,887) (70,643)
Loss from discontinued operations (27) (6,191) (285) (16,483)
Dermatology Therapeutics Segment        
Segment Reporting Information [Line Items]        
Revenue, net 193   411  
Research and development 6,577 17,615 16,121 37,352
General and administrative   359   477
Goodwill impairment   18,504   18,504
Loss from operations (6,384) (36,478) (15,710) (56,333)
Loss from discontinued operations (27) (5,298) (284) (14,720)
Contract Research Segment        
Segment Reporting Information [Line Items]        
Revenue, net 3,657 3,807 7,064 8,995
Cost of revenue 3,082 3,819 6,468 8,856
General and administrative 688 613 1,440 1,145
Loss from operations (113) (625) (844) (1,006)
Corporate and Other        
Segment Reporting Information [Line Items]        
Revenue, net (1,804) (2,921) (4,022) (6,846)
Cost of revenue (1,693) (2,825) (3,810) (6,655)
Research and development (111) (96) (212) (191)
General and administrative 4,884 6,497 10,333 13,304
Loss from operations $ (4,884) (6,497) (10,333) (13,304)
Loss from discontinued operations   $ (893) (1) (1,763)
Intersegment Eliminations | Contract Research Segment        
Segment Reporting Information [Line Items]        
Revenue, net     $ (4,022) $ (6,846)
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.20.2
Legal Proceedings (Details)
Jan. 24, 2020
item
Executive officer  
Other Commitments [Line Items]  
Number of defendants 2
EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 76 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 171 346 1 false 57 0 false 9 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) Sheet http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) Statements 5 false false R6.htm 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 10101 - Disclosure - Organization and Nature of Business Sheet http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusiness Organization and Nature of Business Notes 8 false false R9.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 10301 - Disclosure - Fair Value of Financial Assets and Liabilities Sheet http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities Fair Value of Financial Assets and Liabilities Notes 10 false false R11.htm 10401 - Disclosure - Property and Equipment, Net Sheet http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNet Property and Equipment, Net Notes 11 false false R12.htm 10501 - Disclosure - Intangible Assets Sheet http://www.aclaristx.com/role/DisclosureIntangibleAssets Intangible Assets Notes 12 false false R13.htm 10601 - Disclosure - Accrued Expenses Sheet http://www.aclaristx.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 13 false false R14.htm 10701 - Disclosure - Debt Sheet http://www.aclaristx.com/role/DisclosureDebt Debt Notes 14 false false R15.htm 10801 - Disclosure - Stockholders' Equity Sheet http://www.aclaristx.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 10901 - Disclosure - Stock-Based Awards Sheet http://www.aclaristx.com/role/DisclosureStockBasedAwards Stock-Based Awards Notes 16 false false R17.htm 11001 - Disclosure - Net Loss per Share Sheet http://www.aclaristx.com/role/DisclosureNetLossPerShare Net Loss per Share Notes 17 false false R18.htm 11101 - Disclosure - Leases Sheet http://www.aclaristx.com/role/DisclosureLeases Leases Notes 18 false false R19.htm 11201 - Disclosure - Related Party Transactions Sheet http://www.aclaristx.com/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 19 false false R20.htm 11301 - Disclosure - Agreements Related to Intellectual Property Sheet http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualProperty Agreements Related to Intellectual Property Notes 20 false false R21.htm 11401 - Disclosure - Income Taxes Sheet http://www.aclaristx.com/role/DisclosureIncomeTaxes Income Taxes Notes 21 false false R22.htm 11501 - Disclosure - Discontinued Operations Sheet http://www.aclaristx.com/role/DisclosureDiscontinuedOperations Discontinued Operations Notes 22 false false R23.htm 11601 - Disclosure - Segment Information Sheet http://www.aclaristx.com/role/DisclosureSegmentInformation Segment Information Notes 23 false false R24.htm 11701 - Disclosure - Legal Proceedings Sheet http://www.aclaristx.com/role/DisclosureLegalProceedings Legal Proceedings Notes 24 false false R25.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPolicies 25 false false R26.htm 30303 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) Sheet http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables Fair Value of Financial Assets and Liabilities (Tables) Tables http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities 26 false false R27.htm 30403 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNet 27 false false R28.htm 30503 - Disclosure - Intangible Assets (Tables) Sheet http://www.aclaristx.com/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) Tables http://www.aclaristx.com/role/DisclosureIntangibleAssets 28 false false R29.htm 30603 - Disclosure - Accrued Expenses (Tables) Sheet http://www.aclaristx.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.aclaristx.com/role/DisclosureAccruedExpenses 29 false false R30.htm 30903 - Disclosure - Stock-Based Awards (Tables) Sheet http://www.aclaristx.com/role/DisclosureStockBasedAwardsTables Stock-Based Awards (Tables) Tables http://www.aclaristx.com/role/DisclosureStockBasedAwards 30 false false R31.htm 31003 - Disclosure - Net Loss per Share (Tables) Sheet http://www.aclaristx.com/role/DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://www.aclaristx.com/role/DisclosureNetLossPerShare 31 false false R32.htm 31103 - Disclosure - Leases (Tables) Sheet http://www.aclaristx.com/role/DisclosureLeasesTables Leases (Tables) Tables http://www.aclaristx.com/role/DisclosureLeases 32 false false R33.htm 31503 - Disclosure - Discontinued Operations (Tables) Sheet http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.aclaristx.com/role/DisclosureDiscontinuedOperations 33 false false R34.htm 31603 - Disclosure - Segment Information (Tables) Sheet http://www.aclaristx.com/role/DisclosureSegmentInformationTables Segment Information (Tables) Tables http://www.aclaristx.com/role/DisclosureSegmentInformation 34 false false R35.htm 40101 - Disclosure - Organization and Nature of Business (Details) Sheet http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusinessDetails Organization and Nature of Business (Details) Details http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusiness 35 false false R36.htm 40201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 36 false false R37.htm 40202 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details) Sheet http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillDetails Summary of Significant Accounting Policies - Goodwill (Details) Details 37 false false R38.htm 40203 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details) Sheet http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails Summary of Significant Accounting Policies - Stock-Based Compensation (Details) Details 38 false false R39.htm 40204 - Disclosure - Summary of Significant Accounting Policies - Recent Pronouncements (Details) Sheet http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentPronouncementsDetails Summary of Significant Accounting Policies - Recent Pronouncements (Details) Details 39 false false R40.htm 40301 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) Sheet http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails Fair Value of Financial Assets and Liabilities (Details) Details http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables 40 false false R41.htm 40302 - Disclosure - Fair Value of Financial Assets and Liabilities - By Type (Details) Sheet http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails Fair Value of Financial Assets and Liabilities - By Type (Details) Details http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables 41 false false R42.htm 40401 - Disclosure - Property and Equipment, Net (Details) Sheet http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails Property and Equipment, Net (Details) Details http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetTables 42 false false R43.htm 40501 - Disclosure - Intangible Assets (Details) Sheet http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails Intangible Assets (Details) Details http://www.aclaristx.com/role/DisclosureIntangibleAssetsTables 43 false false R44.htm 40502 - Disclosure - Intangible Assets - Future Amortization Expenses (Details) Sheet http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails Intangible Assets - Future Amortization Expenses (Details) Details 44 false false R45.htm 40601 - Disclosure - Accrued Expenses (Details) Sheet http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://www.aclaristx.com/role/DisclosureAccruedExpensesTables 45 false false R46.htm 40701 - Disclosure - Debt (Details) Sheet http://www.aclaristx.com/role/DisclosureDebtDetails Debt (Details) Details http://www.aclaristx.com/role/DisclosureDebt 46 false false R47.htm 40801 - Disclosure - Stockholders' Equity (Details) Sheet http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails Stockholders' Equity (Details) Details http://www.aclaristx.com/role/DisclosureStockholdersEquity 47 false false R48.htm 40901 - Disclosure - Stock-Based Awards (Details) Sheet http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails Stock-Based Awards (Details) Details http://www.aclaristx.com/role/DisclosureStockBasedAwardsTables 48 false false R49.htm 40902 - Disclosure - Stock-Based Awards - Option Activity (Details) Sheet http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails Stock-Based Awards - Option Activity (Details) Details 49 false false R50.htm 40903 - Disclosure - Stock-Based Awards - RSUs (Details) Sheet http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails Stock-Based Awards - RSUs (Details) Details 50 false false R51.htm 40904 - Disclosure - Stock-Based Awards - Compensation (Details) Sheet http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails Stock-Based Awards - Compensation (Details) Details 51 false false R52.htm 41001 - Disclosure - Net Loss per Share (Details) Sheet http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails Net Loss per Share (Details) Details http://www.aclaristx.com/role/DisclosureNetLossPerShareTables 52 false false R53.htm 41002 - Disclosure - Net Loss per Share - Anti-dilution (Details) Sheet http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails Net Loss per Share - Anti-dilution (Details) Details 53 false false R54.htm 41101 - Disclosure - Leases (Details) Sheet http://www.aclaristx.com/role/DisclosureLeasesDetails Leases (Details) Details http://www.aclaristx.com/role/DisclosureLeasesTables 54 false false R55.htm 41201 - Disclosure - Related Party Transactions (Details) Sheet http://www.aclaristx.com/role/DisclosureRelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.aclaristx.com/role/DisclosureRelatedPartyTransactions 55 false false R56.htm 41301 - Disclosure - Agreements Related to Intellectual Property (Details) Sheet http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails Agreements Related to Intellectual Property (Details) Details http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualProperty 56 false false R57.htm 41401 - Disclosure - Income Taxes - Rate Reconciliation (Details) Sheet http://www.aclaristx.com/role/DisclosureIncomeTaxesRateReconciliationDetails Income Taxes - Rate Reconciliation (Details) Details 57 false false R58.htm 41501 - Disclosure - Discontinued Operations - Loss (Details) Sheet http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails Discontinued Operations - Loss (Details) Details 58 false false R59.htm 41502 - Disclosure - Discontinued Operations - Assets and Liabilities (Details) Sheet http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails Discontinued Operations - Assets and Liabilities (Details) Details 59 false false R60.htm 41503 - Disclosure - Discontinued Operations - Cash Flow (Details) Sheet http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsCashFlowDetails Discontinued Operations - Cash Flow (Details) Details 60 false false R61.htm 41504 - Disclosure - Discontinued Operations (Details) Sheet http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsDetails Discontinued Operations (Details) Details http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsTables 61 false false R62.htm 41601 - Disclosure - Segment Information (Details) Sheet http://www.aclaristx.com/role/DisclosureSegmentInformationDetails Segment Information (Details) Details http://www.aclaristx.com/role/DisclosureSegmentInformationTables 62 false false R63.htm 41701 - Disclosure - Legal Proceedings (Details) Sheet http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails Legal Proceedings (Details) Details http://www.aclaristx.com/role/DisclosureLegalProceedings 63 false false All Reports Book All Reports acrs-20200630x10q.htm acrs-20200630.xsd acrs-20200630_cal.xml acrs-20200630_def.xml acrs-20200630_lab.xml acrs-20200630_pre.xml acrs-20200630xex10d2.htm acrs-20200630xex31d1.htm acrs-20200630xex31d2.htm acrs-20200630xex32d1.htm http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "acrs-20200630x10q.htm": { "axisCustom": 0, "axisStandard": 24, "contextCount": 171, "dts": { "calculationLink": { "local": [ "acrs-20200630_cal.xml" ] }, "definitionLink": { "local": [ "acrs-20200630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "acrs-20200630x10q.htm" ] }, "labelLink": { "local": [ "acrs-20200630_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "acrs-20200630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "acrs-20200630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 476, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 20, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 26 }, "keyCustom": 38, "keyStandard": 308, "memberCustom": 21, "memberStandard": 33, "nsprefix": "acrs", "nsuri": "http://www.aclaristx.com/20200630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Fair Value of Financial Assets and Liabilities", "role": "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities", "shortName": "Fair Value of Financial Assets and Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Property and Equipment, Net", "role": "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Intangible Assets", "role": "http://www.aclaristx.com/role/DisclosureIntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "acrs:AccruedLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Accrued Expenses", "role": "http://www.aclaristx.com/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "acrs:AccruedLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Debt", "role": "http://www.aclaristx.com/role/DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Stockholders' Equity", "role": "http://www.aclaristx.com/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Stock-Based Awards", "role": "http://www.aclaristx.com/role/DisclosureStockBasedAwards", "shortName": "Stock-Based Awards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Net Loss per Share", "role": "http://www.aclaristx.com/role/DisclosureNetLossPerShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "acrs:LesseeOperatingAndFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Leases", "role": "http://www.aclaristx.com/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "acrs:LesseeOperatingAndFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Related Party Transactions", "role": "http://www.aclaristx.com/role/DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "reportCount": 1, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Agreements Related to Intellectual Property", "role": "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualProperty", "shortName": "Agreements Related to Intellectual Property", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Income Taxes", "role": "http://www.aclaristx.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Discontinued Operations", "role": "http://www.aclaristx.com/role/DisclosureDiscontinuedOperations", "shortName": "Discontinued Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - Segment Information", "role": "http://www.aclaristx.com/role/DisclosureSegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11701 - Disclosure - Legal Proceedings", "role": "http://www.aclaristx.com/role/DisclosureLegalProceedings", "shortName": "Legal Proceedings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)", "role": "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables", "shortName": "Fair Value of Financial Assets and Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "acrs:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Intangible Assets (Tables)", "role": "http://www.aclaristx.com/role/DisclosureIntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "acrs:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "acrs:AccruedLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.aclaristx.com/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "acrs:AccruedLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_aDG2pVrqYEajaORSioFplw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_aDG2pVrqYEajaORSioFplw", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Stock-Based Awards (Tables)", "role": "http://www.aclaristx.com/role/DisclosureStockBasedAwardsTables", "shortName": "Stock-Based Awards (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Net Loss per Share (Tables)", "role": "http://www.aclaristx.com/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "acrs:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Leases (Tables)", "role": "http://www.aclaristx.com/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "acrs:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31503 - Disclosure - Discontinued Operations (Tables)", "role": "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsTables", "shortName": "Discontinued Operations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31603 - Disclosure - Segment Information (Tables)", "role": "http://www.aclaristx.com/role/DisclosureSegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Organization and Nature of Business (Details)", "role": "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "shortName": "Organization and Nature of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "acrs:ContingentConsiderationPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_srt_RangeAxis_srt_MaximumMember_TROmIRziuUWBlp4yciv5Qg", "decimals": "2", "first": true, "lang": null, "name": "acrs:ProbabilityOfSuccessOfAchievingRegulatoryAndSalesMilestones", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_TM-gha9h6E2rFU0d-sWnVw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "acrs:ContingentConsiderationPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_srt_RangeAxis_srt_MaximumMember_TROmIRziuUWBlp4yciv5Qg", "decimals": "2", "first": true, "lang": null, "name": "acrs:ProbabilityOfSuccessOfAchievingRegulatoryAndSalesMilestones", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_TM-gha9h6E2rFU0d-sWnVw", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_4_1_2019_To_6_30_2019_L6vTLdfAnkG12MvykKBLdA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details)", "role": "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillDetails", "shortName": "Summary of Significant Accounting Policies - Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "Unit_Standard_pure_TM-gha9h6E2rFU0d-sWnVw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40203 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)", "role": "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails", "shortName": "Summary of Significant Accounting Policies - Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": "INF", "lang": null, "name": "acrs:ConcentrationOfCreditRiskNumberOfFinancialInstitutions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_9WDhOQT-XkmMZUf0PyNJbQ", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeasesTextBlock", "acrs:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40204 - Disclosure - Summary of Significant Accounting Policies - Recent Pronouncements (Details)", "role": "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentPronouncementsDetails", "shortName": "Summary of Significant Accounting Policies - Recent Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_4_1_2020_To_6_30_2020_V8CQFNfiPUWh67OFokOhHA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "role": "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_4_1_2020_To_6_30_2020_V8CQFNfiPUWh67OFokOhHA", "decimals": "-3", "lang": null, "name": "acrs:CostAndExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)", "role": "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails", "shortName": "Fair Value of Financial Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_us-gaap_BusinessAcquisitionAxis_acrs_ConfluenceMember_u6K52nLOSUuMCVlJmisrnA", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Fair Value of Financial Assets and Liabilities - By Type (Details)", "role": "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails", "shortName": "Fair Value of Financial Assets and Liabilities - By Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Property and Equipment, Net (Details)", "role": "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails", "shortName": "Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_12_31_2019_3hLZF7qOdESd2a0BYrbZaA", "decimals": "-3", "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "acrs:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Intangible Assets (Details)", "role": "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "acrs:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Intangible Assets - Future Amortization Expenses (Details)", "role": "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails", "shortName": "Intangible Assets - Future Amortization Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "acrs:AccruedLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Accrued Expenses (Details)", "role": "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "acrs:AccruedLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_3_31_2020_srt_CounterpartyNameAxis_acrs_SiliconValleyBankMember_jwtibqohMEiQZ2ros4suvA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_pdyILrXTxk2Nm3a0Q8SGAw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Debt (Details)", "role": "http://www.aclaristx.com/role/DisclosureDebtDetails", "shortName": "Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_3_31_2020_srt_CounterpartyNameAxis_acrs_SiliconValleyBankMember_jwtibqohMEiQZ2ros4suvA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_pdyILrXTxk2Nm3a0Q8SGAw", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_pdyILrXTxk2Nm3a0Q8SGAw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Stockholders' Equity (Details)", "role": "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "lang": null, "name": "us-gaap:DividendsPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Unit_Standard_shares_pdyILrXTxk2Nm3a0Q8SGAw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Stock-Based Awards (Details)", "role": "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "shortName": "Stock-Based Awards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": "4", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_TM-gha9h6E2rFU0d-sWnVw", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_12_31_2019_3hLZF7qOdESd2a0BYrbZaA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_pdyILrXTxk2Nm3a0Q8SGAw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Stock-Based Awards - Option Activity (Details)", "role": "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails", "shortName": "Stock-Based Awards - Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_pdyILrXTxk2Nm3a0Q8SGAw", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_4_1_2020_To_6_30_2020_V8CQFNfiPUWh67OFokOhHA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)", "role": "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_4_1_2020_To_6_30_2020_V8CQFNfiPUWh67OFokOhHA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_QFRjQgay7Ua-uiNDoeC6-w", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_pdyILrXTxk2Nm3a0Q8SGAw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40903 - Disclosure - Stock-Based Awards - RSUs (Details)", "role": "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails", "shortName": "Stock-Based Awards - RSUs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_QFRjQgay7Ua-uiNDoeC6-w", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_pdyILrXTxk2Nm3a0Q8SGAw", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_4_1_2020_To_6_30_2020_V8CQFNfiPUWh67OFokOhHA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40904 - Disclosure - Stock-Based Awards - Compensation (Details)", "role": "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails", "shortName": "Stock-Based Awards - Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_4_1_2020_To_6_30_2020_V8CQFNfiPUWh67OFokOhHA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_4_1_2020_To_6_30_2020_V8CQFNfiPUWh67OFokOhHA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Net Loss per Share (Details)", "role": "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails", "shortName": "Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_pdyILrXTxk2Nm3a0Q8SGAw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Net Loss per Share - Anti-dilution (Details)", "role": "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails", "shortName": "Net Loss per Share - Anti-dilution (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_pdyILrXTxk2Nm3a0Q8SGAw", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "acrs:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_2_28_2019_z1tvGVYWz02CnvTNOtL94Q", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NetRentableArea", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_sqft_A-Cog-8QlU-eY1Gfi13-iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Leases (Details)", "role": "http://www.aclaristx.com/role/DisclosureLeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "acrs:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_2_28_2019_z1tvGVYWz02CnvTNOtL94Q", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NetRentableArea", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_sqft_A-Cog-8QlU-eY1Gfi13-iQ", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_acrs_MallinckrodtPlc.Member_S_qGoeyiGE2DmL_uOxad6w", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableRelatedParties", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Related Party Transactions (Details)", "role": "http://www.aclaristx.com/role/DisclosureRelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_acrs_MallinckrodtPlc.Member_S_qGoeyiGE2DmL_uOxad6w", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableRelatedParties", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_4_1_2020_To_6_30_2020_V8CQFNfiPUWh67OFokOhHA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Agreements Related to Intellectual Property (Details)", "role": "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails", "shortName": "Agreements Related to Intellectual Property (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_acrs_EPIHealthLLCMember_h9j9OjIBok6akUNB3QnCxg", "decimals": "2", "lang": null, "name": "acrs:PercentageOfUpfrontAndLicenseFees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_TM-gha9h6E2rFU0d-sWnVw", "xsiNil": "false" } }, "R57": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Income Taxes - Rate Reconciliation (Details)", "role": "http://www.aclaristx.com/role/DisclosureIncomeTaxesRateReconciliationDetails", "shortName": "Income Taxes - Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_4_1_2019_To_6_30_2019_L6vTLdfAnkG12MvykKBLdA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Discontinued Operations - Loss (Details)", "role": "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails", "shortName": "Discontinued Operations - Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_4_1_2019_To_6_30_2019_L6vTLdfAnkG12MvykKBLdA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_12_31_2019_3hLZF7qOdESd2a0BYrbZaA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41502 - Disclosure - Discontinued Operations - Assets and Liabilities (Details)", "role": "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "shortName": "Discontinued Operations - Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_15HUCfcWzka-_4A_JNrRyw", "decimals": "-3", "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TTZcTRtQm0eQF_7q5l2Law", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HYKIT4x9BUKP2z7JjBFGRw", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2019_To_6_30_2019_l2qkrlww2Ui4IjrCPgiRQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortizationDiscontinuedOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41503 - Disclosure - Discontinued Operations - Cash Flow (Details)", "role": "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsCashFlowDetails", "shortName": "Discontinued Operations - Cash Flow (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2019_To_6_30_2019_l2qkrlww2Ui4IjrCPgiRQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortizationDiscontinuedOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_12_31_2019_3hLZF7qOdESd2a0BYrbZaA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41504 - Disclosure - Discontinued Operations (Details)", "role": "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsDetails", "shortName": "Discontinued Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "As_Of_6_30_2020_srt_ProductOrServiceAxis_acrs_RhofadeProductMember_OKRN_rrO1kmYrpnfoUVTCA", "decimals": "-3", "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_DGnS9BZT60WS6XGUYLj5Vg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41601 - Disclosure - Segment Information (Details)", "role": "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_DGnS9BZT60WS6XGUYLj5Vg", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_24_2020_To_1_24_2020_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_iffKfROOoEa6svJDrmt5VQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LossContingencyNumberOfDefendants", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_9WDhOQT-XkmMZUf0PyNJbQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41701 - Disclosure - Legal Proceedings (Details)", "role": "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails", "shortName": "Legal Proceedings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_24_2020_To_1_24_2020_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_iffKfROOoEa6svJDrmt5VQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LossContingencyNumberOfDefendants", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_9WDhOQT-XkmMZUf0PyNJbQ", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RUS1gBsYlkWuV1V2ud_KxQ", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Organization and Nature of Business", "role": "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusiness", "shortName": "Organization and Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20200630x10q.htm", "contextRef": "Duration_1_1_2020_To_6_30_2020_rMA53YQY8ESSzWQJpTE3JA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 57, "tag": { "acrs_AccruedLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accrued expenses and other liabilities that are classified as current at the end of the reporting period.", "label": "Accrued Liabilities Disclosure Current [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "acrs_AccruedResearchAndDevelopmentCostsCurrent": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The liability for the aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. This is the portion of that liability expected to be paid within one year of the date of the statement of financial position.", "label": "Accrued Research And Development Costs, Current", "terseLabel": "Research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentCostsCurrent", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "acrs_AgreementAndPlanOfMergerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for Agreement and Plan of Merger.", "label": "Agreement And Plan Of Merger [Member]", "terseLabel": "Agreement and Plan of Merger" } } }, "localname": "AgreementAndPlanOfMergerMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "domainItemType" }, "acrs_AgreementTermDuration": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The term of agreement.", "label": "Agreement Term, Duration", "terseLabel": "Term of agreement" } } }, "localname": "AgreementTermDuration", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "durationItemType" }, "acrs_AmendmentFeesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of amendment fees payable due to amendment in agreement.", "label": "Amendment Fees Payable", "terseLabel": "Amendment fees payable" } } }, "localname": "AmendmentFeesPayable", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "acrs_AmendmentFeesPayablePerInstallment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of amendment fees payable per installment due to amendment in agreement.", "label": "Amendment Fees Payable, Per Installment", "terseLabel": "Amendment fees payable, per installment" } } }, "localname": "AmendmentFeesPayablePerInstallment", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "acrs_AssetPurchaseAgreementPayables": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying balance as of the balance sheet date of payables under asset purchase agreement with EPI health.", "label": "Asset Purchase Agreement Payables", "terseLabel": "Payable to EPI Health" } } }, "localname": "AssetPurchaseAgreementPayables", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails", "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "acrs_AssetPurchaseAgreementThresholdConditionalPotentialSalesMilestoneReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of threshold potential sales milestone payments receivable upon the achievement of specified levels of net sales of products.", "label": "Asset Purchase Agreement, Threshold Conditional Potential Sales Milestone Receivable", "terseLabel": "Potential milestone payments" } } }, "localname": "AssetPurchaseAgreementThresholdConditionalPotentialSalesMilestoneReceivable", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "acrs_BusinessCombinationMaximumContingentConsiderationMilestonePaymentsPerAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In a business combination, the maximum contingent consideration to be paid based upon achievement of certain milestones as set forth in the Agreement and Plan of Merger.", "label": "Business Combination Maximum Contingent Consideration Milestone Payments Per Agreement", "terseLabel": "Additional contingent consideration based on milestones, maximum, per Agreement" } } }, "localname": "BusinessCombinationMaximumContingentConsiderationMilestonePaymentsPerAgreement", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "acrs_BusinessCombinationMilestonePaymentEquityInterestsIssuedAndIssuable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of shares issued and issuable relating to milestone payment under business combination.", "label": "Business Combination Milestone Payment Equity Interests Issued and Issuable", "terseLabel": "Number of shares" } } }, "localname": "BusinessCombinationMilestonePaymentEquityInterestsIssuedAndIssuable", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "sharesItemType" }, "acrs_BusinessCombinationMilestonePaymentEquityInterestsIssuedAndIssuableFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the fair value of milestone payment issued in shares under business combination.", "label": "Business Combination Milestone Payment Equity Interests Issued and Issuable Fair Value", "terseLabel": "Fair value of common stock" } } }, "localname": "BusinessCombinationMilestonePaymentEquityInterestsIssuedAndIssuableFairValue", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "acrs_BusinessCombinationMilestonePaymentPaidInCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of milestone payment paid in cash under business combination.", "label": "Business Combination Milestone Payment Paid in Cash", "terseLabel": "Payment in cash" } } }, "localname": "BusinessCombinationMilestonePaymentPaidInCash", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "acrs_CollaborationAgreementAggregatePaymentsToBeMadeOnAchievementOfDevelopmentMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of aggregate payment agreed to be made by the company on achievement of certain development milestones.", "label": "Collaboration Agreement, Aggregate Payments To Be Made On Achievement Of Development Milestone", "terseLabel": "Aggregate milestone payments" } } }, "localname": "CollaborationAgreementAggregatePaymentsToBeMadeOnAchievementOfDevelopmentMilestone", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "acrs_CollaborativeArrangementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Agreements Related to Intellectual Property" } } }, "localname": "CollaborativeArrangementDisclosureAbstract", "nsuri": "http://www.aclaristx.com/20200630", "xbrltype": "stringItemType" }, "acrs_CollaborativeArrangementPortionOfCashConsiderationPaidIntoEscrow": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The portion of cash consideration paid into escrow under collaborative arrangement.", "label": "Collaborative Arrangement Portion Of Cash Consideration Paid Into Escrow", "terseLabel": "Cash deposited in escrow" } } }, "localname": "CollaborativeArrangementPortionOfCashConsiderationPaidIntoEscrow", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "acrs_CommonStockNumberOfVotesPerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of votes for each share of common stock.", "label": "Common Stock Number Of Votes Per Share", "terseLabel": "Number of votes per share" } } }, "localname": "CommonStockNumberOfVotesPerShare", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "integerItemType" }, "acrs_ConcentrationOfCreditRiskNumberOfFinancialInstitutions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of financial institutions at which the entity's cash, cash equivalents and marketable securities are held in amounts in excess of federally insured limits.", "label": "Concentration Of Credit Risk, Number Of Financial Institutions", "terseLabel": "Number of financial institutions holding entity funds" } } }, "localname": "ConcentrationOfCreditRiskNumberOfFinancialInstitutions", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" ], "xbrltype": "integerItemType" }, "acrs_ConfluenceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to Confluence, an entity acquired by the entity.", "label": "Confluence [Member]", "terseLabel": "Confluence" } } }, "localname": "ConfluenceMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails", "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "acrs_ContingentConsiderationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for contingent consideration.", "label": "Contingent Consideration, Policy [Policy Text Block]", "terseLabel": "Contingent Consideration" } } }, "localname": "ContingentConsiderationPolicyPolicyTextBlock", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "acrs_ContractResearchSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to segment that earns revenue from the provision of laboratory services to clients through Confluence, the Company's wholly-owned subsidiary. Laboratory service revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis.", "label": "Contract Research Segment [Member]", "terseLabel": "Contract Research Segment" } } }, "localname": "ContractResearchSegmentMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "acrs_CostAndExpenses": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of cost of revenue and expenses incurred during the period.", "label": "Cost And Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostAndExpenses", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "acrs_DebtInstrumentFinalPaymentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage fee of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument Final Payment Fee Percentage", "terseLabel": "Final payment fee percentage" } } }, "localname": "DebtInstrumentFinalPaymentFeePercentage", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "percentItemType" }, "acrs_DebtInstrumentNumberOfConsecutiveEqualMonthlyInstallmentPrincipalAndAccruedInterest": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of consecutive equal monthly installments of principal and accrued interest under debt repayment schedule.", "label": "Debt Instrument, Number Of Consecutive Equal Monthly Installment Principal And Accrued Interest", "terseLabel": "Number of consecutive monthly installments" } } }, "localname": "DebtInstrumentNumberOfConsecutiveEqualMonthlyInstallmentPrincipalAndAccruedInterest", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "integerItemType" }, "acrs_DebtInstrumentRedemptionFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage fee of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Fee, Percentage", "terseLabel": "Prepayment fee percentage" } } }, "localname": "DebtInstrumentRedemptionFeePercentage", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "percentItemType" }, "acrs_DermatologyTherapeuticsSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to dermatology therapeutics segment, which is focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.", "label": "Dermatology Therapeutics Segment [Member]", "terseLabel": "Dermatology Therapeutics Segment" } } }, "localname": "DermatologyTherapeuticsSegmentMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "acrs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails": { "order": 4.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails" ], "xbrltype": "monetaryItemType" }, "acrs_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails": { "order": 5.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of sales and marketing expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Sales And Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails" ], "xbrltype": "monetaryItemType" }, "acrs_EPIHealthLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to EPI Health LLC.", "label": "E P I Health L L C [Member]", "terseLabel": "EPI Health LLC" } } }, "localname": "EPIHealthLLCMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "domainItemType" }, "acrs_EmployeeConsultantsAndDirectorsStockOptionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.", "label": "Employee Consultants And Directors Stock Options [Member]", "terseLabel": "Options to purchase common stock" } } }, "localname": "EmployeeConsultantsAndDirectorsStockOptionsMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "domainItemType" }, "acrs_EpiHealthLlcMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information about EPI Health, LLC.", "label": "Epi Health Llc [Member]", "terseLabel": "EPI Health, LLC" } } }, "localname": "EpiHealthLlcMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "acrs_EquityCompensation2017InducementPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the 2017 Inducement Plan, a non-shareholder approved stock plan adopted pursuant to the \"inducement exception\" provided under NASDAQ listing rules. The only persons eligible to receive grants of awards under the 2017 Inducement Plan are individuals who satisfy the standards for inducement grants under NASDAQ rules, generally including individuals who were not previously an employee or director of the Company. Under the terms of the 2017 Inducement Plan, the Company may grant up to 1,000,000 shares of common stock pursuant to nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit (\"RSU\") awards, and other stock awards. The shares of common stock underlying any awards that expire, are otherwise terminated, settled in cash or repurchased by the Company under the 2017 Inducement Plan will be added back to the shares of common stock available for issuance under the 2017 Inducement Plan.", "label": "Equity Compensation2017 Inducement Plan [Member]", "terseLabel": "2017 Inducement Plan" } } }, "localname": "EquityCompensation2017InducementPlanMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "domainItemType" }, "acrs_EquityCompensationPlan2012Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The 2012 Equity Compensation Plan, as amended and restated, providing for the sale or issuance of common stock or restricted stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors and consultants.", "label": "Equity Compensation Plan2012 [Member]", "terseLabel": "2012 Equity Compensation Plan" } } }, "localname": "EquityCompensationPlan2012Member", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "domainItemType" }, "acrs_EquityIncentivePlan2015Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The 2015 Equity Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, cash-based awards and other stock-based awards.", "label": "Equity Incentive Plan2015 [Member]", "terseLabel": "2015 Equity Incentive Plan" } } }, "localname": "EquityIncentivePlan2015Member", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "domainItemType" }, "acrs_EskataProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to ESKATA product.", "label": "Eskata Product [Member]", "terseLabel": "ESKATA" } } }, "localname": "EskataProductMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails" ], "xbrltype": "domainItemType" }, "acrs_FairValueOfWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The fair value of warrants.", "label": "Fair Value of Warrants", "terseLabel": "Fair value of warrants" } } }, "localname": "FairValueOfWarrants", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "acrs_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "acrs_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of finite-lived and indefinite-lived intangible assets, excluding goodwill, in total and by major class.", "label": "Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table]" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "acrs_IntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NA", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureAbstract", "nsuri": "http://www.aclaristx.com/20200630", "xbrltype": "stringItemType" }, "acrs_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Lab equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "acrs_LaboratoryResearchRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Laboratory service revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis and are generally billed on a monthly basis in arrears for services rendered. Revenue related to these contracts is generally recognized as the laboratory services are performed, based upon the rates specified in the contracts.", "label": "Laboratory Research Revenue [Member]", "terseLabel": "Contract research" } } }, "localname": "LaboratoryResearchRevenueMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "acrs_LesseeOperatingAndFinanceLeasesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of operating and finance leases.", "label": "Lessee Operating And Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingAndFinanceLeasesTextBlock", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "acrs_LicenseAndCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "License and collaboration agreement for the development of products containing specified JAK inhibitors developed for the treatment of alopecia areata and other dermatological conditions.", "label": "License And Collaboration Agreement [Member]", "terseLabel": "License and Collaboration Agreement" } } }, "localname": "LicenseAndCollaborationAgreementMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "domainItemType" }, "acrs_MallinckrodtPlc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for Mallinckrodt plc.", "label": "Mallinckrodt Plc. [Member]", "terseLabel": "Mallinckrodt plc." } } }, "localname": "MallinckrodtPlc.Member", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "acrs_NumberOfFinancingLeaseArrangements": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of lease financing arrangements .", "label": "Number of Financing Lease Arrangements", "terseLabel": "Number of lease financing arrangements" } } }, "localname": "NumberOfFinancingLeaseArrangements", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "integerItemType" }, "acrs_NumberOfInstallments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of installments for payments to be made or received under the agreement.", "label": "Number of Installments", "terseLabel": "Number of installments" } } }, "localname": "NumberOfInstallments", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "integerItemType" }, "acrs_OperatingLeaseAssetRecordedAsResultOfNewAccountingStandard": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating lease asset recorded as a result of new accounting standard.", "label": "Operating Lease Asset Recorded As Result Of New Accounting Standard", "terseLabel": "Operating lease asset recorded as a result of new accounting standard" } } }, "localname": "OperatingLeaseAssetRecordedAsResultOfNewAccountingStandard", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "acrs_OperatingLeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Operating Leases [Abstract]", "terseLabel": "Operating Leases:" } } }, "localname": "OperatingLeasesAbstract", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "acrs_OperatingLeasesAmortizationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of amortization expenses in connection with operating leases.", "label": "Operating Leases, Amortization Expense", "terseLabel": "Amortization expense" } } }, "localname": "OperatingLeasesAmortizationExpense", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "acrs_OperatingLeasesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Representing information pertaining to operating leases.", "label": "Operating Leases [Member]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeasesMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "acrs_OtherRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to revenue not otherwise specified.", "label": "Other Revenue [Member]", "terseLabel": "Other revenue" } } }, "localname": "OtherRevenueMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "acrs_PaymentForMilestoneAchieved": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash outflow for milestone achieved per agreement.", "label": "Payment For Milestone Achieved", "terseLabel": "Milestone payment" } } }, "localname": "PaymentForMilestoneAchieved", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "acrs_PercentageOfUpfrontAndLicenseFees": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage of upfront and license fees.", "label": "Percentage of Upfront and License Fees", "terseLabel": "Percentage of upfront and license fees" } } }, "localname": "PercentageOfUpfrontAndLicenseFees", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "percentItemType" }, "acrs_PotentialMilestonesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future payments that could be paid upon achievement of certain milestones per agreement.", "label": "Potential Milestones Payable", "terseLabel": "Potential milestones payable" } } }, "localname": "PotentialMilestonesPayable", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "acrs_ProbabilityOfSuccessOfAchievingRegulatoryAndSalesMilestones": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage of probability of success of achieving regulatory and sales milestones.", "label": "Probability of Success of Achieving Regulatory and Sales Milestones", "terseLabel": "Probability of success of achieving regulatory and sales milestones" } } }, "localname": "ProbabilityOfSuccessOfAchievingRegulatoryAndSalesMilestones", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "acrs_RhofadeProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to RHOFADE product.", "label": "Rhofade Product [Member]", "terseLabel": "RHOFADE" } } }, "localname": "RhofadeProductMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails" ], "xbrltype": "domainItemType" }, "acrs_RigelPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rigel Pharmaceuticals, Inc., a counterparty to an agreement entered into with reporting entity.", "label": "Rigel Pharmaceuticals Inc [Member]", "terseLabel": "Rigel" } } }, "localname": "RigelPharmaceuticalsIncMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "domainItemType" }, "acrs_RoyaltiesPayableTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The period of time for which royalties are to be paid per the Agreement and Plan of Merger", "label": "Royalties Payable, Term", "terseLabel": "Royalty term" } } }, "localname": "RoyaltiesPayableTerm", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "durationItemType" }, "acrs_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of amortizable finite-lived intangible assets, in total and by major class, including the gross carrying amount and accumulated amortization, and indefinite-lived intangible assets not subject to amortization, excluding goodwill, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Schedule Of Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "acrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "N/A.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "stringItemType" }, "acrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Options, Weighted Average Remaining Contractual Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "stringItemType" }, "acrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageIncreaseToSharesAvailableForGrantFromCommonStockOutstandingAtEndOfPrecedingCalendarYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage of increase to the number of shares available for grant from the common stock outstanding as of the end of the preceding calendar year.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Increase To Shares Available For Grant From Common Stock Outstanding At End Of Preceding Calendar Year", "terseLabel": "Percentage increase to shares available for grant from common outstanding as of preceding December 31 (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageIncreaseToSharesAvailableForGrantFromCommonStockOutstandingAtEndOfPrecedingCalendarYear", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "percentItemType" }, "acrs_SignificantAccountingPoliciesPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for presentation of accounting policies in interim reports.", "label": "Significant Accounting Policies [Policy Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesPolicyTextBlock", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "acrs_SiliconValleyBankMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for Silicon Valley Bank.", "label": "Silicon Valley Bank [Member]", "terseLabel": "SVB" } } }, "localname": "SiliconValleyBankMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "domainItemType" }, "acrs_StockBasedCompensationExpenseDiscontinuedOperations": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsCashFlowDetails": { "order": 2.0, "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of stock based compensation expense relating to discontinued operations.", "label": "Stock Based Compensation Expense Discontinued Operations", "terseLabel": "Stock-based compensation expense" } } }, "localname": "StockBasedCompensationExpenseDiscontinuedOperations", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "acrs_SummaryOfAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Summary Of Accounting Policies [Line Items]" } } }, "localname": "SummaryOfAccountingPoliciesLineItems", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "acrs_SummaryOfAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting details about accounting policies.", "label": "Summary Of Accounting Policies [Table]" } } }, "localname": "SummaryOfAccountingPoliciesTable", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "acrs_TermLoanFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to term loan facility with Silicon Valley Bank.", "label": "Term Loan Facility [Member]", "terseLabel": "Term Loan Facility" } } }, "localname": "TermLoanFacilityMember", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails", "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "acrs_UnauditedInterimFinancialInformationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of unaudited interim financial information.", "label": "Unaudited Interim Financial Information Policy [Policy Text Block]", "terseLabel": "Unaudited Interim Financial Information" } } }, "localname": "UnauditedInterimFinancialInformationPolicyPolicyTextBlock", "nsuri": "http://www.aclaristx.com/20200630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r352" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r354" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r350" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r130", "r135" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r66", "r108" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails", "http://www.aclaristx.com/role/DisclosureDebtDetails", "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "label": "Executive Officer [Member]", "terseLabel": "Executive officer" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r138", "r205", "r207", "r345", "r346" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails", "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails", "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails", "http://www.aclaristx.com/role/DisclosureDebtDetails", "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r140", "r302" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r57" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r27", "r45", "r141", "r142", "r206" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedParties": { "auth_ref": [ "r44", "r106", "r300", "r303", "r304", "r342" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.", "label": "Accounts Receivable, Related Parties", "terseLabel": "Invoice amount" } } }, "localname": "AccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r31", "r32", "r59" ], "calculation": { "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r55", "r182" ], "calculation": { "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails", "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r71", "r73", "r74" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r70", "r74", "r75", "r275" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r46" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paidin capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r213", "r215", "r250", "r251" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r194", "r197", "r202" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Fair value of warrants issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r215", "r244", "r249" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r151", "r209" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset Backed Securities [Member]", "terseLabel": "Asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r132", "r326", "r337" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r28", "r29", "r65" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r278" ], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r0", "r1", "r18", "r20", "r179", "r185" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Discontinued operations - current assets", "totalLabel": "Discontinued operations - current assets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r149" ], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r150" ], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r147", "r158" ], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Available-for-sale Securities [Abstract]", "terseLabel": "Marketable securities:" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r144", "r148", "r158" ], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 }, "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Marketable securities", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails", "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r146", "r158" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r217", "r246" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r260", "r261" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r95", "r264" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r262", "r263" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r100", "r101", "r102" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Additions to property and equipment included in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r34", "r99", "r104" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash, cash equivalents and marketable securities" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r93", "r98", "r103" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r93", "r286" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r16", "r93" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsCashFlowDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "totalLabel": "Total non-cash items" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Initial exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r111" ], "lang": { "en-US": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Common stock warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails", "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r265", "r266", "r268" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Agreements Related to Intellectual Property" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualProperty" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]", "terseLabel": "Agreements Related to Intellectual Property" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Legal Proceedings" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r192", "r193" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Legal Proceedings" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsFairValueDisclosure": { "auth_ref": [ "r41" ], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of arrangements with third parties, including, but not limited to, operating lease arrangement and arrangement in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services.", "label": "Commitments, Fair Value Disclosure", "terseLabel": "Acquisition-related contingent consideration" } } }, "localname": "CommitmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "verboseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r43", "r197" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r43" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.00001 par value; 100,000,000 shares authorized at June 30, 2020 and December 31, 2019; 42,691,114 and 41,485,638 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r78", "r80", "r81" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r122", "r335" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk and of Significant Suppliers" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r209", "r212", "r347" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate Non Segment [Member]", "terseLabel": "Corporate and Other" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r86" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "acrs_CostAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost Of Sales [Member]", "terseLabel": "Cost of revenue." } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r196" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r37", "r38", "r39", "r327", "r329", "r336" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails", "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "verboseLabel": "Basis spread over LIBOR" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r61" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Annual interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r62" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails", "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument Redemption Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument Redemption Period One [Member]", "terseLabel": "Prepayment prior to the first anniversary of the Funding Date" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument Redemption Period Three [Member]", "terseLabel": "Prepayment after the second anniversary of the Funding Date but before October 1, 2023" } } }, "localname": "DebtInstrumentRedemptionPeriodThreeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument Redemption Period Two [Member]", "terseLabel": "Prepayment between the first and second anniversaries of the Funding Date" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r62", "r109", "r198", "r199", "r200", "r201", "r288", "r289", "r290", "r334" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Schedule of the fair value of available for sale marketable securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r254", "r256" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r96", "r180" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": { "auth_ref": [ "r17", "r96" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsCashFlowDetails": { "order": 1.0, "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.", "label": "Depreciation and Amortization, Discontinued Operations", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortizationDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r96", "r131" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-Based Awards" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwards" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stock-Based Awards" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Discontinued Operations" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "auth_ref": [ "r8", "r25", "r104", "r117" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.", "label": "Discontinued Operations, Policy [Policy Text Block]", "terseLabel": "Discontinued Operations" } } }, "localname": "DiscontinuedOperationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "auth_ref": [ "r0", "r1", "r18", "r185" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Accounts receivable, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "auth_ref": [ "r0", "r1", "r18", "r179", "r185" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "auth_ref": [ "r0", "r1", "r18", "r179", "r185" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r15" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of revenue (excludes amortization)" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": { "auth_ref": [ "r15" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization", "terseLabel": "Amortization of definite-lived intangible" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "auth_ref": [ "r15" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails": { "order": 3.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "auth_ref": [ "r15" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "totalLabel": "Total costs and expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "auth_ref": [ "r15" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "terseLabel": "Loss from discontinued operations", "totalLabel": "Loss from discontinued operations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails", "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "auth_ref": [ "r15" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Total revenue, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]" } } }, "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r26", "r189" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Discontinued Operations" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r38", "r40", "r328", "r338" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "terseLabel": "Dividend declared" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Loss per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "verboseLabel": "Net loss per share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average recognition period unrecognized stock-based compensation cost (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options", "terseLabel": "Unrecognized compensation, RSUs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Unrecognized stock-based compensation cost, options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Assets and Liabilities Measured at Fair Value" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r278", "r279", "r280", "r284" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r280" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount", "terseLabel": "Transfers from Level 1 to Level 2" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r280" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount", "terseLabel": "Transfers from Level 2 to Level 1" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r209", "r210", "r212", "r279", "r308" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r278", "r279", "r281", "r282", "r285" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value of Financial Assets and Liabilities" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Assets and Liabilities" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r209", "r210", "r212", "r279", "r309" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r209", "r210", "r212", "r279", "r310" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r209", "r210", "r212", "r279", "r311" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net", "terseLabel": "Transfers into or out of Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r283", "r285" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r110", "r255" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.", "label": "Federal Income Tax Expense (Benefit), Continuing Operations", "terseLabel": "Federal income tax benefit" } } }, "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIncomeTaxesRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r294", "r297" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Finance lease payments" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "Finance lease right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r153", "r154", "r155", "r156", "r157", "r159", "r160", "r161", "r162" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r174" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Schedule of estimated future amortization expenses" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r175" ], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r175" ], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r175" ], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r175" ], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r168", "r170", "r174", "r177", "r313" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Future amortization expenses" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r174", "r313" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r168", "r173" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r174" ], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Definite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Remaining life" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FixedIncomeSecuritiesMember": { "auth_ref": [ "r209", "r212" ], "lang": { "en-US": { "role": { "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity.", "label": "Fixed Income Securities [Member]", "terseLabel": "Commercial paper" } } }, "localname": "FixedIncomeSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r87" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "acrs_CostAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r104", "r171" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r96", "r163", "r164", "r166" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "acrs_CostAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill Impairment", "terseLabel": "Goodwill impairment", "verboseLabel": "Goodwill impairment charge" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails", "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research And Development [Member]", "terseLabel": "IPR&D" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r85", "r97", "r115", "r269" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "totalLabel": "Loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r2", "r3", "r4", "r5", "r6", "r14", "r21", "r270" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "terseLabel": "Loss from discontinued operations", "totalLabel": "Loss from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share", "terseLabel": "Net loss from discontinued operations per share, basic and diluted" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r1", "r8", "r9", "r10", "r11", "r12", "r13", "r19", "r22", "r23", "r24", "r187", "r188" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r259" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r95" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r95" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r95" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r95" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r169", "r176" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r169", "r176" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Gross cost" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Intangible Assets, Gross (Excluding Goodwill) [Abstract]", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r167", "r172" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r134" ], "lang": { "en-US": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Elimination [Member]", "terseLabel": "Intersegment Eliminations" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r298" ], "calculation": { "http://www.aclaristx.com/role/DisclosureLeasesFutureMaturitiesOfLeaseLiabilitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Schedule of supplemental balance sheet information related to operating leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r58" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r50", "r330", "r341" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r60" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r278" ], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r0", "r1", "r18", "r20", "r179", "r185" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Discontinued operations - current liabilities", "totalLabel": "Discontinued operations - current liabilities" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r39", "r329", "r336" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Loan borrowed" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails", "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r39", "r195", "r329", "r339" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt, net" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNumberOfDefendants": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of defendants named in a legal action.", "label": "Loss Contingency, Number of Defendants", "terseLabel": "Number of defendants" } } }, "localname": "LossContingencyNumberOfDefendants", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r119", "r128" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Organization and Nature of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]" } } }, "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r94", "r97" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r76", "r79", "r83", "r97", "r117", "r332", "r344" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Basic and diluted net loss per share attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetRentableArea": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net rentable area for properties owned.", "label": "Net Rentable Area", "verboseLabel": "Area leased, sublease agreement" } } }, "localname": "NetRentableArea", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "areaItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Costs and Expenses [Abstract]", "verboseLabel": "Costs and expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Loss from operations", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r292" ], "calculation": { "http://www.aclaristx.com/role/DisclosureLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aclaristx.com/role/DisclosureLeasesFutureMaturitiesOfLeaseLiabilitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lease liability", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails", "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r292" ], "calculation": { "http://www.aclaristx.com/role/DisclosureLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "terseLabel": "Financial position" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r292" ], "calculation": { "http://www.aclaristx.com/role/DisclosureLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "terseLabel": "Financial position" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization and Nature of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r31", "r32", "r33", "r59" ], "calculation": { "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r270", "r271", "r274" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r67", "r287" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r77", "r80", "r82", "r197" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r68", "r71" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "terseLabel": "Unrealized gain (loss) on marketable securities, net of tax of $0", "verboseLabel": "Unrealized gain (loss) on marketable securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r69", "r72" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax", "verboseLabel": "Unrealized gain (loss) on marketable securities, tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other intangible assets" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r30", "r31", "r59" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Current portion of lease liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r88" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Expenses" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r145" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r89" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r217", "r246" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r42" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r42" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r42" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r42" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r42" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at June 30, 2020 and December 31, 2019" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r28", "r51", "r52" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r91" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from debt financing (including warrants), net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sales and maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r90", "r247" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of employee stock options and the issuance of stock" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]", "terseLabel": "Production information" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product sales, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r76", "r79", "r92", "r132", "r136", "r270", "r272", "r273", "r276", "r277" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r55", "r183" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails", "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r54", "r181" ], "calculation": { "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross", "verboseLabel": "Gross cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails", "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r35", "r36", "r183", "r343" ], "calculation": { "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails", "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r35", "r183" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r35", "r181" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails", "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r211", "r301", "r303", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r253", "r348" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "acrs_CostAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted stock unit awards" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r47", "r202", "r340" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r204", "r205" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue, Net", "terseLabel": "Revenue, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails", "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r105", "r208" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition, Policy [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Available-for-sale Securities [Line Items]", "terseLabel": "Fair value of the Company's available for sale marketable securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r1", "r8", "r9", "r10", "r11", "r12", "r13", "r19", "r22", "r23", "r24", "r187", "r188" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of discontinued operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r215", "r243", "r249" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r215", "r243", "r249" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r278", "r279" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r55", "r183" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r107", "r301", "r303", "r304", "r305", "r306" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r129", "r132", "r133", "r134", "r165" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r129", "r132", "r133", "r134", "r165" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Summary of results of operations by segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r217", "r246" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r222", "r233", "r235" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Assumptions used to determine fair value of stock options granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of restricted stock units activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segment [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Information" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r95" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited and cancelled, estimated grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted, estimated grant-date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Number of shares outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted average grant date fair value, ending balance (in dollars per share)", "periodStartLabel": "Weighted average grant date fair value, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "RSU, Weighted Average Grant Date Fair Value Per Unit" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Stock Option Valuation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock-based awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations", "negatedLabel": "Forfeited and cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r223", "r225" ], "lang": { "en-US": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Units outstanding, end of period", "periodStartLabel": "Units outstanding, beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "terseLabel": "RSU, Number of Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional shares available" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Forfeited and cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Shares, Forfeited and cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted (in shares)", "verboseLabel": "Number of Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value of stock options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r246" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r224", "r246" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Shares, ending balance", "periodStartLabel": "Number of Shares, beginning balance", "terseLabel": "Options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, ending balance (in dollars per share)", "periodStartLabel": "Weighted Average Exercise Price, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Options, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r237" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Number of Shares, Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Number of Shares, Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options vested and expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r214", "r221" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price, Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Term of award (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r239", "r248" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Options exercisable (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Options vested and expected to vest (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r110", "r257", "r258" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.", "label": "State and Local Income Tax Expense (Benefit), Continuing Operations", "terseLabel": "State income tax benefit" } } }, "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIncomeTaxesRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r7", "r132", "r165", "r186", "r190", "r191", "r345" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r64", "r197" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross", "verboseLabel": "Vesting of restricted stock units, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r42", "r43", "r202", "r216", "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r43", "r48", "r49", "r143" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r312" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r209", "r331" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U S Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency debt securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r120", "r121", "r123", "r124", "r125", "r126", "r127" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants issued to SVB" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average common shares outstanding, basic and diluted (in shares)", "verboseLabel": "Weighted average shares of common stock outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsLossDetails", "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8475-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r26": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918631-209977" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r299": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r349": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r351": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r352": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r353": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r354": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r355": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" } }, "version": "2.1" } ZIP 82 0001558370-20-009814-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-20-009814-xbrl.zip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�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Ð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�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…IU$D%'CB?V+L3!X_/GM*@D/84WEAD[W]94($,J5* M^I''8/R\8H=1C3"%FG!LS-+E27_(;;2F1;_$% ?MW>DL1-[ 3W3)28V'WW0= M4Z7MV@NTXI%B:-*7!TDT; 64OO2E #N:]$_#JRY\QPA0=(=Y^W+@LV<[OHWP MM@<%-Y"P=T!N!T]+, N_Y+$:S ,#C@#L@_3:8C!T0D+(*)(<%C65MI*G,$E+ ME=S8K9VS%4@(.Q(R_UW+)Y#S&1Y3Z!L?[57X]&S1'# <6NCDQF>!T%$S=L;" M?'Q/HQ>Z,7U?(+V^N*@?6E=.)6/6%=$.&: M)/MA*>NDQLB?[4\ER)9J96)Z'W!SRW344EL6^++ 5J0KD5\B53 T1&3S5_>[Z) "3BVAW,)-6,:N0FDS:_*UY]*2 M[:*M)6C:>X=OV3-]X(E$FU-D6B1E.SM\26\]I'Y(YS 66"#H M&EYH&NLRUGWZS4NPL3 69-O&;L$Q)0ELT6:KF%L%,?L+$VU)3D;C;9G.) @O MS^VZ6UN,^XB6?G5_:0QJ6:0I,C'J:1AL+ZK:.S5VMDK4CUD M- 8R(H%>TN<*.U>AHN$V_/)*9^TJ21U])I,I@,VM':/9O7-]F.3TTU1)Q2]* @ !2P7V/@+L3>2R9BF*@WS.-!%7G+CHIOX. MQOD=WWA\XBD[VMC1ZRU?;/NIJ=3M-286[[&U?/FU!LC??_CS8;@\VT72F5K+ M..-RL4'D-P71&V,! [5G69KJWMV-J1A2R.%!\N0LC&_Q6Y;ZZ[3'8 \5BRB M@EQB]5%7D.T^%*11YQ_(>)'[DB0 IZ/GGI6T2-1[&F6ZJREHUYLD?-T.$LDB M-CUV.+Y[PZYSP3F3["\YDM 300(=HXWKD+#]_,YYO&P2V) MR06(8=C66)*2H$,D;:!@DQN:[T.^[+T4[E^A7@R>1JOQ,[*6-#,!(:8;VS.. M=1(,P8Y&[^[B#A.J_AJ7*V/M%X[J^O;<[DV-OVRH.&A/1DL8IMLFAP9\W5CQ M@3[@6W3_:H?='A;@T>7VMKR HMW%P_@[3)='@V:.BXUHTNA>4_B%(?WM_/#S M'?;H&*2^3] @)5>/>T@J_ 8L@+\)P_$[N!PG'3VBJG>39)X?]KZ@*$A0#_;W$WBC*24!7@+ZJ%9@U3A[*Q G(_'PV9O[[[^* MN7SQY^X^MA=M7=*V(_,K?&F."SSI=*AQ$A><)$VG!9?!H_S"ST? Y\>RW=B& M##%(TFYG;HM[("I!\.CLZ?8A/(D:?&'T.H,^8%XARY,H]HBZ2?HXQ MTL1(LQ]I?#S&F^/L^I#17TOB9;Z435HG9=L0=EZ >'(8PT)B%7RYR>NXK6@S M-I^7N6*KI[$13+:Z!2>_-][-K[?-8I+#ZGSVDE'L)<_O/O;YQ,0>R4)U7Q,P M?6/+-V;FH6'F06J@G9]]F;_42QIP"FGZA%?E)]YT^XN7KUN[;='<2DN<]"<[ M\3U2<*&8O!MDQ1):RXY([PLC^T-OAFF)8H-V3QI^/.9EW?#XGV/LV]&<0%6GKU)R?^^B6 3'N!<'5&*4 M"Q7*[;K"M_6XV!L>8]!+&+3@-[ZI0_OM8-(,@%0+$T/.#J #&P1[.!!8 MQ KVOJ*=W4RPB24Z;0I;V &(-S$JQJCXDEN&%N30#@A[\XK]ZIH]!VN,M7P+ M7A9WOV1WX7@&[Z)6+9>+J^7B:KG7$-2'5\O%'/NX.?;;HZ+V?"$[D_Z/*HM/&M?X*,E*:[';A.=MIEX"--I%G,&3D M',G=WEM]E3K%_L3/W%?8-_.>EAR=\@6K1*X\&Y5*7 MB!L&@4=/[ZM8)-NV)^7M!.YV^H4&^Y+I+T;MY9UN4';;NZW^07L!]=J"\7W5 MX?[1=,_,37*;4I(6PF\M2]_3GOK9KD@[Y8=.WU>[UG(+MG9SN\1>^&Y5">]/ M7QBXN0N';\AI(^=&C?T-'$6P?OV!XH/7ZR'<5GH&Z7>B>)4+CG'CMVIHJ-D7 M1TYL^:IIK#FQMP4AC?[YK7@2@O;<1=+SU9X[(;V$6_F#\?&94_!C%SLG1YND M_2.M_?%!V:Y.Q=%H F+'0M(-3$.QCYY@[.R\K>9CP* H>#V'*JD*IX.%#P/= M*[[^UJ5%;^WUX^LA^7*"#]:4[9:"$RYGEX(CH]2P>7Z:G6CD<]),#NOX2#T@F4I](-&IAZTAO%'J&X2, M3VBHUEP"J]LX-'<]T(!RJQ#>@:D\P]QA,G)85:_DAT?)__&-3T8@2MY?[)%-UT1N$[4X6B:.Q,38] MATV*I$ZPJ^F8]!ER>H(098JV, )9*-N(8C@K17'#D"RH: M"FV7[;28BIE5C%IO1RTZ%M9%,'N":XP^,?H\@SY.?S/U%5W*Q&=: <9H%J/9 M,VCF=X0Z31['9(!RTEK$89P8?U[ 'W_'Q2!G.JKZR+?X[=#'3+R?HFS2_H7> MG'=DY3X7]Y;7:;=[Y4*70#]U*=CG*Z9Y-%YW[4"&M-O@T':4P]?I=Q*D6:8D M6'0XBBB-)6^JJ*3" P7Z&^K&I >AH/#R?,O!NR=3C"'I(+LS)NQQ,Y9*HRR2 MZ&(4<>#MDW;N:_:'L'9>@"W)"4A]0QL2=*P#'=(@PFWMNA[]8 ZX[Y!38K/* M/2-O2-=OTGD1-^B-C,&8ICIQ[0?@50)I=SEV/)1TZL>2AU>,<$X)\2CB]%=[ M\WOB*?SNZ#+:('4N8=^O[8$Y6R^WXQYX^[8/=Y\C<_M=Q";:?IT[UP=';JQY M].DF[#%*.'?,NR5__,(RIYH]=&6%(222VT6,>*]1.RFBV[WSD;31"+YB/)#Z MEN$D&+8ACE.O"S#Q&,MC9^2*W5?6#PUR]20NYW5#)MW,/%]QT&/K0'>TXW4@ M)+SU>/^$%#+I!5W5<)-T<(L#=\E1[&QON!/4WC?)*DP^W2\O)Z_1\#&-7(J MOS(91(#U;7%!^=96_9#BMR$5*"E?Z,#O@'XP+(_LS2YHL#O!^MIJT &A;I / MB6A-),42IRMNO27A3#HZ.%^+3.+".4).8V#? ,@#M1-V[US25'AW,-=K#DQF MKSEU&_L[AR0.IEPV[SWK,EOQLJ45$75TE8OT/ MFQ/]F8"7FS$[HAJOK1E2"$DNA#"*&TBB(/8$F0<,?(/T>:4Y"40X\\8T00._ M*(F7O.*6,-.AA=0J=<>[)7P/F6*,3]LQ;A[!HP'O)PF4SL!"Q1;:(2WKF#=D@PX;>W$;5\_7RO8CFL6RJ__NGW("WZ/ZLB,G-7PW5:!5 VY) M)&+)>ZB!PRKL@1HT)8EDY(XD2;7]2E2*\60B!1&&1&'T,GCIL$X<>^3A@VU* M*-+^81MT<,J.VXIZ/_;MS+&V#=L_,.=GDIN81C'KP<4S.NN$S.NPD\M04<7M MS7%W='H'R&T\L"+S(SLQ,>%T>#;<,<1;+5;PENB8D9V\<_HLJ@]XC\-COQ'^ M) $/+X_.LG./!]#Q1MWZ_!D)NQF]B+/^*7U M ;M W,81VA=?4R<:;FB* -&Z>Y\ <./?Q1F=(6-$=;< M'C6CZ1[9NN^HK)%B,)O/LZO@1K158NMNIN@<\ZA1U;RL1^K,<]N8;[F>?%3H MY\H6]>[Z0&(X2.TE8(TUS028>T\F-NQKL/=5@^FW$K[P\25514A?2[2.2&6J MB%$WW178K9?)W::1;F#.9RB;LJ6-',D0W CO[K:$O@ 2"-E$)I<3J M =DJNH(H-=,:#V<@2% :^U0QD+"JR.L@$J1>(\?F M$LX "LK5G $D=MBA##L$(]T+7_0)EX-'^)_@FU&BT^M[DNAD;88'@Y<^P@[O M&+3UGD:F("[@E3(RGHFFT0'B;EM5F0XM(=*:2@)0YQ4[*TO:KO/RIJYM35Q74S85RFFDM1W\H#P*HP>!UQX['WE!4<6)N5BXA&-RG4O7/8+=BY/;J+(B M=2&NQD#3"VBM/[94-*6%\3?SA_RG6_?CSH-$K/S#^),^U4.K!*S>76Z_@6S" M[\N1U:VGD:_"=[TST80^UXG#V!-R_I"7?WIU+7L7.8&Y5[\:A?$?\%B78%R M$KKY _VY<-I#SR,Q8OC9&,M>M=) .O0XS,"P^\&Z@U3\!&1/Z73)!4YC]POQ M.F7N !ZI'>AWA JC&]PTO>4@Y*4%93KX=/21V7,$ [3NL@%\A:P^]U)?1=AS M\+9#VGY\I?'(#3DG#A.$_9G/ HXP':R?LR^>1OEXX#+.UP^\??L&R6,.+(2G M!R[Q*%C/CN.&.&]RP3WYG"WV$+1]G@@M,!7MR#2NMQ7^.FS;]7OO&XRV-6[, M)]3M6:#[OH*$9>,YC@ZE#@@R;HQ8C<3:L O[/%/#'5[VK(*!8EVA*2&8$$-& M>^*W$:PI]B=Q5M)"W*4&>R$?!Q M@NWHU,98,W;@E)(*:'ZB'0O?_9!\SVTSL/W'X//)H/$Y#OY&5N544,J>!XCX M/[ XEA15NBY2HDCP)A9JTV]Y(YSWOX04:L]I3S3B@EJ!^D(;HEB+$Z9N9TDY MS_1&*P/7E4E!K:N7B-2IAND)B%AP-M!5YA+8)V2^LGT<5UW =VP5I[\$$U\I M.N\Q+5,2IJJF:),-LP Y0/1QM]&;,P:/L#/\D(8;[.C%SF0\>M-OV@;:"5A% MCH7 !RN\B:E:;U__EY\O?IXE=A/<2/+&K^W8?>CNC!^'WX MI.."X"85!3WR/E263.+U=GD7&1_BM_?J+Q/^X0W#VS&APF0B&?DOQ)'_./+_ MC2+_+S%1GL1H4!2X=HWCR!-I2V+JS[-TT.T>+5XWT3=GM^QPF X&'VT-P,<' M=!($-C"_>9_)Y5MJIUI1S[+JM@/#'CN.EYC\[HI%[!3OL36B>6PS*)1-"O5, MX5]14]GBALUXMKZ"+Y%!=Y(DDF7@JE0[T0Y!ETD@_V_J4B/?G-+.:Q88#F0[]@EL5[2O M(Y-="(:/'DFD(_P:M77#,2B=J]O2Z<86Z0=&$F9IGR2[U@R50U.FB3R*XBY' M[DD3:;>?LWO;"=\)2&,[.PUDN_8(H_N^" 3M]T2V#M:7-I<%M]?1X7>0^(3# M]P-(1\(R8TEWT S$)SG>;MSZH+V/H*F7!D6&F[470F4@V87[79E7P59YY:I MP7:(CT\%'%9(NS=2:6 9-(."OIU@=G!;N"$'Q6RZHQ56M)L:XA"]BRT$QB[,4(NZ=N'$A&HA4=AUC,CK,[0'Q(5"ZKPQ)]+\-JZWX&DL-0 M0>O!M!W3RUAW6BYNARL#K]J7K*XY!2.X 5YAP)30*2-ZY4-WT&FK[9_'6@^^ MP6!&&$4@F5$"=;HKI-6F35N[JQ'8)!-?5@U3M_SS"N!=!G 5P Q>]]K!DN)( MI+E=:'KWZB3\DR)8]SC!]'[:[W#;'T<3V]R6;(3%8185!@/)MYQ:GL/%!3LO MV4Z5\)J]>2QTRSLID4Q&/*#[#NHC]!W5\:YZN5V$':@(>4,6,<.*WN<$M'/@ MQ])V1)EB)&**LT75WHZ?#'#3NOAB9NF(5\AIC2GPKYCY/!N0(VBFC9.6L>4T MV4J2HRY CS.YA=0DW].9!4,K:-YP,R\20\)'6\K&]?GZT,;EBQY_V]V]4T?F MD_]!Q/*ZU/H_?>M92&3AN0,=.RZ&:6>_9KR5O:3KLC^')8Z\.;H,'6SG!.X) MM^8/]DAWR6VS):VHH>!U@':)>T?3 0F(:%,\B=,8T='Q;[T$XQPRL8LR8M(*QB#L^]4E^"FU'>% MU&[I].ZUT.H<;0,&H4R!9+^3H"S%'/H=!6F%$, K@/@60#FE+O0R97T;9(8+ M,P%G_YK);=!MF1T.Y/PU7?[Z!LOPDOD]]=-12*E%X9V!VM-"""Q4C%S7E*-NT"[^VG: DMP*1L:PUL)<845%YC_D4R[[GWUN M)1]R^(IQ#L^"1U61-E8;O"I 1ZN=>,Q?<6-\U9!2$AJX1+T'(OMX1& MD6>2(D\US?4B.%?^$OXZK&8!(+.A@QU(3IA]K5M,M]'='3MW$(3P@X#<\]&6PX)>]>,/V% C&WL&:[OB]68L.Z ML]\J@!%H Z,ZH#?LYI*Y"N. MZ2=LL17>8RO;K6:,J:O4;(6"J$O792%^,SQB# ML0&L$^MY#9^76Y[;>JWA%.W0^.SV04/Q=B:+S9Y[!K5BW*U9$U@ MJ5^J@K!T925@#A6%<*U>2KQ!3++4SQH8*D0;1NPAO9_L/Q#QI_)*L@^8T]7& MY@KQ[X^N-:+CQ-)9-IEA_W1-)N\U7B\(?T$:J1Q3-(OVB;.H"]A/-$Y%EU.T MXI5SH,^+1.>=K&^Z,?3)&\[&7+J%%[VAU):>8CO(1C$68WPT8.9UDR.=+_D% M*7\S&O8,*NN1''*;:# V?9"(7R9*?_.] \1.G%G^IX:-D)F8DG^/ MDM,)IHI6[PVQ>J\D'IN>$"IR%-J41YD]YS&VDT"R'9J>D &LQIHN^!)B L[1 M(&W=T*&L:SSMG.&V5AGK\,V5IL\<%[#K^L'6PNC_FY.,]>W0J&H[E+P'>1,7 MG686>]%HM*'->HFS0W58BZ^/#-$T%#I0S%)EMPIXCFG[L!=-Q_29+6<-35K2 MW5EH^UN].-##P@YB6C"2(M.F<8;G2_< L[4U0MB>8V+N79$=^06.2PIZ[;XV M-L-<6",%KL_YB],.&1N N*\,N)ZPH1YA;EC#9[>GV!&NY;NKO&9%_2Z8"2 Y=-F@XN@<8"(H4+)L: M3(5TQKJPP!1(LU38$"&+\BUL8'O#:!?ZUMS"W.8FK.\#RDJ"[-K4G5?8G(*C M&_;FG^R,5J&4QEW*CT _L$SI@WG=_IX99"'\\4V2UO[W]MB9 V _.,_FI%B,+R(4 M%X'".KZ(+[^(PDDN%5]$""XB9DVAN8B8-87B(F+6%)*+B%E3:"XB9DVAN(B8 M-87D(K@3-A-?Q/M=!)E\NCU^]K<\&Y]WZH+C\/2[N5X+A@\5CQ_LZ_]PJ B: M@A_^[X_LCU^$4 I E'/B 4Y4A%NL&1*C8IQ(PP>"L/ *"#[G+3W@'Z7QLC2; M< )GHQBA/H[,GE=^CA,J+VDBQPF5E]2"+^6DTR?%<%/9'W65$IHYU2R#5T7CSYC! M;+&!8**H($C2>/PS;/S!'B9C_+WO\MYZBJ^E^=]/5OZHTW^&3R:LI_]TWPM) M3PPM.&)2.-[3QZ00DT),"C$I?(':^X[($':CURWIXE+D!>YP2=T=+AD1(_:] ML37\'.K?40SV[;(6)KU54[AUQUTEC?04<@8QQT;GQQJ=7QC-##5T*._[:NB\ MMV99?$ZOC,DJ)JN8K'Z!K.S^=S%IQ:05DU8T)5:DU?R0:O,%\H*>A@/DGM'F MCX(%AM]A\/F'C*1[(95@,['[*\;F[X'-L2LWQN7O@LM<@LNQL>LWHJ[?0A " M=)G7<_"KC<\H M$[2_+.LH^-51L*7CY#XQ_L;X&^/O][K:&'^_,?Y&6LF+FE?4J5HRR,"R."4V MMF>_LSW[:U&?=*$8.WIBPH@)8Z<.IIB)R2(FBY@L_G][;]K<-I*LC7Y_(\Y_ M0/3IOF&_ =$$=\IG)D(MV]V:<;?[6)[I>S\YBD!1Q!@$.%@DV;E4V:+]K!K8J&UBH4N6L.?Y=%]BHU*A&I$Z#7>>96$ MUNYLJT$HU]PC?XH\ZMF=GJG!,Q1<7PIV^G;7V>2"&1(V)'R\L.@ZLGWE.':S MVWYM8J.UCHW^PD,>LX",0>9-_=!/TIB0IXS;6V^W=Q_"ZZQ=W:[=[;=,#,@P M@V&&OUI]\+-,GL PP\DQP^[VKCT8]C>9NR;X6?W@YR]1Y#WX06#YTQGS8Q/W MK%OWD*H5])QDUY#M#7D,@Q@&.6,&<09VM[FI/L#PA^&/$^&/W0UD8@H3$*Y7 M0/BM:C'E+AV8,G[^:7?BJUX&9'Z,DL<9Q-+6B&;.\)B9L]?0@"%<0[@O3[B=MMUK-@WA&L*M!N$^ZB5+&%[;5LA-A>_997[.-L'C##9F=PS5&ZH_0:H?= W1&Z(_,Z)W3*UM M#8.Z12+?A:O\,(/7;>*>8]O<#%45:E\K)N9V.BM;'% MCN$(PQ'GQA$]VQF:TGG#%.? %$_K ._T]MJ*I=:&;VT"X;_SU K *C;Q@D/& M"]K [5Z4C0)^,'8O+<^/A_;XCS#A?06M#]5MTO#(T4G&\,A3XLY#>]#O&1XQ M/')V//*DT/' ;O4/T\*[9A;TFY3!OE9F8'ND'C^$MZ27[=[2N$:EESQP)##8 MVQ)&V'EAB_0BZ MP8*1!'X44O.\'YO:%^,HMM()A__'G%M3>-(DL3B\R;/^EH7<:C=MJ]5L->G. M5M,9VOB6&7<1@"68V_0]OL:-IK/83^ ^^ \,#Z:.B-9C#G.'087P V47\&6S M.,(5A=?#%0$#.<;2*)Y;L![WO@LWI)'E!C[,-L&!1=G=Q())CH.,ARYO6*+6 M3M33JZFZ49CX28HIBS%.L95/$7&UHSD+4K\8"GP=@GN7L "^@PL^__KIP]6[ M]]:KZ/M\RE/VGRCP8?:3N1='[@1$C>_QUY8;2!)X-W[H3EL"?=["TV,?;>O#3B?7^CQOK5P[#F=C6QX_7]*CB.S6Y M$R7KI[&[@DC"3'FLIMGJ:" '8LYM1QLU_?M?_TRMO4=V0&YU]&B8^I\TMB&6 A?'KIN;0S:32[;#D-H@SX4TZLXS3ZW1?: M*\U,)U-=L].9!;)A_)#: O8+.&7 MZH/^UE[AE0I!H[FI4LHL2_(T5J^00L01 UZ;:IK"D .N-^*Q MYWNV>=J'F_7@$;-^4=Y_X2CTOA?!C0+\\B\_=']XJE8:-EZV9&>PPWILBDQ^ MH2S1;R)+])ZR1'DL\F45%:,F:L\51U(31SP1\UPU M@I4%HJ:EW;15<8M1(^?",$:-BN&)?:J3U5#4R:/3JK4:P+FU/>N/%B>.Y MO4FCNL)"^]XF3RD]ER(;S;7 MK&]I(9UFOI(+,S5ZN2*B]T@L-G@JB[6=AO.R1/!<'GIU$UKI),H2%GK)ZY6\ M])0S6H\K/7N1NE?\OS.@%UQ]N;GH=)LO>>CL,*1?VM?U=L1+GJT[A!(]W%'+ M;5G\2IZD['>:!SA&>284?81I&HI>I&C'=@:;>NC46'P9.GXJ'1\XQO?T/A"= M%4 (V[V%ZIE(3K_?KXT7L.]N%=67)(>?9%UU2;-5-Y_VR!M]%I.L)37WNFTC MM PM5\XZ>@HM=SK+[7].*L;41*TW+'[O4T8=D9HG2TUUR;G:'?[PYVRCC6-IETX3\S:GP6(NM,:+DNQM.@ M>\)!MC]XG$1AR(.-UI/Q%XRO>)9A!,?N=PYQ*.V\&>.\9U]+QFC9W>$A L_G M+3//G3%J8R)V!O6/KMVFD?OM8L00X16Q7L$:9.NRK6=!QVS/6SQB.\M*KX[0=\=>G3WK0UP^IV6<\5 M+1SWH/^.,*]]ER[9G9XY\OI\A68HO*H4[O3MKK/'X'@]C3E#XFNMK6J1^,[F MEN/8S6Y[C<7U)F4PG\H0X]Y7[5]9DOKCN?C*#^'%Z66[MSC4S]ML.FL%QVB-P(,SZ8\(2;K68E;\QC?'"G5_0 M:C8LT83[_>(4L>VQ]:"Q+9IK.N/GJ\PKK^\"# /_KQ=F=Y?F)BV#OA#>.XVA*J[BX>NF$I6*H=&&>S;1K*&O](XI]/)%R2TK6FF1TG>!Y:HXD@ C O2F0-U ![!O]]QZGP=5 M1OL<;"W6#$E[' 7 0D2Z:*A90'C(/_^!UR EWFDKQ\HKIQCVLDK+)BRDQ]5L_H0#6\*[<\2 =RX^'#B; M'#?/OU_Q?%098]@K-7_U-QGBER,0B]\N'F#&;V=1XJ/LN"0= 5NU\,S\=S9* M4$;SMVDTN^S"U&!KPP2$R?22/J&&>=6T05[_]'IA!0X'IH=3W]73A$GF_S[3 MZW0VNM8OO$/2'Z07+VW666V$T^AM#..9C3C01O0;SC%EEMD((YK,1IB-,**I MPAMAE'5%-L*(IHIL1+_1')J-V-]&/+Z(9[.G?9*8\)MYOZZ8\-VG8L*WFE7' MA/]" >/?1,#X/06,R\#P+Z:1:T8,I\D12Q1QJ -Y&U53K5?%Z(G:<\6Q],01 M"Z"?JTF1UE/UR*#1']9:C6"!T)[T MQHL3QW/G*K3D\K]+\W\^70P;K4[-Z0*KUXT]\1)" XCCN(?IGTL>G6#5>=1EK#0 M2UZOY*5]M&PY+"L\L^N:4?C7/]]F] M_B%0QL^$IH\P34/3RZV'G?:F4]DU%F"&CI_P ;^G(W'U=D.3J+:]%$=C MGB1^%,IC& &_@T]COJ=&( #J;VVC<V6IPPSV:S*$XM>,B][YY<$*I"?04/ MGNO9(LQ?WN.KI?KJM Z#;7_.K'#PG(QAA2>U(NP>"&VKA@:>8873CYNUVLWZ MQ\U$?Z<=^I<8-Z9*\NH1]&M"$>LXN-MN&A^]@I,TQ+V/F'&G73>A9HC;A-TV MA=V<4PZ[/0;JM%[>155]*R'4:H3D<6S@$]2"%5ZN)Q;N.(.3\>.K2CIB]A4F MG6HMUXER6J][(.RN&IJJAM..A9%WW$.(>S..N^W>/L"\#G[^1X!YF?CCGEWU MHR.F;"^TW8-2K!82S)-"D':WORF+9BA\-QUG*+RJ%-ZW.[W]HGG5T+PS%+[6 MW*H6A>]L;SGV8-@W8%X;8#.*$ZP;H6IR0)L-*$8+Z#4Y*L[Z,Q\%_!!SZ1X@ M(EO\;L-O]QS&$PMT( $?$^*PXED4(ZP5#'":(;8/C="-DC2Q=7PB[3T:0M,, M/H2I?%86QXA^$["')/-3G%WBQOY(0.BD$Q_OQ,I*FR[7 ([FG,47V,KT C]M MPSLJ1J(696/Y9K$LRN*.QF/X0<-Q\D-$MA S3[D["<&_NIN+1:!G"L"LX@9& MR%]@J6_=P(V/7@!86K/ER^4*6@=4K:6K&\#BH3R:2*+,Q0T2YTOT=%U[HKW5 MT8+]@C7:K<6^K?_U?TH-:9?<6RD9M6G)-A$M$I)W_$+TNV5C>/,E"Q[8/%%" M=]AH*Z%[F0O7-J4>FHUV]R=+^XSKL;284_;]0ENR$@Z,O*T,!:.^W-)W5^X, MPJJT0*^C ($_Y<0Z3J/??:&]6LC"M#63AEF3F(__\L-_?_ETO:HQPU-?*?[$ M!X%*!"8(2AVWY%<:#>'BHGM,0#W [M=P-4J77+"SO^Y ^>5]6[4=+Z8<2KI@ MC4]?B"/XY9Z3:$ZRF(4N)]Z&9WSC)!.4#"[+RB4Y$W,O<_/'7:Q ?P/I&^"2 M*Y"PZT__O'EWX0Q!>H,BF_KNZ2*#K<@]DM;>TF[CERCR'GQ0?#?3&?-CA/T[ M812PQU@X[W8'LT,,0VO&8U2 2) A$")(:G]J^?FJPKQ9DG(#TQ*Q!#<]X!CZ LF?PJ6 ZI0HVE*REA, 18T5#%W46'!2EEWBOZT:;H3V >2BS\Z@T;7@@T/T*IX MB/U48/Y)", ,[ANQ@"0*7*V>=;I,_@SX/V%;W81@_7+KE43\>VU;(3\VV D"5) 4X+.HUBPBV M\"O:R["(8V7[/_CIQ+J%S\#3UC]9$/"Y]3,+O]D6#.[VGS_;!:HO&(8Q*%-B M\M\(XQ4'5W)W\@%$0@R-_9 8*D!K'[3RC,6(+0QC!KY+8 E&\^(>7] 3&"4A MXC.+)[@LF4AD973%D*>3LHG_A"65D*&PI,ZCEQ1^08\M'Z#'1ZE8Q4_?X>V> M]4'.^>/'ZS6+]\E-(XF*.J#W@D!D/OU$8JA\R7#?RV9$F2;*/D:@8_ 4;$ YQA/,5D::04KDD+H78PIN2%+X@ M[A&1BQ'G(9H<+!&R!I@2C34_\A*TAA+TYSTYK8 PT.$M+ &>!>D7^(PVV$=1 M"$O"@=1H'GP-XOB*T1/HM4ZI44ZIUBM8 ^MW,.N\^0TWHZ8$G,5'P MVE,1/].",Z]/5Z94?AA+PNQ1&$#UB8"U303,1,!.* *VNVUR#?H4S-%$Z--; M_WL9TJCL(Z >*364KH@8K"B >+FKL!%&-%5F(XQHJL1&&-%4D8TPHJDR&V%$4R4VPHBFBFR$TVAV MS$;L;R,>>U!K6V3CL$!-3XY9OZAZ/#9RTW-790]0O;!$]8;J71D=?2GLWM,F MIY>Y*MN,@J-+DU7RPFC>"HK*6L'5#@>U5K%[A#$V='%2=+%' M&&-#%R=#%ZL0C,_29%@(<#37N/]EO&9GKWC-QA@Y?;]M#XC.[<:PVESVZB84 MC+8.UODL!7+]G@[!,]7M6G986(R59W]P6,OU>Y@9UCA M?&=O6,&P@F$%PPI','OW2 QU+""76K.B>8]LV6 \TY?U3(\-LE#5U1&R[]BKLV^4=,Z M>PU#&&H^C4G6DII-R-=0\^E0LV.WFYL0;\_+=JQ'B+A:GE8]!9BI:#(53885 M#"L85C"L8%C!L(*)I]8EGGJ=@WPJ[(J5Q[C.0EZ=A5@Z3^ECZ-?0KZ'?T]I: M0[\G3+^U-O+J$?A96$UNYLJP$-DVEG2'A^I)PNV\[O4W&IB%A0\+'BXRN(]M7+<=N=5NO37BTUN'17WC( M8Q:0-^OM]^Y#>)VUK^LX=K^_Z4R2X0;##>?##1U[V.H9 M;C#<<&K-H:D4SCA4:4;C2/#\+27>R2;63S9VU M>O9@T-]K:, 0KB',+QQ1F9TU:QE@8+KAVXTY=8K M6<+PVK9";BI\SR[S<[8)'L4/UI4/W3ZLP,0%?MPKM% M2M^%J_PP@]=MR>X;M]RXY:?OEF^L(A@.#E.]9!BD0A1A&&3G:H5AUS"(89 S M8Y G545T[&;O,&G9SG 3)M!YV;ZUB27_SE,K ,/8N/R'/!7; M!G;WHFP4\(/Q>VEY?CSTH=TVX="#RS9A;TFY3!OE9F8'ND'C^$MZ27[=[2N$:EESQP)##8 MV$YD\3B\![/^EL6,NHID$XT706^PGXGO!RN")@(,58&L5S"U;CWG?AAC2RW,"'N<+'";#[W<2"*8Z#C(K=>VN6Q4G&PA1'@"-E20*7P;?NA"7PYUW,.7:WMA[\=&*]_^/&^I7#DR=J M3"=*BT_C4842;GBUS*LE['3!H:U&?Y%#6_ODT)@'#'D#R)J8#W7=.LZ+LG@C M]QUS\6K)!R5TT'<%.JCU/N\(>K*.8:?4 M_-7?9+=?CF+.OET\P(S?SJ+$QVJ!2Y(W('\6GIG_SD9)%&0I?YM&L\LN3 W, MES !03>]I$\HK5XU[0OXZ?7""KST=FL7PH^[&NHPR?S?9\7V6XUF_X@[)%U) M>O'29IW51CA;RJ_,1AQH(_J-YC%EEMD((YK,1IB-,**IPAMAE'5%-L*(IHIL M1+_1-:)ICQOQV!K^;9[VX68]>,2L7Y3W]QXS='F8\OBE%L&- OSR+S]T?WBJ M5AHV7C8G/]AA/39%)F_][]9O(J+\GB+*>23R9=5QS2CA--EAB1X.LBK;]%*M M5\4HB=ISQ9&4Q!$KWI^K1# +*;+?[::MTN!&C9P+PQ@U8M2(X8I]J9'64]7( MH-&KMQK!&I8]Z8T7)X[GSE5HR>5_E^;_?+H8-IQVS>G"&1I[XF6$QK#1JS=Q M7$]8>,?+Y"&UYT)TL[EF?4L+Z33SE5R8J='+%1&]1V*QP5-9K.TTG)K^2EIQS!>%SAV;Y909T\L9P!O>#JR\U%I]M\R3,EAR'] MTKZNMR->\NC,(93HX4Y2;:K=L=]#2/\#9 MOX,+,$/'3Z7C T?YGGS0N[>J+=AV?Z%Z1I+3[_=KXP?L^SAZ]27)X2=92UWB MV(/N)EUBJ/E,)UE+:F[9[7[+B"U#S?6UC[K.BDY1)Q5=:CGMP8G9]I5J\%-' MF776_KQC]YKMTXQ158@TSGOV=66,P2$8X[QEYKDS1ETLPT&S_H$ST8KJ;U=_ MM_QP KN>1O$^ #/J2<)G(:7.04_UVEWCCYM)G@0M#^S>T#%"RU!SC0TEN]GM MG7(0[<)I.E:G^Y/U)9KA**U;/"[N1Z%Q$XR+:*('4@YTVYM2088MS.S/DBV& M]J!G@FJ&,4Q0#6W%H=UNKX =J6=<;6L?8./K5$EV50U2L);JS+';W9YQY2LX M24/>^ZG/;.V1O.MIE!GR/BF;J]/?+9-9S^C<'SQ.HC#DP4:KR_@9]?$Q7YS3 MSSH>T;9[O4,@V9TWIYR(3CQK3ND>#/.QCD:BX90S#^4Y=G=X B5RMVGD?KL8 M,42(1*Q(,"'9NMQN)4G;Q.Y,<&/7X$:_:RKGJCA)0]Y[\6S:SA[)NYYFF2'O M4S.R>J<ML:=,C^$J4L,#6%^W7?R\3=!N+VHFP4\(-1=VD55O:DW(-R/,*\]LVU77O8 M-(WQGJ_N#(E7E<3;?=OIF:.^AL37F5[5(O&=0Y0MQVYU6VMBE&]2!O.I#C$2 M;K(&!^T&8&WA;DWDP_/-P)>\!![T6D2,5D<+CXHIHLM8QGS^K_]3 K-><@0D MW6C3DC S+2*A.WXAL++9&-Y\R8('-D\420X;.>;.94YZ;0K6-AOM[D^6]AG7 M8VDQI^S[A;9DDF(O CY.+^5MZKM8('O++[=@=LN=2:/990ND'A("_"DGUG$: M_>X+[=5"W+JM27QF36(^_LL/__WET_4"+3[KE>)/?! (C'C*@A)BG_Q*HR%< M7'0>D,VL:&Q=P]5 5DE.]6P7RB_OVZKMV#OQ_RM+4G\\%U_Y(;!L>MGN+3+Y MYVWND#6.8DN"J%A>%@-Q6>F$6XG_W9I&A"#-"4$:T4!A!VT+<;NL6>S#>V . M(MF0I' %K!X(-C?P0SKDK[^-N; .L"CP/AR(]B>M$=R<1A:S_IBPA%N.E3\C MC7W\=\)2ZX$E5%\2<+S<#ZV_L3!C\=Q"?+F&]2(3;377313&E^+0M)G@\]44 M6FQA#@U+@ 2\7QP-MF6W'GC,K2""_VCO\S*.JX)CE/,&FMIMD=>^#7N9BK?A M(UE,5#\#4HM@5O?X>O$9UOJ!:\L-2PLC2E(0@*57/D3Q-PM&Y<*J^QYLI)7P M@+LT4M@B(A7@3IVWIBE*6J$%&6Q%:WHW 4O=4%Z8Z52LVF$*X:RXP%,VP*S!7XO!N"';I#A;I3X:LH]>B$;CYD/"ZWS.Y)2$.!_ MO3B[LSP_<9'4YO9JLE_8#_'SXO/5 CZ%,XFM(:+JZ=D#V*8P0W M:.LI.&OM'MJK2$/MP?+)"[HJ65-0I]&#I *Q-A/./!=LF'0S4<-?:9RYJ1@[ M<#<+0[C+%<+TEL]2/AW!XW0J^8)DMC7#_(BE1R$N!R.'ELU0;"2*;5F29-,9 M/C79SIG,2C+7Y4DRSH)UND.3^D3,(._2O;9FUALM&9+M?>$@BF9C* V,6]'),II;U/@_SCO8YV%JL&;+K M. I +!#ADG('PD.9\!]X#5+BG;9RK+QR2@A=5FG9Y"2DNR;J?FKORDR M<"G<3+"OO*WN7?X[&R6H=_A;]/2Z,#78VC !83*]I$^H,U\U;=!!/[U^87]O M<;NU"V>[@W46?ONSPV#.QEC?"^^0C(G0BY>8 M,LMLA!%-9B/,1AC15.&-,,JZ(AMA1%-%-J+?: [-1NQO(QY?5KC9TS[/ MF/6+\OX+9]7WO0AN%."7?_FA^\-3%Z39<%ZVMG2PPX)L"D_>^M^MWT2X^#V% MB_-@Y,OJXYJ1PFGRPQ(]'.K \4;%5.M5,5JB]EQQ+"UQQ,,9S]4BF&,4N;]V MTU9)0*-'SH5CC!XQ>L1PQ;[T2.NI>F30Z ]KK4:P[F9/>N/%B>.Y>G436NDDRA(6>LGKE;RTC_Y3AV6% M8W>//P07E+9XO4GQHDU(#GWX>N69S/WUR=B8IJ'I M19KN8,OIPW11.K0 ,W3\Y%YAAPWX/:.59[NU[IC\H_JE']EBBJ,Q3Q(_"N4Q MC(#?X3DEOJ?61 SLM0O1&5#S64RREM3[9=L1EVOEV0TS% =9JB-(=AJUS]V)KI6 M[=##Q#@R59)7U8.OJJ4*G;:)M1GR/B6;J]T42QF^-EFNM<=QK.T\)2![]))" &30QR#V[ZD>'VM[P-2U.(N9>Y^>,N M5H!FP<8&*$X4$M'UIW_>O+M ?#]X-I_Z[NG"#ZU(;)! V'*J_YM4CPHC$'2*Y+=QI2Y[#@:.D8B#^"7$(4<'B M*$#(PJF?36W)ZT(6,@M1Z*Q[%F2 XGA MA##E8,X@0%P6QW.\BAZEIG%52$U:JIB[:'[ 2EEWBOJT:;H3V 7"+OW1&32Z M%FQW@.+J(?93 2LF4<8RN&_$ I(G<+5ZUNFR^#,0QH30O@E!K7+KE005>VU; M(3\\%8"TQS-B_M\03-@"(4(%2N>XK)$@&P* M.P[Y-BG;!X]>-HD[^&.STU@U_0V,N'Y_%1*I;KTW=XMV=]D+/^^/': MMFJ)_-TUR-_<('^'IXS\71*^*V7<)S>-)*;K@(0#V"7,IY_(&BA? H;9C,5[ ME&S&HM LBH\16'[D)[Y#!&1T[S-8QD\SB3=[RHBEC[$B;A;!B.TR6/%*&&!T MI?F=[P*!W_LP-G+Z2;&Y?D*^.WK#X\C-$D6X/L9+(AC'.&!3\/"C>%Z"P)[% MT5W,IB* @ X(>LT<4= Y_T:, @Z]0+\F/HBF4QZ["#D,=X+?7; !H2A'.%\1 M20HI64O&B[ N\"8P*F#.%(RAR,2(\Q M?Y8(E>5T M"SCRW6>H629Z8$E,%-1<*N)C6O#E]>G*E$H.8Z,D\_^=^9Z*UUVS&7HGUF>> M "6Y)XV\_!@Y=NN3GXV2!C[,!!H\2#+B[MP 1VL_ ,W A9P)^9V("9):18RH MI("F+QBPB";[Z"E(D'$7MD78']*<&0<9QT$ EUUE=S!JE*=]&H4'5D 8I3(L MF:)TF"M)H9[^IQRL=(&\A4%8&/$EU@]02"5P,P8X,02<:%Y(.@$S^VYB)2Q M#.HQ/87#4%,4I; ,>21REHW R47+@V,D2:P(PT?=XPAG 7-)?E@$9HSR. K5 M6&_*#AW,D#P$X?P( ?41G4-\Y*UXZ]RZNHNY>*)R%4]7RCR:?J]HLTI^NJ1? MCZC3%C2*.WD/6ZNR"&@IQKZ+HC\W#47@6B!Y%SN. :O>H.$H[U6M_37>YF.6 MQ<5@&5P&JII[/M) C*^+E19)I-$IHW(NALG(;:7M%*RGC%)K!BK)G=L:9=)5 MS"*#(8T>6 RJ-2C)-E?*-E*X\3W3**&K+8I$E M<:7)PD!$N"*8FV^8+;,\%%Q='1&R113'BD#.W DA9LLT&F7;D$RTWZP,)EZ6 MJ\+127F )E+CPRG#X239%LOL/3& $-N:#?#AN M9@MH'L/-3#SRDS8"4K#%JI5H8SF$,:;_P<8TZ+&.HI']4^PV;[121%S=D3W+ MG=RFS6!>0-?6/\%SX'/K9Q9^LQ;0$,R*+_N>A16Q9$2P1YD07[:8'" Y[GV/ M"P_R1\=I-/,P+GI%2GB!$ '9N!S=08L&'@/*T&)33#>C7RL&K]3UKB,!/4IJ M&473?"' C6ZGM-F$G/4C<"?2,@Z4/P!"" +Q3B ">!?H\1F6H\R"+,FOR\>%L1C7C3,MY6"C MVR\RH4"?^G!;ZX:+E W&@Z!2#"+@<_4Y=!K6%9)EEB*A4NXV'YKP&>0@\',6 MRHBG7$G*GHXXI94I7<+F(@ <+K_X2:Q,EX49A2_D.\G!$FLK?1&X%-HE$$JC ACV9LH&@=RY>*'>W^I.IGHMB_$]<5!"FDLQ+< MB\XUW35+98QR1A)!?*F1MY:U3W4!DJA(/N4E_T5AP(ACVIRGP[NH6IB/3A1X MJ4D*@XBQ<.^>@SN:"K\R\*=8AD/6S4BZB!HC)>!Q^F.?>Q2+F$F'$7Z@\%TY M4HTI=.Z%&+% 2Q"X5TGU*!8Z-J0J.[00ST(6/[\>O685!SU3<6 J#DZHXF#W M6 1%;#]@LN*$U+BB()FR41(%6[H_@5.NXIIZM(+*I38^V-Y[?-1AQH(YQ& M=^,91;,1!]J(86,X,!M1@8TPHJDB&V%$4T4V0J!:FXW8UT8\LMG-9I/UL)C7 M2T[@R_48>(1(/C8(]G-7)4?%[CX*%5M?HSGZ[@PS;J+X-.0N"\YY;U9)17FE53U5OOBL=T\CT/UO_-49!ZR1%0.R;,;6*.[/2"I']$5JU/B)N M40ND^$=$)JO3Z,SIV[U6;[G3F:%P0^'/"7!5A\*[+;LW7$'A53?$,;'T7'U69+=.ZDU[T'*,'V:X MZ>#F=-WJVNU>]^Q@0Y[8-CS/L%UI7N3)GHEZ 7@ /"R^*D\I MDI@_.OU&+^^3@DVCA$>O6GHM('+@V2O588_ZC;7ZC9:Z?76WVS *+X2YXN&\ M\L86/PX;_<5.9>4$*]SL3EAX)YK9:;WR6\+O2=& 8*B>LK$?.5"P$LZVDM6OB#F+@=3+G\' M=B-??&]O>A7W/]0:#7,.8H?T0U^(I?:2"JR#@\1WP MR2VV(+1%4_,HSK^W]6ZH>9O"S[]^^G#U[KTU91[7-XH@;L06O8/74)O:MB,Z MLJ^;Q-;9+TQ)85Y,$43B/TRU=!0'RJF?@]YX5D$ %6@QU.O.US)0%WZ8Y-*B M;J7435LN;MVTOP(6Q)7].(L>#M1Y!A8.7$:ON#BRWO]Q8_W*69!.WMURUW5+229<)ZC$+U?WH&U MZRWZX@"][BR?]+:*^YQ^OT_WX!\MISW( MY;W2#<5&E!6#H%'L3ATE0E1OPQ 373 ;@T(IL1*@B_9L;6VHWS+I&O*NH[Q[ M(:D)3W9HI3EX'&?N%U^4A(H^"J=0C:;'Y6/-%F2;#69+MZ5MY./-ED&_T7FB MV=)N%[D2_<]*F TK],1.[UVE M (2NI2;RF>H/S+!1 JJG9)-6WJH=D$2%%F@O: $IQR^4$*4KWRG+D:V:\^5 M8RU-57 ',*W ;:2?+<(7K-C!DLGV2N&G*Q>4%6MJ$!X]X_U9&W-&% M6"3&S>I?%[#+^O]1D&WV;N:"9G LF O- YH+FH0\<7/A::&@F[R6S82"GAX* M6E416)@M/[8U-2W-*EO9&U+KP<4NYY[$4=#%4ZIUHI^N;5'?;NKLMLI>F&4@ MH5FR[4&M?M'K7OHD^HV8%1,R6G"RUA>_2B13MZYL?=.5C9NN;.')=&5[20=V MB[!MK8B][UO:.DY?MX>>(6X'0]UGWBINN]44MTR8^MC# M7*2S1"B"^E=KV'.^0#\(,;=)W>4I_*;0&40S]97Q)*#8/(:$G;9G$=I./@74 M.!/(6QAHBB<\0Y!-W[- I4]03R<*L6DE$J>?$."V0$#Z],^;=Q)W>)]R+LSM@<2!73-4E&AC E,TIR#J"@&JZ%]81QIX>D/B%KQH("Z*,..T%T(3@ ?$<-5OE[-3RU;KNFP:2YN60'O M)YJIXZ1B[P*-P7F!O(HB,8MITG*EX44C;/FNA1[%;!"%C/KU>V\B'>P4^&K5 M/$]7ICY:?GPB+D!M-$=])8#:)"H>[*?@A7S3A73)66-)JL"6C;A=CFP*T$"A MY8KB%(WM$DS9P" YH9RLC8@C0)_OXKT!&V%!1"11(=3#DVPV"Z@H(N!W$BE& M\$S,[[) W%",@(*?'KC)/J$+(SP.W0&R9,(1 Q$'IB@%EVF<@8L#3"J540FJ M4*'.P)WWE.?AN!Y^*%)O,OPLX%-AN;@GLR(P8H3%72.=#-5NP*YD$DX4H_LQ M\V0\G86B1$,"."#MEB@VQW9(X&7^&"@0EIO(Q59I!)4X$Z2CZ$7#(57B7LC6 M6Q:/6,B3BT_?$8;MRJ7M:S6;K5*.*\[(4_:B65K0Q.W[:X$^#9]_9XG'_FW= M8H( \4) OHE")DEGB8)/%=-$^Q(G@SC9@CUR+(NB8.@.B5D8E3-$'T3V,52D MVTXC#A)#*D/^788Y-J"?K@Y'"/S'\1AKLH1[AD)B, X]]%@#>(,\_1"#HG>;%_UHBC:5JE83I4*XKR*:S$I[QG](^ ME7/6+2>U-+!X$OU]1ZM4,QD)NT5995OL.TW\DJS%)#9PRQQ!N>#+?,A7Q1!Q M4Y.2(7?/_$"ABS',Q"-^/"P+V;ZA9H@@TIZ+$#/"-@+=D)0,*,JL(F#J6(S0 M'ULQ Q/9L_7WE6F,A_2P+!%KIDFX7"@0@"K8CA>DG4=9XA. #2D\?C=O6)\* M9!Q*1^,[5^T*#@(G["'<$4X2DYVN%&6%C?X0P:\$7'<71",D=!A7-"6I%8J' M)KG$PVPMC!%6/LX$F< 0Q%+<1QA6I5'Y4LY*]%C\M2!DP8ZY>_./T,P!#=+$$AU"@)))M[GZ 0/(XC+9AW8R509N%RIP5BZ/MP8IU0G#; MU5;];C8O\O^B-;#"JLTK1E>8":3_B&BXLC)TP$?@4S"A \$> 0O11%D&'C?: MX:_29UO+$CJ<(<;!5= 9MC-"CV64:BH"*"J4B,BAA721"@^.Z@$F40!.:X)3 M=_IOK>@!26'BSPHL0Q][('MVSCHD0&3%<%)213AD69\CH9,EK<32H &1. 9O MF0ITA/#/>5JB+A-O8OA% #Y:8GB% MI<)V!!4I%&-9I6,V="H16<$H9PC&*L&6A;0#^^&;< F$T->-=6$]K0P'+ 5& M2))['*U^- RGB"PYAM>!O61+>8V' ZLD3Q\!#?6\,2JQK'V#XH!H2L>(&OO? MN:?+ B7/Q!3+Q^7E98-9T<2V^''CH!<'N7 RE&@:QK=P-I2.4VHO+1_W_'_^ M>]CK#]\NCF/A3*B^2669?PRQ(WD23XXL,EB)UB7[+H:2R;:0EB@E+GE!74O' M2PVM&5H#_WO&;9'X "?5EAY;(K,'B<(H7UGW7 H*IZK(1:0=O,Q-!89X<2O] MM*(T?(4_9USVYHS-#8!AK# MY)B(^>7'?1%_TW=%L3XH:'3GR^AD M$Y9$8;U3D!\PBR.,/PD5RXA0&29B72;QU*?HP,'_U0T\!$U+M5(H">$W'@3< M3?$$,3QKQC$@*N-/PO <<^%BH=.T\O(+E0)V ^9/D[>6H6U#V^MI6^0NT \O MGY]4Y$'^O")2_D$(VL-/:ZAQZB<@*MLR93(/7 6 MA^6\ELAIQ#$>/J1XP%N\T-"[H??U\E<1$%*3:NBB4DN""%&SH]N>B"+0XNBN MM'E%IACH5E'^Q)\)OK %8XB#)3QIK*?$BH19#UU+C4D$K 5"^^G3"+:&%5GY M:]@ /S7EU:4D,+8.FLTM8LD\1H05@O\6Q3$4[?^3S4-N6W_P,$SFP3T+?69E M(:9-&>;?14D_*TYGD!LW(>(6A9,RF?S)32.,N+::K;96-"/'$&'I@2A3U,)= M8F0PB-NT87V,,BP^^A&+6&-MR:)S74ZCF1_ND9NUX\&LAHYO>345#2SR)^_V+%%W./H756U$Y!N# MJD3/AGI>B+W/!X\%J=3]+ \BJ?H2F<^A:J$I^X;5HGZ(1TI$H#Q_KCJ35*I] MD2<_YWDY8O["3J-BXF.YIF(,_P-+J-H4^(^<&%B"=JLC*K+/W;W4%Z+E#%9#17,6B".X8=%'Y?WMWZ^^ M7)6*\0L#+K5B"D"BG$*)!:(NB!ZL!/OI\0O/O_-3+'C%@AEV)YZ'!Y<2T##PE1$SN MNV;I)(KE("=M[32&R"IF]!MD+-&OZ_EL(*_V!W\B M+%,*?M/+%G*&@T&)N$6R,JZG9>U4K"1I6!]$8&4=9XKA ML5#/P>"![J)_#?PL5FB#G,!Z:7#D.?V]>NQ42EK("='P*>04&RIT 8.[//7@ M$AOC'84]*!F8.I:)T>$4\IO'7/6.U-OEH?[GU(\63-*@Z$78;3;M9K.)5W"8 M&_608V&&9\N$\70%AD506*%_RX*YM$#_E!5=,VG+8*P_EV$/?"% 59A'^;3L MW*#!W1!3^7=^? %$)NJZDOBDT)OH7)H+0"KBQ:$KL2'W $VR1!T&E^0/X[_Z M.\QU AR+A5Q"U$[ V9:RUEHE:Q??:.L67$&W,-K,-279J^4/%1_G[3Y6F4() MF#2X77I]-87XP_R4#"@(H"BJCO<]G\4^+RH$(Q$8T?7_)IGD#!XED[#]_K)2 M+#AWRL(14WK<9+3P!VX)R.!HU;Z$BJ-TJTSO=+'*#Q)6<"W+QH>F M;-R4C9]VV7A)YC,9&D$9(,Z B5Z[=PS-#[(3"MDCCVAK<0K0R?+L&IDX*PR' M7,ZLL$"4H,HEEZIJ76..B">5;9(E?8+VR5:7[-%F@@UFR106IXCFRYZS1;]H MV\+CS4%Q=E2<_P&326$/E)2)T$)PA;*%R.KEWV>^ZBZOG7*G Y#"N9I?C.87 M\J.J$,'[\6OU*#HC"3X!V:^:[O!C-YOB:34ZZ ^C(3@&[!?1T$V'?D,;2$\^R:. MF8K2#3J^-Z;!_G]1_(W\5G7]!G;.K1 UA-QQ(H]H#??JO=S)0!(TN=0:' VE M?-!4&;!:$!;NS0;!M[1(6PVMLGN;FXJBG9_6,O")MJ%V $:[-$#'JQP-E/T' MEVS(?&F6>!I+&Q1;"TNW6"+RUF!;+AXAA9\[@FU4L$UPJ??DHBB"N'I%ZA 6U M:#P9&ZD2-A+'+A1:13D5G(WI[%=N,JTNU3V*M0036CU<8SL]OFB!8@ZXNZ*- M"%8'%4=8R;U$JHW%4=V\X%4(J,^?!!,LQ-'M4B%M?E)7KZB5I[2P/CS,\"RL MZ+99<&61M@LU^4$5.'F/&: YA&( $?2%.B$4XQ=M.+#CA6S#*GB5>%%0%LG M,,*N2'EG!7#@HYCZ**K.0 (^#+LI$CH$4)+L^*+53N7&E6Y6%>WXL((35^4\ M*/ 18)KC\<7/$LOL%K',K"NMFL54H"G^],!^1SHBW:*AI8@V4=AG& @OS!N$ M /%Z$=U0M'/$6VTIR\<7)0"Y4@G1J@2P;%U6),:(YJ5.N'U_?;H)BMU)^3W: M;[@OO\31 QENU(N.0O"9(64Q5/3#__;IYUMJDC=#24P^BX4C;#7?8I)MHI8ZKZG[,0(&_#D-SU$62 5V ,U#IKA.PFPR;]' M>S)_0,/Z4R:2?>#2^PC?-+O$!1A8VB\]OLTIDC-L/RKJ)][D(//WJ[:*DK*W!YZ,[I M*M$*2O71YM]GM+DB0D?#P)Y6 O59EE+3"\!J1RJ_]ZG@5B%#BS9\2Z"M:&U+ MIU8$QW&N_VC<-LH/+;6LWM2N=KEL7'2MQ)'FC9/'C- $+-@ [/>M\'@67IFC M,:IW_QH]8$]^6S\5FTRB.!6-2$-&:5HZQQ(]7- KP9X9^T%>G2.@BFB=,3PT MC@(_LC771O8C%X9'B! #W,/>8* :?M*P$%M]KCV.L0E7AJ.F/!>3DQ@64U7/%4ICHVGJ79R>8'AFDDAV@ M\W1BF3=!%(H.R20+9'=HV+!7_FM9ZPRC%Y>F:,IC':;85>Q 3AVEW%3;!!CY\LO;- NB!>)K^35 %6C*.O1%%+U;N";E.XJ8)1%Z7ASS1+"C?2 MR>J%9ZE$:I&=68)?QMI9!J*M*9("%[/(IT+> @-7Q><+8I%O"Y#ZDDR!/SPQ,B,&UHJ!HIGE7+ #]9M/\EZ6 M*FM&+*;:9JM6%2+8)IMJ+_67H$.<\&"*D:.!HPGY4BMMF1Y:;)_M%:%W+(<% M,2/;#2$!R2+J5;AG9[O;9F2U'=F^ CZC0;/;&3J=KP./C[]V!KS]=3AN.E^Y M.VJR?JLY9,V!]$$+M[5#I^^C( %6^P.1-#WT ;]V^IUV_Z@>:Z=AJ:&1&"@& M=YKN:&D8K]AKZW_\TG-%\ -/7/LNAO?1 \C/KA7N^_I%\T]PT9ZD]LCADZ%L MKU@X5U^X6;YPM@ISE]-0GRD%Y;39A=-]Q5_334[7DW\5M6VWA5/U_KMT8B0B MCS-L=T28?$J:C"K[Z&2$=B$V'1W+1CIK1EC$NL%:AZ40KA681.3PXV\^]C>; M"FI9B*'+!1"^/_:I()!:5$_+7V_?7>:D9I0%E@7-(YRNG8%2_ MV[JE"HY O!:#7441CKWVIG6+2]:XOL(8,''=;)J)=- *8%EU\ =)(FVR<0>\*S_*/;= MY?80@W M%(C,8DJ^TT (AH:\6GALT4M[.U.A )KRM&$5^$3!G"K%BG7;998B*I4O5,A1 M>(B#W \4-"CDETAE(I/\*_/NU%%2;6-4W\B+$0]!=J?2/P>Z1S 3+)V-$B"Z M8)<)4D&/G(LJ#$OF"=HJB%"8WX3%RB "1" !AH-]GX2K+;TM'89*!MM%%?0W M'OB3*"+D91FW(&"61 O TC)@W!A/ M%\MN/'A(-<=,4C&3'"#I+6$0DNS0Y*,HYJ;&PB" / P%I5BEE&,H: &0XEFY MEI.Q/EJ[Z2SP:2;D>LZB /&,2-%H!(;OH]I%GX+A#6L!KL$/<8'"M%12Z8L* M1QJRW"[@0S_1 ,=D1)C',19RQ=8X9IE';\,F1Z+7O(2[PM=C[-+(Q5)61%=> M^8%7ZG=&*, :,M0U$.(8; 6ER#X)A94WKQ2_?\@5FOS=IGB"9&S9Q$'$$>$A M5/NGNECO(*=6A;+H@:&7E]2*$HW2J=!MX'- CT54C8P"GMOH]G,F+X)^*.G1 M:/&*^K\=)ON (B-?*3EW$3]$9I7ROE .FE"AC$Y-&C'5K8#!,04,IH"A$@4, M+Q&\&&T+7EP7AL%-*%&69=S"^H261B$#A: %TC(!#!7 B&4:2-@D/!1'%(HE MS?- A THEY4,N,)1C-6RJD@[]9\ ?<*"3>%U=8I/Y*=S@#X9NQ E>E*5S(5! M.Q^CKMM!PQG MC_6]7BD<_,?5YR\W-Y^^_/K^\\WO'SY]_NWJR\VGW[_V^_UAOW>D4#".R;JY M:5@T+$L;EW6P,/#2L!ZU#QC,=CXBGC<%8SFJR>1K;]#J]0;'C*\[#8M&96G# MVN.2MA[+8RMGHZRV;O$-6@OX9[7%],;UUV+"UP$8W!@R!;UL5G]O/FDH&GD) MM84-Q68!83:.Q]9'N(O!BQ-?=("C#QC7]O#<7R;K(5W:%]'>7L0G\'[L>8O? M<$_JHXU6#C[:NF_ [@8L!N\153>;41>ZO <='G;!4UC^7_-.25@_]\Y/TMAW M4["*,G S5>? VRC#(%!8_*XU!LC/W6<2'T)&FZ1G7 2/59!8]D*EL%8Q1=#2 M_$Y%)46Y17\.>4QUY;(EG'_#:%JI MLP#6I8@#RQZ;BE:B&+R;L&",#R4"H697>)A78"'#"-1)8(S&%:5*JK>8EP,G MB],Q91\Z^,E5<*FG([A MIKGHR;\NA,:^*G+64-BV?'+G]#@*+J*VGJ$WD.W!'L/H\"@@I14BS7-BH M_6:N%H^/[KAH)4HM9_1[-6-%F"FR/]^,*OYX\3R940\XMK]5=*Z2YWGOVQ+E M*E%J2.3%S"#5[+2C(MUJNY2,*1&*K$301(GJ0K2%)$)&D%6("Z")NV6;0U91 M2-E@R_.1^?'ALEPK#DK*[LY.JQ"KGB5"CL*(D-D>2H?&(97#KK)#E,&A97\H M^(X)(7J ;,VH<%2PG%)IMZX2W"#:&3K]&4=Y.(^@QTX4P% 5=-9O%U.0+T\"H6=X'3S M4E^1?UPUX)C+\Z245M#>$N5=N3MJ4#AG^0[1(T8E(/^5>3[%?$JM-HSN>+$3 M_&I#!7]HVPI4!U3/"Q&>$X> ,MQ-(N0H#2'QKWB^LL(QN'COWT4Q-4@WFWS. M4WN!Z$K18-EZQ^F,.TKP0\58SG93=(/4Z2X'7O[.L3+@*@ABF2Y0'Y4B\8K- MTIIDKW)KMJ27Q(/1H?F3!=\PD_$"49:%\(H'3K@K>JZCOE\.MEB%UM\IV++: M@,$L+ZAU$J4^*GA^G!&UG8A!^. M3#=Y%Y3"+=L0?Y!"&:6CV%N%'5N4D$O:V$(9-^@[; A5Z4K_(Y"P\ V1NI?E)]>5=JLJ-/,K\+@M,>9%V"3/<5\M:RZ:IFJ*U-U=4)55]N2+9O%G#63 MD;>8TU$ 6:6[.C"$XHIJ>>%)JR-46^Q%HX9?[#S;56W@RJO&?JT8N>=N:@.J*9D5=D6H"JA[!'JB]MCA#H\201)C" M9M;4;+_\#+VZ0;7N4 UQW97-5N-;;>JR;2"Q%SJ^@\ MV@OLJP+1'?1'HTYK\-5ICMG7#FMY7X?]7OMK:^2T.J-AM]5WQDL'TITK;#GV M@5$(XVNOW>FUFD>MD[MJ4!,T2P[I-$^?/^G83RXZP ];ZH0CCDCFF$,!,4L1D1Z&40J*F)4 MQ.I]+N% $N'9'AX@#@9>3%V_QF*;BQ)K45GMZ47,LJ\]5C%Y/'%C?R2<0)D" M_P-/_-V -[J*?K2NJ?C.*]%5:?D\T=_S>*0LR\:6^K(F>Z'_*'K>PA'-8WJW M[Z_I87P4B_QOU_1'V7-YKQGJXE WR=+/)!0^%V5Z*$!^SI4Q_E4<^OA#I9"1 MMZ_9#&,_,%#N[5OZ/L_D//;J/]HZU@-I*_:H)-/QP*4X79*+:-'Z*6]I@/); MX6KG'9G+XKQ U.3W47"?HRF$=Q%^SMM&R392>?^)@J<@8Y-CQ,9J#;;;F/")<:BO_-A,@XE%LKXDRRW1J"*O!ZK&PDAZ\;P_HQC(]U?. M MC33_$="Q6\$C5T7^#4=4PPH4X-:*[)C&+,[@G)6T&I8.<^S*VJ0_I$PF0] M(C:2Z%>:S&(L)BQ:4&!K03GVU5E&$;3/UV^I0RZZA=@CEZJJ(]GT'6%4\&+1 M_$"W+%-K-IDGQ$=!Y"K.!:>4 +;SH'GY >"$PY!DO1G.EV9&32Q4C*U\@U@; M E''IGM1F*@.M0E7C>TG8C_$_*@Q1_[HI,!_!P$=4%D;)>/N_9APD;09)2CQ M^-U<%S\I-OC'_C1I&>P&7HBG\R@N]$"9;PV50S0%!5'"X971G*OV&!HU$ICY MAF<4;1ZPU4)(-7SWA9I1Y?:R%S'L?IS-TI(/+_(T8%+,Z6L=WT>$0.0?\*2[ MF$VEJX -BKWQYYPV MDDF6>M&#UDB%(.A$YK1H2*7NS2\O='>)3B59YV0X7F7J2'*1GKMVUB87_/G# M_9 J7:,L40);W:W8FDZXA*@,4F%&7(@HXCIC;26$O,9? K..K#JY(.R>P5)* M'L,6U)%LPZX. .7ZCP:FBY8DHY9"X//[8<.Z)>-*B++50\6RFMP(Q5XTRFF7 M#]+?*H#"L%8HSNZPCX]' 7AM9XI+5=7PZ?YVX5^'Q:?)#%WXZIMD""AJ% M8$F7";V<+U[)KE#;*D@OF= R4? &>^W"Y=@?1!,P=@Z%DX(^B&*260I.@+K% M)5CP([6?0E&SBT;B\JBX_G04ZZ)]#T+JN+)$G)!M-,0VFI21/D](*BQ["3+F M)5L*B Y(B_[=@O&Y9/@UK.N<"H%=8?_@=456 IL!$9YP&$=!0$).0@+3?F/O M.?&N&39Y@EO_D]M,DR@1<0!,5V:Q2Q;< XN]=0,AYI4^D[0Q1!,GA9^D8Q$M M^$O 8&GD8C\=?TS]$*301B'&/9[/8QI)H-):UD.T33V$J8&KIP2ZQXPC.P$E@4*LPF@4_(BH+:TOSDF+,TI7J6CV5DJT,U?Z29(.R$05 M$H)A@B/GM?8Z.UY6,I4ODF]JFB;C_-1 M-=,P>L=80KN7S131I8*MA"F/P2M74!FS1G'$R@&?(+>*%+)2NC10!HM6Z],@)I T#H#.8W;J8^H+,$>''+"5SWE;1>SUP9.MN MD;TB'85?1B0]X"6I].!E\^;BY'7.#@7Z($&^%%$8+=*S$-+<,2BD&&VI7ZRJ MM4?@WG#G!ZI&_&IH9/+HBZD,K2O7I0#N':J+ B9N#I+E&ZI[(40PA"[H3W4Q M5G2V5*_V&%+3R(R)&#JMA6[T4B_D1,7,) <)W307=AT8J\$R@)Z(PJAA;LAV M%D-?$3&V-U3S2,Q=,(P)@LC$=YX2WTD7H-'X:I$!J+S0K$"B*HW]OEH()%($D M-I;2:)=EMTL6?9Y<&8$U#BK(*P,3"IC;:!3XJ@5,<9QPT\M$V >^%K'L\I$\ M:L9HD27MZ+M["N=TQ P:)&*=*5H6FC._3.A;G MF4VL.4NCM](O)>Q*,C\3]!K>"AJ[TR0<@]W(K41'46W2+8: 84 P]A4[]C2]D M?C7W^:WX7MOLUU>2"M# &H M0%:#*W92E'=KE";*S.$[CX\9F"FEZKKE$R$%EO#*<@=Y_G95F8,E-1+9.]H: MJ2XZ(SR++N>4+$0^!'.II!H%D&7*GT*EL59 G+KJ^;0Q5 1" M+)U0Y%B&C")9:2:VF&L8N!KA"H^<6"P$EL7S;NIPP*(U 6(R$QY9U61NWV,NFU ;?^2Z11"QHKX)OH# ./"4\,!I=7_= [BN=IERQRCXH-E)^> M"\I\$EHY*"B*>]FC-0]/2N"R&<B0 EV#1/.=X$Y7U[Q,N@X!>R*E2V\8=U\Q(PS M,)POCI=%)$4I:*NR.ECU!U/)IG2.!42BG1^2) QB*8<)0%<>9I-LKPOVAG6C MD8@8GPC@+*:V&=U9'N$XDZM%I)I;N@7)VLKZ&)%.<46-CBRH1 5&I7+J902; M#!LJ4+<200AD[43E2F7LZJ*W U$/B*1"R41E"OVI5=[FZ7B?>&M8'4%$R M%:X7[XB4J_)EA-K*VYA(I;39=5J H ^%25FR*/645NG2DJV*866IJ+&2:2?C M-[AGXBD%,GU+%2K+TNI125V(9VETA?-UL$#E,71NC"6]L]4 M;5\^ \TO$/H-_%(Y95("A'Q*FD4=K)SG*C W=T'8H1=5M(>G7#QAI.KQ&+T" M<\+B:PC!W9% EV@A7XOL(C5(K'(CQ!UB@S5O[_#X4.C[[V!P M)VB& _]E4U$UE.C5_:HKL(S6B_8-Z I0DC\E!036;!1C)4U>D;GRKM&/V3V\ L54WM97#'HLHBC8HD1&#T0(IM1 T2X: M%N:%T<4I$]-8]<7]Z$?3D:Q@T]I8BH:::/%,T!V(\\0/Y54)L1[D%'4!\1.9 MIRK3-_PK\HX408DP $8Z;3[CI>2M@HB5C4:$PLT?CJ//* L:Y<45\-.E>/0K M_[5$SA<=.VG(Y7:= M,*8'";LN3*C=N0"YK> 7MRQ$<6>VU9NHPN5LQQ6N%N!,!VOS%()U%3/'*3;'U.I4&84S/1GL/ M1R\HKM7*&:'4(4L^3S2P%]%JD)VP39XHMR!*4J [5"%!?$1=_1(!F\<$Y/-D M\2$5IZ?RK#G;+P%2UA:C $"QM1\ A'#+=) MNU,V(^):VZDI%E#-@O)SM>X=U/I'D4J8^(DHBI"Q(4IG9 'Q^&A.%7 "ZUF, MN)RI*/603S80J:0U!91.HD:NA*=Z_ZHU'J\H#\%"V"D(#Y>)V-2(KY-EHLF: M/ _USL ZT2MT*P5P4L^+;R(\M[JY84YJ^I;2&C9X(ZK+I9BXR:1;)"R9$G@ M_7CPBK)@]Z X/)N.FA?-F,51341@FH#+@,?1I%\PBG7&)#, :"+CY;2,[)@" M"DD=0%JU7L6(J$Y/.@]41,2U0T,8P!(!SZ(?F5Q/55E7U!1*9LY/A8VWO#E/ M.CW)JMI"<5(:XO0LX))82E5JJH1"F(255Z"7- .I,5>R6&; MH.-%J#.?NJ)EN69"1\D6HK[:QA6O,LW@JF25;;/N50&KDGZB%QL>SI0)0.03 MB3HF0]J+L&-*G.5A<%0.X,SSG'WT@E8T]3P,>9!WJOHK25DDHS:).+PNRP6 M_+BH6=)%@LB';&!=Y"OAM92$5YYAUWR6%6)KP6![Y$I9E,.E"NNBB+?IH\DW64U,1RM3RS M57F&'I!#1A/R_T5#2?MJC,MVOHW&[^=5E_=:HV^SW MV-!9:HS7^D>(/7$2*JFY9:!]H_%[X,)T_K7?[S5;ZHZC=,EK-2Q]>!:-#W=) MC% W7)!<_R'L' D]>SX]]=:/#(D^8/-+/\3F%!>C ,364BI!5Q-%"HP4!FX^ M3>#W"-R=BG=YDVS@=(#<^9!_;;H.L,%@Z'X=N"W@A:$W[@V:;- =+;-![_UW MZKZ2?.TZS4Q+9*3%(6\8+B]+.$7ZH/^AAZ ME)'44H1-[0N1'R3BP.=> -U&67K)LC22)#D<-H9]RO6E,?S?R^D##1:7!9*@ MA$&69P<;3N\G?>;R?6H5WJ3>KL]J-8;#38\ZW"8YNV_2(^8WZ#4&G:UK]886 M_[$;(,E#&LO.[+M%K:(ME;Y^P54=/(H%)>O]SRBVWH#8:^0L^&A"63=EJG:; M,0PT5&?:(I*T_.]3IB_IZ,A;OK;J8H?5>!>Y&28LR[/?3OG@^>TJ=_8C+$BM MR[*(Y0U_MH2OG' \ZGR+W=TJ*>LSVPH2]1;.;3><:A+GLRW8BI%?>3ZJ_&F2 MIK/+-V\>'AX:"7<;=]']FZO8G6#[P#? M=^B #]IL=YPWS.E>M!SX^-7AW]N>TYBDTPH45%UI8:W/*JQU70Z&W90S3B+> M^YD\5#P#8;TJHF5P,\9'Q:$ 6#DN:LS32%GW0L$"-:O 5/&=CE#[9)NWV.YTWS(T3892VVP[_[C2[(\_EPVY%+--; M/"'L662@3N79U-ML)%LZ"$Q1)HHC9[$?6*VA0J(>B5J\$4\?N&R5J=FP^--5 M]AW(()MB[U%XO4O WM2Q_>/'Z\=9N< 'W0UF[O\*J)U@OJ)/T/\^RM+%UJ'] MNMNYVW(PQO(UEN_IQ6]@%*W_^]_5I,_ST):%KNNUF]]1V7FMBNBY#]1>N:3F MKO7FBWBB42G*T MT2DK7+QZ7O YW02K*XJPB@$HQ#.0"&TC$*HED*HBH^Q02$4<.A&(1B% M4$]^- IAI4)H@8=@-$*5-$*KFBY"LLU'H&C1SBICV.P9E6%41J49UJB,U8D* MIW'S^VTU"?2D=<;_^_/GC]:-[#YCJ>-FUBO1;TI^[:FOO0C>)-M*(;:,['!S M@SLJ,"2M=XCH2.GE$1<=?[#7 [TF97>B"0\BT7B>S#7GST#6$!>J][U^#$U/ M80<";F3UR_UI-&CUI<:U+R2_LNT"S>X\@:-3=YM:=\"FS MBE/#1GQ6B32-^#3B4XK/ZZN/U:314^K_ZX;<1 L0;85I-0C7" MU A3*4S?O?]031H]9V'Z#M&2?"-+C2PULK1&LO3CU<_5I-%SEJ4?V8@'1HP: M,6K$:$W$Z!^?WU>31L]9C/ZAX84;:6JDJ9&FM9"FG6K2YTE+TFM"7?H# 1M6 M9_=?$3QW*H\!ZH)78ET@EI( P2F.K#N+&7W52$9KI/'T.32*6:BV,]HWV.Z$ M_M2:;S2<(9^N:-!1;GZR2X<8]<39]Q6/HUCRGSVZCF;>&":.0YVMO88,. MJVDU\;U:GYH7ZPY2GFD:JU?D\R$"VX%(6XW^8!.-:HNH/1NI#('"%9^HOR\> M8C:[%+UU'F"V6WO:Y+^S41(%62H7?6F&U6R-KFWTKD)AV&^T'+/@>UKPQZC% M;93^ C/>I9KZ$:3Q B/\0+U#L&<)UG0UGF9P'&-EJ[^T A"J ,/*L>Q&'#&% MQED<^LD$5A_XD NP1^8B!!]B5Z6(Q/;OO!E,+)K!Z-"8SL#Z1^.V<=W(ZZB= M=KXS(4' _\+^ P,GO&JCB:QTNLO08!;ZD=;DIM;?Q0PG5 M"6\B3"[QO#AO'X"04IQ DZ;,PP5 ""T$<*+^:P)>"1LD(QU&8QOO9+%'2'X$ MPC6W[B349QE,+(#A9FCK*/A',8#ZD/$N33Z.2\5_:"0GT&6:SJO1ZU=.\S4A MH<+^?.9W*OM^>_%W!.V:9L&=#D1Z^_[:)DY G$ZD9'6(@,B<2SN3L-=&V'PB MYAX8KGB_K$6ES54WVHC93AVU!08@@CLARK@MN LQ1)%JIPCW[LNN& \2-/H; M\& @HM .;Q".I-OPJI%L>!;38(!%>R M-HQZ-@NH\P9!5\KGTV)D,X1&3!-"6N1)BGQK96$^<3>:S1<7:)&LE1%^.%5] M<%#"/0]*(CPU/:_KL5'_J]-O-;]VG+[[E?7Z+?ASW.DWAXSQ3OL'>>*D9ITR M>Z93)C>=,L-C=\K\0?':[) M\Z0O:JN\E;>&CU@R#N%G9]CNV MF'JC1Q/(RI6$]H;VD[2J,2 3@ MA!^D\A.8][TT,[Q*SWP2-JF\5*182SHB*0P_CE7WYH_5"]B5U=?[SZ M?'-K??GU_>>K/][_X\O-]:TM%-W-[]=/C&?4:GN>*U1K-IUM,JM*TZDTS;UC M*;^TKK([L'%5O^NJ$];/\\LG$,L1X5"7I_ F>0.WLL#ZDP7?>%P38C$"JLH" MRM"3H:>]IBYBGO@>E]VKKR<^'R_W*C*49BCM^=/QRTX816/]%$;FPJ^O/H4J MTK4$D??Z?][X=3&U# U6F@:78P$Z&9Z,P;_'>=: +E]\@H92C6MZ>J[I!]"M MWZS/V7@-]Y'NKZQV+DUZC MR)O#?R;I-/CK_P]02P,$% @ ]SL'43;;D*K^"@ .4$ !@ !A8W)S M+3(P,C P-C,P>&5X,3!D,BYH=&WM7'M3VT@2_RIS;.V&;-FR#5E@;98J8XM% M5WZ5+99-;>6/L32RYJ+7C488WZ>_[AG)2#8!E@7R(E5)L#33T]//7W<[.?Y7 MO6Y&/HTS@@;NQD(8LD<02C$IXNN?2)'2<)C;DXG1@]W(<,DF)XU.1,OG; MSH5]5C^"%9++@)T<-XJ_]=IY[*Y.CEU^15*Y"MAO.R$5"Q[599S 71+9@9T- M>+VQYKJ^Y*[TVZUF\\=.0EV71XMZP#S9;K6,PX.;9X(O_)N'L;Y<6[" 2G[% MD/H=9X?PP6>*POX!?"Z="1N38IL71[+NT9 'J_8;FXL>*0EM'ZM2/9M:S3@"^ 37S:T5RU\>-.4@NN45Z3L"H@"W2[VP*\C;Y//\U'? !)DKW M)/@;MY$'7/K,FLYLL'ASU(??-K''Y'@N3GH#:V3UN@/2'?5);SP!1]G M%Y/)X#WI_CXU35R_EM/SW_,_62JYM[KKHDBMX,/E:1+059M'BN@\B)V/97)H M[OHSCUP0H;(0K4UEK>@Y2._$]GE*_JX,_X[\"-!7.H2 Q",9$YJ2V"/_SB(& MMZL1%9QV);+QTP]'>WO-SAW4$2F#S3=V)@UBT?VBJ7W@+ M+E))NA!270RKR)DZKM5Y6R/S%:&12^9,+AF+2-<)J !^;)\)FK!,M$2MR MC!JAI _VOZ2"$3@KR8\CN\_)>\Y/E6=D>,)$?+WJ^2PD@T&OPES 0XXY(.!T MS@,N5\!N"+EC];RLWG!4YM98BW2#:^0TC2$G*$\2S(/$!DR#E8#H&8_ 8B X M<3>C0;!"RZ&%D4RHD*NG$8,N%P M^#C+D@0,I;L0C&% J!'F>=I^\@C5S18@$'* (:KU#D,4>]8(M6:E[#DO9:Q? MK>Y=EG)0/^85C.W*[=>21$T"SB1>+ \@S6H-+.1"E3X>!5S+N8D$VE&@060 MZ S] 9(;(F3TB(IL:QNB=J NF3.M!:P]! ECEWM%GE(\!2,CR%CGV%HEE,+:W-.0)0G*Q*/!&$"W 5NH M/#R/(:K5U';4&Y*N>IHF_%+:R1/M4REG&_V7ZJ.GO41>4T*Y)>-0K\D?J7*U M>?,9RT[\>(]1/C2&W'F-SI90L-8MA96E#]"RGB;48>TH7@)&AD-;QOVQYO') ML<\\9;(V$Z$"P@;DXM9!L].C"9<@$(P9$E^2+,5XDDD2Q1+2@U07NNP \Z6N%2J](P"]5>NB!?@20FNA%1&^L,S7:K2*-)% MG$1=4 ]\%7 !Z2:"!Z1%,E!%H(YDUPFO9D#T>?TS:+*$/PI$N,16:$)7U3R6 MGT@\IMC[Z^>??_Z 'AY"[E.5 9*^E6'%+R0RUX:DCL1D["A6G-^'DU0=H.QT8@'J$C%4N1C"L'8!J%3<3;#_ M9F"C:4XGRCSJR$PH.K!34<&B/LT '.4WAKOPV%7X[*:7H2/?+5)RW;RGFXL( M*2IJFHQ!QE%)FG.:(C(H8; \_Z-D&5.P$4*-DZ6@%Y^ALA$*8BA6AZ'Q*J>$ M=>H45 ^P!S)C:4I%7N3#C;- XB4I]@"P!YXR) 2Q0?\,HIZR108ZB6%35P-' M4!6LL7TN7,4>-CU2F:YUIP/\ICX^:0BUB@4T@'39"%ZXG? (#&IO:PG-"^]+ MBT!:QOEY *5S@(ZYP0#JNZF+'2R?(P?G.1 MH22=!VPC)3Z@XUXB6J%4=U@0=*X8B &"7"Y,3?;%>_9;+2'$39^K';6)$-1: MB4,>" %A.TM IPZX&JSKF5.[:XV(U0=8;)U99I]8(RA=AEW;&H_(>7=&3DUS M1,P_>X.+/KP]FXZ'4.!8,WAT;IU:-KSO=2]F)H$?X>GIV#XGN]9;,AK;!*B8 M4ROO)N]:\/1R?#'HPQ;L+4],V[*M/\S!>SAG.CR[&!#K+!]5P;.^->L-QC.S M#X%J:,UFP,^,=*3[6%>ILTV#)23JW( /#XQW MAS]VYK$ ')4CM.;6^.IEQF)?PABL;-5W'4Q. 8WFIUU!EH1JN9V&$/;J#DW2 M;?Q[Q5.NF^EMG[L0@7-DU=SO;%O7XX=JKV7&_67&_K.6&4- ,) U:,3BK%)M MFM<.2U1;$6 J@)04 .T:NWVBOPCX%Q)IK*"0KE#UN"+2P"O=+E@$0X2"]+P, MMD(X=IC:I%.Q02Q/PVA$3A1)>0%WY'I^=1L7ZZ;11@-/F0@O;R$!_Z@HJM>X#0F\D<["^CQW5'J4(^$'1D)"I*IK6A:G:77C"ARJ0 M*#PQBL'@*WGI[M;80X/G76)M;DGU5N-X@GCZG8+&O5?0^ H:7T'C(]#/;4;\ M0KCN.QTO0@BXM.R1.9L1-6D" GTI:>!CYPO3+3B#,RQ.GIXKB1G3P%[1L:M_HB&+?P .H5TMT.*SR%+"G]6 7YA*=O+]RK4T MJ'D6H7Y&/WRJG-,Z*N><$0U9NY@ ;KGGMW9;&[\87USWCTGE.QNSA.%7VC"1 M?C$7?T#R^+0K?=EIY?6>W]@][_PR4&_0G4+MB5_6ZD[,"]OJS6I0Q_:,SPK< M;FW4E#G_ZL';-WZ])\*F7Q_.:1H'SXQTG@CRCQ@-R"4-/C+Q_:+2UCOC%>Q_ M?6#_5:BO%=3?JZ JT>Y;NVBE>)H(AE^RAV-^HF'2(3US_#U,F;9'OZ: M%=-',L$QI8RWNK+PZ*'_PNK#Z\SJ&Y]9_?,!U57,W?OF4PW]WP*H_V?@Y/]0 M2P,$% @ ]SL'4<>;I=MP"0 Y3P !@ !A8W)S+3(P,C P-C,P>&5X M,S%D,2YH=&WM6_]3VS@6_U=T=&X+,W&[/RKV>9"=.H!2VUV[@TID"EI^D)_E]/N^+[,-_!,$@2WD60[3:7' MX? R3.U$[H52*0/-V,9;1X?4@C^!QT>'$["<12G7!NR[K:OAA^ ):RP$HX. MP^JWEQVI>'9T&(L;9NQ,PKNM"==CD056Y;B6W/:P9XBW5V1N@ZF(;=IMMUK_ M[.4\CD4V#B0DMKO?/#A8-&DQ3N=MRB^MJT%R*VZ QJZ-&DG@NCM2-NVM3G!? MS[SJEZC,!@F?"#GKOAZ*"1AV!E-VJ28\>]WP+?C;@!;)ZYZ3-N(_@$/C\J3( M($C!J=ENMG_N6;BU 9=BC+-1:\]O2+?U(NEJGAMA4 LI[*R;BCB&# 5^>G70:>WV#D,2_*YZU;8O0FB! M?L+^]0>7P],/I_WCX>GY&3O_P"XN3\_ZIQ?'']G@]T'_:GCZ[P$VH\3@\GOO M[[>LX^+J\O/5\=F0#<_9YT&?5O/3J_:;5F^WU:%E#7\9L,_'E^^/SP:?@_/? M/P[^8,?](=WIM%J=_U?+6=+KM(%#<GAE49ON8_:EE-4FG_7[0F0I*V:N+EJ_L)/W6ZZ?0AM7%_6VJAWRE)^ M TS#C8 I.G";"L-^+;A&C,L9NX1<:8MNG7U0>L+:K>!7EBB-8L!R5$+%#+(8 M^_VKR(#MMAK,>7Z5L.-(<<* MM<@41KXX'1<9X]F,%9G5!:#:&-BZL!B-FK,)7FF!5)SP")LT4Q,,<:SRGS0)(V=5@ZV'$2GTZ-D2/W(Y48(353%L']P@B)27/ M#72K/WH_V(2=_H'D,U78;B)N(>[5:EU>RVI[EJEESA=[^V5E;AFC#RYD5?&_ MP%-W6&J;[WR%)^K/%S=ZKEOOW;;ON+VE8U!'=I>S5ZS!ETT-%':I5HGXG M8/ *X>3"S*\#OD$1<,0+\_@N%(J. '%;SN2#6U5H' !])QD]>624@LR-0S6. MA2^OQP.^_(E$4$:W"S WREB!;@KTZZB+45+$KD9MBI$1L<#LE!8@? SN(I2, M1BH,Q<6./XT+HIW_5@90(8OQ G7*.1E+@1DNAAVX+*?$(K[&'CY:KR<9^-<( M2! C ^R/9CY'\8_G&E;]WSN8HZ=NFR5&70G;H6/#1>O-1??$3-NC%\5&CXX+ M[I#2XR.*1W,3\MF-B(ERN%&9LWIND*XH82<>XCJN. %92G"/'4HA[IN6&-+1 MAV,&3VY+HK6$WX5IM^6"\D+GR$S&I3Q1A/;I%'"I_Q@RS&0D$A3>@9R8CT2* MS'H20H84.09):T%#NV\V'/0B.2AZYAPTN.&R<&$# 122!"(Z<#;UACPQK?C37B9\X:)QZ0=X%-!PMEE<+=N9<]GA"O4&ZDHJC0!-]:(G+/ MJ!-E++;3\3V.9? AL3_].9\_D+NG2X(\A)'$BG2I>(3LX,Y$Z+@D*^9Z[7BM M4F[F61O%((ZW(';!F=N/,G":,2FN098')"ORC6_>HK^;JS95U[]6UMQ_H557 M=]H>5_306/A8Q,(J;>;YAFO (2<382W P'- M2&%&0_=C@?JY0;81R!@_&(I/\#>592KV@3\+@>H[IBFRR)VF[+STNNK#?G7% MC>%!-< M,VZ16TP9;-Q[BEHZQ T47RP41VL.10R!$XVNIX' ._\K?5;J/1:O[/ ^**XL/Q>_YT\G!=6 MU=-P1TS5I-4"RYS\BP2D*J+9QQ%J.[$"Z-J7 [61R:KI[95J=ZKK@ BL.T)_ M=!U,HN-&:5,93OG?53 0D;W$)4$/FS-T'J".>'0]UJK(XF#YB*7V9>KRC5*ISHJ2E<>J?Q%;MM0_B%W] MU#;'I"_P,1)/,%OK\ALEJF.M@X-F9V_N*GU;RZ7S_A->]TWPT7\!4$L#!!0 M ( /<[!U'']X^[:PD .L\ 8 86-R#,Q9#(N M:'1M[5OQ4]NX$OY7='3N"C-QG 1H:4*9H2',<=-"CX;W[GY4['6L0;%\DDS( M^^O?KF0G3J"47E][@9?.%+"\DE;R?KO?KNS#GX)@D*4\BR!FOPX_O&>QBHH) M9)9%&KC%UJFP*1NJ/.<9^P!:"RG9.RWB,3#VIOFZV6KN'P3!T2&.U"^[J*S+ M#L+78:?5:;%VN[O;ZG;>L.,/;/MJV-]QPB<7_>&?'P=^SH]7[]Z?]=E6$(;_ MWNV'X(MU=D;H.IB&W:;;=:/_=R'LXKV=>]4M4 M9H.$3X2<=5\.Q00,.XA9N;<"E&.-LU-KS&](M]V*T-.O4=QPI&>/-P6TJ1L+^\J+]JM7;;3<[ MA^$(=R__;KHNJT;2U3PWPJ J4MA9-Q5Q#!D*_/+BH-/:[1V&)/A=]:KM883X M OT5F]@?7 [/3L_ZQ\.SBW-V<?KH[/AVQXP3X-^K2:TC!:'5K6\-[X?/ IN/CC_>!/ M=MP?TIU.J_5_:SE+>ITUV"DZQ&MV622):K (M!7)C-F4V^Y:[X[E(PELI'0, M^NU6:PM5E[+TB?-KD_.HO,8>&O_'\VEHI1&7I?$Y.T2/W)NFPD) ':&;J:GF MV.3<9&>ON8_:EE-4FG_7[0G04ULU<7/5@H:?NMUT^Q#:N+ZLM5'OC*7\!IB& M&P%3C.(V%8;]7G"-&)L+:K>!WEBB-8L!R5$+%#+(8^_U6 M9,!V6PWFPK]*V'$DN<:QABG@PX$"GZ)IL+,L:K)MZDVVTFGU-(R%L6C;UC6T M>SN]Q7Z%9 NA,Z&-A:^MA7?6V\+?<>/8*9O,V#5NI 1DL0UOZ-J;=ZQ0BTPA M_<7IN,@8SV:LR*PN -5&=NNX,1HU9Q.\TH)+EO (FS13$V&955[NCD &$1C# M]8Q$)OP:''+F8QILBU$9G%+2HF@.$HB$1D*.8DC1#6J"IL70'J*4F8)^+/I/ M04,Y""U@(@QR1]IX3^$UF!PBIV -LI%"H\--&J.6 MC1K$3*7,'6TW*'MB*-M;;Y0-ETR2'F#[=<^4."KS! H'*DD$7FZ;'9]\D=&> M,:[!P0/-7=!S)FX'AIZY,"EU([$)AD0*BW0="Q-)90KL1\%2*^EQDFL508S- MAFTC+&) G'G;']Q&*<_&@(S08OXBP7@%VKL\:.]O0TV?]G[LFW;C_8F)W^@>0S5=AN(FXA[M5*7U[+:GN6GJB\0Z5+U.\$ M#%XAG!SA_#+J&\2%(UZ8QWYJM X $91,GJ*S2@%F1N'JAV+ MJ%YG!KX:BHZ@Y+D+,#=*UD W!49XU,4H*6)7LC;%R(A88)Y*"Q">C3NNDM%( MA2&&[#RI<73:17)E !6RR!RH4\[)6 K,=9& X+*<$@NFC3T\;Z^G&_C7"$@0 M.0+V1S.?H_C'^QI6_=\[F*.G;ILE1EU%VZ%CXXO6VQ?=PYZV1\_*&SV:%]QQ M2H]G%(_V3>C/;D1,+H<;E3FKYP;=%:7NY(>XCBN?@%Y*<(\=2B;NFY8\I',? MSC-XY[8D6DO]'5>[+1>4%SI'SV1<\A-%:)]. 5<$&$.&.8U$!X5W("?/1R)% M9KT30@\IP0-\I?W5PNNUX MK5)NYED;<1#GMR!VY,SM1TF<9DR*:Y#E4%70;(L"/J3EWM"'X^QHX%YY/LL?,M* G9!#*)=-CS+-TCQ33'! M->,6N<64C./>0]4R*FZ@^&RA.%IS*"(/3C2&G@8" US41&BY=UE*##8\C139 MC9(W0%PRX^/RE1Q=!EJ8Y%+- .].4^6C*E]"."+R?T*TFT\,*S]"KQ-\4%UV M7(P+Y"NO_2N :_U2*KUJ[_#\=HO2M*W*I3PJD_>*O5I@?%%A6'[7_TXRS@NK MZKFXH[<0*H&M?$]1&)JNFEUFJW:FN W)@W1'& MH^M@BJO_XA<*\_M\9)0L+/0J1"^O[X=;0*WGXTL^_K..\N?#_G^S_3]@^YUG M?3B-?>1S6%?Z9U-P\Q+58W>8! MK?GJ^JF A)W.^>:%KQ9M'M8ZKFZ[/#*GE_SG3ZRL[^U\)C_PT6UM][X6@=,Y M)1WQZ'JL59'%P?+)2NW[U.4;I5*=%26K&%7_+K9LJ7\6N_K!;8YI7N!9$4\P M/^OR&R6JTZR#@V9G;QXJ% MY+TM!P FR0 !@ !A8W)S+3(P,C P-C,P>&5X,S)D,2YH=&WM&FESVD;T MK[R2:6-WT 5V3 1AALAX0B?!+LA-^W&15FC'0JNN5L'TU_?M2@)!FS1)QPEI M[1D#VN/=U[[5X#O#&*5"L:"HA$)1('%TS&8//LXRD\(8* MP9($7@H6+BG <_/"M,WSGF$,!PC)J[;PU(6>=6%U[(X-CN-V;;?KP.@-G-SZ MWJE>?'GM^;_=C$N<-[SC M3@NG#];<&VL6RMAU;/O[?D;"D*5+(Z&1=,_-7F\W)-@RWH[QDC57T(1(]HXJ MV VH04*)=]2>^E01*V1&QJM%\*Q*UDL=C#NBXW M+G@2XN3X/F8+)J';,9V!M4#!90]&YCY5:G6-YQW+D8J$R8T;LS"D*2[XX4FO M8W?[ TLM?%"Z&N(+T+6H^ 3Y>>.9/[F:>"-_%/_%7-'S5;M[/Y[6CJ@W\-3@]N MS;GIF3 ?>THGX'3/[?8QDS^:P^CR^L8?HP)VG!PSQ;5HG]O/T#[ ?S6&^6CV M"YDP)1>/T8D8C9 "943D2KJ.(!8@3D8R"A B6@Q]303**\T'>ADD:F'OL M>'R%I<^FYJ2MP5YA37*'@HLBWJYP7+$4RRB&E#1P*#@5@#90$L2 R.AB S@O M6:2$*V,BV[6.%C37$HZ1KKN4KQ.*=99[U-8MR0+UMN BI.)%RVXA:TE2E3K; MYSPC0?6,.P3^AULT2A(!2:I8H:T:"ZW^.D;]&VHC=5$2J*)^6?U4MEZAJ"E_ M4/$86(!)OM*X&K7@1T0RQ]R&)TN&3;Z/AGY_9Z-*O?"R+0-9,-S&B& M<0)+>KCB8@6.;?RL(H>VU@QIX"'H& _%2F%KMT&5?5K@T8-HL%+9:>X! MT0$ !XB4Z VXC:CPLBL1]USO1L-G047$S@6C(D'2 B0Z42ZDCR@'(2Y7;K2+ M."<$ YO8#9R?A-M(UPQ8?>7>.W59RE8M;>*/'OAM>F#GV_! EJ)7K4K_"! D M03BARL[*0@\< 2+"E&]FF.J4J;?5.H+GOAK/QN4AKM1- M@3!%CGZ'VHX)5BBJ-,,))O Q#7-=,& P)5O%7 SR8I]+3?>%)NK0E]&-6T,9 M#RS<,X20;'3E4RR+7):1VOR:9X#/T*_JC6B(+UJJM=*JPU\%I8R"1L"3A&0Y M=>L?35*?[6)7V9ZQ&P-EH\:>"@- MZ&3]X3KO,!Q5L;.J5)SL'E P+(0GMO[[@*J^A(RLW&H>]/^NH/M\;S_6:N83 MG>GX-=AHG!P4EI]FJU^7DT<[_-R@_B48_&_8V,?U,0<+,3S)!,/C788V2;<+ M>+G@]-$^C\X^W] M7T=4_5D2!+KY4UY/T$;G=]O591)T74U5\RF'E$L(*5W1$,TVJ=\:.;A&4G%L MVVOU^&K%\KQN154P$/Y"]<("+C(N],LDBPUBBJB@::!F5"LDW2@L*+U_N,;1 MO95#*G9W6-W].ZRJJ;UWV76RCBD."EB14-W.1%Q0M9!$LH(<(I%U9T;)25U, MV7TEK%.4C*@:<65$UI0O:8J$)@TFE0P21%D0Q+K7^\L+%'7)ZOOZ<,W"/]YV M)!8DN%L*C@)0K1 NW+H";+Q/LC]164WGP(KJFK'Y'DLUTGR-Y? %F0Q9,'-D4$L! A0#% @ ]SL'4&UL4$L! A0#% @ ]SL'4:))4$2' M2@ ='T% !4 ( !S\< &%C#$P<2YH=&U02P$"% ,4 " #W.P=1-MN0JOX* M Y00 & @ $9A0, 86-R#$P9#(N M:'1M4$L! A0#% @ ]SL'4<>;I=MP"0 Y3P !@ ( ! M39 # &%C&5X M,S%D,BYH=&U02P$"% ,4 " #W.P=1ZH7DO2T' ";) & M @ &4HP, 86-R#,R9#$N:'1M4$L%!@ * H *I@( />J P $! end